

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005418

International filing date: 18 February 2005 (18.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/547,681
Filing date: 25 February 2004 (25.02.2004)


Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1295636



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 21, 2005

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.**

**APPLICATION NUMBER: 60/547,681
FILING DATE: February 25, 2004
RELATED PCT APPLICATION NUMBER: PCT/US05/05418**



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c)

Docket Number **P-16115** Type a plus sign (+) inside this box **+**

INVENTOR(S)/APPLICANT(S)

LAST NAME	FIRST NAME	MIDDLE NAME	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
Allen	John	Gordon	Indianapolis, Indiana
Briner	Karin		Indianapolis, Indiana
Cohen	Michael		Indianapolis, Indiana
Galka	Christopher	Stanley	Carmel, Indiana
Martinez-Grau	Maria	Angeles	Madrid, Spain
Hellman	Sarah	Lynne	Indianapolis, Indiana
Rothhaar	Roger		Indianapolis, Indiana
Reinhard	Matthew	Robert	Indianapolis, Indiana
Rodriguez	Michael	John	Indianapolis, Indiana
Tidwell	Michael	W.	Indianapolis, Indiana
Victor	Frantz		Indianapolis, Indiana
Williams	Andrew	Caerwyn	Windlesham Surrey, England
Zhang	Deyi		Carmel, Indiana

TITLE OF THE INVENTION (280 characters max)

6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT_{2C} RECEPTOR AGONISTS

CORRESPONDENCE ADDRESS

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288



25885

PATENT TRADEMARK OFFICE

STATE **IN** ZIP CODE **46206-6288** COUNTRY **USA**

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification Number of pages **444** ☐ Small Entity Statement
☐ Drawing(s) Number of Sheets ☐ Other (Specify)

METHOD OF PAYMENT (check one)

☐ A check or money order is enclosed to cover the Provisional filing fees
☒ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number: **05-0840**
PROVISIONAL FILING FEE AMOUNT (\$) **\$160.00**

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.
☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,
SIGNATURE **R. Craig Tucker**

Date **02 / 25 / 04**

REGISTRATION NO.
(if appropriate)

45,165

TYPED or PRINTED NAME **R. CRAIG TUCKER**

☐ Additional inventors are being named on separately numbered sheets attached hereto

PROVISIONAL APPLICATION FOR PATENT FILING ONLY

"Express Mail" mailing label number **EL 018700146 US** Date of Deposit **2-25-04**
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Printed Name **QUEEN THOMAS**

Signature

**6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES
AS 5-HT_{2C} RECEPTOR AGONISTS**

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has a rich pharmacology arising from a heterogeneous population of at least seven receptor classes. The serotonin 5-HT₂ class is further subdivided into at least three subtypes, designated 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C}. The 5-HT_{2C} receptor has been isolated and characterized (Julius, *et al.*, U.S. Patent No. 4,985,352), and transgenic mice lacking the 5-HT_{2C} receptor have been reported to exhibit seizures and an eating disorder resulting in increased consumption of food (Julius *et al.*, U.S. Patent No. 5,698,766). The 5-HT_{2C} receptor has also been linked to various other neurological disorders including obesity (Vickers *et al.*, *Psychopharmacology*, 167: 274-280 (2003)), hyperphagia (Tecott *et al.*, *Nature*, 374: 542-546 (1995)), obsessive compulsive disorder (Martin *et al.*, *Pharmacol. Biochem. Behav.*, 71: 615 (2002); Chou-Green *et al.*, *Physiology & Behavior*, 78: 641-649 (2003)), depression (Leysen, Kelder, *Trends in Drug Research II*, 29: 49-61 (1998)), anxiety (Curr. Opin. Invest. Drugs 2(4), p. 317 (1993)), substance abuse, sleep disorder (Frank *et al.*, *Neuropsychopharmacology* 27: 869-873 (2002)), hot flashes (EP 1213017 A2), epilepsy (Upton *et al.*, *Eur. J. Pharmacol.*, 359: 33 (1998); Fitzgerald, Ennis, *Annual Reports in Medicinal Chemistry*, 37: 21-30 (2002)), and hypogonadism (Curr. Opin. Invest. Drugs 2(4), p. 317 (1993)).

Certain substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds have been disclosed as useful therapeutics as for example:

US 4,265,890 describes certain substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds as dopaminergic receptor antagonists for use as antipsychotics and antiemetics, *inter alia*.

EP 0 285 287 describes certain substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds for use as agents to treat gastrointestinal motility disorders, *inter alia*.

"Express Mail" mailing label number <u>ELO18700140US</u>		Date of Deposit <u>2-25-04</u>
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
<u>Queen Thomas</u>	<u>Queen Thomas</u>	Signature
Printed Name		

WO 93/03015 and WO 93/04686 describe certain substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds as alpha-adrenergic receptor antagonists for use as agents to treat hypertension and cardiovascular diseases in which changes in vascular resistance are desirable, *inter alia*.

5

WO 02/074746 A1 describes certain substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds as 5-HT_{2C} agonists for the treatment of hypogonadism, obesity, hyperphagia, anxiety, depression, sleep disorder, *inter alia*.

10

WO 03/006466 A1 describes certain substituted tricyclic hexahydroazepinoindole and indoline compounds as 5-HT ligands and consequently their usefulness for treating diseases wherein modulation of 5-HT activity is desired.

15

High affinity 5-HT_{2C} receptor agonists would provide useful therapeutics for the treatment of the above mentioned 5-HT_{2C} receptor-associated disorders including obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and hypogonadism. High affinity 5-HT_{2C} receptor agonists that are also selective for the 5-HT_{2C} receptor, would provide such therapeutic benefit without the undesirable adverse events associated with current therapies. Achieving selectivity for the 5-HT_{2C} receptor, particularly as against the 5-HT_{2A} and 5-HT_{2B} receptors, has proven difficult in designing 5-HT_{2C} agonists. 5-HT_{2A} receptor agonists have been associated with problematic hallucinogenic adverse events. (Nelson *et al.*, Naunyn-Schmiedeberg's Arch. Pharm., 359: 1-6 (1999)). 5-HT_{2B} receptor agonists have been associated with cardiovascular related adverse events, such as valvulopathy. (V. Setola *et al.*, Mol. Pharmacology, 63: 1223-1229 (2003), and ref. cited therein).

20


25

Previous references to substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine compounds as potential therapeutics have predominately recited their uses as alpha adrenergic and/or dopaminergic modulators. Adrenergic modulators are often associated with the treatment of cardiovascular diseases (Frishman, Kotob, Journal of Clinical Pharmacology, 39: 7-16 (1999)). Dopaminergic receptors are primary targets in the treatment of schizophrenia and Parkinson's disease (Seeman, Van Tol, Trends in Pharmacological Sciences, 15: 264-270 (1994)). It will be appreciated by those skilled in

30

the art that selectivity as against these and other physiologically important receptors will generally also be preferred characteristics for therapeutics for the specific treatment of 5-HT_{2C} associated disorders as described above.

5 The present invention provides selective 5-HT_{2C} agonist compounds of Formula I:



I

where:

- 10 R¹ is hydrogen, fluoro, or (C₁-C₃)alkyl;
 R², R³, and R⁴ are each independently hydrogen, methyl, or ethyl;
 R⁵ is hydrogen, fluoro, methyl, or ethyl;
 R⁶ is -C≡C-R¹⁰, -O-R¹², -S-R¹⁴, or -NR²⁴R²⁵;
 R⁷ is hydrogen, halo, cyano, (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro
 15 substituents, (C₂-C₆)alkenyl optionally substituted with 1 to 6 fluoro substituents,
 (C₃-C₇)cycloalkyl, (C₁-C₆)alkoxy optionally substituted with 1 to 6 fluoro
 substituents, (C₁-C₆)alkylthio optionally substituted with 1 to 6 fluoro substituents,
 Ph¹-(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl-O-, or Ph¹-(C₀-C₃)alkyl-S-;
 R⁸ is hydrogen, halo, cyano, or -SCF₃;
 20 R⁹ is hydrogen, halo, cyano, -CF₃, -SCF₃, or (C₁-C₃)alkoxy optionally substituted with 1
 to 6 fluoro substituents;
 R¹⁰ is -CF₃, ethyl substituted with 1 to 5 fluoro substituents, (C₃-C₆) alkyl optionally
 substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl,
 Ar¹-(C₀-C₃)alkyl, or Ph¹-(C₀-C₃)alkyl;
 25 R¹² is Ph²-(C₁-C₃)alkyl, Ar²-(C₁-C₃)alkyl, (C₁-C₆)alkyl-S-(C₂-C₆)alkyl,
 (C₃-C₇)cycloalkyl-S-(C₂-C₆)alkyl, phenyl-S-(C₂-C₆)alkyl, Ph²-S-(C₂-C₆)alkyl,
 phenylcarbonyl-(C₁-C₃)alkyl, Ph²-C(O)-(C₁-C₃)alkyl,
 (C₁-C₆)alkoxycarbonyl(C₃-C₆)alkyl, (C₃-C₇)cycloalkyl-OC(O)-(C₃-C₆)alkyl,
 phenyloxycarbonyl-(C₃-C₆)alkyl, Ph²-OC(O)-(C₃-C₆)alkyl, Ar²-OC(O)-(C₃-C₆)alkyl,
 30 (C₃-C₇)cycloalkyl-NH-C(O)-(C₂-C₄)alkyl-, Ph¹-NH-C(O)-(C₂-C₄)alkyl-,
 Ar²-NH-C(O)-(C₂-C₄)alkyl-, or R¹³-C(O)NH-(C₂-C₄)alkyl;

R¹³ is (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹, Ar², or (C₁-C₃)alkoxy optionally substituted with 1 to 6 fluoro substituents, Ph¹-NH- or N-linked Het¹;

R¹⁴ is Ar² which is not N-linked to the sulfur atom, Ph², R¹⁵-L-, tetrahydrofuranyl, tetrahydropyranyl, or phenyl-methyl substituted on the methyl moiety with a
5 substituent selected from the group consisting of (C₁-C₃)-*n*-alkyl substituted with hydroxy, (C₁-C₃)alkyl-O-(C₁-C₂)-*n*-alkyl, (C₁-C₃)alkyl-C(O)-(C₀-C₂)-*n*-alkyl, and (C₁-C₃)alkyl-O-C(O)-(C₀-C₂)-*n*-alkyl,

wherein Ph² and Ar² when Ar² is pyridyl, may also, optionally be substituted with phenyl-CH=CH- or phenyl-C≡C-,

10 said phenyl-CH=CH- or phenyl-C≡C- being optionally further substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro
15 substituents, and

wherein when Ar² is pyridyl, the pyridyl may alternatively, optionally be substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents, and

20 wherein the tetrahydrofuranyl and tetrahydropyranyl may optionally be substituted with an oxo substituent, or with one or two groups independently selected from methyl and -CF₃;

R¹⁵ is -OR¹⁶, cyano, -SCF₃, Ph², Ar², quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, phthalimido, -NR¹⁷R¹⁸, -C(O)R²², or a saturated heterocycle selected from the group
25 consisting of pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl, tetrahydrofuranyl, and tetrahydropyranyl,

wherein Ph² and Ar² when Ar² is pyridyl, may also optionally be substituted with phenyl-CH=CH- or phenyl-C≡C-,

30 said phenyl-CH=CH- and phenyl-C≡C- being optionally further substituted on the phenyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro

substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and

wherein Ar² may alternatively, optionally be substituted with a substituent selected from the group consisting of (C₃-C₇)cycloalkyl-(C₀-C₃)alkyl, Het¹-(C₀-C₃)alkyl, pyridyl-(C₀-C₃)alkyl, and phenyl-(C₀-C₃)alkyl, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,

said pyridyl-(C₀-C₃)alkyl and phenyl-(C₀-C₃)alkyl optionally being further substituted with 1-3 substituents independently selected from halo, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -SCF₃, and

wherein when Ar² is pyridyl, the pyridyl may alternatively, optionally be substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents, and

wherein the pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl is substituted with oxo- on a carbon atom adjacent to the ring nitrogen atom, or is N-substituted with a substituent selected from the group consisting of (C₁-C₆)alkylcarbonyl, (C₁-C₆)alkylsulfonyl, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)₂-, Ph¹-(C₀-C₃)alkyl-C(O)-, and Ph¹-(C₀-C₃)alkyl-S(O)₂-, and

may optionally be further substituted with 1 or 2 methyl or -CF₃ substituents, and when oxo-substituted, may optionally be further N-substituted with a substituent selected from the group consisting of

(C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, and Ph¹-(C₀-C₃)alkyl, and

wherein tetrahydrofuranyl and tetrahydropyranyl may optionally be substituted with an oxo substituent, and/or with one or two groups independently selected from methyl and -CF₃;

L is branched or unbranched (C₁-C₆)alkylene, except when R¹⁵ is -NR¹⁷R¹⁸ or Ar²-N-linked to L, in which case L is branched or unbranched (C₂-C₆)alkylene, and when L is methylene or ethylene, L may optionally be substituted with gem-ethano, and when R¹⁵ is Ph², Ar², or a saturated heterocycle, L may alternatively, optionally be

substituted with a substituent selected from the group consisting of hydroxy, cyano, -SCF₃, (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, (C₁-C₆)alkoxycarbonyl optionally further substituted with 1 to 6 fluoro substituents, (C₁-C₆)alkylcarbonyloxy optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl-(C₀-C₃)alkyl-O-, (C₃-C₇)cycloalkyl-(C₀-C₃)alkyl-O-C(O)-, and (C₃-C₇)cycloalkyl-(C₀-C₃)alkyl-C(O)-O-;

R¹⁶ is hydrogen, (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₁-C₆)alkylcarbonyl, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-, Ph¹-(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl-C(O)-, Ar²-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl-C(O)-;

R¹⁷ is (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, *t*-butylsulfonyl, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-sulfonyl, Ph¹-(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl-C(O)-, Ph¹-(C₀-C₃)alkylsulfonyl, Ar²-(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl-C(O)-, Ar²-(C₀-C₃)alkylsulfonyl, R¹⁹OC(O)-, or R²⁰R²¹NC(O)-;

R¹⁸ is hydrogen or (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or R¹⁷ and R¹⁸, taken together with the nitrogen atom to which they are attached form Het¹ where Het¹ is substituted with oxo- on a carbon atom adjacent to the ring nitrogen atom, or

R¹⁷ and R¹⁸, taken together with the nitrogen atom to which they are attached, form an aromatic heterocycle selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, and 1,2,4-triazolyl,

said aromatic heterocycle optionally being substituted with 1 to 2 halo substituents, or substituted with 1 to 2 (C₁-C₄)alkyl substituents optionally further substituted with 1 to 3 fluoro substituents, or mono-substituted with fluoro, nitro, cyano, -SCF₃, or (C₁-C₄)alkoxy optionally further substituted with 1 to 3 fluoro substituents, and optionally further substituted with a (C₁-C₄)alkyl substituent optionally further substituted with 1 to 3 fluoro substituents;

R¹⁹ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl, or Ph¹-(C₀-C₃)alkyl,

R²⁰ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl, or Ph¹-(C₀-C₃)alkyl,

R²¹ is hydrogen or (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or R²⁰ and R²¹, taken together with the nitrogen atom to which they are attached, form Het¹;

R²² is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents,

5 (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, R²³-O-, Ph¹-(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl, or R³²R³³N-;

R²³ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl;

R²⁴ is (C₁-C₆)alkoxy(C₂-C₅)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₁-

10 C₆)alkylthio(C₂-C₅)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl,

(C₃-C₇)cycloalkyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl, phenyl(C₁-C₃) *n*-alkyl,

Ph²-(C₁-C₃)-*n*-alkyl, Ar²(C₀-C₃) *n*-alkyl, phenyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl,

phenyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl, Ph¹-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl,

15 Ph¹-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl,

pyridyl-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl,

pyridyl-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl, or Ar³(C₁-C₂)alkyl,

where Ar³ is a bi-cyclic moiety selected from a group consisting of indanyl, indolyl,

dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl,

20 benzo[1,3]dioxolyl, naphthyl, dihydrobenzopyranyl, quinoliny, and isoquinoliny,

said Ar³ optionally being substituted with phenyl(C₀-C₁)alkyl optionally further

substituted with 1 to 6 fluoro substituents, or substituted with

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, or substituted with 1-3 substituents

independently selected from the group consisting of halo, oxo, methyl, and

25 -CF₃,

said phenyl(C₁-C₃) *n*-alkyl, Ph²-(C₁-C₃) *n*-alkyl, or Ar²(C₀-C₃) *n*-alkyl

optionally being substituted on the *n*-alkyl moiety when present with

(C₁-C₃)alkyl, dimethyl, or gem-ethano,

said Ar²(C₀-C₃) *n*-alkyl being alternatively optionally substituted with a

30 substituent selected from the group consisting of (C₃-C₇)cycloalkyl-

(C₀-C₃)alkyl, Het¹-(C₀-C₃)alkyl, pyridyl-(C₀-C₃)alkyl, and phenyl-

(C₀-C₃)alkyl, and optionally further substituted with one methyl, -CF₃,

cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,

said pyridyl-(C₀-C₃)alkyl and phenyl-(C₀-C₃)alkyl optionally being further substituted with 1-3 substituents independently selected from halo, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -SCF₃, and said Ph²-(C₁-C₃) *n*-alkyl and Ar²(C₀-C₃) *n*-alkyl where Ar² is pyridyl, also
5 optionally being substituted on the phenyl or Ar² moiety, respectively, with phenyl-CH=CH- or phenyl-C≡C-,
said phenyl-CH=CH- or phenyl-C≡C- being optionally further substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally
10 further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and
said Ar²(C₀-C₃) *n*-alkyl where Ar² is pyridyl, alternatively, optionally being substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one
15 methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,
said phenyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl, or phenyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl optionally being substituted on the phenyl moiety with (C₁-C₂)-S(O)₂-, or with 1 to 5 independently selected halo substituents, or with 1 to 3
20 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and
said pyridyl-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl and
pyridyl-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl optionally being substituted
25 on the pyridyl moiety with methyl, -CF₃, or 1 to 3 halo substituents;
R²⁵ is hydrogen, (C₁-C₃)alkyl optionally substituted with 1 to 6 fluoro substituents, or allyl;
R²⁶ is hydrogen, (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or (C₃-C₇)cycloalkyl(C₀-C₃)alkyl;
R²⁷ is hydrogen or (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or
30 R²⁶ and R²⁷, taken together with the nitrogen atom to which they are attached, form Het¹;

R²⁸ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, tetrahydropyran-3-yl(C₀-C₃)alkyl, tetrahydropyran-4-yl(C₀-C₃)alkyl, tetrahydrofuranyl(C₀-C₃)alkyl, Ph¹-(C₀-C₂) *n*-alkyl, or Ar²-(C₀-C₂) *n*-alkyl,

5 said Ph¹-(C₀-C₂) *n*-alkyl and Ar²-(C₀-C₂) *n*-alkyl optionally being substituted on the alkyl moiety when present with (C₁-C₃)alkyl, dimethyl, or gem-ethano;

R²⁹ is hydrogen or (C₁-C₃)alkyl;

R³⁰ is hydrogen, (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl,

10 R³¹ is hydrogen or (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, or R³⁰ and R³¹, taken together with the nitrogen atom to which they are attached, form Het¹,

 said Het¹ also optionally being substituted with phenyl optionally further substituted with 1 to 3 halo substituents;

15 R³² and R³³ are each independently hydrogen or (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, or R³² and R³³, taken together with the nitrogen atom to which they are attached, form Het¹;

Ar¹ is an aromatic heterocycle substituent selected from the group consisting of furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, and pyridyl, any of which may optionally
20 be substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C₁-C₃)alkyl, (C₁-C₃)alkoxy, -CF₃, -O-CF₃, nitro, cyano, and trifluoromethylthio;

Ar² is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furanyl, oxazolyl, isoxazolyl,
25 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, and benzimidazolyl, any of which may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy
30 optionally further substituted with 1 to 6 fluoro substituents, and wherein pyridyl and pyridazinyl may also optionally be substituted with (C₁-C₆)alkylamino optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, or (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-amino;

Het¹ is a saturated, nitrogen-containing heterocycle substituent selected from the group consisting of azetidiny, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, and thiomorpholinyl, any of which may optionally be substituted with (C₁-C₆)alkyl or with 2 methyl substituents;

5 Ph¹ is phenyl optionally substituted with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents;

10 Ph² is phenyl substituted with:

a) 1 to 5 independently selected halo substituents; or
b) 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, nitro, hydroxy, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents; or

15 c) 0, 1, or 2 substituents independently selected from the group consisting of halo, cyano, -SCF₃, methyl, -CF₃, methoxy, -OCF₃, nitro, and hydroxy, together with one substituent selected from the group consisting of

i) (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents or
20 mono-substituted with hydroxy, (C₁-C₃)alkoxy, or (C₁-C₂)-S(O)₂-,

ii) (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents,

iii) (C₁-C₆)alkyl-C(O)-(C₀-C₃)alkyl optionally further substituted with 1 to 6 fluoro substituents,

iv) carboxy,

25 v) (C₁-C₆)alkoxycarbonyl optionally further substituted with 1 to 6 fluoro substituents,

vi) (C₁-C₆)alkyl-C(O)-(C₀-C₃)-O- optionally further substituted with 1 to 6 fluoro substituents,

vii) (C₁-C₆)alkylthio optionally further substituted with 1 to 6 fluoro substituents,

30 viii) (C₁-C₆)alkylsulfinyl optionally further substituted with 1 to 6 fluoro substituents,

- ix) (C₁-C₆)alkylsulfonyl optionally further substituted with 1 to 6 fluoro substituents,
- x) (C₁-C₆)alkylsulfonyl-(C₀-C₁)alkyl-O- optionally further substituted with 1 to 6 fluoro substituents,
- 5 xi) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl,
- xii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-O-,
- xiii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-,
- xiv) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-O-C(O)-,
- xv) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S-,
- 10 xvi) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)-,
- xvii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)₂-,
- xviii) Ph¹-(C₀-C₃)alkyl,
- xix) Ph¹-(C₀-C₃)alkyl-O-,
- xx) Ph¹-(C₀-C₃)alkyl-C(O)-,
- 15 xxi) Ph¹-(C₀-C₃)alkyl-O-C(O)-,
- xxii) Ph¹-(C₀-C₃)alkyl-C(O)-(C₀-C₃)alkyl-O-,
- xxiii) Ph¹-(C₀-C₃)alkylthio,
- xxiv) Ph¹-(C₀-C₃)alkylsulfinyl,
- xxv) Ph¹-(C₀-C₃)alkylsulfonyl,
- 20 xxvi) Ar²(C₀-C₃)alkyl
- xxvii) Ar²(C₀-C₃)alkyl-O-
- xxviii) Ar²-(C₀-C₃)alkyl-S-,
- xxix) Ar²(C₀-C₃)alkyl-C(O)-,
- xxx) Ar²(C₀-C₃)alkyl-C(S)-,
- 25 xxxi) Ar²-(C₀-C₃)alkylsulfinyl,
- xxxii) Ar²-(C₀-C₃)alkylsulfonyl,
- xxxiii) Het¹(C₀-C₃)alkyl-C(O)- optionally substituted on the Het¹ moiety with Ph¹,
- xxxiv) Het¹(C₀-C₃)alkyl-C(S)- optionally substituted on the Het¹ moiety with Ph¹,
- 30 xxxv) N-linked Het¹-C(O)-(C₀-C₃)alkyl-O-,
- xxxvi) R²⁶R²⁷N-,
- xxxvii) R²⁸R²⁹-N-(C₁-C₃)alkoxy,

xxxviii) $R^{28}R^{29}N-C(O)-$,

xxxix) $R^{28}R^{29}N-C(S)-$,

xl) $R^{30}R^{31}N-S(O)_2-$,

xli) $HON=C(CH_3)-$; and

5 xlii) $HON=C(Ph^1)-$;

or a pharmaceutically acceptable salt thereof, subject to the following provisos:

- a) no more than two of R^1 , R^2 , R^3 , R^4 , and R^5 may be other than hydrogen;
- b) when R^2 is methyl, then R^1 , R^3 , R^4 , and R^5 are each hydrogen;
- c) when R^3 is methyl, then R^2 and R^4 are each hydrogen;
- 10 d) when R^3 is methyl, R^7 and R^8 are each $-OH$, and R^1 , R^2 , R^4 , R^5 , and R^9 are each hydrogen, then R^6 is other than cyclohexylthio, furanylthio, or phenylthio; and
- e) When R^{12} is $Ar^2-(C_1-C_3)alkyl$, then R^7 is other than hydrogen or R^9 is other than chloro.

15

This invention also provides pharmaceutical compositions which comprise a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier, diluent, or excipient.

20

In another aspect of the present invention, there is provided a method for increasing activation of the 5-HT_{2C} receptor in mammals comprising administering to a mammal in need of such activation an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

25

The present invention also provides a method for treating obesity in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

30

The present invention also provides a method for treating obsessive/compulsive disorder in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Furthermore, the present invention provides a method for treating depression in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

5 Furthermore, the present invention provides a method for treating anxiety in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

10 In preferred embodiments of the above methods of treatment utilizing a compound of Formula I, or a pharmaceutically acceptable salt thereof, the mammal is a human.

15 In another aspect of the present invention, there is provided a compound of Formula I for use in selectively increasing activation of the 5-HT_{2C} receptor and/or for use in treating a variety of disorders associated with decreased activation of 5-HT_{2C} receptors. Preferred embodiments of this aspect of the invention include a compound of Formula I for use in the treatment of obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism. Particularly preferred embodiments of this aspect of the invention include the treatment of obesity, obsessive/compulsive disorder, depression, and/or anxiety.

20

25 In another aspect of the present invention, there is provided the use of one or more compounds of Formula I in the manufacture of a medicament for the activation of 5-HT_{2C} receptors in a mammal. In preferred embodiments of this aspect of the invention, there is provided the use of one or more compounds of Formula I in the manufacture of a medicament for the treatment of obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism. Particularly preferred embodiments of this aspect of the invention include the use of one or more compounds of Formula I in the manufacture of medicaments for the treatment of obesity, obsessive/compulsive disorder, depression, and/or anxiety.

30

Additionally, the present invention provides a pharmaceutical formulation adapted for the treatment of obesity, or for the treatment of obsessive/compulsive disorder, or for the treatment of depression, or for the treatment of anxiety, each of which comprise a

compound of Formula I in association with a pharmaceutically acceptable carrier, diluent or excipient.

In those instances where the disorders which can be treated by 5-HT_{2C} agonists are known by established and accepted classifications, their classifications can be found in various sources. For example, at present, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV™) (1994, American Psychiatric Association, Washington, D.C.), provides a diagnostic tool for identifying many of the disorders described herein. Also, the International Classification of Diseases, Tenth Revision (ICD-10), provides classifications for many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for disorders described herein, including those as described in the DSM-IV and ICD-10, and that terminology and classification systems evolve with medical scientific progress.

15

The general chemical terms used throughout have their usual meanings. For example, the term "alkyl" refers to a branched or unbranched saturated hydrocarbon group. The term "*n*-alkyl" refers to an unbranched alkyl group. By way of illustration, but without limitation, the term "(C₁-C₂)alkyl" refers to methyl and ethyl. The term "(C₁-C₃) *n*-alkyl" refers to methyl, ethyl, and propyl. The term "(C₁-C₃)alkyl" refers to methyl, ethyl, propyl, and isopropyl. The term "(C₁-C₄) *n*-alkyl" refers to methyl, ethyl, *n*-propyl, and *n*-butyl. The term "(C₁-C₄)alkyl" refers to methyl, ethyl, propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, and *tert*-butyl. The term "(C₁-C₆)alkyl" refers to all branched and unbranched alkyl groups having from one to six carbon atoms. The term "(C₃-C₆)alkyl" refers to all branched and unbranched alkyl groups having from three to six carbon atoms. The term "(C₂-C₆)alkyl" refers to all branched and unbranched alkyl groups having from two to six carbon atoms.

(C_x-C_y)alkyl may also be used in conjunction with other substituents to indicate a branched or unbranched saturated hydrocarbon linker for the substituent, where x and y indicate the range of carbon atoms permitted in the linker moiety. By way of illustration, but without limitation, -(C₀-C₁)alkyl refers to a single bond or a methylene linker moiety; -(C₀-C₂)alkyl refers to a single bond, methylene, methyl-methylene, or ethylene linker

30

moiety; $-(C_0-C_3)$ alkyl further includes trimethylene, alpha- or beta-methyl ethylene, or ethyl methylene. $-(C_1-C_2)$ alkyl, $-(C_1-C_3)$ alkyl, $-(C_1-C_4)$ alkyl, and $-(C_1-C_6)$ alkyl refer to branched or unbranched alkylene linkers having from 1 to 2, 3, 4, or 6 carbons, respectively.

5

The term "alkenyl" refers to a branched or unbranched unsaturated hydrocarbon group. By way of illustration, but without limitation, the term " (C_2-C_6) alkenyl" refers to a branched or unbranched hydrocarbon group having from 2 to 6 carbon atoms and 1 or more carbon-carbon double bonds. Allyl means a propyl-2-en-1-yl moiety ($CH_2=CH-$
10 CH_2-).

10

The term " (C_3-C_7) cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cycloalkylalkyl refers to a cycloalkyl moiety linked through a branched or unbranched alkylene linker, as for example, but without limitation, $-CH_2-$,
15 $-CH_2CH_2-$, $-CH(CH_3)-$, $-CH_2CH_2CH_2-$, $-CH_2CH(CH_3)-$, $-CH(CH_3)CH_2-$, $-CH(CH_2CH_3)-$, and the like. (C_3-C_7) cycloalkyl($C_0-C_{1, 2, \text{ or } 3}$)alkyl, refers to cycloalkyls linked through a single bond (i.e. C_0 -alkyl) or an alkylene linker. Each alkyl, cycloalkyl, and cycloalkylalkyl group may be optionally substituted as provided for herein.

15

20 The terms "alkoxy", "phenyloxy", "sulfonyloxy", and "carbonyloxy" refer to an alkyl group, phenyl group, sulfonyl group, or carbonyl group, respectively, that is bonded through an oxygen atom.

20

The terms "alkylthio", "trifluoromethylthio", "cycloalkylthio" ("cyclohexylthio"),
25 "phenylthio", and "furanylthio" refer to an alkyl group, trifluoromethyl group, cycloalkyl (cyclohexyl) group, phenyl group, or furanyl group, respectively, that is bonded through a sulfur atom.

25

The terms "alkylcarbonyl", "alkoxycarbonyl", "phenylcarbonyl", and
30 "phenyloxycarbonyl", refer to an alkyl, alkoxy, phenyl, or phenyloxy group bonded through a carbonyl moiety.

30

The term "alkylcarbonyloxy" refers to an alkylcarbonyl group bonded through an oxygen atom.

The terms "(C₁-C₆)alkylsulfinyl", "Ph¹-(C₀-C₃)alkylsulfinyl", and "Ar²-(C₀-C₃)alkylsulfinyl", refer to an alkyl, Ph¹-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl, respectively, group bonded through a sulfinyl moiety (-SO-).

The terms "alkylsulfonyl" (*t*-butylsulfonyl), "(C₃-C₇)cycloalkylsulfonyl", "phenylsulfonyl", "Ph¹-(C₀-C₃)alkylsulfonyl", and "Ar²-(C₀-C₃)alkylsulfonyl", refer to an alkyl (*t*-butyl), (C₃-C₇)cycloalkyl, phenyl, Ph¹-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl group bonded through a sulfonyl moiety (-SO₂-).

The term "phenylamino" refers to a phenyl group bonded through a nitrogen atom.

The term "N-linked" means that the referenced moiety is linked through its nitrogen atom, by way of illustration, but without limitation, N-linked Het¹ means the Het¹ moiety is linked through a nitrogen atom in the ring of the Het¹ moiety, and N-linked Ar² means the Ar² moiety is linked through a nitrogen atom in the ring of the Ar² moiety.

The term "halo" refers to fluoro, chloro, bromo, or iodo. Preferred halo groups are fluoro, chloro, and bromo. More preferred halo groups are fluoro and chloro.

The term "heterocycle" is taken to mean a saturated or unsaturated 4 to 7 membered ring containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, said ring optionally being benzofused. Exemplary saturated heterocycles, for the purposes of the present invention, include azetidiny, pyrrolidinyl, piperidinyl, homopiperidinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, and the like. Exemplary unsaturated heterocycles include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, and the like. Exemplary benzofused heterocyclic rings include, but are not limited to, indolyl, dihydroindolyl, indazolyl, benzisoxazolyl, benzimidazolyl, benzofuranyl, dihydrobenzofuranyl, benzoxazolyl, benzo[1,3]dioxolyl, benzothiophenyl, benzothiazolyl,


quinolinyl, isoquinolinyl, benzopyranyl, dihydrobenzopyranyl, cinnolinyl, quinazolinyl and the like, all of which may be optionally substituted as provided for herein, which also includes optionally substituted on the benzene ring when the heterocycle is benzofused.

5 In one embodiment, preferred heterocycles include pyrrolidinyl, piperidinyl, homopiperidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, isoxazolyl, 1,2,4-oxadiazolyl, thiophenyl, thiazolyl, 1,2,3-thiadiazolyl, pyridyl, pyridazinyl, indolyl, dihydroindolyl, benzimidazolyl, benzofuranyl, dihydrobenzofuranyl, benzoxazolyl, benzo[1,3]dioxolyl, benzothiophenyl, benzothiazolyl, quinolinyl,
10 isoquinolinyl, and benzopyranyl, all of which may be optionally substituted as provided for herein.

In yet another embodiment, preferred heterocycles include pyridyl, pyridazinyl, and thiophenyl.

15

The terms "gem-", "geminal", or "geminate" refer to two identical substituents bonded to a common carbon atom, as for example, but without limitation, gem-methyl, meaning two methyl groups bound to a common carbon atom, as for instance in a 3,3-dimethyltetrahydrobenzofuranyl group. For the purposes of this application, gem-ethano
20 means an ethylene substituent wherein both carbons are bound to the same carbon atom of the substituted group to form a cyclopropyl moiety, as for example, but without limitation, the ethano substituent on the 2-phenyl-(1,1-ethano)ethylamino group below:



25

It is to be understood that when a basic definition of a group lists optionally allowable substituents, and in another place that group is said to also optionally be substituted with other recited substituents, then those other recited substituents are intended to be added to the list of optionally allowable substituents listed in the basic
30 definition of the group. Conversely, if in another place that group is said to be alternatively, optionally substituted with other recited substituents, then those other

recited substituents are intended to replace the list of optionally allowable substituents recited in the basic definition of the substituent. For example, but without limitation, Ar² has a basic definition that recites that any of the listed heteroaromatic groups may "optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and wherein pyridyl and pyridazinyl may also optionally be substituted with (C₁-C₆)alkylamino optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, or (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-amino." This is to be understood to mean that any of the listed heteroaromatic groups may optionally be substituted with [1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents], and that when Ar² is selected to be pyridyl or pyridazinyl, the list of substituents selectable for the 1 to 3 substituents is expanded to also include [(C₁-C₆)alkylamino optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, and (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-amino]. Likewise, in the definition of R¹⁴, the terminology "wherein . . . Ar² when Ar² is pyridyl, may also, optionally be substituted with phenyl-CH=CH- or phenyl-C≡C- . . ." is understood to mean that the list of substituents selectable for the 1 to 3 substituents optionally allowed on Ar² = pyridyl is again expanded to also include [phenyl-CH=CH- or phenyl-C≡C- . . .]. Conversely, in the definition of R¹⁴, the terminology "wherein when Ar² is pyridyl, the pyridyl may alternatively, optionally be substituted with R²⁸R²⁹N-C(O)- and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents", is understood to mean that when R¹⁴ is selected to be Ar² = pyridyl, then the list of 1 to 3 independently selected substituents optionally allowable in the basic definition of Ar² is superseded by "R²⁸R²⁹N-C(O)- and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents."

The term "amino protecting group" as used in this specification refers to a substituent commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. Examples of such amino protecting groups include the formyl group, the trityl group, the acetyl group, the trichloroacetyl group, the

trifluoroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, carbamoyl-type blocking groups such as benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl ("Fmoc"), *t*-butoxycarbonyl (*t*-BOC), and like amino protecting groups. The species of amino protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of subsequent reactions on other positions of the molecule and can be removed at the appropriate point without disrupting the remainder of the molecule. The selection and use (addition and subsequent removal) of amino protecting groups is well known within the ordinary skill of the art. Further examples of groups referred to by the above terms are described by T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3rd edition, John Wiley and Sons, New York, NY, 1999, chapter 7, hereafter referred to as "*Greene*".

The term "pharmaceutical" or "pharmaceutically acceptable" when used herein as an adjective, means substantially non-toxic and substantially non-deleterious to the recipient.

By "pharmaceutical composition" it is further meant that the carrier, solvent, excipients and/or salt must be compatible with the active ingredient of the composition (e.g. a compound of Formula I). It is understood by those of ordinary skill in this art that the terms "pharmaceutical formulation" and "pharmaceutical composition" are generally interchangeable, and they are so used for the purposes of this application.

The term "effective amount" means an amount of a compound of Formula I which is capable of activating 5-HT_{2C} receptors and/or elicit a given pharmacological effect.

The term "suitable solvent" refers to any solvent, or mixture of solvents, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction.

It is understood that compounds of the present invention may exist as stereoisomers. As such, all enantiomers, diastereomers, and mixtures thereof, are included within the scope of the present invention. Where specific stereochemistries are identified in this application, the Cahn-Prelog-Ingold designations of (R)- and (S)- and the cis and trans designation of relative stereochemistry are used to refer to specific isomers

and relative stereochemistry. Known optical rotations are designated by (+) and (-) for dextrorotatory and levorotatory, respectively. Where a chiral compound is resolved into its isomers, but absolute configurations or optical rotations are not determined, the isomers are arbitrarily designated as isomer 1, isomer 2, etc. While all enantiomers,
5 diastereomers, and mixtures thereof, are contemplated within the present invention, preferred embodiments are single enantiomers and single diastereomers.

It is generally understood by those skilled in this art, that compounds intended for use in pharmaceutical compositions are routinely, though not necessarily, converted to a
10 salt form in efforts to optimize such characteristics as the handling properties, stability, pharmacokinetic, and/or bioavailability, etc. Methods for converting a compound to a given salt form are well known in the art (see for example, Berge, S.M., Bighley, L.D., and Monkhouse, D.C., *J. Pharm. Sci.*, 66:1, (1977)). In that the compounds of the present invention are amines and therefore basic in nature, they readily react with a wide variety
15 of pharmaceutically acceptable organic and inorganic acids to form pharmaceutically acceptable acid addition salts therewith. Such salts are also embodiments of this invention.

Typical inorganic acids used to form such salts include hydrochloric,
20 hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, metaphosphoric, pyrophosphoric acid, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include chloride, bromide, iodide,
25 nitrate, acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, isobutyrate, phenylbutyrate, α -hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, citrate, formate, fumarate, glycolate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate,
30 malonate, mandelate, nicotinate, isonicotinate, oxalate, phthalate, terephthalate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, benzenesulfonate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate (mesylate), naphthalene-1-sulfonate,

naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, p-toluenesulfonate, xylenesulfonate, tartrate, and the like.

It is well known that such compounds can form salts in various molar ratios with the acid to provide, for example, the hemi-acid, mono-acid, di-acid salt, etc. Where in the salt formation procedure, the acid is added in a specific stoichiometric ratio, unless otherwise analyzed to confirm, the salt is presumed, but not known, to form in that molar ratio. Terms such as "(acid)_x" are understood to mean that the molar ratio of the salt formed is not known and can not be presumed, as for example, but without limitation, (HCl)_x and (methanesulfonic acid)_x.

Abbreviations used herein are defined as follows:

- "2B-3 ethanol" means ethanol denatured with toluene.
- "AIBN" means 2,2'-azobisisobutyronitrile.
- "Anal. Calc'd" or "Anal. Calcd" means calculated elemental analysis.
- "APCI" means atmospheric pressure chemical ionization.
- "bp" means boiling point.
- "BINAP" means *rac*-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl.
- "Boc" or "t-Boc" means *tert*-butoxycarbonyl.
- "Brine" means a saturated aqueous sodium chloride solution.
- "CV" means calorific value of oxygen.
- "DBU" means 1,8-diazabicyclo[5.4.0]undec-7-ene.
- "DCE" means 1,2-dichloroethane.
- "DCM" means dichloromethane (i.e. methylene chloride, CH₂Cl₂).
- "DIBAL-H" means diisobutylaluminum hydride.
- "DIEA" means *N,N*-diisopropylethylamine.
- "DMAP" means 4-(dimethylamino)pyridine.
- "DME" means 1,2-dimethoxyethane.
- "DMEA" means *N,N*-dimethylethylamine.
- "DMF" means *N,N*-dimethylformamide.
- "DMSO" means dimethylsulfoxide.
- "DOI" means (±)-1-(2,5-dimethoxy-4-[¹²⁵I]-iodophenyl)-2-aminopropane.
- "EDC" means 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride.

"EDTA" means ethylenediaminetetraacetic acid.

"EE" means energy expenditure.

"EtOAc" means ethyl acetate.

"GC-MS" means gas chromatography – mass spectrometry.

5 "GDP" means guanosine diphosphate.

"GTP" means guanosine triphosphate.

"GTP[³⁵S]" means guanosine triphosphate having the terminal phosphate substituted with ³⁵S in place of an oxygen.

10 "HATU" means O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

"HMPA" means hexamethylphosphoramide.

"HOBT" means 1-hydroxybenzotriazole hydrate.

"HPLC" means high-pressure liquid chromatography.

"HRMS" means high-resolution mass spectrometry.

15 "ISPA" means immunoadsorption scintillation proximity assay.

"*m*-CPBA" means *meta*-chloroperoxybenzoic acid.

"mp" means melting point.

"Ms" in a chemical structure means the methanesulfonyl moiety (-SO₂CH₃).

"MS (ES+)" means mass spectroscopy using electrospray ionization.

20 "MTBE" means methyl *t*-butyl ether.

"NBS" means *N*-bromosuccinimide.

"NMP" means 1-methyl-2-pyrrolidinone.

"NMR" means nuclear magnetic resonance.

"Pd/C" means palladium on activated carbon.

25 "RQ" means respiratory quotient.

"SCX chromatography" means chromatography on an SCX column or cartridge.

"SCX column" or "SCX cartridge", as used herein, refers to a Varian Bond Elute® silica based strong cation exchange resin column or disposable cartridge or equivalent.

30 "Sudan III" means 1- [(4-phenylazo)phenylazo]-2-naphthalenol.

"Tf" in a chemical structure means the trifluoromethanesulfonyl moiety (-SO₂CF₃).

"TFA" means trifluoroacetic acid.

"THF" means tetrahydrofuran.

"TLC" means thin layer chromatography.

While all of the compounds of the present invention are useful as 5-HT_{2C} agonists, certain classes are preferred, as for example, compounds having any of the following

5 enumerated selections of substituents: Compounds wherein

- 1) R⁷ is halo;
- 2) R⁷ is chloro;
- 3) R⁷ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents;
- 4) R⁷ is (C₁-C₃)alkyl optionally substituted with 1 to 6 fluoro substituents;
- 10 5) R⁷ is -CF₃;
- 6) R⁷ is (C₃-C₆)alkenyl optionally substituted with 1 to 6 fluoro substituents;
- 7) R⁷ is (C₃-C₆)alkenyl;
- 8) R⁷ is cyano;
- 9) R¹⁻⁵ are each hydrogen;
- 15 10) R⁴ is methyl or ethyl;
- 11) R⁴ is methyl;
- 12) R³ is methyl;
- 13) R⁸ is hydrogen;
- 14) R⁹ is (C₁-C₃)alkoxy;
- 20 15) R⁹ is methoxy;
- 16) R⁹ is halo;
- 17) R⁹ is chloro;
- 18) R⁶ is -C≡C-R¹⁰;
- 19) R¹⁰ is Ph¹-(C₀-C₃)alkyl;
- 25 20) R¹⁰ is Ph¹-(C₁-C₂)alkyl;
- 21) R¹⁰ is Phenyl(C₀-C₃)alkyl;
- 22) R¹⁰ is (C₃-C₇)cycloalkyl(C₀-C₃)alkyl;
- 23) R¹⁰ is (C₃-C₇)cycloalkylmethyl;
- 24) R¹⁰ is (C₄-C₆)alkyl;
- 30 25) R¹⁰ is branched (C₄-C₆)alkyl;
- 26) R¹⁰ is (C₁-C₆)alkyl substituted with 2-6 fluoro substituents;
- 27) R¹⁰ is Ar¹-(C₀-C₃)alkyl;
- 28) R¹⁰ is Ar¹-(C₁-C₂)alkyl;

- 29) R^6 is $-O-R^{12}$;
30) R^{12} is $Ph^2-(C_0-C_3)alkyl$;
31) R^{12} is $Ph^2-(C_1-C_2)alkyl$;
32) R^{12} is $Ph^2-(C_1-C_2)alkyl$ and Ph^2 is substituted with 1-3 halo substituents;
5 33) R^{12} is $Ph^2-(C_1-C_2)alkyl$ and Ph^2 is substituted with 1-3 fluoro substituents;
34) R^{12} is $Ph^2-(C_1-C_2)alkyl$ and Ph^2 is substituted with cyano;
35) R^{12} is $Ph^2-(C_1-C_2)alkyl$ and Ph^2 is substituted with $R^{30}R^{31}N-S(O)_2$;
36) R^{12} is $Ph^2-(C_1-C_2)alkyl$, Ph^2 is substituted with $R^{30}R^{31}N-S(O)_2$, R^{30} is
10 $(C_1-C_3)alkyl$ optionally further substituted with 1-3 fluoro substituents and
 R^{31} is hydrogen;
37) R^{12} is $Ar^2-(C_0-C_3)alkyl$;
38) R^{12} is $Ar^2-(C_1-C_2)alkyl$;
39) R^{12} is $Ar^2-(C_1-C_2)alkyl$ and Ar^2 is pyridyl, thiazolyl, oxazolyl, or pyrazolyl,
each optionally substituted with methyl;
15 40) R^{12} is benzazolyl- $(C_1-C_3)alkyl$;
41) R^{12} is $Ph^2-C(O)-(C_1-C_3)alkyl$;
42) R^{12} is $Ph^2-C(O)-(C_1-C_3)alkyl$ and Ph^2 is substituted with 1 to 3 halo
substituents;
43) R^{12} is $Ph^2-C(O)-(C_1-C_3)alkyl$ and Ph^2 is substituted with 1 to 3 halofluoro
20 substituents;
44) R^{12} is $Ph^1-S(O)_2$;
45) R^{12} is $(C_1-C_6)alkyl-O-C(O)-(C_3-C_6)alkyl$;
46) R^{12} is $(C_1-C_3)alkyl-O-C(O)-(C_3-C_6)alkyl$;
47) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$;
25 48) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$ and R^{13} is Ph^1 ;
49) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$, R^{13} is Ph^1 ; substituted with 1 to 3 halo
substituents;
50) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$ and R^{13} is $(C_3-C_7)cycloalkyl$;
51) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$ and R^{13} is pyridyl;
30 52) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$ and R^{13} is $(C_1-C_3)alkoxy$;
53) R^{12} is $R^{13}-C(O)NH-(C_2-C_4)alkyl$ and R^{13} is $(C_3-C_7)cycloalkyl$;
54) R^6 is $-S-R^{14}$;
55) R^6 is $-S-R^{14}$ and R^{14} is Ph^2 ;

- 56) R^6 is $-S-R^{14}$, R^{14} is Ph^2 substituted with 1 to 3 halo substituents;
57) R^6 is $-S-R^{14}$, R^{14} is Ph^2 substituted with cyano;
58) R^6 is $-S-R^{14}$, R^{14} is Ph^2 ; substituted with cyano and 1 to 2 halo substituents;
59) R^6 is $-S-R^{14}$ and R^{14} is Ar^2 ;
5 60) R^6 is $-S-R^{14}$, R^{14} is Ar^2 , and Ar^2 is optionally substituted pyridyl or pyridazinyl;
61) R^6 is $-S-R^{14}$, R^{14} is Ar^2 , and Ar^2 is optionally substituted thiophenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl;
62) R^6 is $-S-R^{14}$ and R^{14} is tetrahydrofuranyl or tetrahydropyranyl;
10 63) R^6 is $-S-R^{14}$ and R^{14} is tetrahydrofuranyl or tetrahydropyranyl and the tetrahydrofuranyl or tetrahydropyranyl is substituted with oxo on a carbon adjacent to the ring oxygen;
64) R^6 is $-S-R^{14}$ and R^{14} is $R^{15}-L-$;
65) L is (C_1-C_2) alkylene;
15 66) L is branched (C_2-C_3) alkylene;
67) L is methyl-methylene;
68) L is di-methyl-methylene;
69) L is methyl-ethylene;
70) L is gem-di-methyl-ethylene;
20 71) L is gem-ethano-ethylene;
72) R^{15} is Ph^2 ;
73) R^{15} is Ph^2 substituted with 1 to 3 halo substituents;
74) R^{15} is Ph^2 substituted with cyano;
75) R^{15} is Ph^2 substituted with (C_1-C_6) alkoxy;
25 76) R^{15} is Ph^2 substituted with (C_1-C_6) alkoxy optionally further substituted with 1 to 3 fluoro substituents;
77) R^{15} is Ph^2 substituted with (C_1-C_6) alkoxy (C_1-C_1) alkyl;
78) R^{15} is Ph^2 substituted with (C_1-C_6) alkoxy (C_1-C_1) alkyl further substituted with 1 to 3 fluoro substituents;
30 79) R^{15} is Ph^2 substituted with (C_1-C_6) alkylthio;
80) R^{15} is Ph^2 substituted with (C_1-C_6) alkylthio optionally further substituted with 1 to 3 fluoro substituents;
81) R^{15} is Ph^2 substituted with (C_1-C_6) alkylthio (C_1-C_1) alkyl;

- 82) R^{15} is Ph^2 substituted with $(C_1-C_6)alkylthio(C_1-C_1)alkyl$ further substituted with 1 to 3 fluoro substituents;
- 83) R^{15} is Ph^2 substituted with $(C_3-C_7)cycloalkyl(C_0-C_1)alkyl$;
- 84) R^{15} is Ph^2 substituted with $(C_1-C_6)alkylsulfonyl(C_0-C_1)alkyl$ optionally further substituted with 1 to 3 fluoro substituents;
- 85) R^{15} is Ph^2 substituted with $(C_1-C_6)alkylsulfinyl(C_0-C_1)alkyl$ optionally further substituted with 1 to 3 fluoro substituents;
- 86) R^{15} is Ph^2 substituted with $Ph^1-(C_0-C_1)alkyl-sulfonyl$;
- 87) R^{15} is Ph^2 substituted with $Ph^1-(C_0-C_1)alkyl$;
- 88) R^{15} is Ph^2 substituted with $R^{26}R^{27}N-$;
- 89) R^{15} is Ph^2 substituted with Het^1 ;
- 90) R^{15} is Ph^2 substituted with $(C_1-C_6)alkyl-C(O)-$ optionally further substituted with 1 to 3 fluoro substituents;
- 91) R^{15} is Ph^2 substituted with $(C_1-C_6)alkyl-O-C(O)-$ optionally further substituted with 1 to 3 fluoro substituents;
- 92) R^{15} is Ph^2 substituted with Ph^1 ;
- 93) R^{15} is Ph^2 substituted with $Ph^1(C_0-C_3)alkyl-O-$;
- 94) R^{15} is Ph^2 substituted with $Ph^1(C_0-C_3)alkyl-C(O)-$;
- 95) R^{15} is Ph^2 substituted with $Ph^1(C_0-C_3)alkyl-C(O)-$;
- 96) R^{15} is Ph^2 substituted with $Ar^2(C_0-C_3)alkyl-C(O)-$;
- 97) R^{15} is Ph^2 substituted with $Ar^2(C_0-C_3)alkyl-C(O)-$ and Ar^2 is pyrazolyl optionally further substituted as provided for in Ar^2 ;
- 98) R^{15} is Ph^2 substituted with $R^{28}R^{29}N-C(O)-$;
- 99) R^{15} is Ph^2 substituted with $R^{28}R^{29}N-C(O)-$ and R^{28} is $(C_1-C_6)alkyl$;
- 100) R^{15} is Ph^2 substituted with $R^{28}R^{29}N-C(O)-$ and R^{28} is $(C_3-C_7)cycloalkyl(C_0-C_3)alkyl$;
- 101) R^{15} is Ph^2 substituted with $R^{28}R^{29}N-C(O)-$ and R^{28} is $Ph^1-(C_0-C_2)-n-alkyl$ optionally substituted on the alkyl moiety when present with $(C_1-C_3)alkyl$, dimethyl, or gem-ethano;
- 102) R^{15} is Ph^2 substituted with $R^{28}R^{29}N-C(O)-$ and R^{28} is $Ar^2-(C_0-C_2)-n-alkyl$ optionally substituted on the alkyl moiety when present with $(C_1-C_3)alkyl$, dimethyl, or gem-ethano;
- 103) R^{15} is Ph^2 substituted with $Het^1-C(O)-$;

- 104) R^{15} is Ph^2 substituted with $Het^1-C(O)-$ further substituted with Ph^1 ;
105) R^{15} is Ar^2 ;
106) R^{15} is Ar^2 further substituted with methyl;
107) R^{15} is Ar^2 further substituted with $(C_3-C_7)cycloalkyl(C_0-C_2)alkyl$, Het^1 ,
5 pyridyl, or phenyl optionally further substituted with methyl, $-CF_3$, cyano,
 $-SCF_3$, or with 1 to 3 halo substituents;
108) R^{15} is pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furanyl,
 oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-
10 oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, or 1,3,4-
 thiadiazolyl, any of which may optionally be substituted with 1 to 3
 substituents selected from the group consisting of halo, cyano, $-SCF_3$, $(C_1-$
 $C_6)alkyl$ optionally further substituted with 1 to 6 fluoro, and $(C_1-C_6)alkoxy$
 optionally further substituted with 1 to 6 fluoro.
109) R^{15} is pyridyl optionally further substituted as provided for in Ar^2 ;
15 110) R^{15} is tetrahydrofuranyl or tetrahydropyranyl, either optionally being
 substituted with an oxo substituent, or with one or two groups selected
 independently from methyl and $-CF_3$;
111) R^{15} is tetrahydrofuranyl or tetrahydropyranyl, being substituted with an oxo
 substituent, and optionally being further substituted with one or two groups
20 selected independently from methyl and $-CF_3$;
112) $R^{15}-L-$ is pyrid-2-yl-methyl;
113) $R^{15}-L-$ is pyrid-3-yl-methyl;
114) $R^{15}-L-$ is pyrid-2-yl- $CH(CH_3)-$;
115) $R^{15}-L-$ is pyrid-3-yl- $CH(CH_3)-$;
25 116) R^{15} is pyridazinyl optionally further substituted as provided for in Ar^2 ;
117) $R^{15}-L-$ is pyridazin-2-yl-methyl;
118) $R^{15}-L-$ is pyridazin-3-yl-methyl;
119) $R^{15}-L-$ is pyridazin-2-yl- $CH(CH_3)-$;
120) $R^{15}-L-$ is pyridazin-3-yl- $CH(CH_3)-$;
30 121) R^{15} is pyridyl further substituted with $(C_3-C_7)cycloalkyl(C_0-C_2)alkyl$, Het^1 ,
 pyridyl, or phenyl optionally further substituted with methyl, $-CF_3$, cyano, $-$
 SCF_3 , or with 1 to 3 halo substituents;

- 122) R^{15} is pyridazinyl further substituted with (C_3-C_7) cycloalkyl (C_0-C_2) alkyl, Het¹, pyridyl, or phenyl optionally further substituted with methyl, $-CF_3$, cyano, $-SCF_3$, or with 1 to 3 halo substituents;
- 123) R^{15} is $R^{22}-C(O)-$;
- 5 124) R^{15} is $R^{22}-C(O)-$ and R^{22} is (C_1-C_6) alkyl optionally substituted with 1 to 6 fluoro substituents;
- 125) R^{15} is $R^{22}-C(O)-$ and R^{22} is (C_1-C_6) alkoxy optionally substituted with 1 to 6 fluoro substituents;
- 126) R^{15} is $R^{22}-C(O)-$ and R^{22} is (C_3-C_7) cycloalkyl (C_0-C_3) alkyl;
- 10 127) R^{15} is $R^{22}-C(O)-$ and R^{22} is (C_3-C_7) cycloalkyl (C_0-C_3) alkyl-O-;
- 128) R^{15} is $R^{22}-C(O)-$ and R^{22} is Ph¹-(C_0-C_3)alkyl;
- 129) R^{15} is $R^{22}-C(O)-$ and R^{22} is Ph¹-(C_0-C_3)alkyl-O-;
- 130) R^{15} is $R^{22}-C(O)-$ and R^{22} is Ar²-(C_0-C_3)alkyl;
- 131) R^{15} is $R^{22}-C(O)-$ and R^{22} is Ar²-(C_0-C_3)alkyl-O-;
- 15 132) R^{15} is $R^{22}-C(O)-$ and R^{22} is $R^{32}R^{33}N-$;
- 133) R^{15} is phthalimido;
- 134) R^{15} is $R^{17}R^{18}N-$;
- 135) R^{15} is $R^{17}R^{18}N-$ and R^{17} is (C_1-C_3) alkoxy-C(O)-;
- 136) R^{15} is $R^{17}R^{18}N-$ and R^{17} is (C_3-C_7) cycloalkyl $(C_0-C_2)-C(O)-$;
- 20 137) R^{15} is $R^{17}R^{18}N-$ and R^{17} is Ph¹-(C_0-C_2)-C(O)-;
- 138) R^{15} is $R^{17}R^{18}N-$ and R^{17} is Ar²-(C_0-C_2)-C(O)-;
- 139) R^{15} is $R^{16}O-$;
- 140) R^{15} is $R^{16}O-$ and R^{16} is (C_1-C_6) alkoxy-C(O)-;
- 141) R^{15} is $R^{16}O-$ and R^{16} is (C_3-C_7) cycloalkyl $(C_0-C_2)-C(O)-$;
- 25 142) R^6 is $R^{24}R^{25}N-$ and R^{24} is (C_1-C_6) alkoxy (C_2-C_5) alkyl optionally substituted with 1 to 6 fluoro substituents;
- 143) R^6 is $R^{24}R^{25}N-$ and R^{24} is (C_1-C_6) alkylthio (C_2-C_5) alkyl optionally substituted with 1 to 6 fluoro substituents;
- 144) R^6 is $R^{24}R^{25}N-$ and R^{24} is (C_3-C_7) cycloalkyl (C_0-C_1) alkyl-O- (C_1-C_5) alkyl;
- 30 145) R^6 is $R^{24}R^{25}N-$ and R^{24} is (C_3-C_7) cycloalkyl (C_0-C_1) alkyl-S- (C_1-C_5) alkyl;
- 146) R^6 is $R^{24}R^{25}N-$ and R^{24} is phenyl (C_1-C_3) *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano;

- 147) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ph^2-(C_1-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano;
- 148) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano;
- 5 149) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano, wherein Ar^2 contains a nitrogen atom, and Ar^2 is substituted;
- 150) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano, wherein Ar^2 contains a nitrogen atom, and Ar^2 is substituted with
10 (C_1-C_6) alkoxy optionally further substituted with 1 to 6 fluoro, (C_1-C_6) alkylamino optionally further substituted with 1 to 6 fluoro, or (C_3-C_7) cycloalkyl (C_0-C_2) alkyl optionally further substituted with 1 to 6 fluoro;
- 151) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano, and wherein Ar^2 is pyridyl or pyridazinyl and is substituted with (C_1-C_6) alkoxy optionally further substituted with 1 to 6 fluoro, (C_1-C_6) alkylamino optionally further substituted with 1 to 6 fluoro, or
20 (C_3-C_7) cycloalkyl (C_0-C_2) alkyl optionally further substituted with 1 to 6 fluoro;
- 152) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl optionally substituted on the *n*-alkyl moiety when present with (C_1-C_3) alkyl, dimethyl, or gem-ethano, and wherein Ar^2 is pyridyl substituted with $R^{28}R^{29}N-C(O)$ - and R^{28} is
25 (C_3-C_7) cycloalkyl (C_0-C_2) alkyl or Ph^1 and R^{29} is hydrogen;
- 153) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ar^2(C_0-C_3)$ *n*-alkyl, wherein Ar^2 is pyridyl substituted with $R^{28}R^{29}N-C(O)$ - and R^{28} is (C_3-C_7) cycloalkyl or phenyl optionally substituted with 1 to 3 halo, preferably fluoro, and R^{29} is hydrogen;
- 154) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ph^1-(C_0-C_1)$ alkyl-O- (C_1-C_5) alkyl;
- 155) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ph^1-(C_0-C_1)$ alkyl-S- (C_1-C_5) alkyl;
- 156) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ph^1-(C_0-C_1)$ alkyl-C(O)NH- (C_2-C_4) alkyl;
- 157) R^6 is $R^{24}R^{25}N$ - and R^{24} is $Ph^1-(C_0-C_1)$ alkyl-NH-C(O)NH- (C_2-C_4) alkyl;
- 30

158) R^6 is $R^{24}R^{25}N$ - and R^{24} is pyridyl- (C_0-C_1) alkyl-C(O)NH- (C_2-C_4) alkyl optionally substituted on the pyridyl moiety with methyl, $-CF_3$, or 1 to 3 halo substituents;

159) R^6 is $R^{24}R^{25}N$ - and R^{24} is pyridyl- (C_0-C_1) alkyl-NH-C(O)NH- (C_2-C_4) alkyl optionally substituted on the pyridyl moiety with methyl, $-CF_3$, or 1 to 3 halo substituents;

160) R^6 is $R^{24}R^{25}N$ - and R^{24} is Ar^3 -(C_1-C_2)alkyl;

161) R^6 is $R^{24}R^{25}N$ - and R^{24} is Ar^3 -methyl;

It will be understood that the above classes may be combined to form additional preferred classes. Exemplary combinations include, but are not limited to:

162) Any one of preferred embodiments 19) through 161) (the preferred selections for R^6), combined with any one of preferred embodiments 1) through 9) (the preferred selections for R^7);

163) Any one of preferred embodiments 19) through 161) (the preferred selections for R^6), wherein R^7 is halogen;

164) Any one of preferred embodiments 19) through 161) (the preferred selections for R^6), wherein R^7 is chloro;

165) A preferred combination according to 162), 163), or 164), wherein R^{1-5} , and R^8 are each hydrogen;

166) A preferred combination according to 162), 163), or 164), wherein R^{1-5} , R^8 and R^9 , are each hydrogen.

167) Any one of preferred embodiments 37), 38), or 39), wherein R^7 is other than hydrogen;

168) Any one of preferred embodiments 37), 38), or 39), wherein R^9 is hydrogen;

169) Any one of preferred embodiments 37), 38), or 39), wherein R^7 is other than hydrogen and R^9 is hydrogen;

170) Any one of preferred embodiments 37), 38), or 39), wherein R^7 is chloro and R^9 is hydrogen;

Generally, when R^6 is $-S-R^{14}$, then $R^{15}-L$ - is the more preferred R^{14} . When R^{14} or R^{15} is substituted Ar^2 , para-substitution is preferred. When L is present, particularly

preferred are methylene, and methyl-methylene. Particularly preferred R^{15} -L- is when R^{15} is Ph^2 and L is methylene. Also particularly preferred is when R^{15} is Ph^2 and L is methyl-methylene. Also particularly preferred is when R^{15} is Ar^2 and L is methylene. Also particularly preferred is when R^{15} is Ar^2 and L is methyl-methylene.

Also generally, when R^6 is $-NR^{24}R^{25}$, then $Ph^2-(C_1-C_3)$ -*n*-alkyl is particularly preferred over phenyl(C_1-C_3)-*n*-alkyl.

10


The compounds of the invention can be prepared according to the following synthetic schemes by methods well known and appreciated in the art. Suitable reaction conditions for the steps of these schemes are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Likewise, it will be appreciated by those skilled in the art that synthetic intermediates may be isolated and/or purified by various well known techniques as needed or desired, and that frequently, it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, the skilled artisan will appreciate that in some circumstances, the order in which moieties are introduced is not critical. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound being synthesized, the starting compound, and the relative liability of the substituted moieties as is well appreciated by those of ordinary skill in the art. All substituents, unless otherwise indicated, are as previously defined, and all reagents are well known and appreciated in the art.

25

Compounds of Formula I where R^6 is an acetylene-linked substituent may be prepared as illustrated in Scheme I where Pg is a suitable protecting group for a secondary amine such as, but not limited to, 2,2,2-trifluoroacetyl or *tert*-butoxycarbonyl, and variables R^1 , R^2 , R^4 , R^5 , R^7 , R^8 , R^9 and R^{10} are as previously defined.

30


Scheme I




5 Mix the 6-triflate of the 2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepines (a) with an appropriately substituted acetylene, a suitable palladium/copper catalyst mixture in a solvent, typically DMF, using triethylamine as base, and heat to afford the desired compound (b). Deprotection reaction and the standard extractive and chromatographic techniques afford the desired compound (1a).

10 The appropriate 6-triflate of 2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepines (a) may be prepared as described in Scheme II. Compound (a) may be prepared from 1-naphthol. 1-Naphthol can be converted to 5-hydroxy-1,4-dihydronaphthalene (c) by Birch reduction using ammonia and lithium metal at low temperature. Methylation of the 6-hydroxy
15 group affords the compound (d). Ozonolysis of (d) and subsequent reduction with sodium borohydride provide the diol (e). After converting the two hydroxyl groups into two good leaving groups, for example methanesulfonates, cyclize the compound (f) to the 6-methoxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepines (g) with aqueous ammonia under pressure. Protect the ring nitrogen with a variety of alkyl halides, acid chlorides or
20 anhydrides such as trifluoroacetic anhydride to give compound (h). Subsequently convert the methyl ether (h) to the phenol (i) with BBr₃ in dichloromethane or other methods well known in the literature [see for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and sons, Chapter III, New York (1999)].

25 Functionalization of the aromatic ring to introduce substituents R⁷, R⁸ and R⁹ are well known in the art and very depending on the substitution desired. Subsequent trifluoromethanesulfonylation of the 6-hydroxy (j) affords the desired 2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepines (a).

Scheme II


Alternately, compound (g) could be prepared from 1,2-bis(cyanomethyl)-3-methoxybenzene (l), previously described in the literature (*J. Med. Chem.* 1984, 27, 918-921), as shown in Scheme III below.

Scheme III

10

Compounds of Formula I where R^6 is an oxygen-linked substituent may be prepared as illustrated in Scheme IV where Pg is a suitable protecting group for secondary amine, such as 2,2,2-trifluoroacetyl or tert-butoxycarbonyl, and variables R^7 , R^9 and R^{12} are as previously defined.

15


Scheme IV

5 Compound (m) can be prepared by treating 6-hydroxy-2,3,4,5-tetrahydro-1H-benzo[d]azepines (j) with an appropriate alkylation reagent, such as an alkyl halide or sulfonate, and a base in a suitable solvent, typically acetone, ethanol or acetonitrile, followed by the standard extractive and chromatographic techniques. Deprotection of the ring nitrogen gives the compound (1b). Alternately, compound (m) can be obtained by
 10 Mitsunobu reaction with an appropriate alcohol, a phosphine reagent such as triphenylphosphine, and diethyl azodicarboxylate (DEAD) or 1,1'-(azodicarbonyl)-dipiperidine in an anhydrous solvent, for example THF.


15 Compounds of Formula Ic where R⁶ is a nitrogen-linked substituent may be prepared as illustrated in the Scheme V. The 6-triflate protected 2,3,4,5-tetrahydro-1H-benzo[d]azepines (a) can be converted to the compounds (n), under Buchwald conditions, by treatment with an appropriate amine (q) in the presence of an effective palladium catalyst, and a base in a suitable solvent, typically toluene or 1,4-dioxane under an inert atmosphere. Introduction of a second substituent R²⁵, if needed, may be performed.
 20 Standard work-up and chromatographic techniques followed by deprotection, give the compound (1c).

25 Alternately 6-amino-2,3,4,5-tetrahydro-1H-benzo[d]azepines (p) can be transformed to the desired compounds (n) by reaction with an appropriate bromide (r), and an appropriate base in a suitable solvent.

Bromides (r) are either commercially available or may be prepared by methods well known to the skilled artisan. Amines (q) are either commercially available or may be prepared by methods well known to the skilled artisan.

Scheme V

- 5 Compounds of Formula I where the R⁶ is a sulfur-linked substituent may be prepared as illustrated in the Scheme VI.

Scheme VI

Heat the appropriately substituted 3-(tert-butoxycarbonyl-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine (s) with an appropriate base in a suitable solvent, such as methanol, to obtain the intermediate thiol (t). Isolate the intermediate thiol (t), if required, and treat it with an appropriate electrophile (halide or alkyl sulfonate). Isolate the compound (u) by standard extractive and chromatographic techniques and deprotect to afford the desired compound (Id).

The requisite halides or alkyl sulfonates are either commercially available or may be prepared by methods well known to the skilled artisan.

The skilled artisan will also appreciate that not all of the substituents in the compounds of Formula I will tolerate certain reaction conditions employed to synthesize the compounds. These moieties may be introduced at a convenient point in the synthesis, or may be protected and then deprotected as necessary or desired, as is well known in the art. The skilled artisan will appreciate that the protecting groups may be removed at any convenient point in the synthesis of the compounds of the present invention. Methods for introducing and removing protecting groups used in this invention are well known in the art; see, for example, Greene and Wuts, *Protective Groups in Organic Synthesis*, 3rd Ed., John Wiley and sons, New York (1999).

The following Preparations and Examples are illustrative of methods useful for the synthesis of the compounds of the present invention. Exemplified compounds are also particularly preferred compounds of the present invention.

General Procedure 1-1.

Dissolve the appropriately substituted 3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine in ammonia/methanol solution (1.0–7.0 M). Stir for 1–16 h at ambient temperature unless otherwise specified. Remove the volatiles *in vacuo*. Purify by chromatography on silica gel eluting with 1–20% 2M ammonia/methanol in DCM, or by SCX chromatography eluting with 1.0–7.0 M ammonia in methanol.

General Procedure 1-2

Dissolve the appropriately substituted 3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 equiv.) in methanol. Add a 0.5 M aqueous solution of potassium carbonate (4.0 equiv.) and stir at ambient temperature for 6 h. Concentrate *in vacuo* and partition the residue between water and DCM. Extract the aqueous phase twice with DCM. Dry the combined organic extracts over Na₂SO₄, filter and concentrate *in vacuo*. If needed, purify by chromatography on silica gel eluting with 1-20% 2M ammonia/methanol in DCM, or by SCX chromatography eluting with 1.0-7.0 M ammonia in methanol.

10

General Procedure 1-3

Dissolve the appropriately substituted 3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 equiv.) in methanol or ethanol (0.1 to 2M solution) and add from 10-50% by volume of a 1.0-5.0 N aqueous solution of sodium hydroxide or lithium hydroxide. Stir the reaction mixture at ambient temperature for 0.25-16 h and concentrate *in vacuo*. Partition the residue between EtOAc or DCM and water. Separate and dry the organic fraction over Na₂SO₄, filter, and concentrate *in vacuo*. Purify by SCX chromatography, followed by chromatography on silica gel eluting with 1-20% 2M ammonia/methanol in DCM or reverse phase HPLC.

15
20**General Procedure 1-4**

Dissolve the appropriately substituted 3-*tert*-butoxycarbonyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in 4M hydrogen chloride in dioxane or 1M hydrogen chloride in ethyl ether and stir the mixture for 2-16 h at ambient temperature unless otherwise specified. Remove the solvent *in vacuo*. If a solid is obtained, wash the solid with ether and filter under vacuum to afford the desired hydrochloride salt. If an oil is obtained, dissolve the oil in the minimal volume of DCM, methanol or EtOAc and add ether to precipitate out the solid. Remove the solvent *in vacuo*, wash the solid with ether and filter. Dry the solid *in vacuo* or under a stream of nitrogen.

25
30**General Procedure 1-5**

Dissolve the appropriately substituted 3-*tert*-butoxycarbonyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in a mixture of trifluoroacetic acid/DCM (from 1:0 to 1:10 ratio) and

stir the reaction for 1-16 h at ambient temperature. Concentrate *in vacuo* and either subject the residue to SCX chromatography or partition the residue between saturated aqueous NaHCO₃ and DCM or EtOAc. Dry the organic layer over Na₂SO₄ and concentrate *in vacuo*. Purify by either chromatography on silica gel (eluting with 1-20%
5 2M ammonia/methanol in DCM) or reverse phase HPLC.

General Procedure 1-6

Add acetyl chloride (40 equiv.) to cold methanol (0 °C) and stir for 5 min. Then add a solution of the appropriately substituted 7-chloro-3-(*tert*-butoxycarbonyl)-2,3,4,5-
10 tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.) in methanol. Stir the reaction at ambient temperature for 12 h. Remove the solvent *in vacuo*, basify with saturated aqueous NaHCO₃ and extract three times with DCM. Dry the combined organic extracts over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel, eluting with 1-20% 2M ammonia/methanol in DCM.
15

General Procedure 2-1

Dissolve the purified free base (1 equiv.) in acetone, ether or methanol and add a solution of succinic acid (1 equiv.) in a minimal volume of acetone or methanol. Stir for 1 h at ambient temperature. Concentrate to an oil, add a minimal volume of DCM and
20 ethyl ether to precipitate out the salt. Alternatively, to precipitate out the salt, allow the reaction mixture to stand 1-16 h at ambient temperature, 4 °C or -10 °C and add ether or hexane. Filter and wash the solid with ether or hexane to obtain the succinate salt. Alternatively, evaporate the solvent *in vacuo*, wash the solid with ether and filter or decant the solvent to obtain the succinate as a solid. Dry the solid *in vacuo* or under a
25 stream of nitrogen.

General Procedure 2-2

Dissolve the purified free base (1 equiv.) in a minimal volume of acetone, dioxane, methanol or DCM and add an excess of 4M hydrogen chloride in dioxane or a
30 1M solution of hydrogen chloride in ethyl ether. Stir for 1 h and evaporate the solvent to obtain the salt as a solid. Alternatively, allow the reaction mixture to stand 1 to 16 h at ambient temperature and add ether or hexane to precipitate out the salt. Filter and wash the solid with ether or hexane to obtain the salt as a solid. Alternatively, evaporate the

solvent *in vacuo*, wash the solid with ether, filter or decant the solvent to obtain the hydrochloride salt as a solid. Dry the solid *in vacuo* or under a stream of nitrogen.

General Procedure 2-3

5 Dissolve the purified free base in methanol, add a solution of ammonium chloride (1 equiv.) in methanol and stir for 1 h. Slowly remove the volatiles *in vacuo*. Dissolve the residue in methanol and remove most of the solvent *in vacuo*. Add anhydrous ethyl ether or EtOAc to precipitate out the hydrochloride salt. Collect the solid, wash the solid with ether and then dry the solid *in vacuo* or under a stream of nitrogen.

10

General Procedure 2-4

 Dissolve the purified free base (1.0 equiv.) in methanol. Add a 0.5 M solution of methanesulfonic acid in methanol (2.0 equiv). Mix well, stir for 1 h, then remove the solvent *in vacuo*. Dissolve the residue into a minimal volume of DCM. Add ethyl ether
15 to precipitate out the solid. Remove the solvent *in vacuo* to form a foam. Dry *in vacuo* or under a stream of nitrogen to obtain the methanesulfonic acid salt.

General Procedure 2-5

 Dissolve the purified free base (1 equiv.) in a minimal volume of acetone and add
20 a solution of oxalic acid (1 equiv.) in a minimal volume of acetone. Allow the mixture to stand 10 min to 16 h at ambient temperature to -10°C, and/or add ether or hexane to precipitate out the solid. Filter and wash the solid with ether or hexane to obtain the oxalic acid salt as a solid. Dry the solid *in vacuo* or under a stream of nitrogen.

25


General Procedure 3

 Dissolve the appropriately substituted 3-*tert*-butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.),
PdCl₂(PPh₃)₂ (0.1 equiv.), tetrabutyl ammonium iodide (3 equiv.), and copper(I) iodide
(0.3 equiv.) in triethylamine/DMF (1:5). Stir the mixture for 5 min at ambient
30 temperature, add the appropriately substituted acetylene (2 equiv.) and heat at 70 °C for 2-16 h in a sealed tube. Cool the reaction mixture to ambient temperature, dilute with EtOAc/hexane (1:1) and wash with water. Dry the organic fraction over Na₂SO₄, filter

and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures.

Preparation 1

5 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine



- 10 **5-Methoxy-1,4-dihydronaphthalene:** Add powdered potassium carbonate (193.1 g, 1.397 mol) to a solution of 5-hydroxy-1,4-dihydronaphthalene [68.08 g, 90% potency based on ¹H-NMR, 0.4657 mol, from Societa Italiana Medicinala Scandicci, s.r.l., Reggello (Firenze), Italy] in ethanol (700 mL). Cool the solution to 0°C with ice/water and add dimethyl sulfate (88.1 g, 66.1 mL, 0.699 mol) dropwise, maintaining the
- 15 temperature between 5°C and 10°C. Then heat the reaction mixture to 40°C until the TLC (10:1 hexane/EtOAc) shows the absence of starting material (about 2 h). Filter off the solids by vacuum filtration and remove the solvent *in vacuo*. Dilute the residual brown oil with diethyl ether (500 mL), wash with 10% aqueous NH₄OH (500 mL), water (500 mL), brine (500 mL), dry the organic layer over Na₂SO₄, filter and concentrate *in*
- 20 *vacuo* to give the crude product as a brown oil (73 g). Purify the crude product by short path distillation under vacuum (bp 120-130°C/ 5 Torr) to give the desired intermediate as a clear oil (69.0 g, 92.5% potency corrected) (contains some 1,2,3,4-tetrahydro-5-methoxynaphthalene as an impurity). ¹H NMR (300 MHz, CDCl₃), δ 7.15 (t, 1H, *J* = 7.9),

6.72 (dd, 2H, $J = 15.7, 7.9$), 5.93-5.88 (m, 2H), 3.83 (s, 3H), 3.42-3.39 (m, 2H), 3.30-3.28 (m, 2 H); $R_f = 0.58$ eluting with 10:1 hexane/EtOAc.

2,3-Bis-(2-hydroxyethyl)-1-methoxybenzene: Charge a four-neck 5 L flask equipped
5 with an over-head mechanical stirrer, reflux condenser, thermocouple, and gas dispersion
apparatus with 5-methoxy-1,4-dihydronaphthalene (264.54 g, 89.5% potency based on
 ^1H -NMR, 1.478 mol) in DCM (1.3 L) and 2B-3 ethanol (1 L). Add sudan III (10 mg) to
give a faint red color. Cool the solution to -65°C or lower, then pass O_3 through the
solution until the solution turns a light yellow color and the TLC (10:1 hexane/EtOAc,
10 KMnO_4 stain) shows the absence of the starting material (about 30 h). Transfer the
solution via cannula into a slurry of NaBH_4 (97.8 g, 2.59 mol) in 2B-3 ethanol (500 mL)
cooled in ice/water. It is important that the temperature be maintained at or above 0°C , as
for example between 0°C and 10°C , throughout the transfer to ensure the ozonide is
completely reduced to the diol. After the transfer is complete, warm the solution to
15 ambient temperature and stir for about 30 min. Cool the slurry to 0°C with ice/water then
slowly add acetone (540 mL, 7.4 mol) to remove excess NaBH_4 . After all the solids
dissolve, remove the solvent *in vacuo*. Dissolve the yellow solid in DCM (1 L) and water
(1 L), separate the layers and extract the aqueous layer with DCM (750 mL). Wash the
combined organic layers with brine (1.5 L), add toluene (750 mL) and remove the solvent
20 *in vacuo*. Dissolve the solid in DCM (500 mL) with heating, then add toluene (750 mL)
and concentrate the solution *in vacuo* to give the desired intermediate as a light yellow
solid (283.7 g, 89% potency corrected, mp $82-83^\circ\text{C}$) (contains 1,2,3,4-tetrahydro-5-
methoxynaphthalene as an impurity (8.6%)). Further purify the product by vacuum drying
overnight at 75°C , 5 Torr, to remove all but trace amount of the 1,2,3,4-tetrahydro-5-
25 methoxynaphthalene impurity. ^1H NMR (300 MHz, CDCl_3), δ 7.16 (dd, 1H, $J = 8.2,$
7.6), 6.83 (s, 1H, $J = 7.0$), 6.76 (s, 1H, $J = 8.2$), 3.85-3.77 (m, 7H), 3.01-2.91 (m, 4H),
2.35 (s, 2H); ^{13}C NMR (300 MHz, $\text{DMSO}-d_6$), δ 157.5, 138.9, 126.5, 125.2, 122.0, 108.4,
62.1, 60.5, 55.3, 36.1, 29.6; IR (KBr): 3006, 2960, 2886, 2829, 1583, 1461, 1440, 1264,
1091, 1041 cm^{-1} ; MS (ES+) m/z 178 ($\text{M}+\text{H}^+$); Anal. Calc'd for $\text{C}_{11}\text{H}_{16}\text{O}_3$: C, 67.32; H,
30 8.22; N, 0. Found: C, 67.26, H, 8.10, N, 0.21; $R_f = 0.23$ eluting with 95:5
DCM/methanol.

2,3-Bis-(2-methanesulfonyloxyethyl)-1-methoxybenzene: To a slurry of 2,3-bis-(2-hydroxyethyl)-1-methoxybenzene (50.6 g, 0.258 mol, 1 equiv.) and triethylamine (78.3 g, 0.774 mol, 3 equiv.) in DCM (500 mL) at 0°C, add dropwise a solution of methanesulfonyl chloride (65.0 g, 0.567 mol, 2.2 equiv.) in DCM (100 mL) over 45 min.

5 The addition is exothermic and the methanesulfonyl chloride is added at a rate to keep the temperature below 10°C. After the addition is complete, warm the reaction to ambient temperature. Wash the solution with water (2 x 500 mL), and then brine (750 mL). Dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo* to obtain the desired intermediate as a dark yellow oil (87.4 g, 96.2%), which is used in the next reaction
10 without further purification. An analytical sample is obtained by flash column chromatography eluting with 100% diethyl ether. ¹H NMR (300 MHz, CDCl₃), δ 7.20 (t, 1H, *J* = 7.9), 6.82 (s, 1H, *J* = 7.2), 6.80 (s, 1H, *J* = 8.2), 4.41-4.34 (m, 4H), 3.83 (s, 3H), 3.16-3.09 (m, 4H), 2.91 (s, 3H), 2.87 (s, 3H); ¹³C NMR (300 MHz, CDCl₃), δ 158.07, 136.55, 128.26, 123.34, 122.39, 109.24, 69.88, 69.08, 55.55, 37.35, 37.14, 32.57, 26.47;
15 ¹³C NMR (300 MHz, DMSO-*d*₆), δ 157.58, 136.79, 127.81, 122.91, 122.00, 109.33, 70.19, 68.88, 55.55, 36.49, 36.47, 31.56, 25.72; IR (KBr): 1586.8, 1469.4, 1358.51, 1267.3, 1173.9, 1105.4, 972.4, 954.6, 914.3 cm⁻¹; MS (ES+) *m/z* 257 (M+H)⁺; Anal. Calc'd. for C₁₃H₂₀O₇S₂: C, 44.31; H, 5.72; N, 0. Found: C, 44.22, H, 5.68, N, 0.13; R_f = 0.72 eluting with 95:5 DCM/methanol.

20

6-Methoxy-2,3,4,5-tetrahydro-1H-benzodiazepine: Dissolve 2,3-bis-(2-methanesulfonyloxyethyl)-1-methoxybenzene (474.4 g, 1.346 mol) in acetonitrile (7 L) and split the mixture into two equal lots. In two separate runs, add concentrated aqueous NH₄OH (3.5 L) and charge the solution to a pressure vessel (PARR apparatus). Heat the
25 solution in a closed reactor to 100°C over 20 min (internal pressure reaches about 100 psi), and maintain at 100°C until the reaction is complete (about 1 h, HPLC monitored). Cool the reaction mixture to ambient temperature. Combine the two lots and remove the solvent *in vacuo*. Dissolve the residue in MTBE (3.5 L) and water (3.5 L). Adjust the pH to 6.5 using 2M aqueous NaOH or 1M aqueous HCl as appropriate (typically the pH is
30 about pH=5.1 and the adjustment requires about 50 mL 2M aqueous NaOH). Discard the organic layer, adjust the aqueous layer to pH=13 using 50% NaOH (about 150 mL). Extract with MTBE (2 x 3.5 L), wash the combined organic layers with brine (3.5 L), dry over Na₂SO₄, filter and concentrate *in vacuo* to give the title compound as a crude yellow

oil that solidifies upon standing (179.3 g). Use the material for the next step without further purification. Prepare an analytical sample by purification by two Kugelrohr distillations to give a clear oil that solidifies upon standing, mp 44.3-45.0°C. ¹³C NMR (300 MHz, DMSO-*d*₆) δ 156.1, 144.4, 130.3, 126.2, 121.5, 108.9, 55.5, 48.2, 47.9, 39.9, 29.1; MS (ES+) *m/z* 163 (M+H)⁺; Anal. Calc'd for C₁₁H₁₅NO: C, 74.54; H, 8.53; N, 7.90. Found: C, 74.28, H, 8.62, N, 7.86.

6-Methoxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride: Dissolve crude 6-methoxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (35.1 g, 0.198 mol) in 2B-3 ethanol (250 mL), heat the solution to reflux and add 2M HCl in ethanol (108.9 mL, 0.218 mol, 1.1 equiv.). Slowly add heptane (700 mL) over 10 min, then remove the heating mantle and cool the solution to ambient temperature, and finally continue the cooling with an ice/water mixture. Collect the resulting solid by vacuum filtration and wash with cold ethanol:heptane (1:2) (3 x 100 mL), air-dry for 15 min under vacuum, then further dry the product in a vacuum oven at 60°C for 1 h to give the desired intermediate as a white granular solid (35.53 g, 63%): mp 246.6-246.9°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.82 (broad s, 1H), 7.12 (dd, 1H, *J* = 7.6, 7.9), 6.88 (d, 1H *J* = 8.2), 6.78 (d, 1H, *J* = 7.3), 3.75 (s, 3H), 3.20-3.00 (m, 8H); ¹³C NMR (300 MHz, DMSO-*d*₆) δ 156.2, 141.3, 127.4, 127.2, 121.6, 109.7, 55.7, 44.9, 44.7, 31.6, 21.7; MS (ES+) *m/z* 178 (M+H)⁺; Anal. Calc'd for C₁₁H₁₅ClNO: C, 62.12; H, 7.11; N, 6.59. Found: C, 61.95, H, 7.64, N, 6.58.

6-Methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: To a slurry of 6-methoxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine hydrochloride (35.3 g, 0.165 mol, 1 equiv.) and triethylamine (69.1 mL, 0.496 mol, 3 equiv.) in DCM (300 mL) cooled at 0°C with ice/water, add dropwise a solution of trifluoroacetic anhydride (25.7 mL, 0.182 mol, 1.1 equiv.) in DCM (40 mL) over 30 min, but at a rate that maintains the temperature below 10°C. After the addition is complete, warm the reaction mixture to ambient temperature and stir until the reaction is complete (verify by TLC using 9:1 CH₂Cl₂:methanol, about 2 h.). Wash the solution with water (2 x 350 mL), and then brine (350 mL), dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo* to give desired intermediate as a yellow oil that solidifies upon standing (44.9 g, 96%). Use the material without further purification in the next step. Prepare an analytical sample by chromatography on silica gel eluting with 40% diethyl ether in hexane, mp 74-76°C. ¹H

NMR (300 MHz, CDCl₃), δ 7.16-7.11 (m, 1H), 6.81-6.74 (m, 2H), 3.81 (s, 3H), 3.79-3.64 (m, 4H), 3.11-3.07 (m, 2H), 2.99-2.95 (m, 2H); ¹H NMR (300 MHz, DMSO-*d*₆), δ 7.13 (dd, 1H, *J* = 1.5, 7.0), 7.08 (d, 1H, *J* = 1.5), 6.88-6.74 (m, 1H), 3.75 (s, 3H), 3.67-3.61 (m, 4H), 3.04-2.92 (m, 4H); ¹³C NMR (300 MHz, DMSO-*d*₆), δ 156.43, 156.38, 155.06, 155.00, 154.60, 154.54, 154.14, 154.08, 141.31, 141.04, 127.44, 127.18, 127.05, 127.01, 122.27, 121.94, 121.90, 118.46, 114.64, 110.80, 109.52, 109.41, 55.63, 55.61, 47.11, 47.07, 46.67, 46.63, 45.61, 45.16, 35.90, 34.65, 26.18, 24.91; Anal. Calc'd for C₁₃H₁₄F₃NO₂: C, 57.14; H, 5.16; N, 5.13. Found: C, 57.17, H, 5.27, N, 5.08.

- 10 **6-Hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** To a 1M solution of BBr₃ (1.1 L, 1.6 equiv.), cooled at 0°C with an ice-water bath, add 6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (187 g, 0.684 mol) in DCM (200 mL) over 1 h., while maintaining the temperature between 0°C and 10°C. Warm the reaction mixture to ambient temperature and stir until HPLC indicates
- 15 completion of the reaction (about 2 h.). Cool the solution to 0°C and transfer it via cannula into an ice/water solution (1.2 L), thereby precipitating the product as a white solid. Add EtOAc (2 L) to dissolve most of the precipitate, separate the layers and concentrate the organic layer *in vacuo*. Extract the aqueous layer three times with EtOAc (2 x 2 L, 1 x 1 L). Wash the combined organic layers with water (2 L), and then brine (2
- 20 L), dry over Na₂SO₄, filter and concentrate *in vacuo* to give the desired intermediate as a light yellow solid (166.3 g, 94%). Use the product for the next step without further purification. Prepare an analytical sample by chromatography on silica gel eluting with 40% diethyl ether in hexane: mp 183.0-185.2°C. ¹H NMR (300 MHz, DMSO-*d*₆), δ 9.39 (s, 1H), 6.94-6.88 (m, 1H), 6.72-6.68 (m, 1H), 6.61-6.57 (m, 1H), 3.67-3.32 (m, 4H),
- 25 2.99-2.86 (m, 4H); ¹³C NMR (300 MHz, DMSO-*d*₆), δ 154.50, 141.47, 141.18, 126.77, 126.64, 125.77, 125.33, 120.38, 120.32, 118.49, 114.67, 113.64, 113.47, 47.31, 47.27, 47.00, 46.96, 45.83, 45.49, 36.17, 34.93, 26.46, 25.18, 20.66, 14.00; MS (ES+) *m/z* 260 (M+H)⁺; Anal. Calc'd. for C₁₂H₁₂F₃NO₂: C, 55.60; H, 4.67; N, 5.40. Found: C, 55.51, H, 4.71, N, 5.29

30

7-Chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Heat a mixture of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (120 g, 0.4629 mol) and toluene (14.4 L) to 70°C for 45 min until most

of the starting material is dissolved. Add diisobutylamine (1.197 g, 1.62 mL, 9.26 mmol) followed by addition of sulfonyl chloride (62.48 g, 37.19 mL, 0.463 mol) in toluene (360 mL) over 20 min. Stir the reaction mixture for 50 min and then add additional sulfonyl chloride (4.536 g, 2.70 mL, 0.0336 mol) neat and stir the reaction mixture for 15 min at 70°C. Cool the reaction mixture to 24°C over 30 min and then add 1N hydrochloric acid (2.00 L). Separate, wash the organic layer with saturated aqueous NaHCO₃ (2.00 L), brine (2.00 L) and then dry over Na₂SO₄. Filter and remove the solvent with a rotary evaporator at 70°C until about 672.5 g remains using the minimum effective vacuum in order to maintain a vapor phase sufficient to prevent drying above the solvent line and self-seeding, thus preventing crystallization under these conditions. Using toluene heated to 70°C, transfer the light-yellow solution to a preheated (70°C) 3-neck flask equipped with a mechanical stirrer. Lower the temperature to 58°C over 1 h. If available, seed the solution with crystals of 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine from a prior synthesis to enhance crystallization. After 30 min, reduce the temperature further to 55°C and observe the initiation of the crystallization process. Hold the temperature at 55°C for 2 h. followed by 4 h. at 45°C, then turn off the heat allowing the mixture to slowly reach 24°C (ambient temperature). After stirring for 8 h. with the heat off, cool the mixture to 0°C for 2 h. followed by 2 h. at -10°C. Collect the resulting dense, white, granular crystals by vacuum filtration at -10°C. Rinse the crystals twice with cold (-10°C) toluene and vacuum dry at 50°C, 5 Torr, for 12 h., to obtain the desired intermediate as a white solid (120.7 g, 99.5% purity, 88.8%): mp 133-134°C. MS (ES+) *m/z* 294 (M+H)⁺. Anal. Calc'd for C₁₂H₁₁ClF₃NO₂: C, 49.08; H, 3.78; N, 4.77; Cl, 12.07. Found: C, 49.01; H, 3.63; N, 4.72; Cl, 12.32.

7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Cool a solution of 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (60 g, 0.204 mol), triethylamine (62.6 mL, 0.448 mol, 2.2 equiv.), and DCM (590 mL) in an ice bath and add dropwise trifluoromethanesulfonic anhydride (43.5 mL, 0.258 mol, 1.26 equiv.) over 70 min. Remove the ice bath and stir the reaction mixture for 2 h. Wash the reaction mixture sequentially with water (500 mL), 1N aqueous HCl (500 mL), water (500 mL), and brine (500 mL). Dry the organic layer over Na₂SO₄ and concentrate *in vacuo* to give the crude product as a brown solid (90 g). Dissolve the solid in warm toluene (200 mL). Further

purify by plug filtration chromatography over silica gel (500 g) eluting sequentially with hexane (1 L), hexane/EtOAc (9:1, 1L), hexane/EtOAc (4:1, 1L), and hexane/EtOAc (7:3, 9L). Pool the eluents and evaporate the solvent to obtain the product as a yellow tan solid (86.3 g). Dissolve the solid in warm EtOAc (86 mL) and then add hexane (700 mL). If


5

available, seed the solution with crystals of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine from a prior synthesis to enhance crystallization. Allow the mixture to stand at ambient temperature for 30 min. Cool the mixture at about -10°C for 2 h., filter, rinse the crystals with cold (-10°C) hexane/EtOAc, and air-dry on the filter under vacuum to obtain the title compound as a first crop of crystals (73.54 g). Concentrate the mother liquor to obtain a solid (12.7 g). Recrystallize the solid in a mixture of EtOAc/hexane (15 mL:121 mL) to obtain additional title compound (7.65 g, total yield: 81.19 g, 93%).

15

Preparation 2

3-(2,2,2-Trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine




20

Cool a solution of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (2 g, 7.72 mmol), triethylamine (1.4 mL, 10.1 mmol) and DCM (50 mL) in a cryogenic bath set at -30 °C and add dropwise trifluoromethanesulfonic anhydride (1.7 mL, 10.1 mmol) over 20 min. Stir at -30°C for 2 h and then warm to ambient temperature overnight. Wash the reaction mixture sequentially with water (100 mL), 1N aqueous HCl (100 mL), water (200 mL), and brine (200 mL). Dry the organic layer over Na₂SO₄ and concentrate *in vacuo* to give the title compound as a colorless to light yellow oil (2.7 g, 89%) that was used without purification. Obtain an analytical sample by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the title compound as an off-white waxy solid. GC-MS *m/z*: 391 (M⁺).

30

Preparation 3

3-*tert*-Butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



5


Dissolve 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (5 g, 19.3 mmol) in 7*N* ammonia in methanol (50 mL) and stir at ambient temperature for 16 h. Concentrate the reaction mixture to an oil and use without further purification. Dissolve the residue in a solvent mixture consisting of methanol (20 mL), DCM (10 mL) and water (100 mL), and add potassium carbonate (5 g) and di-*tert*-butyl-dicarbonate (5.05 g, 23.2 mmol). Stir the reaction mixture at ambient temperature for 16 h and concentrate *in vacuo*. Extract the aqueous phase with DCM, dry over Na₂SO₄, filter and concentrate. Use the residue without further purification. Dissolve the material in a mixture of DCM (300 mL) and pyridine (30 mL) and cool in an ice bath.

10 Add dropwise to the stirred solution trifluoromethanesulfonyl anhydride (5.84 mL, 34.7 mmol) and stir the reaction mixture for 2 h at ambient temperature. Dilute the reaction mixture with DCM (400 mL) and wash with 2.5*N* aqueous HCl. Dry the organic fraction over Na₂SO₄, filter and concentrate to give the title compound as a yellow solid (6.1 g, 80%). MS (ES⁺) *m/z*: 396 (M+H)⁺.

20

Preparation 4

7-Fluoro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine




25

Add *N*-fluoro-4,6-bis(trifluoromethyl)-pyridinium 2-sulfonate (3.02 g, 9.6 mmol) to a stirred mixture of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-


benzo[d]azepine (2.5 g, 9.6 mmol) and hexafluoro-2-propanol (10 mL) in DCM (150 mL). Stir at ambient temperature for 16 h. Concentrate the reaction mixture and partition the residue between EtOAc and 1N aqueous HCl. Wash the organic fraction with saturated aqueous NaHCO₃, brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1, 6:1, 5:1 and 3:1) to give 7-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a white solid (1.8 g, 68%). Dissolve 7-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.5 g, 5.41 mmol) in a mixture of DCM (20 mL) and pyridine (2 mL) and cool in an ice bath. Add dropwise to the stirred solution a mixture of trifluoromethanesulfonic anhydride (1.64 mL, 9.74 mmol) in DCM and stir the reaction for 1.5 h at ambient temperature. Dilute the reaction with DCM (300 mL) and wash with 2.5N aqueous HCl. Dry the organic fraction over Na₂SO₄, filter and concentrate to give the title product as a white solid (2.2 g, 99%). MS (ES⁺) *m/z*: 410 (M+H)⁺.

Preparation 5

3-*tert*-Butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine



Dissolve 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3 g, 10.2 mmol) in 7 N ammonia in methanol (50 mL) and stir at ambient temperature for 16 h. Concentrate the reaction mixture to an oil and use without further purification. Dissolve the residue in a solvent mixture consisting of DCM (25 mL) and saturated aqueous potassium carbonate solution (25 mL) and add di-*tert*-butyl-dicarbonate (2.2 g, 10.2 mmol). Stir the reaction mixture at ambient temperature for 4 h, concentrate *in vacuo* and extract the aqueous residue with DCM. Dry the organic fraction over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:5) to give the title compound as a white solid (2.3 g, 76%). MS (ES⁻) *m/z*: 296 (M-H)⁻.

Example 1**6-(3-Phenyl-prop-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5

Use a method similar to the General Procedure 3 to couple 3-*tert*-butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.6 g, 1.5 mmol) with 3-phenyl-1-propyne (0.38 mL, 3 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 40:1 and 20:1) to give 3-*tert*-butoxycarbonyl-6-(3-phenyl-prop-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an orange oil (400 mg, 74%).


10

Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-6-(3-phenyl-prop-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (68 mg, 0.19 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 20:1 and 10:1) to obtain the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a tan solid (48 mg, 85%). MS (ES+) m/z : 262 (M+H)⁺.

15

Examples 2-4 may be prepared essentially as described in Example 1 by using 3-*tert*-butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate alkyne. Overall yields and MS (ES+) data are shown in the Table below.

20




25

Ex	R	Compound	Yield (%)	MS (ES+) m/z
2	Benzyl	6-(4-Phenyl-but-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	60	276 (M+H) ⁺
3	Cyclopentyl	6-(3-Cyclopentyl-prop-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	73	254 (M+H) ⁺
4	Cyclohexyl	6-(3-Cyclohexyl-prop-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	79	268 (M+H) ⁺

Example 5

6-(3,3-Dimethyl-but-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




5

Use a method similar to the General Procedure 3 to couple 3-*tert*-butoxycarbonyl-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.5 g, 1.3 mmol) with 3,3-dimethyl-1-butyne (0.31 mL, 2.5 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1) to give 3-*tert*-butoxycarbonyl-6-(3,3-dimethyl-but-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (304 mg, 74%).

Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-6-(3,3-dimethyl-but-1-ynyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 50:1, 20:1, 15:1 and 10:1) to obtain the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a tan solid (171 mg, 53%). MS (ES+) m/z : 228 (M+H)⁺.

Example 6

6-(3,3-Dimethyl-but-1-ynyl)-7-fluoro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5 Use a method similar to the General Procedure 3 to couple 7-fluoro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 g, 2.4 mmol) with 3,3-dimethyl-1-butyne (0.599 mL, 4.9 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1) to give 6-(3,3-dimethyl-
10 but-1-ynyl)-7-fluoro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (700 mg, 84%).

 Use a method similar to the General Procedure 1-3 to deprotect 6-(3,3-dimethyl-but-1-ynyl)-7-fluoro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.
15 Purify by SCX chromatography followed by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (1:0, 50:1, 20:1, 15:1 and 10:1) to obtain the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (589 mg, 83%). MS (ES+) *m/z*: 246 (M+H)⁺.

20 **General Procedure 4-1**

 Add 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.), the appropriate alkylating agent (1.2 equiv.), ground K₂CO₃ (3 equiv.) and KI (0.1 equiv.) to a proper solvent (acetone, ethanol or acetonitrile) and heat to reflux for 6 to 16 h unless otherwise specified. Cool the reaction mixture to
25 ambient temperature, quench with 1*N* aqueous HCl and extract the aqueous layer three times with EtOAc. Combine the organic fractions, wash with saturated aqueous NaHCO₃, brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures.

General Procedure 4-2


Add 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[*d*]azepine (1 equiv.), the appropriate alcohol (1.1 equiv.), triphenylphosphine (1.2 equiv.) and diethyl azodicarboxylate (1.1 equiv.) sequentially to anhydrous THF. Stir the mixture at ambient temperature under nitrogen. Re-add triphenylphosphine (1.2 equiv.) and diethyl azodicarboxylate (1.1 equiv.) if the reaction is not completed (monitored by TLC). Dilute the mixture with EtOAc, wash with saturated aqueous NaHCO₃, brine, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures.

General Procedure 4-3

Add 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.), the appropriate alcohol (1.2-1.5 equiv.) and triphenylphosphine (1.5 equiv.) sequentially to anhydrous THF. Stir the mixture at 0°C under nitrogen for 10 min. Add 1,1'-(azodicarbonyl)dipiperidine (1.5 equiv.) and let the mixture warm to ambient temperature over 16 h. Dilute with ether, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures.

Preparation 6

7-Chloro-9-fluoro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



1-Fluoro-4-methoxy-2-(2-nitro-vinyl)-benzene: Heat 2-fluoro-5-methoxybenzaldehyde (15 g, 97.4 mmol) with nitromethane (32 mL, 584 mmol) and ammonium acetate (30 g, 390 mmol) in acetic acid (136 mL) under reflux for 30 min. Evaporate the solvent and dissolve the residue in ether. Wash the organic fraction with water, saturated aqueous NaHCO₃ and evaporate to give the desired intermediate (18.7 g, 97%). GC-MS *m/z*: 197 (M)⁺.

2-(2-Fluoro-5-methoxyphenyl)-ethylamine: Cautiously add sulfuric acid (14.7 mL, 265 mmol) dropwise at 0°C to lithium aluminum hydride (1M solution in THF, 565 mL) with efficient stirring. Warm the mixture to ambient temperature for 20 min and then cool back to 0°C. Add a solution of 1-fluoro-4-methoxy-2-(2-nitro-vinyl)-benzene (18.7 g, 95 mmol) in THF (150 mL) by cannula and stir 2.5 h at ambient temperature. Cool the mixture to 0°C, cautiously add water (4.6 mL) followed by 2N aqueous NaOH (4.6 mL) and water (6.5 mL). Remove the precipitate by filtration and evaporate the filtrate to give the desired intermediate (16 g, 100 %). MS (ES⁺) *m/z*: 170 (M+H)⁺.

N-(2,2-Dimethoxy-ethyl)-2,2,2-trifluoro-N-[2-(2-fluoro-5-methoxy-phenyl)-ethyl]-acetamide: Dissolve 2-(2-fluoro-5-methoxyphenyl)-ethylamine (16 g, 95 mmol) and dimethoxy acetaldehyde (60 % aqueous, 21.5 mL, 142 mmol) in methanol (500 mL). After 1.5 h, cautiously add sodium borohydride (5.39 g, 142 mmol) at 0°C and then stir at ambient temperature for 3 h. Add acetone and evaporate the mixture. Dissolve the residue in DCM (250 mL), cool to 0°C and add triethylamine (26.5 mL, 190 mmol) and trifluoroacetic anhydride (20.1 mL, 142 mmol). After 30 min, wash the mixture with 1N aqueous HCl (4 x 100 mL), brine and saturated aqueous NaHCO₃. Dry the organic layer over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel to give the desired intermediate (19.7 g, 59%). MS (ES⁺) *m/z*: 322 (M-OMe)⁺.

9-Fluoro-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3-dihydro-1H-benzo[d]azepine: Dissolve N-(2,2-dimethoxy-ethyl)-2,2,2-trifluoro-N-[2-(2-fluoro-5-methoxy-phenyl)-ethyl]-acetamide (5 g, 14.2 mmol) in chlorobenzene (100 mL). Add polyphosphoric acid (5 g) and P₂O₅ (2.5 g) and heat at 80°C for 2 h. Add water to the hot mixture, cool to

room temperature and extract with DCM. Dry the organic extracts over Na_2SO_4 and concentrate *in vacuo* to obtain the desired intermediate (3.0 g, 73%). MS (ES+) m/z : 290 (M+H)⁺.

- 5 **9-Fluoro-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**
Dissolve 9-fluoro-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3-dihydro-1H-benzo[d]azepine (9.4 g, 32.4 mmol) with 10 % Pd/C (dry basis, Degussa type, 1.4 g, 0.65 mmol) in EtOAc/ethanol (1:1, 200 mL) and stir at ambient temperature under a balloon of hydrogen for 4.5 h. Filter the mixture through a pad of silica gel and evaporate the filtrate to obtain
10 the desired intermediate (8.6 g, 91%). MS (ES+) m/z : 292 (M+H)⁺.

- 9-Fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**
Dissolve 9-fluoro-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (8.1 g, 27.7 mmol) in DCM (250 mL), cool to 0°C and add boron
15 tribromide (5.24 mL, 55.5 mmol). Stir at ambient temperature for 1.5 h, wash the mixture with brine, dry the organic layer over Na_2SO_4 and concentrate *in vacuo* to obtain the desired intermediate (7.6 g, 99%). MS (ES+) m/z : 278 (M+H)⁺.

- 7-Chloro-9-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** Dissolve 9-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.0 g, 3.6 mmol) in toluene (36 mL) with
20 diisopropylamine (41 μL , 0.29 mmol). Warm to 60°C and add dropwise a solution of sulfonyl chloride (0.32 mL, 3.97 mmol) in toluene (10 mL). After 2 h, wash the mixture with brine, dry the organic layer over Na_2SO_4 and evaporate onto silica gel. Purify by
25 chromatography on silica gel eluting with EtOAc/hexane (0:1 to 1:0) to obtain the desired intermediate (1.0 g, 92%). MS (ES+) m/z : 312 (M+H)⁺.


- 7-Chloro-9-fluoro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** Cool a solution of 7-chloro-9-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (2.5 g, 8.0 mmol), pyridine
30 (3.25 mL, 40.2 mmol) and DCM (80 mL) at 0 °C and add dropwise trifluoromethanesulfonic anhydride (2.43 mL, 14.5 mmol) over 20 min. Stir at room temperature for 1 h. Wash the reaction mixture sequentially with 1N aqueous HCl,

saturated NaHCO_3 solution and brine. Dry the organic fraction over Na_2SO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (gradient from 19:1 to 1:1) to obtain the title compound (3.1 g, 87%).

5


Preparation 7

4-Bromomethyl-*N*-methyl-benzenesulfonamide



10 Mix 4-(bromomethyl)benzenesulfonyl chloride (2.7 g, 10 mmol), anhydrous potassium carbonate (1.4 g, 10 mmol) and anhydrous THF (60 mL) under nitrogen. Cool the mixture in an ice bath, add dropwise a 2M solution of methylamine in THF, and stir at this temperature for 30 min. Remove the ice bath and stir at ambient temperature for 16 h. Dilute with EtOAc then wash with 1N aqueous HCl. Separate the organic layer, dry
15 over Na_2SO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 4:1, 7:3 and 13:7) to obtain the title compound (1.5 g, 71%). MS (ES+) m/z : 266 (M+H)⁺.

20 The compounds of Preparations 8-9 may be prepared essentially as described in Preparation 7 by using 4-(bromomethyl)benzenesulfonyl chloride and the appropriate amine. Yields and MS (ES+) data are shown in the Table below.




Prep.	NH-R	Compound	Yield (%)	MS (ES+) m/z
8	NH-CH ₂ CH ₃	4-Bromomethyl- <i>N</i> -ethyl-benzenesulfonamide	43	278 (M+H) ⁺
9	NH-CH ₂ CH ₂ F	4-Bromomethyl- <i>N</i> -(2-fluoroethyl)-benzenesulfonamide	39	296 (M+H) ⁺


25

Preparation 10

Thiazol-2-yl-methanol




Mix under nitrogen 2-thiazolecarboxaldehyde (1.1 g, 10 mmol) and ethanol (30 mL). Add sodium borohydride (416 mg, 11 mmol) at 0°C. Stir and warm the mixture slowly to ambient temperature for 12 h. Quench with saturated aqueous ammonium chloride and concentrate *in vacuo*. Dilute the residue with EtOAc and wash with brine. Dry the organic fraction over Na₂SO₄ and concentrate *in vacuo* to obtain the title compound as an oil (1.0 g, 87%). MS (ES⁺) *m/z*: 116 (M+H)⁺.

Preparation 11(1-Methyl-1*H*-pyrazol-3-yl)-methanol

Dissolve 3-dimethoxymethyl-1-methylpyrazole (1.562 g, 10 mmol) in acetone (100 mL), add *p*-toluenesulfonic acid (190 mg, 1.0 mmol) and stir at ambient temperature for 12 h. Remove volatiles *in vacuo*, dissolve the residue in EtOAc, wash with saturated aqueous NaHCO₃, dry over Na₂SO₄, filter and concentrate *in vacuo* to afford an oil. Dissolve the oil in methanol (15 mL), add sodium borohydride (567 mg, 15 mmol) and stir the reaction mixture at ambient temperature for 12 h. Remove volatiles *in vacuo*, dissolve the residue in EtOAc, wash with saturated aqueous NaHCO₃, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (6:1) to give the title compound as an oil (530 mg, 47%).

Preparation 12

6-(2-Amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine



6-(2-*tert*-Butoxycarbonylamino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Use a method similar to the General Procedure 4-3; using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (277 mg, 0.94 mmol) and *N*-(*tert*-butoxycarbonyl)ethanolamine (244 mg, 1.51 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (1:0 and 3:1), the desired intermediate (392 mg, 95%). MS (ES⁺) *m/z*: 337 (M+H-Boc)⁺.

10


6-(2-Amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Dissolve 6-(2-*tert*-butoxycarbonylamino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (997 mg, 2.28 mmol) in 4M hydrogen chloride in dioxane (15 mL) and stir at ambient temperature for 30 min. Concentrate to obtain the hydrochloride salt. Dissolve the salt in DCM and wash with saturated aqueous NaHCO₃. Extract the basic aqueous layer with DCM. Dry the combined organic extracts over MgSO₄, and concentrate *in vacuo* to afford the title compound (731 mg, 95%). MS (ES⁺) *m/z*: 337 (M+H)⁺.

15

20

The compounds of Preparations 13-14 may be prepared essentially as described in Preparation 12 by using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate alcohol. Overall yields and MS (ES⁺) data are shown in the Table below.


25



Prep	n	Compound	Yield (%)	MS (ES+) <i>m/z</i>
13	1	6-(3-Amino-propoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine	94	351 (M+H) ⁺
14	2	6-(4-Amino-butoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine	89	365 (M+H) ⁺

Example 7

7-Chloro-6-(4-fluorobenzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




5

Prepare a slurry of sodium hydride (60% in mineral oil; 99 mg, 2.5 mmol) in DMF (4 mL) and heat to 65°C. Add a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.84 mmol) in DMF (5 mL) dropwise and stir for 1 h. Add a solution of 4-fluorobenzyl bromide (191 mg, 1.0 mmol) in DMF (1 mL), stir at 65°C for 1.5 h and cool to ambient temperature. Add water (1 mL) and concentrate the mixture to an oily residue. Partition the residue between EtOAc/hexane (1:1) and water. Dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo*. Dissolve the residue in DCM, wash with 2N aqueous NaOH, dry the organic layer over Na₂SO₄, filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1 and 7:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(4-fluorobenzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.

Use a method similar to General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-(4-fluorobenzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by SCX chromatography followed by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 50:1, 20:1, 15:1 and 10:1) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (178 mg, 50%). MS (ES+) *m/z*: 306 (M+H)⁺.

Example 8

7-Chloro-6-(4-cyanobenzyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




5 Combine 3-*tert*-butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (200 mg, 0.67 mmol), potassium carbonate (111 mg, 0.8 mmol), and 4-cyanobenzyl bromide (263 mg, 1.34 mmol) in DMSO (5 mL) and heat the stirred mixture to 100° C for 24 h. Cool to ambient temperature and partition the mixture between water
10 and EtOAc/hexane (1:1). Wash the organic layer with brine and dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (5:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(4-cyanobenzyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil.

15 Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-(4-cyanobenzyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as an off-white solid (66 mg, 27%). MS (ES+) *m/z*: 313 (M+H)⁺.

20

Example 9 7-Chloro-6-[2-(4-fluorophenyl)-2-oxo-ethoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




Use a method similar to the General Procedure 4-1, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (294 mg, 1.0 mmol) and 2-bromo-4'-fluoroacetophenone (260 mg, 1.2 mmol) to give, after purification by chromatography on silica gel eluting with hexane/EtOAc (7:1), 7-chloro-6-[2-(4-fluorophenyl)-2-oxo-ethoxy]]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a solid (402 mg, 93%). MS (ES+) *m/z*: 430 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[2-(4-fluorophenyl)-2-oxo-ethoxy]]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (402 mg, 0.93 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (96:4) to give the free base of the title compound (278 mg, 89%). MS (ES+) *m/z*: 334 (M+H)⁺. Use a method similar to the General Procedure 2-3 to give the title compound.

Example 10

7-Chloro-6-(4-methylsulfamoyl-benzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Dissolve under nitrogen 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.68 mmol) in acetone (30 mL). Add powdered anhydrous potassium carbonate (276 mg, 2.0 mmol) and powdered potassium iodide (11.3 mg, 0.068 mmol) followed by 4-bromomethyl-*N*-methyl-benzenesulfonamide (528 mg, 2.0 mmol). Stir the reaction mixture at ambient temperature for 12 h. Concentrate *in vacuo*, dilute with EtOAc and wash twice with 1N aqueous HCl. Separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel

eluting with hexane/EtOAc (1:0 and 4:1) to obtain 7-chloro-6-(4-methylsulfamoyl-benzyloxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (201 mg, 60%).

- 5 Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(4-methylsulfamoyl-benzyloxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (196 mg, 0.41 mmol). Purify by SCX column to give the free base of the title compound (110 mg, 70%). MS (ES+) *m/z*: 381 (M+H)⁺. Use a method similar to the General Procedure 2-2 to obtain the title compound.

10

Examples 11-12 may be prepared essentially as described in Example 10 by using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate bromide. MS (ES+) data are shown in the Table below.




15

Ex.	NH-R	Compound	MS (ES+) <i>m/z</i>
11	NH-CH ₂ -CH ₃	7-Chloro-6-(4-ethylsulfamoyl-benzyloxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	395 (M+H) ⁺
12	NH-CH ₂ -CH ₂ F	7-Chloro-6-[4-(2-fluoroethylsulfamoyl)-benzyloxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	413 (M+H) ⁺

Example 13 Allen 1 (2136887 PR2-A03413-132)

7-Chloro-9-fluoro-6-(4-fluorobenzyloxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



5

Dissolve 7-chloro-9-fluoro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.25 g, 0.8 mmol) in DMF (8 mL), add potassium carbonate (0.56 g, 4.0 mmol) and 4-fluorobenzyl bromide (0.46 mL, 2.4 mmol). After 14 h at 90 °C, dilute with ether and wash with brine. Dry the organic layer over Na₂SO₄ and evaporate onto silica gel. Purify by chromatography on silica gel eluting with EtOAc/hexane (0:1 to 1:0) to obtain 7-chloro-9-fluoro-6-(4-fluorobenzyloxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

10


15

Use a method similar to the General Procedure 1-1, using 7-chloro-9-fluoro-6-(4-fluorobenzyloxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine, to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to obtain the title compound (275 mg, 95%). HRMS calc'd for C₁₇H₁₇NOF₂Cl 324.0902, found 324.0957.

20

Example 14

7-Chloro-6-(pyridin-2-ylmethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




Prepare a slurry of sodium hydride (60% in mineral oil, 168 mg, 4.2 mmol) in DMF (4 mL) and heat to 65° C. Add dropwise a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.84 mmol) in DMF (5 mL) and stir for 1 h. Add a solution of 2-(bromomethyl)-pyridine hydrobromide (256 mg, 1 mmol) in DMF (1 mL), stir at 65° C for 0.5 h and cool to ambient temperature. Add water (1 mL) and concentrate the reaction mixture to an oily residue. Partition the residue between EtOAc/hexane (1:1) and water. Dry the organic layer over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(pyridin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.


Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-(pyridin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (228 mg, 67%). MS (ES+) *m/z*: 289 (M+H)⁺.

Example 15

7-Chloro-6-(pyridin-3-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Disuccinate



Use a method similar to the Example 14, using 3-*tert*-butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.84 mmol) and 3-(bromomethyl)-pyridine hydrobromide (256 mg, 1 mmol) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 with two equivalents of succinic acid to give the title compound as a white solid (354 mg, 80%). MS (ES+) *m/z*: 289 (M+H)⁺.

Example 16**7-Chloro-6-(thiazol-2-ylmethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**


5

Use a method similar to the General Procedure 4-2, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and thiazol-2-yl-methanol (86.2 mg, 0.75 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (9:1 and 7:3), 7-chloro-6-(thiazol-2-ylmethoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (163 mg, 61%). MS (ES+) m/z 391 (M+H)⁺.

10

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(thiazol-2-ylmethoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to obtain the free base of the title compound (99 mg, 81%). MS (ES+) m/z : 295 (M+H)⁺. Use a method similar to the General Procedure 2-2 to give the title compound.

15

Example 17**7-Chloro-6-(thiazol-5-ylmethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

20

Use a method similar to the General Procedure 4-2, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (294 mg, 1.0 mmol) and 5-hydroxymethylthiazole (127 mg, 1.1 mmol) to give, after chromatography on silica gel


25

eluting with EtOAc/hexane (1:3), 7-chloro-6-(thiazol-5-ylmethoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (350 mg, 89%). MS (ES+) *m/z*: 391 (M+H)⁺.


- 5 Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(thiazol-5-ylmethoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (350 mg, 0.90 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give the free base of the title compound (203 mg, 76%): MS (ES+) *m/z*: 295 (M+H)⁺. Use a method similar to the General Procedure 2-2 to give
- 10 the title compound.

Examples 18-19 may be prepared essentially as described in Example 17 by using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate alcohol. Overall yields and MS (ES+) data are shown in the Table below.

15



Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
18		7-Chloro-6-(5-methyl-isoxazol-3-ylmethoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	47	293 (M+H) ⁺
19		7-Chloro-6-(1-methyl-1 <i>H</i> -pyrazol-3-ylmethoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	39	292 (M+H) ⁺

Example 20**7-Chloro-6-(3-methylthio-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

5

Use a method similar to the General Procedure 4-2, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-(methylthio)-1-propanol (191 mg, 1.8 mmol) to give, after chromatography on silica gel eluting with EtOAc/hexane (1:8), 7-chloro-6-(3-methylthio-propoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (65 mg, 14%).


10

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(3-methylthio-propoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (65 mg, 0.17 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to give the free base of the title compound (25 mg, 51%). MS (ES+) m/z : 286 (M+1)⁺. Use a method similar to the General Procedure 2-1 to give the title compound.

15


Example 21**7-Chloro-6-(4-methylthio-butoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

20



25

Use a method similar to the Example 20, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 4-(methylthio)-1-butanol to give the title compound. MS (ES+) m/z : 300 (M+1)⁺.

Example 22**7-Chloro-6-(3-pyridin-2-yl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride**

5


Use a method similar to the General Procedure 4-3, using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (50 mg, 0.17 mmol) and 3-(2-pyridyl)-1-propanol (35 mg, 0.255 mmol) to give, after reverse phase HPLC (10-95% of solvent B in 12.8 min, 25 mL/min; solvent A: water, 0.1% trifluoroacetic acid; solvent B: acetonitrile, 0.1% trifluoroacetic acid; column: YMC SH-341-5, S-5 μ m, 12 nm, 100 x 20 mm), 7-chloro-6-(3-pyridin-2-yl-propoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

15





Use a method similar to the General Procedure 1-1, using 7-chloro-6-(3-pyridin-2-yl-propoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a solid (26 mg, 39%). MS (ES+) m/z : 317 (M+H)⁺.

20

Examples 23-26 may be prepared essentially as described in Example 22 by using 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate alcohol. Overall yields and MS (ES+) data are shown in the Table below.




25

Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
23		7-Chloro-6-[2-(4-methyl-thiazol-5-yl)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	83	323 (M+H) ⁺
24		7-Chloro-6-(2-pyridin-2-yl-ethoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	83	303 (M+H) ⁺
25		7-Chloro-6-(3-pyridin-3-yl-propoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	83	317 (M+H) ⁺
26		6-[3-(1 <i>H</i> -Benzimidazol-2-yl)-propoxy]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	8	356 (M+H) ⁺

Example 27

6-(2-Benzoylamino-ethoxy)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Combine benzoyl chloride (19.3 mg, 0.137 mmol), PS-morpholine (109 mg, 0.272 mmol), 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (46 mg, 0.137 mmol) in DCM (1.5 mL) and stir at ambient temperature for 16 h. Filter the resin, wash with DCM and concentrate *in vacuo*. Purify by reverse phase HPLC (10-95% of solvent B in 12.8 min, 25 mL/min; solvent A: water, 0.1% trifluoroacetic acid; solvent B: acetonitrile, 0.1% trifluoroacetic acid; column: YMC SH-341-5, S-5μm, 12 nm, 100 x 20 mm) to give 6-(2-benzoylamino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.

Use a method similar to the General Procedure 1-1, using 6-(2-benzoylamino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a solid (51 mg, 98%). MS (ES+) *m/z*: 345 (M+H)⁺.

5










Examples 28-40 may be prepared essentially as described in Example 27, using 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine or 6-(3-amino-propoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine or 6-(4-amino-butoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate acyl chloride. Overall yields and MS (ES+) data are shown in the Table below.


10



Ex.	NH-CO-R	n	Compound	Yield (%)	MS (ES+) <i>m/z</i>
28		2	7-Chloro-6-[2-(4-chlorobenzoylamino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	46	380 (M+H) ⁺
29		2	7-Chloro-6-[2-(3-chlorobenzoylamino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	63	380 (M+H) ⁺
30		2	7-Chloro-6-[2-(2-chlorobenzoylamino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	18	380 (M+H) ⁺
31		2	7-Chloro-6-[2-(4-fluorobenzoylamino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	18	363 (M+H) ⁺

15

Ex.	NH-CO-R	n	Compound	Yield (%)	MS (ES+) <i>m/z</i>
32		2	7-Chloro-6-{2-[(pyridine-4-carbonyl)-amino]-ethoxy}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	4	346 (M+H) ⁺
33		2	7-Chloro-6-[2-(cyclopropanecarbonyl-amino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	47	309 (M+H) ⁺
34		2	7-Chloro-6-{2-[(pyrrolidine-1-carbonyl)-amino]-ethoxy}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	6	338 (M+H) ⁺
35		2	7-Chloro-6-[2-(cyclohexanecarbonyl-amino)-ethoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	40	351 (M+H) ⁺
36		3	7-Chloro-6-(3-ethoxycarbonylamino-propoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	63	327 (M+H) ⁺
37		3	6-(3-Benzoylamino-propoxy)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	72	359 (M+H) ⁺
38		3	7-Chloro-6-{3-[(pyridine-4-carbonyl)-amino]-propoxy}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	12	360 (M+H) ⁺
39		4	7-Chloro-6-(4-ethoxycarbonylamino-butoxy)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	49	341 (M+H) ⁺
40		4	6-(4-Benzoylamino-butoxy)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	56	373 (M+H) ⁺

Example 41**7-Chloro-6-[2-(2-fluorobenzoylamino)-ethoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**


5

Dissolve 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 0.297 mmol) in DCM (5 mL). Add 2-fluorobenzoyl chloride (39 μ L, 0.326 mmol), triethylamine (62 μ L, 0.445 mmol) and stir at ambient temperature for 72 h under nitrogen atmosphere. Dilute with DCM, add 1M aqueous HCl and extract the aqueous phase with DCM. Dry the combined organic extracts over MgSO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3 and 2:1) to give 7-chloro-6-[2-(2-fluorobenzoylamino)-ethoxy]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (111 mg, 82%).

15

Use a method similar to the General Procedure 1-1, using 7-chloro-6-[2-(2-fluorobenzoylamino)-ethoxy]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a solid (112 mg, 95%). MS (ES+) m/z : 363 (M+H)⁺.

20

Example 42**7-Chloro-6-{2-[(pyridine-2-carbonyl)-amino]-ethoxy}-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5


Combine picolinic acid (40 mg, 0.327 mmol), EDC (57 mg, 0.297 mmol) and HOBT (40 mg, 0.297 mmol) in DCM (3 mL). Stir for 10 min at ambient temperature. Add 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 0.297 mmol). Stir for 16 h at ambient temperature. Dilute with DCM, add water and extract the aqueous layer with DCM. Wash the combined organic extracts with 1M aqueous NaOH and brine. Dry the organic layer over MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (3:2) to give 7-chloro-6-{2-[(pyridine-2-carbonyl)-amino]-ethoxy}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (94 mg, 74%).

Use a method similar to the General Procedure 1-1, using 7-chloro-6-{2-[(pyridine-2-carbonyl)-amino]-ethoxy}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a solid (81 mg, 72%). MS (ES+) *m/z*: 346 (M+H)⁺.

20

Example 43

7-Chloro-6-{2-[(pyridine-3-carbonyl)-amino]-ethoxy}-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



5


Use a method similar to Example 42, using nicotinic acid (40 mg, 0.327 mmol) and 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 0.297 mmol) to give the title compound as a solid (105 mg, 93%). MS (ES+) m/z: 346 (M+H)⁺.

10

Example 44

7-Chloro-6-[2-(3-phenyl-ureido)-ethoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

15




Combine phenyl isocyanate (16.3 mg, 0.137 mmol), 6-(2-amino-ethoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (46 mg, 0.137 mmol) in DCM (1.5 mL) and stir at ambient temperature for 16 h. Concentrate *in vacuo*. Purify by reverse phase HPLC (10-95% of solvent B in 12.8 min, 25 mL/min; solvent A: water, 0.1% trifluoroacetic acid; solvent B: acetonitrile, 0.1% trifluoroacetic acid; column: YMC

20

SH-341-5, S-5 μ m, 12 nm, 100 x 20 mm) to give 7-chloro-6-[2-(3-phenyl-ureido)-ethoxy]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.

5 Use a method similar to the General Procedure 1-1, using 7-chloro-6-[2-(3-phenyl-ureido)-ethoxy]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a solid (8 mg, 15%). MS (ES+) *m/z*: 360 (M+H)⁺.


10 Examples 45-46 may be prepared essentially as described in Example 44 by using phenyl isocyanate and the appropriate 6-(3-amino-propoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine or 6-(4-amino-butoxy)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Overall yields and MS (ES+) data are shown in the Table below.



15

Ex.	NH-CO-R	n	Compound	Yield (%)	MS (ES+) <i>m/z</i>
45		3	7-Chloro-6-[3-(3-phenyl-ureido)-propoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	36	374 (M+H) ⁺
46		4	7-Chloro-6-[4-(3-phenyl-ureido)-butoxy]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	28	388 (M+H) ⁺

Example 48

7-Chloro-6-(3-methoxycarbonyl-propyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Succinate

5
10 Add methyl 4-bromobutyrate (1.9 mL, 10.4 mmol) to a mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-hydroxy-2,3,4,5-tetrahydro-benzo[d]azepine (310 mg, 1.0 mmol), DBU (0.23 mL, 1.6 mmol) and DMF (10 mL) at ambient temperature under nitrogen. Stir the reaction mixture for 16 h. Dilute with hexane/EtOAc (1:1, 60 mL), wash the mixture with 10% aqueous NaCl (4 x 25 mL), dry the organic layer over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (19:1 to 2:3) to obtain 3-*tert*-butoxycarbonyl-7-chloro-6-(3-methoxycarbonyl-propyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (303 mg, 73%). MS (ES+) *m/z*: 398 (M+H)⁺.

20 Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-(3-methoxycarbonyl-propyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (295 mg, 0.74 mmol). Purify by SCX chromatography followed by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound (160 mg, 52%). MS (ES+) *m/z*: 298 (M+H)⁺.

25

General Procedure 5-1

Dissolve the appropriately substituted 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1 equiv.), palladium(II) acetate (0.1-0.4 equiv.), BINAP (0.2-0.8 equiv.; BINAP/catalyst ratio 2:1) and cesium carbonate (1.4-3.0 equiv.) in toluene (0.2-0.05 M solution). Add the amine (1-3 equiv.), degas the mixture with vacuum/nitrogen or argon purge and heat at 80-110°C for 4-16 h. Cool the

30

mixture to ambient temperature, dilute with EtOAc, filter through a pad of silica gel or through Celite® washing with EtOAc or ether, and evaporate the solvent to obtain the crude mixture. Alternatively, partition the reaction mixture between brine or saturated aqueous NaHCO₃ and EtOAc, ether or DCM, dry the organic layer over Na₂SO₄, and concentrate to obtain the crude mixture. Purify the crude mixture by chromatography on silica gel eluting with hexane/EtOAc mixtures and further SCX chromatography if needed.

General Procedure 5-2

Dissolve the appropriately substituted 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.), tris(dibenzylideneacetone)dipalladium(0) (0.1-0.5 equiv.), BINAP (0.2-1.0 equiv.; BINAP/catalyst ratio 2:1) and cesium carbonate (1.4 equiv.) in toluene (0.05-0.5 M solution). Degas under vacuum and fill three times with nitrogen. Add the appropriately substituted amine (1.0-5.0 equiv.) and heat the mixture to 80-100°C for 2-16 h in a sealed flask under a nitrogen atmosphere. Cool the reaction flask to ambient temperature, dilute the mixture with EtOAc or DCM, filter through Celite® and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures and further SCX chromatography if needed.

General Procedure 5-3

Add the appropriately substituted 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.), the appropriate amine (1.2-3.0 equiv.), palladium(II) acetate (0.2-0.4 equiv.), tris(dibenzylideneacetone)dipalladium(0) (0.1-0.2 equiv.), BINAP (0.6-1.2 equiv.; BINAP/catalysts ratio 2:1), cesium carbonate (2-2.5 equiv.) and toluene or 1,4-dioxane (0.05-0.2 M solution) to a flask, degas and fill three times with nitrogen. Heat the mixture at 80-100°C for 10-16 h. Dilute the mixture with EtOAc, wash with saturated aqueous NaHCO₃ and brine, dry over Na₂SO₄, filter and concentrate *in vacuo* to give the crude mixture. Alternatively remove the volatiles from the reaction mixture to give directly the crude mixture, or filter the reaction mixture through Celite® and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc mixtures and further SCX chromatography if needed.

General Procedure 5-4

Combine 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine, the appropriate bromide (1.0-2.0 equiv.), potassium or cesium carbonate (1.0-2.0 equiv.) and toluene, DMF or acetonitrile in a sealed tube and heat at 50-150°C for 3-72 h. Cool to ambient temperature and evaporate the solvent *in vacuo* to obtain the crude mixture. Alternatively, partition the reaction mixture between diethyl ether/brine (1:1), dry the organic layer over anhydrous Na₂SO₄ and concentrate to obtain the crude mixture. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1, 7:3 and 3:2).

General Procedure 6-1

Dissolve 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid (1 equiv.), HATU (1 equiv.), DIEA (2 equiv.) and the appropriately substituted amine (1 equiv.) in DCM or DCM/DMF and stir at ambient temperature for 4-16 h. Concentrate *in vacuo*, dissolve the residue in DCM and wash successively with saturated aqueous NaHCO₃, 1N aqueous HCl, water, brine, and dry over Na₂SO₄. Filter and concentrate the solution and use the material without further purification. Deprotect the residue using the General Procedure 1-5 and purify by SCX chromatography.

General Procedure 6-2

Dissolve 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid or 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylic acid lithium salt (1 equiv.), HATU (1 equiv.), DIEA (2 equiv.) and the appropriately substituted amine (1 equiv.) in DCM or DCM/DMF and stir at ambient temperature for 4-16 h. Concentrate *in vacuo*, dissolve the residue in DCM and wash successively with saturated aqueous NaHCO₃, water, brine, and dry over Na₂SO₄. Filter and concentrate the solution and use the material without further purification. Deprotect the residue using the General Procedure 1-5 and purify by SCX chromatography.

General Procedure 6-3

Dissolve the appropriately substituted acetophenone (1.0-1.2 equiv.) in THF, add titanium(IV) ethoxide (33-35% TiO₂, 2.0 equiv.) and the corresponding (*R*)-2-methyl-2-

propanesulfinamide or (*S*)-2-methyl-2-propanesulfinamide (1.0 equiv.). Heat the mixture to 40-60 °C for 2-16 h under a nitrogen atmosphere. Cool the reaction to -78°C, then add the cold mixture over 3-10 min to a slurry of THF/NaBH₄ (2-4 M) at -78 °C. Allow the mixture to warm up to ambient temperature over 2-16 h. Pour the mixture into brine, filter the resulting slurry through Celite® and wash thoroughly with EtOAc. Concentrate *in vacuo*. Dilute the oil with EtOAc, wash with brine and extract the aqueous phase with EtOAc. Dry the combined organic extracts over Na₂SO₄ and concentrate *in vacuo*. Purify the crude sulfinamide on silica gel eluting with hexane/EtOAc mixtures to obtain the major diastereomer. Dissolve the major diastereomer in excess of 4M hydrogen chloride in dioxane, stir the mixture for 1 h and concentrate *in vacuo* to a solid. Slurry the solid in diethyl ether, then filter *in vacuo* to obtain the hydrochloride salt of the desired amine. The free base of the amine is prepared either via SCX chromatography or by basic extraction.


15

General Procedure 6-4

Add the appropriately substituted benzonitrile portion wise to a flask containing a slurry of lithium aluminum hydride (3.0-6.0 equiv.) in diethyl ether (0.1-0.3 M solution) under a nitrogen atmosphere. Stir the mixture for 1 h and quench slowly with water (0.5-2.0 mL), followed by 5N aqueous NaOH (0.5-2.0 mL). Filter the slurry through Celite® and wash the cake with diethyl ether. Concentrate *in vacuo* to obtain the desired amine. If additional purification is needed, dissolve the amine in ether and add an excess of 2M hydrogen chloride in ether. Filter to obtain the desired amine as the hydrochloride salt. Prepare the free base by using SCX chromatography or by dissolving the hydrochloride salt in an aqueous solution of cesium carbonate (1.0-5.0 equiv.) or saturated aqueous NaHCO₃ (1.0-5.0 equiv.). Extract the mixture with DCM or toluene, dry over Na₂SO₄ and concentrate *in vacuo* to obtain the amine.

Preparation 15**7-Cyano-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine**

5

**7-Bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**

10 Dissolve 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (18 g, 69.4 mmol) and DIEA (0.98 mL) in DCM (1.4 L). Add dropwise a solution of NBS (12.4 g, 69.4 mmol) in DCM (500 mL) over 75 min. Stir the reaction mixture at ambient temperature for 1 h, pour into water (500 mL) and extract the mixture with DCM. Wash the organic fraction with brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give the desired intermediate as a white solid (20.9 g, 89%). MS (ES-) *m/z*: 337 (M-H)⁻.

15

7-Cyano-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

20 Add copper nitrile (2.6 g, 28 mmol) to a solution of 7-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (2.4 g, 7.0 mmol) in anhydrous NMP (45 mL), degas and purge with nitrogen and heat to 150°C for 18 h. Allow the reaction mixture to cool to ambient temperature and then dilute with EtOAc/heptane (2:1) and filter through a silica pad. Dilute the filtrate with water, and extract the aqueous phase twice with EtOAc. Dry the combined organic extracts over MgSO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/heptane (1:4 to 1:1) to obtain the desired intermediate as an orange oil (1.7 g, 86%). MS (ES-) *m/z*: 283 (M-H)⁻.


25

7-Cyano-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Add dry pyridine (3 mL) to 7-cyano-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.1 g, 3.9 mmol) in anhydrous DCM (45 mL) and cool to 0 °C. Add slowly trifluoromethanesulfonic anhydride (1.3 mL, 7.7 mmol), allow the reaction mixture to warm to ambient temperature and stir for 3 h. Dilute with DCM and wash with 2N aqueous HCl. Dry the organic layer over MgSO₄, filter and concentrate *in vacuo* to obtain the title compound as an orange/brown oil (1.6 g, 100%) that was used without purification. MS (ES-) *m/z*: 415 (M-H)⁻.

Preparation 16

3-(2,2,2-Trifluoroacetyl)-6-trifluoromethanesulfonyloxy-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine



6-Hydroxy-7-iodo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Add 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.037 g, 4.0 mmol) and diisopropylamine (60.7 mg, 0.6 mmol) to anhydrous DCM (350 mL) and stir at 10-20 °C. Add slowly a solution of *N*-iodosuccinimide (1.035 g, 4.6 mmol) in DCM (100 mL) over a period of 3 h. Stir the reaction mixture overnight and gradually warm to ambient temperature. Quench the reaction with saturated aqueous NaHCO₃, separate the organic layer, wash the organic layer with 0.1N aqueous HCl, brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:20 to 1:10) to give the desired intermediate as a white solid (1.0 g, 65%). MS (ES+) *m/z*: 386 (M+H)⁺.

7-Iodo-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-


1H-benzo[d]azepine: Add triethylamine (496 mg, 4.90 mmol) to a solution of 6-hydroxy-7-iodo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (945 mg, 2.45 mmol) in DCM (30 mL) at 0 °C. Add dropwise trifluoromethanesulfonic anhydride (1.244 g, 4.41 mmol) and stir at 0°C for 1 h. Warm to ambient temperature overnight. Dilute the mixture with DCM, wash with water, saturated aqueous NaHCO₃ and brine. Dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:6) to give the desired intermediate as a white solid (1.246 g, 98%). MS (ES+) *m/z*: 518 (M+H)⁺.

3-(2,2,2-Trifluoroacetyl)-6-trifluoromethanesulfonyloxy-7-trifluoromethyl-2,3,4,5-

tetrahydro-1H-benzo[d]azepine: Add CuI (367 mg, 1.93 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.852 g, 9.64 mmol) and HMPA (1.728 g, 9.64 mmol) to a solution of 7-iodo-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.246 g, 2.41 mmol) in DMF (8 mL) and heat the mixture at 70 °C for 1.5 h. Add same amount of CuI, methyl 2,2-difluoro-2-(fluorosulfonyl)acetate, and HMPA and stir further for 4 h. Cool the mixture to ambient temperature, quench with saturated aqueous ammonium chloride, separate the organic layer, and extract the aqueous layer with EtOAc three times. Combine the organic layers, wash with saturated aqueous NaHCO₃, brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:20 to 1:10) to give the title compound as a white solid (321 mg, 29%) and to recover the starting material (741 mg, 59%). MS (ES+) *m/z*: 460 (M+H)⁺.

Preparation 17**7-Ethyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine**

5

**9-Bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**

Add dropwise bromine (10.8 mL, 0.21 mol) in acetonitrile (260 mL) to a slurry of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (51.8 g, 0.2 mol) in acetonitrile (400 mL) at 0 °C cooling with ice-water to keep the temperature between 2-5°C. Warm the reaction to ambient temperature and stir for 30 min. Pour the mixture into ice-cold water (2 L) to obtain a white precipitate. Collect the solid by vacuum filtration, wash with water and dry under vacuum at 105 °C. Recrystallize the crude material in toluene/heptane and cool the mixture in an ice bath. Collect the solid by vacuum filtration, wash with heptane and dry under vacuum at 105 °C to obtain the desired intermediate as a white solid (54.63 g, 81%). MS (ES+) m/z : 338 (M+H)⁺.

6-Acetoxy-9-bromo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Under nitrogen atmosphere, mix 9-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (6 g, 17.8 mmol), anhydrous pyridine (0.06 mL, 0.72

mmol), DMAP (222 mg, 1.8 mmol) and acetic anhydride (30 mL). Heat the mixture at reflux for 8 h and then stir at ambient temperature for another 8 h. Concentrate *in vacuo*, dilute the residue in EtOAc, wash with 1N aqueous HCl, and then with saturated aqueous NaHCO₃. Dry the organic layer over Na₂SO₄, filter, and concentrate *in vacuo* to obtain
5 the desired intermediate (5.64 g, 84%) that was used without further purification. MS (ES+) *m/z*: 380 (M+H)⁺.

7-Acetyl-9-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Under nitrogen atmosphere, mix 6-acetoxy-9-bromo-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (2.8 g, 7.4 mmol) and
10 nitrobenzene (5 mL). Add anhydrous aluminum chloride (980 mg, 7.4 mmol). Heat at 180°C for 2 h. Cool the mixture to ambient temperature. Add concentrated HCl (10 mL) dropwise. Stir the mixture for 30 min. Add 1N aqueous HCl then extract with EtOAc. Dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo*. Purify by
15 chromatography on silica gel eluting with EtOAc/hexane (0:1 to 1:4) to afford the desired intermediate (833 mg, 30%). MS (ES-) *m/z*: 378 (M-H)⁻.

7-Acetyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Mix 7-acetyl-9-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-
20 benzo[d]azepine (833 mg, 2.2 mmol), tetrakis(triphenylphosphine)palladium(0) (150 mg, 0.13 mmol) and sodium formate (224 mg, 3.3 mmol) in anhydrous DMF (15 mL). Degas twice then flush with argon. Keep the flask under argon and heat the reaction at 95°C for 16 h. Dilute with EtOAc then wash with 1N aqueous HCl. Separate the organic layer, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel
25 eluting with EtOAc/hexane (0:1, 1:9 and 1:4) to give the desired intermediate (448 mg, 68%). MS (ES+) *m/z*: 302 (M+H)⁺.


7-Ethyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Under nitrogen dissolve 7-acetyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-
30 1H-benzo[d]azepine (1.0 g, 3.32 mmol) in anhydrous THF (100 mL). Cool the solution to 0°C, add boron trifluoride diethyl etherate (3.4 mL, 26.6 mmol) and sodium cyanoborohydride (836 mg, 13.3 mmol). Remove the ice bath and stir for 5 h at ambient temperature. Dilute with EtOAc and wash with 0.1N aqueous HCl. Separate the organic

layer, dry over Na_2SO_4 , filter and concentrate *in vacuo*. MS (ES-) m/z : 302 (M-H)⁻. Mix the residue with trifluoroacetic acid (40 mL) and anhydrous DCM (50 mL) under nitrogen. Cool to 0 °C in an ice bath and add triethyl silane (3.5 mL, 21.9 mmol). After 15 min, remove the ice bath and stir at ambient temperature for 16 h. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with EtOAc/hexane (1:9) to obtain the desired intermediate (698 mg, 73%). MS (ES-) m/z : 286 (M-H)⁻.

7-Ethyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Under nitrogen mix 7-ethyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (698 mg, 2.4 mmol), triethylamine (0.67 mL, 4.8 mmol) and anhydrous DCM (25 mL). Cool the mixture in an ice bath, add dropwise trifluoromethanesulfonic anhydride (0.81 mL, 4.8 mmol) and stir at ambient temperature for 3 h. Quench with water and extract three times with DCM. Wash the organic extracts with 0.1N aqueous HCl and brine. Dry over Na_2SO_4 , filter and concentrate to obtain the title compound (1.0 g, 100%). MS (ES+) m/z : 420 (M+H)⁺.

Preparation 18

7-Propyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine



6-Allyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Dissolve 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1 g, 3.9 mmol) in acetone (5 mL) and add powdered potassium carbonate (2.8 g, 20 mmol). Add dropwise a solution of allyl bromide (1.04 mL, 12 mmol) in acetone (3 mL) over 10 min

and stir at ambient temperature overnight. Filter solids, wash with acetone and concentrate *in vacuo* to give the desired intermediate as an off-white solid (1.15 g, 98%). GC-MS *m/z*: 299 (M^+).

5 **7-Allyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**

Dissolve 6-allyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.1 g, 3.7 mmol) in DCM (15 mL) and cool to $-15\text{ }^{\circ}\text{C}$. Add 1M boron trichloride in DCM (15 mL, 15 mmol) and warm to ambient temperature. Stir for 30 min at ambient temperature. Add water (50 mL) and extract the aqueous layer three times with DCM.

10 Wash the combined organic extracts with water (100 mL), brine (100 mL), dry over MgSO_4 , filter, and concentrate *in vacuo* to give the desired intermediate (980 mg, 89%) as a light yellow oil which solidified to an off-white solid upon standing at ambient temperature. MS (ES+) *m/z*: 300 ($M+H$)⁺.


15 **6-Hydroxy-7-propyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:**

Dissolve 7-allyl-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.5 g, 5 mmol) in EtOAc (50 mL) containing 10% Pd/C (1.3 g). Stir at ambient temperature at 1 atm with H_2 (balloon) for 30 min. Filter the catalyst and wash with water (100 mL). Extract the resulting filtrate three times with EtOAc, wash the
20 combined organic extracts with brine, dry over MgSO_4 , filter and concentrate *in vacuo* to give the desired intermediate as a white solid (1.45 g, 97%). MS (ES+) *m/z*: 302 ($M+H$)⁺.

7-Propyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Cool a solution of 6-hydroxy-7-propyl-3-(2,2,2-trifluoroacetyl)-
25 2,3,4,5-tetrahydro-1H-benzo[d]azepine (500 mg, 1.9 mmol), triethylamine (390 μL , 2.3 mmol) and DCM (20 mL) in a cryogenic bath set at -35°C and add dropwise over 20 min trifluoromethanesulfonic anhydride (325 μL , 2.3 mmol). Stir at this temperature overnight. Wash the reaction mixture sequentially with water, 1N aqueous HCl, water, and brine. Dry the organic layer over Na_2SO_4 and concentrate *in vacuo*. Purify by
30 chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain the title compound as an off-white waxy solid (550 mg, 75%). MS (ES+) *m/z*: 434 ($M+H$)⁺.

Preparation 19

6-Amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine

7-Chloro-6-(4-methoxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-

trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (15 g, 35.3 mmol),
 10 with 4-methoxybenzylamine (13.7 mL, 106 mmol) using tris(dibenzylideneacetone)-
 dipalladium(0) (1.62 g, 1.76 mmol), BINAP (4.40 g, 3.5 mmol) and cesium carbonate
 (16.1 g, 49.4 mmol) at 80°C for 17 h. Filter the mixture through a pad of Celite® and
 evaporate the filtrate. Dissolve the residue in DCM and filter through a pad of silica gel.
 Evaporate the filtrate and purify by chromatography on silica gel eluting with
 15 hexane/EtOAc (1:0 to 2:3) to give the desired intermediate as a white solid (12.4 g, 86%).
 MS (ES+) *m/z*: 412 (M+H)⁺.


6-Amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:

Treat 7-chloro-6-(4-methoxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-
 20 1*H*-benzo[*d*]azepine (5.41 g, 13.1 mmol) with 2,3-dichloro-5,6-dicyano-1,4-
 benzoquinone (3.59 g, 15.8 mmol) in toluene (66 mL) at ambient temperature for 2 h.
 Dilute the mixture with EtOAc and wash with saturated aqueous NaHCO₃ (5 x 100 mL).
 Extract the aqueous layer with ether, combine the organic extracts and evaporate to a
 volume of 300 mL. Extract the organic phase with 1*N* aqueous HCl (5 x 100 mL), and
 25 then wash the combined aqueous layers with ether (4 x 75 mL). Cool the aqueous phase
 to 0°C, neutralize with 5*N* aqueous NaOH (100 mL), and extract with DCM (5 x 200

mL). Wash the combined organic extracts with brine, dry over Na_2SO_4 and evaporate to obtain the title compound as a white solid (3.6 g, 94%). MS (ES+) m/z : 293 (M+H)⁺.

Preparation 20

- 5 6-(2-Amino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine




- 10 **6-(2-*tert*-Butoxycarbonylamino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** Use a method similar to the General Procedure 5-1, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (150 mg, 0.352 mmol), palladium(II) acetate (8 mg, 0.0352 mmol), BINAP (22 mg, 0.0352 mmol), cesium carbonate (163 mg, 0.5 mmol), *t*-butyl *N*-(2-aminoethyl)-carbamate (254 mg, 1.59 mmol) and toluene (6 mL) to give, after chromatography on silica gel eluting with hexane/EtOAc (4:1), the desired intermediate (136 mg, 89%).

- 20 **6-(2-Amino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** Dissolve 6-(2-*tert*-butoxycarbonylamino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (136 mg, 0.31 mmol) in 4M hydrogen chloride in dioxane (20 mL) and stir at ambient temperature for 25 min. Concentrate to afford the hydrochloride salt. Dissolve the salt in DCM and wash with saturated aqueous NaHCO_3 . Extract the basic aqueous layer with DCM, dry the organic layer over MgSO_4 , filter, and concentrate *in vacuo* to give the title compound (64 mg, 62%). MS (ES+) m/z : 336 (M+H)⁺.

Preparation 21


6-(3-Amino-propylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



Use a method similar to the Preparation 20, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (600 mg, 1.41 mmol) and *tert*-butyl *N*-(3-aminopropyl)-carbamate (1.11 g, 6.34 mmol) to give the title compound (34% overall).

Preparation 22


7-Chloro-6-(4-hydroxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



Dissolve 7-chloro-6-(4-methoxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.667 g) in DCM (40 mL). Add a 1M solution of boron tribromide in DCM (10 mL) at 0°C. Stir the reaction for 12 h and gradually raise to room temperature. Quench the reaction with saturated aqueous NaHCO₃ and extract with DCM three times. Combine the organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to give the title compound as an oil (888 mg). MS (ES+) *m/z*: 399 (M+1)⁺.

Preparation 23

7-Chloro-6-(3-chloro-4-hydroxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine




7-Chloro-6-(3-chloro-4-methoxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Use a method similar to General Procedure 5-3, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.277 g, 3.0 mmol) and 3-chloro-4-methoxybenzylamine (669 mg, 3.9 mmol) to give the desired intermediate as a slightly yellow oil (1.554 g, 100%).

7-Chloro-6-(3-chloro-4-hydroxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Use a method similar to Preparation 22, using 7-chloro-6-(3-chloro-4-methoxybenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.36 g, 3.0 mmol) to give the title compound as an off-white solid (876 mg, 67% yield). MS (ES+) m/z : 433 (M+H)⁺. MS (ES-) m/z : 431 (M-H)⁻.

Preparation 24


3-(*tert*-Butoxycarbonyl)-6-(4-carboxybenzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine



Combine 7-chloro-6-(4-methoxycarbonyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.4 g, 0.82 mmol), potassium carbonate (4 g, 28.9 mmol), methanol (3 mL), water (3 mL) and heat at 50°C for 2 h. Cool the reaction mixture to ambient temperature, add saturated aqueous Na₂CO₃ and dilute with DCM (10 mL). Add di-*tert*-butyl-dicarbonate (2.4 g, 10.9 mmol) by portions. Separate the organic layer and extract the aqueous layer with DCM (3 x 10 mL). Combine the organic extracts, dry over anhydrous Na₂SO₄, evaporate the solvent and purify by chromatography on silica gel eluting with DCM and DCM/methanol (9:1) to give the title compound as a white solid (0.3 g, 80%). MS (ES+) *m/z*: 331 (M+H-Boc)⁺.


Preparation 25

2-Benzyloxyethylamine




(2-Benzyloxyethyl)-carbamic acid *tert*-butyl ester: Dissolve *tert*-butyl-*N*-(2-hydroxyethyl)-carbamate (10 mL, 64.5 mmol) in anhydrous THF (500 mL) at 0 °C. Add sodium hydride (60% in mineral oil, 3.1 g, 77.4 mmol) and stir for 30 min at 0 °C. Add benzyl bromide (9.2 mL, 77 mmol) followed by tetrabutylammonium iodide (3.7 g, 10 mmol) and stir at ambient temperature overnight. Quench with water (500 mL), extract with diethyl ether (3 x 100 mL), wash the combined organic extracts with brine, dry over MgSO₄, filter, and evaporate to give the desired intermediate (15 g), that was used without further purification.

2-Benzyloxyethylamine: Dissolve (2-benzyloxyethyl)-carbamic acid *tert*-butyl ester (15 g) in DCM (50 mL), add trifluoroacetic acid (20 mL) and stir at 0°C for 3 h. Concentrate and dissolve the residue in a minimal amount of DCM. Purify by chromatography on silica gel eluting sequentially with hexane/EtOAc (4:1 and 1:1), EtOAc and 2M ammonia in methanol to give the title compound (8.3 g, 85%).

Preparation 26**(*R*)-2-Benzoyloxy-1-methyl-ethylamine**

5
10
15
(*R*)-3-Benzoyloxy-2-(*tert*-butoxycarbonylamino)-propane: Dissolve (*R*)-(+)-2-(*tert*-butoxycarbonylamino)-1-propanol (875 mg, 5 mmol) in anhydrous THF (50 mL). Add sodium hydride (60% in mineral oil, 210 mg, 5.2 mmol) and stir at 0°C for 30 min. Add benzyl bromide (620 μ L, 5.2 mmol) followed by tetrabutylammonium iodide (20 mg, 0.05 mmol) and stir for 3 h at ambient temperature. Pour the mixture into water (200 mL), extract with DCM (3 x 50 mL), wash with brine, dry over MgSO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (19:1) to give the desired intermediate as a colorless oil (800 mg, 60%).

20
(*R*)-2-Benzoyloxy-1-methyl-ethylamine: Dissolve (*R*)-3-benzoyloxy-2-(*tert*-butoxycarbonylamino)-propane (800 mg, 3 mmol) in DCM (10 mL), add trifluoroacetic acid (5 mL), and stir at 0 °C for 20 min. Evaporate and purify by SCX chromatography to give the title compound as a colorless oil (440 mg, 89%). MS (ES+) *m/z*: 166 (M+H)⁺.

Preparation 27**(*R*)-2-(4-Fluorobenzoyloxy)-1-methyl-ethylamine**

25
(*R*)-2-(*tert*-Butoxycarbonylamino)-3-(4-fluorobenzoyloxy)-propane: Dissolve (*R*)-(+)-2-(*tert*-butoxycarbonylamino)-1-propanol (1.75 mg, 10.5 mmol) in anhydrous THF (50 mL). Add sodium hydride (60% in mineral oil, 480 mg, 12 mmol) and stir at 0°C for 30


min. Add 4-fluorobenzyl bromide (1.5 mL, 12 mmol) followed by tetrabutylammonium iodide (370 mg, 0.1 mmol) and stir for 72 h at ambient temperature. Pour the mixture into water (500 mL), extract with DCM (3 x 150 mL), wash with brine, dry over MgSO_4 , filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with
5 hexane/EtOAc (9:1) to give the desired intermediate as a yellow oil (2.18 g, 77%).

(R)-2-(4-Fluorobenzoyloxy)-1-methyl-ethylamine: Dissolve **(R)-2-(tert-butoxycarbonylamino)-3-(4-fluorobenzoyloxy)-propane** (2.18 g, 7.7 mmol) in DCM (50 mL), add trifluoroacetic acid (25 mL), and stir at 0°C for 20 min. Evaporate and purify by
10 SCX chromatography to give the title compound as a colorless oil (1.2 g, 85%). MS (ES+) m/z : 184 (M+H)⁺.

Preparation 28

(R)-1-Methyl-2-phenoxy-ethylamine

15




(R)-2-(tert-Butoxycarbonylamino)-3-phenoxy-propane: Dissolve **(R)-(+)-2-(tert-butoxycarbonylamino)-1-propanol** (1.75 g, 10 mmol) and phenol (0.95 g, 10 mmol) in
20 anhydrous THF (75 mL). Cool to 0°C, add triphenylphosphine (4.0 g, 15 mmol) and diisopropylazodicarboxylate dropwise and stir at ambient temperature for 18 h. Pour the mixture into water (300 mL), basify to pH 10 with 5N aqueous NaOH, and extract with ethyl ether (3 x 100 mL). Wash the organic phase with brine, dry over MgSO_4 , filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to
25 give the desired intermediate as an off-white solid (340 mg, 14%).

(R)-1-Methyl-2-phenoxy-ethylamine: Dissolve **(R)-2-(tert-butoxycarbonylamino)-3-phenoxy-propane** (340 mg, 1.35 mmol) in DCM (80 mL), add trifluoroacetic acid (35 mL), and stir at 0 °C for 2 h. Evaporate and purify by SCX chromatography to give the
30 title compound as a colorless oil (186 mg, 91%). MS (ES+) m/z : 151 (M+H)⁺.

Preparation 29

4-(Aminomethyl)-2-methyl-thiazole



5

4-(Azidomethyl)-2-methyl-thiazole: Dissolve 4-(chloromethyl)-2-methyl-thiazole (350 mg, 2.37 mmol) and azidotrimethylsilane (315 μ L, 2.37 mmol) in anhydrous THF (1 mL) under nitrogen. Add a 1M solution of tetrabutylammonium fluoride (3.6 mL, 3.56 mmol) in THF and stir at ambient temperature overnight. Pour the reaction mixture into water (10 mL), extract with ethyl ether (3 x 2 mL), wash the organic extracts with brine, dry over MgSO_4 , filter, and evaporate. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the desired intermediate as a colorless oil (165 mg, 45%).

10


4-(Aminomethyl)-2-methyl-thiazole: Add 4-(azidomethyl)-2-methyl-thiazole (165 mg, 1.07 mmol) to a slurry of methanol containing 10% Pd/C (75 mg) and stir vigorously under 1 atm H_2 for 1 h. Filter, evaporate the solvent, and purify by SCX chromatography to give the title compound (55 mg, 40%).

15

Preparation 30

2-Fluoro-4-phenoxy-benzylamine

20



25

(4-Bromo-2-fluorobenzyl)-carbamic acid *tert*-butyl ester: Mix under nitrogen 4-bromo-2-fluorobenzylamine hydrochloride (7.2 g, 30 mmol), di-*tert*-butyl-dicarbonate

(9.8 g, 45 mmol), and potassium carbonate (12.4 g, 90 mmol) in anhydrous THF (200 mL). Stir at ambient temperature for 16 h. Filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain the desired intermediate (6.4 g, 70%). GC-MS m/z : 247 $[(M-C_4H_9)^+]$.

5


(2-Fluoro-4-phenoxy-benzyl)-carbamic acid *tert*-butyl ester: Mix under argon atmosphere (4-bromo-2-fluorobenzyl)-carbamic acid *tert*-butyl ester (2.12 g, 7.0 mmol), phenol (1.32 g, 14 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (129 mg, 0.7 mmol), and cesium carbonate (4.56 g, 14 mmol) in anhydrous NMP (15 mL). Degas the flask, fill
10 with argon and add copper(I) chloride (346 mg, 3.5 mmol) quickly. Degas the flask then fill with argon and heat at 120°C for 5 h. Cool to ambient temperature, dilute with EtOAc and filter. Wash the mixture sequentially with 0.5N aqueous HCl, 0.5N aqueous NaOH and brine. Separate the organic layer, dry over Na_2SO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 3:1) to obtain
15 the desired intermediate (1.28 g, 58%). GC-MS m/z : 260 $[(M-C_4H_9)^+]$.

2-Fluoro-4-phenoxy-benzylamine: Dissolve (2-fluoro-4-phenoxy-benzyl)-carbamic acid *tert*-butyl ester (2.44 g, 7.72 mmol) in DCM (200 mL). Add trifluoroacetic acid (50 mL) then stir at ambient temperature for 16 h. Evaporate the solvent, dissolve the residue in
20 DCM and wash with 1N aqueous NaOH. Dry over Na_2SO_4 and concentrate *in vacuo*. Purify by SCX chromatography to obtain the title compound (557 mg, 33%). MS (ES+) m/z : 201 $(M+H-NH_3)^+$.

Preparation 31

25


2-Fluoro-4-(3'-fluorophenoxy)-benzylamine



Use a method similar to Preparation 30, using (4-bromo-2-fluorobenzyl)-carbamic acid *tert*-butyl ester (2.12 g, 7.0 mmol) and *m*-fluorophenol (1.57 g, 14 mmol) to give the
30 title compound (468 mg, 47% overall).

Preparation 32

4-(2'-Fluorophenoxy)-benzylamine



5

4-(2'-Fluorophenoxy)-benzonitrile: Mix under argon atmosphere 4-bromobenzonitrile (2.0 g, 11.3 mmol), 2-fluorophenol (2.5 g, 22.6 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (203 mg, 1.1 mmol), and cesium carbonate (7.4 g, 22.6 mmol) in anhydrous NMP (19 mL). Degas the flask, fill with argon and add copper(I) chloride (554 mg, 5.6 mmol) quickly. Degas the flask then fill with argon and heat at 120°C for 3 h. Cool to ambient temperature, dilute with EtOAc, filter and wash the filtrate sequentially with 2M aqueous HCl, 0.3M aqueous HCl, 2M aqueous NaOH and brine. Separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate (1.6 g, 66%). MS (ES+) *m/z*: 231 (M+NH₄)⁺.

10
15

4-(2'-Fluorophenoxy)-benzylamine: Add 4-(2'-fluorophenoxy)-benzonitrile (1.5 g, 7.0 mmol) and ethanol wet Raney® activated nickel (0.4 g) to a Parr pressure vessel. Immediately add a 7N solution of ammonia in methanol (170 mL) and seal the vessel. Purge the reaction vessel with nitrogen, pressurize the reaction mixture with hydrogen (3400 KPa), seal the vessel, agitate the reaction and heat to 60°C. Continue the reaction for 18 h, turn off the heat and allow the reaction mixture to cool to ambient temperature. Vent the excess hydrogen from the vessel and purge the vessel with nitrogen. Filter the reaction mixture to remove the Raney® nickel. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (9:1) to obtain the title compound (1.2 g, 79%). MS (ES+) *m/z*: 201 (M+H-NH₃)⁺.


20
25

The compound of Preparation 33 may be prepared essentially as described in Preparation 32 using 4-bromobenzonitrile and 3-fluorophenol. Overall yield and MS (ES+) data are shown in the Table below.

Prep.	Compound	Yield (%)	MS (ES+) <i>m/z</i>
33	4-(3'-Fluorophenoxy)-benzylamine	53	201 (M+H-NH ₃) ⁺

Preparation 34

4-(3'-Isopropylphenoxy)-benzylamine



Use a method similar to Preparation 32 (Step 1), using 4-bromobenzonitrile (2.0 g, 11.3 mmol) and 3-isopropylphenol (3.08 g, 22.6 mmol) to give 4-(3'-isopropylphenoxy)-benzonitrile (885 mg, 33%). MS (ES+) *m/z*: 255 (M+NH₄)⁺.

Use a method similar to the reduction procedure described in Preparation 45 (Step 2), using 4-(3'-isopropylphenoxy)-benzonitrile (875 mg, 3.7 mmol) to give the title compound (703 mg, 79%). MS (ES+) *m/z*: 225 (M+H-NH₃)⁺.


The compounds of Preparations 35-39 may be prepared essentially as described in Preparation 34 by using 4-bromobenzonitrile and the appropriate phenol. Overall yields and MS (ES+) data are shown in the Table below.

Prep.	Compound	Yield (%)	MS (ES+) <i>m/z</i>
35	4-(2'-Isopropylphenoxy)-benzylamine	28	225 (M+H-NH ₃) ⁺
36	4-(3'-Methylphenoxy)-benzylamine	60	197 (M+H-NH ₃) ⁺
37	4-(2'-Methylphenoxy)-benzylamine	59	197 (M+H-NH ₃) ⁺

Prep.	Compound	Yield (%)	MS (ES+) <i>m/z</i>
38	4-(3',5'-Difluorophenoxy)-benzylamine	24	219 (M+H-NH ₃) ⁺
39	4-(3'-Chlorophenoxy)-benzylamine	44	217 (M+H-NH ₃) ⁺

Preparation 40

2-(4-Aminomethyl-phenoxy)-benzonitrile



(4-Hydroxybenzyl)-carbamic acid *tert*-butyl ester: Mix 2,2,2-trifluoro-*N*-(4-
 10 hydroxybenzyl)-acetamide (8.8 g, 40 mmol), and 5N aqueous NaOH (20 mL) in methanol
 (100 mL). Stir at ambient temperature for 4 h. Adjust pH to about 8 with aqueous HCl.
 Add solid sodium bicarbonate (4.4 g, 52 mmol), di-*tert*-butyl-dicarbonate (9.3 g, 40
 mmol) and DCM. Stir at ambient temperature for 16 h. Dilute with DCM, wash with 1N
 aqueous HCl and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1
 15 to 5:5) to obtain the desired intermediate (7.8 g, 87%). MS (ES-) *m/z*: 222 (M-H)⁻.

2-(4-Aminomethyl-phenoxy)-benzonitrile: Mix under argon (4-hydroxybenzyl)-
 carbamic acid *tert*-butyl ester (1.5 g, 6.7 mmol), 2-bromobenzonitrile (813 mg, 4.5
 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (83 mg, 0.45 mmol), and cesium carbonate
 20 (2.2 g, 6.7 mmol) in anhydrous NMP (8.5 mL). Degas the flask and fill with argon. Add
 copper(I) chloride (223 mg, 2.25 mmol) quickly. Degas the flask, fill with argon and heat
 at 120°C for 3 h. Cool to ambient temperature, dilute with EtOAc, filter and concentrate
in vacuo. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and
 3:1). Evaporate the solvent and dissolve the residue in DCM (100 mL). Add

trifluoroacetic acid (20 mL) and stir at ambient temperature for 16 h. Concentrate *in vacuo*, dissolve the residue in EtOAc and wash with 1N aqueous NaOH. Dry over Na₂SO₄ and concentrate *in vacuo*. Purify by SCX chromatography to obtain the title compound (385 mg, 38%). MS (ES+) *m/z*: 225 (M+H)⁺.

5


The compounds of Preparation 41-43 may be prepared essentially as described in Preparation 40 by using (4-hydroxybenzyl)-carbamic acid *tert*-butyl ester (1.5 g, 6.7 mmol) and the appropriate bromide. Overall yields and MS (ES+) data are shown in the Table below.

10

Prep.	Compound	Yield (%)	MS (ES+) <i>m/z</i>
41	4-(2'-Trifluoromethyl-phenoxy)-benzylamine	13	251 (M+H-NH ₃) ⁺
42	4-(3'-Trifluoromethyl-phenoxy)-benzylamine	27	251 (M+H-NH ₃) ⁺
43	4-(Pyridin-3-yloxy)-benzylamine	11	201 (M+H) ⁺

Preparation 44

3-(4-Aminomethyl-phenoxy)-benzonitrile




15

Use a method similar to Preparation 40 (Step 2), using 2,2,2-trifluoro-*N*-(4-hydroxybenzyl)-acetamide (1.0 g, 5.5 mmol) and 3-bromobenzonitrile (673 mg, 3.7 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 3:1).

20 Concentrate *in vacuo*. Dissolve the residue (287 mg, 0.89 mmol) in methanol (25 mL) and add 5N NaOH (7 mL). Stir at room temperature for 4 h. Dilute with DCM and add solid sodium chloride to the mixture. Extract the aqueous layer three times with DCM.

Combine organic extracts, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to

25 obtain the title compound (124 mg, 62%). MS (ES+) *m/z*: 500 (M+H)⁺.

Preparation 45**4-(3,3-Dimethylbutoxy)-benzylamine**

4-(3,3-Dimethylbutoxy)-benzonitrile: Mix 4-cyanophenol (1.2 g, 10 mmol), 1-bromo-3,3-dimethylbutane (5.3 g, 32 mmol), powdered potassium carbonate (4.14 g, 30 mmol), and powdered potassium iodide (166 mg, 1 mmol) in acetone (60 mL). Stir under inert atmosphere and heat at reflux for 48 h. Cool the reaction mixture to ambient temperature. Dilute with acetone, filter and evaporate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate (1.8 g, 89%). MS (ES+) m/z : 221 ($M+NH_4$)⁺.

10

4-(3,3-Dimethylbutoxy)-benzylamine: Mix lithium aluminum hydride (1.0 g, 26.6 mmol) and anhydrous ethyl ether (70 mL) under nitrogen atmosphere. Stir and cool to 0 °C in an ice bath. Add dropwise a solution of 4-(3,3-dimethylbutoxy)-benzonitrile (1.8 g, 8.87 mmol) in anhydrous ethyl ether (20 mL). Stir for 2 h at 0 °C, remove the ice bath and stir at ambient temperature for 18 h. Cool the reaction flask in an ice bath and add carefully dropwise and sequentially water (1 mL), 2N aqueous NaOH (1 mL), and water (2 mL). Stir for 30 min, filter, separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo* to obtain the title compound (1.62 g, 88%). MS (ES+) m/z : 191 ($M+H-NH_3$)⁺.

15

20


25 The compounds of Preparations 46-48 may be prepared essentially as described in Preparation 45 by using 4-cyanophenol and the appropriate bromide. Overall yields and MS (ES+) data are shown in the Table below.

Prep	Compound	Yield (%)	MS (ES+) <i>m/z</i>
46	4-Cyclohexylmethoxy-benzylamine	90	203 (M+H-NH ₃) ⁺
47	4-(2-Cyclohexylethoxy)-benzylamine	94	217 (M+H-NH ₃) ⁺
48	4-(2,2-Dimethylpropoxy)-benzylamine	4	177 (M+H-NH ₃) ⁺

Preparation 49

4-Benzyloxy-benzylamine

5




4-Benzyloxy-benzonitrile: Add 4-cyanophenol (1.191 g, 10 mmol), benzyl bromide (1.881 g, 11 mmol), potassium carbonate (3.455 g, 25 mmol) and potassium iodide (166 mg, 1 mmol) to acetonitrile (80 mL) and heat at reflux for 12 h. Cool, partition between EtOAc and water, separate the organic layer, and extract the aqueous layer with EtOAc. Combine the organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:6) to give the desired intermediate as a white solid (2.098 g, 100%). MS (ES+) *m/z*: 227 (M+NH₄)⁺.

4-Benzyloxy-benzylamine: Use a method similar to Preparation 58, using 4-benzyloxy-benzonitrile (2.098 g, 10 mmol), to give the title compound as a white solid (2.021 g, 94%). MS (ES+) *m/z*: 197 (M+H-NH₃)⁺.

20

Preparation 50

 (\pm) -4-(1-Phenylethoxy)-benzylamine

5


(\pm) -4-(1-Phenylethoxy)-benzonitrile: Add triphenylphosphine (7.869 g, 30 mmol) to a solution of *sec*-phenylethyl alcohol (1.467 g, 12 mmol), 4-cyanophenol (1.191 g, 10 mmol) and diethyl azodicarboxylate (4.528 g, 26 mmol) in anhydrous THF (50 mL) at 0 °C. Stir the reaction at ambient temperature for 12 h. Dilute with EtOAc, wash with
 10 brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:8) to give (\pm) -4-(1-phenylethoxy)-benzonitrile with a small amount of triphenylphosphine (2.49 g total).

(\pm) -4-(1-Phenylethoxy)-benzylamine: Use a method similar to Preparation 58, using
 15 crude (\pm) -4-(1-phenylethoxy)-benzonitrile, to give the title compound as a colorless oil (1.6 g, 70% two steps). MS (ES+) *m/z*: 211 (M+H-NH₃)⁺, 455.3 (2M+H)⁺.

Preparation 51

4-(3,3-Dimethyl-2-oxo-butoxy)-benzylamine

20



2,2,2-Trifluoro-N-(4-methoxybenzyl)-acetamide: Mix under nitrogen atmosphere 4-methoxybenzylamine (13.7 g, 100 mmol) and *N*-methylmorpholine in anhydrous THF (300 mL). Cool to 0°C in an ice bath. Add dropwise a solution of trifluoroacetic anhydride (15.6 mL, 110 mmol) in anhydrous THF (25 mL). Warm up to ambient temperature slowly and stir for 16 h. Concentrate *in vacuo*. Dissolve in EtOAc and wash successively with 1N aqueous NaOH, 1N aqueous HCl, and brine. Separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 and 4:1) to obtain the desired intermediate (19 g, 81%). MS (ES-) *m/z*: 232 (M-H)⁻.


2,2,2-Trifluoro-N-(4-hydroxy-benzyl)-acetamide: Dissolve under nitrogen atmosphere 2,2,2-trifluoro-*N*-(4-methoxybenzyl)-acetamide (11.6 g, 50 mmol) in DCM (250 mL). Cool to 0°C in an ice bath. Add dropwise 1M boron tribromide in DCM (100 mL, 100 mmol) and stir for 20 min after addition. Warm to ambient temperature and stir for 16 h. Cool the reaction mixture in an ice bath and quench very carefully with saturated aqueous NaHCO₃. Separate the organic layer. Extract the aqueous layer twice with chloroform. Dry the combined organic extracts over Na₂SO₄ and concentrate *in vacuo* to obtain the desired intermediate (8.8 g, 40 mmol). MS (ES-) *m/z*: 218 (M-H)⁻.

N-[4-(3,3-Dimethyl-2-oxo-butoxy)-benzyl]-2,2,2-trifluoroacetamide: Mix 2,2,2-trifluoro-*N*-(4-hydroxy-benzyl)-acetamide (438 mg, 2.0 mmol), 1-bromopinacolone (430 mg, 2.4 mmol), anhydrous potassium carbonate (829 mg, 6.0 mmol) and potassium iodide (33 mg, 0.1 mmol) with acetone. Heat under reflux for 12 h. Acidify with 1N aqueous HCl and extract with EtOAc three times. Combine the organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to give the desired intermediate as a colorless oil. MS (ES+) *m/z*: 335 (M+NH₄)⁺. MS (ES-) *m/z*: 316 (M-H)⁻.

4-(3,3-Dimethyl-2-oxo-butoxy)-benzylamine: Add 5N aqueous NaOH (15 mL) to a solution of *N*-[4-(3,3-dimethyl-2-oxo-butoxy)-benzyl]-2,2,2-trifluoro-acetamide (552 mg, 1.74 mmol) in methanol (10 mL) and stir for 2 h at ambient temperature. Extract the mixture with DCM three times. Dry the combined organic extracts over Na₂SO₄, filter

and concentrate. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (92:8) to give the title compound as a colorless oil (337 mg, 87%). MS (ES+) m/z : 205 ($M+H-NH_3$)⁺.

5

Preparation 52*N*-(2-Chloro-acetyl)-piperidine


10

Add chloroacetyl chloride (1.242 g, 11.0 mmol) to a mixture of potassium carbonate (2.073 g, 15 mmol) and piperidine (852 mg, 10 mmol) in THF (50 mL) at 0 °C. Stir the reaction for 12 h and gradually raise to room temperature. Dilute with water, extract with EtOAc three times. Combine the organic extracts and wash sequentially with saturated aqueous NaHCO₃, 0.1N aqueous HCl and brine. Dry over Na₂SO₄, filter and concentrate to give the title compound (1.65 g, 100%).

15

Preparation 53

4-Benzylthio-benzylamine



20

4-Benzylthio-benzonitrile: Mix under argon atmosphere 4-fluorobenzonitrile (1.21 g, 10 mmol), benzyl mercaptan (1.86 g, 15 mmol), and cesium carbonate (6.5 g, 20 mmol) in anhydrous NMP (20 mL). Degas the flask and fill with argon. Heat at 120°C for 3 h. Cool to ambient temperature, dilute with EtOAc, filter and wash with 1N aqueous HCl. Separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by


25

chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate (689 mg, 31%). GC-MS m/z : 225 (M^+).

4-Benzylthio-benzylamine: Use the reduction procedure described in Preparation 45 (Step 2), using 4-benzylthio-benzonitrile (689 mg, 3.1 mmol) to give, after SCX chromatography, the title compound (464 mg, 64%). MS (ES+) m/z : 213 ($M+H-NH_3$)⁺.

Preparation 54

4-(2,2,3,3,3-Pentafluoropropoxy)-benzylamine




4-(2,2,3,3,3-Pentafluoropropoxy)-benzonitrile: Heat a mixture of 4-hydroxybenzonitrile potassium fluoride complex (3.0 g, 16.9 mmol) and 1,1,1,2,2-pentafluoro-3-iodo-propane (10.8 g, 37.2 mmol) in DMSO (80 mL) to 130°C for 20 h. Cool the mixture to ambient temperature, dilute with hexane/EtOAc (1:1, 200 mL) and wash with aqueous 10% NaCl (3 x 50 mL). Dry the organic layer, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 10:2 and 10:3) to obtain the desired intermediate (1.1 g, 26%). GC-MS m/z : 251 (M^+).

4-(2,2,3,3,3-Pentafluoropropoxy)-benzylamine: Use a method similar to the General Procedure 6-4, using 4-(2,2,3,3,3-pentafluoropropoxy)-benzonitrile (1.1 g, 4.1 mmol), to obtain the title compound (1.1 g, 99%). GC-MS m/z : 254 (M^+-H).

Preparation 55

4-(2,2,3,3-Tetrafluoropropoxy)-benzylamine




Use a method similar to Preparation 54, using 4-hydroxy-benzonitrile potassium fluoride complex (4.2 g, 23.7 mmol) and 1,1,2,2-tetrafluoro-3-iodo-propane (10 g, 41.3 mmol), to give the title compound (38% overall). GC-MS m/z : 236 ($M^+ - H$).

5


Preparation 56

4-(2,2,2-Trifluoro-1,1-dimethyl-ethoxy)-benzylamine



- 10 **4-(2,2,2-Trifluoro-1,1-dimethyl-ethoxy)-benzonitrile:** Add 2-trifluoromethyl-2-propanol (3.4 g, 27 mmol) slowly to a slurry of sodium hydride (0.6 g, 60% in mineral oil, washed with hexane) in HMPA (5 mL) under nitrogen. Stir the slurry for 15 min and add a solution of 4-nitrobenzonitrile (2.0 g, 13.5 mmol) in HMPA (10 mL). Stir the resulting purple slurry at ambient temperature for 16 h, dilute with diethyl ether (100 mL) and wash
- 15 with 5% aqueous HCl (30 mL). Separate the layers and extract the aqueous layer with diethyl ether (2 x 50 mL). Combine the organic extracts and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) to obtain the desired intermediate (780 mg, 25%). GC-MS m/z : 229 (M^+).
- 20 **4-(2,2,2-Trifluoro-1,1-dimethyl-ethoxy)-benzylamine:** Use a method similar to the General Procedure 6-4 to reduce 4-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)-benzonitrile (780 mg, 3.4 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (40:1, 20:1 and 10:1) to obtain the title compound (780 mg, 98%). GC-MS m/z : 232 ($M^+ - H$).

25

Preparation 57**(±)-4-(2,2,2-Trifluoro-1-methyl-ethoxy)-benzylamine**


(±)-4-(2,2,2-Trifluoro-1-methyl-ethoxy)-benzonitrile: Add 1,1,1-trifluoro-2-propanol (3.8 g, 66 mmol) slowly to a slurry of sodium hydride (730 mg, 60% in mineral oil, washed with hexane) in HMPA (5 mL) under nitrogen. Stir the slurry for 15 min and add 4-fluorobenzonitrile (2 g, 16.5 mmol). Heat the slurry in a sealed flask to 90°C for 16 h. Cool the mixture to ambient temperature and pour the mixture into a flask containing 5% aqueous HCl (20 mL). Extract the mixture with diethyl ether (3 x 50 mL), and wash with 5% aqueous HCl (25 mL). Dry the organic layer over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain the desired intermediate (2.5 g, 70%). GC-MS *m/z*: 215 (M⁺).

10

15

(±)-4-(2,2,2-Trifluoro-1-methyl-ethoxy)-benzylamine: Use a method similar to the General Procedure 6-4, using (±)-4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzonitrile (1.0 g, 4.6 mmol), to obtain the title compound (1.1 g, 95%). GC-MS *m/z*: 218 (M⁺-H).


20

Preparation 58**3-Methoxybenzylamine**

Add lithium aluminum hydride (3.795 g, 100 mmol) portion wise to a solution of 3-methoxybenzonitrile (5.326 g, 40 mmol) in anhydrous ethyl ether (200 mL) at 0°C. Stir

for 1 h, warm to ambient temperature and continue to stir for 12 h. Quench the reaction with 0.1N aqueous NaOH, filter the solid, dry the filtrate over Na₂SO₄ and concentrate to give the title compound as a colorless oil (5.107 g, 93%). MS (ES+) *m/z*: 138 (M+H)⁺.

5


Preparation 593-(*tert*-Butyl)benzylamine

Dissolve 3-*tert*-butyltoluene (0.5 mL, 2.9 mmol) in carbon tetrachloride (20 mL).
10 Add NBS (530 mg, 3 mmol) and irradiate the reaction mixture with a 250 watt sun-lamp with simultaneous heating to reflux for 1 h. Cool to ambient temperature, filter, and concentrate filtrate to dryness to give crude 1-bromomethyl-3-*tert*-butylbenzene. Dissolve crude 1-bromomethyl-3-*tert*-butylbenzene (600 mg) in anhydrous DMF. Add portion wise sodium azide (260 mg, 4 mmol) and stir at room temperature for 2 h. Pour the mixture
15 into water (250 mL), extract with EtOAc (3x50 mL), wash combined organic extracts with brine, dry over MgSO₄, filter and evaporate solvent to give crude 1-azidomethyl-3-*tert*-butylbenzene, that was used without further purification. Dissolve crude 1-azidomethyl-3-*tert*-butylbenzene in methanol containing 10% Pd/C (75 mg) at 5°C, and stir the resulting slurry under 1 atm H₂ for 1 h. Filtrate, concentrate *in vacuo* and purify by
20 chromatography on silica gel eluting sequentially with hexane/EtOAc (4:1 and 1:1), EtOAc, methanol and 2M ammonia in methanol to give the title compound (255 mg, 53% overall). MS (ES+) *m/z*: 164 (M+H)⁺.

25

Preparation 60


(3-Pyrrolidin-1-yl)benzylamine



Slurry a mixture of (3-bromobenzyl)-carbamic acid *tert*-butyl ester (600 mg, 2.1 mmol, U.S. Pat. Appl. Publ. US 2003134885), pyrrolidine (450 mL, 5.2 mmol), tris(dibenzylideneacetone)dipalladium(0) (200 mg, 0.21 mmol), BINAP (400 mg, 0.63 mmol) and cesium carbonate (960 mg, 2.94 mmol) in anhydrous toluene (10 mL). Degas under vacuum, fill the system with nitrogen and heat in a sealed flask at 90 °C for 18 h. Cool to room temperature, dilute with diethyl ether, filter, and concentrate *in vacuo*. Dissolve the resulting residue in DCM (10 mL) and add trifluoroacetic acid (5 mL). Stir at ambient temperature for 1 h and concentrate *in vacuo*. Purify by chromatography on silica gel eluting sequentially with hexane/EtOAc (1:1), EtOAc and 2M ammonia in methanol. Purify again by SCX chromatography to give the title compound as a brown oil (300 mg, 85% overall). MS (ES+) *m/z*: 178 (M+H)⁺.

Preparation 61

(±)-C-(3-Methyl-2,3-dihydro-benzofuran-5-yl)-methylamine



4-Allyloxy-3-bromo-benzonitrile: Mix 3-bromo-4-hydroxy-benzonitrile (1.520 g, 8.0 mmol), allyl bromide (1.161 g, 9.6 mmol), potassium carbonate (3.317 g, 24 mmol) and potassium iodide (133 mg, 0.1 mmol) in acetone (80 mL). Heat the mixture to reflux for 12 h. Cool to ambient temperature, add EtOAc, wash the organic layer with water, and extract the aqueous layer twice with EtOAc. Dry the combined organic extracts over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:8) to obtain the desired intermediate.

(±)-3-Methyl-2,3-dihydro-benzofuran-5-carbonitrile: Add tri-*n*-butyltin hydride (5.821 g, 20 mmol) and AIBN (411 mg, 2.5 mmol) to a solution of 4-allyloxy-3-bromo-benzonitrile (595 mg, 2.5 mmol). Heat the reaction at reflux for 20 h. Dilute with EtOAc and wash with water. Extract the aqueous layer with EtOAc three times. Combine the




organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:8) to give the desired intermediate as a white solid (474 mg, 100% with a trace amount of tributyltin derivative).

5

(±)-C-(3-Methyl-2,3-dihydro-benzofuran-5-yl)-methylamine: Use a method similar to Preparation 58, using (±)-3-methyl-2,3-dihydro-benzofuran-5-carbonitrile (474 mg, 2.98 mmol) to give the title compound as a colorless oil (410 mg, 84%).

10

The compounds of Preparations 62-64 may be prepared essentially as described in Preparation 61 by using 3-bromo-4-hydroxy-benzonitrile or 4-bromo-3-hydroxy-benzonitrile and the appropriately substituted allyl bromide. MS (ES⁺) data are shown in the Table below.


Prep.	Structure	Compound	MS (ES ⁺) <i>m/z</i>
62		(±)-C-(3-Methyl-2,3-dihydro-benzofuran-6-yl)-methylamine	164 (M+H) ⁺
63		C-(3,3-Dimethyl-2,3-dihydro-benzofuran-5-yl)-methylamine	ND
64		C-(3,3-Dimethyl-2,3-dihydro-benzofuran-6-yl)-methylamine	178 (M+H) ⁺

15

ND= Not determined

Preparation 65

C-(2,2-Dimethyl-3-oxo-2,3-dihydro-benzofuran-5-yl)-methylamine

**N-(2,2-Dimethyl-3-oxo-2,3-dihydro-benzofuran-5-ylmethyl)-2,2,2-trifluoro-**


acetamide: Add 2-bromoisobutyryl bromide (1.724 g, 7.5 mmol) to a solution of 2,2,2-trifluoro-N-(4-methoxy-benzyl)-acetamide (1.166 g, 5.0 mmol) in 1,2-dichloroethane (8 mL) at 15°C, then add powdered anhydrous iron(III) chloride (973 mg, 6.0 mmol). Stir the reaction at 15°C for 3 h and at ambient temperature for 8 days. Add dropwise saturated aqueous potassium sodium tartrate, then water and EtOAc, and stir for 1 h. Filter off the solid, separate the organic layer, and extract the aqueous layer three times with EtOAc. Combine the organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to give the desired intermediate (253 mg, 17%).

C-(2,2-dimethyl-3-oxo-2,3-dihydro-benzofuran-5-yl)-methylamine: Dissolve N-(2,2-dimethyl-3-oxo-2,3-dihydro-benzofuran-5-ylmethyl)-2,2,2-trifluoro-acetamide (253 mg, 0.88 mmol) in 7M ammonia in methanol and stir at ambient temperature for 5 days.

Remove volatiles *in vacuo*, purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (92:8) to give the title compound (44 mg, 26%). MS (ES+) *m/z*: 175 (M+H-NH₃)⁺.

Preparation 66

C-(2,2-Dimethyl-3-oxo-2,3-dihydro-benzofuran-6-yl)-methylamine




2,2,2-Trifluoro-*N*-(3-methoxy-benzyl)-acetamide: Add trifluoroacetic anhydride (6.3 g, 30 mmol) to a solution of 3-methoxybenzylamine (3.43 g, 25 mmol) and *N*-methylmorpholine (3.793 g, 37.5 mmol) in THF (80 mL) at 0°C and stir at this temperature for 4 h. Warm to ambient temperature and stir for 12 h. Dilute with EtOAc, wash sequentially with water, 1N aqueous HCl, saturated aqueous NaHCO₃ and brine. Dry the organic layer over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to give the desired intermediate (5.344 g, 91%).


C-(2,2-Dimethyl-3-oxo-2,3-dihydro-benzofuran-6-yl)-methylamine: Use a method similar to Preparation 65, using 2,2,2-trifluoro-*N*-(3-methoxy-benzyl)-acetamide (1.166 g, 5 mmol), to give the title compound (220 mg, 23% two steps). MS (ES+) *m/z*: 192 (M+H)⁺.

Preparation 67

6-Aminomethyl-2,2-dimethyl-2*H*-chromene




Add 2,2-dimethyl-2*H*-chromene-6-carbonitrile (1.5 g, 8.1 mmol) and ethanol wet Raney® activated nickel (0.4 g) to a Parr pressure vessel. Immediately add 7N ammonia in methanol (170 mL) and seal the vessel. Purge the reaction vessel with nitrogen, pressurize the reaction mixture with hydrogen (3400 KPa), seal the vessel, agitate the reaction and heat to 60°C for 20 h. Turn off the heat and allow the reaction mixture to cool to ambient temperature. Vent the excess hydrogen from the vessel and purge the vessel with nitrogen. Filter the reaction mixture to remove the Raney® nickel. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (9:1) to obtain the title compound (1.5 g, 97%). MS (ES+) *m/z*: 175 (M+H-NH₃)⁺.

Preparation 68**4-(2-Methylthiazol-4-yl)-benzylamine**

- 5 **4-(2-Methylthiazol-4-yl)-benzonitrile:** Suspend 4-cyanophenyl bromide (515 mg, 2.23 mmol) in ethanol (15 mL). Add thioacetamide (171 mg, 2.23 mmol) and sodium bicarbonate (187 mg, 2.23 mmol) and heat the mixture under reflux for 2 h. Concentrate *in vacuo* and dissolve the residue in DCM. Wash the organic fraction with water, dry over Na₂SO₄, filter and concentrate to give a solid. Suspend the solid in ether/hexane and
- 10 filter under vacuum washing with hexane to obtain the desired intermediate as a white solid (415 mg, 93%). GC-MS *m/z*: 200 (M⁺).

- 4-(2-Methylthiazol-4-yl)-benzylamine:** Dissolve 4-(2-methylthiazol-4-yl)-benzonitrile (305 mg, 1.52 mmol) in anhydrous THF (50 mL). Add a 1M solution of lithium
- 15 aluminum hydride in THF (3.05 mL, 3.05 mmol). Heat the mixture overnight under reflux. Cool the reaction mixture with ice/water and work-up sequentially with EtOAc and water. Filter the mixture over Celite®. Separate the organic phase, and extract the aqueous phase with chloroform. Dry the combined organic extracts over Na₂SO₄, filter and concentrate to obtain the title compound as an oil (120 mg) that was used without
- 20 further purification. GC-MS *m/z*: 204 (M⁺).

Preparation 69**4-(Pyridin-4-yl)-benzylamine**


N-(tert-Butoxycarbonyl)-4-bromo-benzylamine: Add di-*tert*-butyl-dicarbonate (1.173 g, 5.375 mmol) and triethylamine (1.087 g, 1.0 mL, 10.75 mmol) to a stirred solution of 4-bromobenzylamine (1.0 g, 5.375 mmol) in anhydrous DCM (15 mL). Stir overnight at ambient temperature, dilute with DCM and wash with water. Separate the organic phase, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 19:1 and 9:1) to obtain the desired intermediate as a solid (1.24 g, 81%).

N-(tert-Butoxycarbonyl)-4-(pyridin-4-yl)-benzylamine: Dissolve *N*-(*tert*-butoxycarbonyl)-4-bromo-benzylamine (0.8 g, 2.807 mmol) in anhydrous DME (12 mL) under nitrogen. Add tetrakis(triphenylphosphine)palladium(0) (0.162 g, 0.14 mmol), pyridine-4-boronic acid (0.513 g, 4.211 mmol), and a 2M aqueous Na₂CO₃ solution (2.8 mL, 5.614 mmol). Heat the reaction overnight at 70°C. Cool the mixture to ambient temperature, dilute with EtOAc, and filter over Celite®. Wash the organic fraction with water, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 4:1 and 1:1) to give the title compound as an oil (0.295 g, 37%). GC-MS *m/z*: 284 (M⁺).

4-(Pyridin-4-yl)-benzylamine: Dissolve *N*-(*tert*-butoxycarbonyl)-4-(4-pyridyl)-benzylamine (363 mg, 1.276 mmol) in anhydrous DCM (10 mL). Add 4N hydrogen chloride in dioxane (10 mL) and stir overnight at ambient temperature. Concentrate *in vacuo* to obtain the hydrochloride salt in pure form as a solid. Dissolve the solid in saturated aqueous NaHCO₃ and extract three times with DCM and three more times with EtOAc. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate to obtain the title compound as a solid (166 mg, 71 %). GC-MS *m/z*: 184 (M⁺).

Preparation 70

4-(Pyridin-2-yl)-benzylamine




4-(2-Pyridyl)-benzaldehyde oxime: Add hydroxylamine hydrochloride (0.379 g, 5.458 mmol) and a solution of NaOH (0.327 g, 8.187 mmol) in water (2 mL) to a solution of 4-(2-pyridyl)-benzaldehyde (0.5 g, 2.729 mmol) in ethanol (10 mL). Heat the mixture at 80 °C for 2 h. Cool to ambient temperature and remove the solvent *in vacuo*. Partition the residue between EtOAc and water. Separate and dry the organic phase over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 4:1) to obtain the desired intermediate (311 mg, 58%). GC-MS *m/z*: 198 (M⁺).

4-(Pyridin-2-yl)-benzylamine: Add Pd/C (10%, 50 mg) and concentrated HCl (2 mL) to a solution of 4-(2-pyridyl)-benzaldehyde oxime (0.29 g, 1.46 mmol) in absolute ethanol (20 mL). Hydrogenate the mixture at 50 psi for 2 h. Filter over Celite®, wash with ethanol and concentrate *in vacuo* to obtain the hydrochloride salt in pure form as a solid. Dissolve the solid in saturated aqueous NaHCO₃, extract the aqueous solution three times with DCM and three more times with EtOAc. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo* to obtain the title compound as a solid (130 mg, 48 %). GC-MS *m/z*: 184 (M⁺).

Preparation 71

4-(1-Methyl-1*H*-imidazol-2-yl)-benzylamine



[4-(1-Methyl-1*H*-imidazol-2-yl)-benzyl]-carbamic acid *tert*-butyl ester: Add 4-(*N-tert*-Butoxycarbonyl-aminomethyl)phenylboronic acid (1.9 g, 7.4 mmol), 2-bromo-1-methyl-1*H*-imidazole (800 mg, 5.0 mmol), tetrakis(triphenylphosphine)-palladium(0) (287 mg, 0.25 mmol) and potassium carbonate (860 mg, 6.2 mmol) to a flask containing toluene (10 mL). Heat the mixture in a sealed flask at 90 °C for 16 h. Cool the mixture, dilute with EtOAc (50 mL), filter through Celite®, and concentrate *in vacuo*. Purify by


chromatography on silica gel eluting with hexane/EtOAc/methanol (49:50:1) to obtain the desired intermediate (1.2 g, 83%). GC-MS m/z : 287(M^+).

- 5 **4-(1-Methyl-1*H*-imidazol-2-yl)-benzylamine:** Dissolve [4-(1-methyl-1*H*-imidazol-2-yl)-benzyl]-carbamic acid *tert*-butyl ester (500 mg, 1.7 mmol) in DCM (20 mL) and trifluoroacetic acid (5 mL). Stir the mixture for 1 h at ambient temperature. Concentrate *in vacuo* and purify by SCX chromatography to obtain the title compound (240 mg, 74%). MS (ES^+) m/z : 188 ($M+H$) $^+$.

10

Preparation 72

4-Ethanesulfonyl-benzylamine



- 15 **4-Ethylthio-benzonitrile:** Combine 4-mercapto-benzonitrile (0.4 g, 2.96 mmol), bromoethane (1.4 mL, 8.88 mmol) and potassium carbonate (3.3 g, 23.7 mmol) in anhydrous DMF (7 mL) and heat at 60°C for 17 h. Cool the reaction mixture to ambient temperature and partition between brine (20 mL) and EtOAc (20 mL). Separate the organic layer, dry over anhydrous Na_2SO_4 and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1) to obtain the desired intermediate as a colorless oil (0.4 g, 83%).

- 20 **4-Ethanesulfonyl-benzonitrile:** Dissolve 4-ethylthio-benzonitrile (0.4 g, 2.4 mmol) in TFA (10 mL) and add slowly hydrogen peroxide (30 w%, 10 mL) at 5 °C. Stir the reaction mixture at ambient temperature for 2 h and partition between brine (20 mL) and DCM (20 mL). Separate the organic layer, dry over anhydrous Na_2SO_4 and concentrate to obtain the desired intermediate as a white solid (0.5 g, 100%). GC-MS m/z : 195 (M^+).


- 25 **4-Ethanesulfonyl-benzylamine:** Combine 4-ethanesulfonyl-benzonitrile (0.7 g, 3.5 mmol), Raney® 3201 nickel (slurry in water, 0.1 g), 2N ammonia in methanol (20 mL) and hydrogenate at 50 psi for 17 h. Filter the reaction mixture through a pad of Celite®

30

and concentrate *in vacuo*. Purify by SCX chromatography to obtain the title compound as a yellow oil (0.3 g, 43%).

Preparation 73


4-(2-Propanesulfonyl)-benzylamine



Use a method similar to Preparation 72, using 4-mercapto-benzonitrile (0.5 g, 3.7 mmol) and 2-bromopropane (1.4 g, 11.38 mmol), to obtain the title compound as a yellow oil (0.3 g, 39% overall).

Preparation 74

4-Aminomethyl-*N*-*tert*-butyl-benzamide



15


***N*-*tert*-butyl-4-cyano-benzamide:** Combine 4-cyanobenzoic acid (30 mg, 2.07 mmol), *tert*-butylamine (0.5 mL, 4.13 mmol), triethylamine (0.4 mL, 2.89 mmol), and HATU (1.1 g, 2.89 mmol) in anhydrous DMF (7 mL). Stir at ambient temperature for 17 h. Partition the reaction mixture between brine (15 mL) and diethyl ether (15 mL), separate the organic layer, dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with DCM to obtain the desired intermediate as a white solid (0.4 g, 89%). MS (ES+) *m/z*: 203 (M+H)⁺.

20

4-Aminomethyl-*N*-*tert*-butyl-benzamide: Combine *N*-*tert*-butyl-4-cyano-benzamide (0.4 g, 1.78 mmol), Raney® 3201 nickel (slurry in water, 0.03 g), 2N ammonia in methanol (20 mL) and hydrogenate at 50 psi for 1 h. Filter the reaction mixture through a pad of Celite®, remove the solvent and purify by SCX chromatography to obtain the title compound as a colorless oil (0.4 g, 95%). MS (ES+) *m/z*: 207 (M+H)⁺.

Preparation 75

4-Aminomethyl-2-fluoro-*N*-*tert*-butyl-benzamide



10

4-Bromo-*N*-*tert*-butyl-2-fluoro-benzamide: Combine 4-bromo-2-fluoro-benzoic acid (5.0 g, 22.83 mmol), thionyl chloride (10 mL, 0.137 mol) in toluene (10 mL) and reflux for 2 h. Evaporate the reaction mixture to obtain 4-bromo-2-fluoro-benzoyl chloride (5.0 g, 93%) and use for the next step without further purification. Dissolve *tert*-butylamine (0.8 mL, 5.12 mmol) and triethylamine (0.8 mL, 6.32 mmol) in anhydrous DCM (20 mL), cool to 0°C and add a solution of 4-bromo-2-fluoro-benzoyl chloride (1.0 g, 4.22 mmol) in anhydrous DCM (10 mL). Stir the reaction mixture at 0°C for 10 min, warm to ambient temperature and continue to stir for 30 min. Wash the reaction mixture with brine (2 x 10 mL), dry the organic extracts over anhydrous Na₂SO₄, evaporate the solvent and purify by chromatography on silica gel eluting with DCM to obtain the desired intermediate as a white solid (1.0 g, 87%). MS (ES+) *m/z*: 275 (M+H)⁺.

***N*-*tert*-Butyl-4-cyano-2-fluoro-benzamide:** Combine 4-bromo-*N*-*tert*-butyl-2-fluoro-benzamide (1.0 g, 3.65 mmol) and copper(I) cyanide (0.7 g, 7.29 mmol) in anhydrous DMF (10 mL) and reflux for 17 h. Cool the reaction mixture to ambient temperature and treat with 50% (v/v) aqueous ethylenediamine (20 mL). Extract the reaction mixture with diethyl ether (3 x 10 mL), combine the organic extracts, wash with brine (2 x 10 mL) and

25


dry the organic layer over Na_2SO_4 . Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1, 7:3 and 3:2) to obtain the desired intermediate as a white solid (0.6 g, 77%). MS (ES+) m/z : 221 ($\text{M}+\text{H}$)⁺.

- 5 **4-Aminomethyl-2-fluoro-*N*-tert-butyl-benzamide:** Combine *N*-tert-butyl-4-cyano-2-fluoro-benzamide (0.6 g, 1.78 mmol), Raney® 3201 nickel (slurry in water, 30 mg), 2N ammonia in methanol (30 mL) and hydrogenate at 50 psi for 1 h. Filter the reaction mixture through a pad of Celite®, concentrate *in vacuo* and purify by SCX chromatography to obtain the title compound as a colorless oil (0.6 g, 96%).

10

Preparation 76

4-Aminomethyl-2-fluoro-*N*-methyl-*N*-propyl-benzamide




15

Use a method similar to Preparation 75, using 4-bromo-2-fluoro-benzoic acid (1.0 g, 4.56 mmol) and *N*-methyl-propylamine (0.5 mL, 5.05 mmol), to give the title compound as a colorless oil (0.5 g, 49%). GC-MS m/z : 224 (M^+).

20


Preparation 77

4-Aminomethyl-*N*-(2,2,2-trifluoro-ethyl)-benzamide










Use the General Procedure 6-1, using 2,2,2-trifluoroethylamine (197 mg, 2 mmol) and 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid, to give the title compound as a clear oil (440 mg, 94%). MS (ES+) m/z : 233 (M+H)⁺.

- 5 The compounds of Preparations 78-93 may be prepared essentially as described in Preparation 77 by using 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid and the appropriate amine. Overall yields and MS (ES) data are shown in the Table below.



10


Preparation	NH-R	Compound	Yield (%)	MS (ES) m/z
78		4-Aminomethyl- <i>N</i> -(2,2,3,3,3-pentafluoro-propyl)-benzamide	100	283 (M+H) ⁺
79		(±)-4-Aminomethyl- <i>N</i> -(2,2,2-trifluoro-1-methyl-ethyl)-benzamide	78	247 (M+H) ⁺
80		4-Aminomethyl- <i>N</i> -(3,3,3-trifluoro-propyl)-benzamide	100	247 (M+H) ⁺
81		(±)-4-Aminomethyl- <i>N</i> -(3,3,3-trifluoro-1-methyl-propyl)-benzamide	100	261 (M+H) ⁺
82		4-Aminomethyl- <i>N</i> -(cyclopentyl)-benzamide	100	219 (M+H) ⁺
83		4-Aminomethyl- <i>N</i> -(cyclohexyl)-benzamide	100	233 (M+H) ⁺
84		4-Aminomethyl- <i>N</i> -(cycloheptyl)-benzamide	80	247 (M+H) ⁺
85		4-Aminomethyl- <i>N</i> -(tetrahydropyran-4-yl)-benzamide	56	ND
86		4-Aminomethyl- <i>N</i> -(4-methyl-phenyl)-benzamide	100	239 (M-H) ⁻

Preparation	NH-R	Compound	Yield (%)	MS (ES) m/z
87		4-Aminomethyl- <i>N</i> -(4-chloro-phenyl)-benzamide	84	259 (M-H) ⁻
88		4-Aminomethyl- <i>N</i> -benzyl-benzamide	59	241 (M+H) ⁺
89		4-Aminomethyl- <i>N</i> -(3,4-difluoro-phenyl)-benzamide	100	ND
90		(<i>R</i>)-4-Aminomethyl- <i>N</i> -(1-phenyl-ethyl)-benzamide	94	255 (M+H) ⁺
91		(<i>S</i>)-4-Aminomethyl- <i>N</i> -(1-phenyl-ethyl)-benzamide	94	255 (M+H) ⁺
92		4-Aminomethyl- <i>N</i> -(1-methyl-1-phenyl-ethyl)-benzamide	22	269 (M+H) ⁺
93		(±)-4-Aminomethyl- <i>N</i> -(1-methyl-2-phenyl-ethyl)-benzamide	85	269 (M+H) ⁺

ND = Not determined

Preparation 94**4-(Piperidin-1-ylcarbonyl)-benzylamine**


5



Use the General Procedure 6-1, using piperidine (373 mg, 4.4 mmol) and 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid to give the title compound as a white solid (1.03 g, 100%). MS (ES⁺) m/z : 219 (M+H)⁺.

10

Preparation 95

4-Aminomethyl-*N*-cyclohexyl-2-fluoro-benzamide


5 **4-Bromo-*N*-cyclohexyl-2-fluoro-benzamide:** Dissolve 4-bromo-2-fluoro-benzoyl chloride (1 g, 4.21 mmol) in DCM and cool the solution in an ice bath. Add triethylamine (0.87 mL, 6.32 mmol) and cyclohexylamine (502 mg, 5.1 mmol) and stir the mixture at ambient temperature for 2 h. Partition the reaction mixture between brine and DCM. Dry
10 the organic layer over Na₂SO₄, filter and concentrate *in vacuo* to give the desired intermediate as a white solid (1.24 g, 98%).

4-Cyano-*N*-cyclohexyl-2-fluoro-benzamide: Heat a mixture of 4-bromo-*N*-cyclohexyl-2-fluoro-benzamide (1.24 g, 4.13 mmol) and copper cyanide (740 mg, 8.26 mmol) in
15 DMF (20 mL) to reflux for 16 h. Cool the mixture to ambient temperature, add aqueous ethylenediamine and stir for 30 min. Extract the mixture with hexane/EtOAc (1:1), dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo*. Purify the residue by chromatography on silica gel eluting with hexane/EtOAc (5:1) to give the desired
intermediate as a white solid (620 mg, 61%). MS (ES-) *m/z*: 245 (M-H)⁻.

20 **4-Aminomethyl-*N*-cyclohexyl-2-fluoro-benzamide:** Dissolve 4-cyano-*N*-cyclohexyl-2-fluoro-benzamide (620 mg, 2.5 mmol) in 7N ammonia in methanol (150 mL) and hydrogenate at 500 psi pressure in the presence of Raney® nickel (500 mg) for 16 h at 60°C. Filter the mixture and concentrate *in vacuo*. Purify by SCX chromatography to give
25 the title compound as a white solid (600 mg, 94%). MS (ES-) *m/z*: 251 (M-H)⁻.


Preparation 96

5-(Aminomethyl)-pyridine-2-carboxylic acid cyclohexylamide



5 **Lithium 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylate:** Dissolve 5-aminomethyl-2-chloro-pyridine (2 g, 14 mmol) and di-*tert*-butyl-dicarbonate (3.37 g, 15.4 mmol) in DCM (30 mL) and stir at room temperature for 2 h. Concentrate the reaction mixture and purify by chromatography on silica gel eluting with hexane/EtOAc (10:1 and
10 5:1) to give 5-(*tert*-butoxycarbonylamino-methyl)-2-chloro-pyridine as a yellow solid (3.6 g, 100%). MS (ES+) *m/z*: 243 (M+H)⁺. Dissolve 5-(*tert*-butoxycarbonylamino-methyl)-2-chloro-pyridine (1 g, 4.12 mmol) in a mixture of ethanol (15 mL) and DMF (5 mL), and add potassium carbonate (427 mg, 3.09 mmol), palladium(II) acetate (92 mg, 0.4 mmol) and diphenylphosphinoferrocene (240 mg, 0.44 mmol). Pressurize the mixture to 15 psi with carbon monoxide gas and heat the reaction mixture to 90°C for 16 h. Filter the reaction mixture, concentrate the filtrate, and partition the residue between water and hexane/EtOAc (1:1). Dry the organic layer over Na₂SO₄, filter, and concentrate *in vacuo*. Purify the residue by chromatography on silica gel eluting with hexane/EtOAc (3:2) to
20 give 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylic acid ethyl ester as a brown oil (920 mg, 80%). MS (ES+) *m/z*: 281 (M+H)⁺. Dissolve 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylic acid ethyl ester (920 mg, 3.28 mmol) in a mixture of water/THF (1:2, 15 mL) and add lithium hydroxide (87 mg, 3.61 mmol). Stir the mixture at ambient temperature for 4 h and concentrate to a solid. Dry the material by azeotrope distillation with toluene to give the desired intermediate as
25 a brown solid (1 g, 100%). MS (ES+) *m/z*: 253 (M+H)⁺.


5-(Aminomethyl)-pyridine-2-carboxylic acid cyclohexylamide: Use the General Procedure 6-2, using cyclohexylamine (1 mL), lithium 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylate (1 g, 3.96 mmol) and DIEA (5 mL) as cosolvent, to give
30 the title compound as a white solid (200 mg, 22%). MS (ES+) *m/z*: 234 (M+H)⁺.

Preparation 97**5-(Aminomethyl)-pyridine-2-carboxylic acid 4-fluoro-benzylamide**

5

Use the General Procedure 6-2, using 4-fluoro-benzylamine (551 mg, 4.4 mmol), lithium 5-(*tert*-butoxycarbonylamino-methyl)-pyridine-2-carboxylate (740 mg, 2.93 mmol) and DIEA (2.6 mL) as cosolvent, to give the title compound as a white solid (200 mg, 26%). MS (ES+) *m/z*: 260 (M+H)⁺.

10

Preparation 98**2-Aminomethyl-5-(2,2,2-trifluoroethoxy)-pyridine**

15


2-Methyl-5-(2,2,2-trifluoroethoxy)-pyridine: Add 5-hydroxy-2-methyl-pyridine (3.3 g, 30.6 mmol), potassium carbonate (17 g, 122.4 mmol) and 2-bromo-1,1,1-trifluoroethane (10 g, 61.2 mmol) to a flask containing DMF (60 mL) and heat to 95°C for 20 h. Cool the mixture, dilute with aqueous 10% NaCl (20 mL) and extract with hexane/EtOAc (1:1, 100 mL). Filter the bi-phasic mixture through Celite®, separate and wash the organic layer with aqueous 10% NaCl (3 x 50 mL) and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) to obtain the desired intermediate (4.1 g, 70%).

20

- 2-Bromomethyl-5-(2,2,2-trifluoroethoxy)-pyridine:** Add 2-methyl-5-(2,2,2-trifluoroethoxy)-pyridine (2.5 g, 13.1 mmol), NBS (2.3 g, 13.1 mmol) and benzoyl peroxide (50 mg) to a flask containing carbon tetrachloride (30 mL). Heat the mixture at 80°C in a sealed flask for 16 h. Cool the flask, add NBS (1.1 g, 6.5 mmol) and benzoyl peroxide (100 mg), then continue heating at 80°C for an additional 5 h. Cool the mixture, dilute with DCM, then wash with saturated sodium bisulfite (10 mL). Collect the organic layer and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain the desired intermediate (460 mg, 13%).
- 2-Aminomethyl-5-(2,2,2-trifluoroethoxy)-pyridine:** Dissolve sodium azide (270 mg, 4.0 mmol) in DMF (30 mL). Cool the solution to 0°C, then add 2-bromomethyl-5-(2,2,2-trifluoroethoxy)-pyridine (440 mg, 1.6 mmol) at 0°C. Slowly heat the mixture from 0°C to 80°C over 30 min. Cool the reaction, dilute with EtOAc (100 mL) and wash with 10% aqueous NaCl (3 x 25 mL). Collect the organic layer and concentrate *in vacuo* to a volume of 50 mL. Transfer the solution to a pressure vessel. Add 10 % Pd/C (Degussa type E101, 50% water by wt, 500 mg) and pressurize the vessel under hydrogen (10 psi) for 1 h with stirring. Filter the mixture through Celite® and wash filter cake with warm methanol followed by DCM. Concentrate *in vacuo*, then purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (20:1) to obtain the title compound (180 mg, 54%). MS (ES+) *m/z*: 207 (M+H)⁺.

Preparation 99

2-Aminomethyl-5-(2,2,2-trifluoro-1,1-dimethylethoxy)-pyridine



5-Chloro-pyridine-2-carbonitrile: Add 2,5-dichloropyridine (6.0 g, 40.5 mmol), zinc cyanide (2.9 g, 24.7 mmol), zinc dust (116 mg, 1.8 mmol) and 1,1'-[bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.98 mmol) to a flask

containing DMF (40 mL). Heat the mixture to reflux for 5 h, then cool to ambient temperature. Dilute the mixture with EtOAc (300 mL) and wash with 10% aqueous NaCl (3x75 mL). Collect the organic layer, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) to obtain the desired intermediate
5 (2.6 g, 46%).


5-Fluoro-pyridine-2-carbonitrile: Add 5-chloro-pyridine-2-carbonitrile (3.0 g, 21.7 mmol) and potassium fluoride (3.9 g, 67.1 mmol) to a flask containing NMP (75 mL). Heat the mixture to reflux for 16 h. Add additional potassium fluoride (1.0 g, 17.2 mmol)
10 and NMP (10 mL), then continue heating at reflux for 3 h. Cool the mixture, dilute with EtOAc, then wash with saturated NaCl (3 x 50 mL). Collect the organic layer, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (20:1) to obtain the desired intermediate (1.5 g, 53%).

5-(2,2,2-Trifluoro-1,1-dimethyl-ethoxy)-pyridine-2-carbonitrile: Add 2-trifluoromethyl-2-propanol (1.1 g, 8.3 mmol) slowly to a slurry of sodium hydride (202 mg, 60% mineral oil, washed with hexane) in HMPA (3 mL) under nitrogen. Stir the slurry for 15 min, then add 5-fluoro-pyridine-2-carbonitrile (510 mg, 4.2 mmol). Stir the slurry for 16 h at ambient temperature. Adjust the mixture to pH 9 with sodium carbonate
20 then extract with diethyl ether (3 x 50 mL). Collect the organic layer, dry over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (95/5 to 80/20) to obtain the desired intermediate (768 mg, 79%). GC-MS *m/z*: 230 (M⁺).

2-Aminomethyl-5-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)-pyridine: Add 5-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)-pyridine-2-carbonitrile (580 mg, 2.5 mmol), 10 % Pd/C (Degussa type E101, 50% water by wt, 400 mg) and trifluoroacetic acid (2 mL) in ethanol (20 mL) to a pressure vessel. Pressurize the vessel to 50 psi with hydrogen for 1 h. Filter the mixture through Celite® and wash the cake with warm ethanol followed by DCM
30 under a nitrogen atmosphere. Concentrate *in vacuo* to obtain the crude product as the trifluoroacetic acid salt. Prepare the free base with SCX chromatography, then purify using silica gel chromatography eluting with DCM/2M ammonia in methanol (20:1) to obtain the title compound (261 mg, 45%). MS (ES⁺) *m/z*: 235 (M+H)⁺.


Preparation 100

(±)-2-Aminomethyl-5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridine



- 5 **(±)-5-(2,2,2-Trifluoro-1-methyl-ethoxy)-pyridine-2-carbonitrile:** Add 1,1,1-trifluoro-2-propanol (971 mg, 8.5 mmol) slowly to a slurry of sodium hydride (205 mg, 60% mineral oil, washed with hexane) in HMPA (8 mL) under nitrogen at 0°C. Allow the
- 10 slurry to warm to ambient temperature and stir for 5 min. Add 5-chloro-pyridine-2-carbonitrile (590 mg, 4.2 mmol), then heat the mixture at 90°C for 4 h. Adjust the mixture to pH 9 with sodium carbonate then extract with diethyl ether (2 x 50 mL). Dry the combined organic extracts over Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (95/5 to 80/20) to obtain the
- 15 desired intermediate (818 mg, 89%). GC-MS *m/z*: 216(M⁺).
- (±)-2-Aminomethyl-5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridine:** Add (±)-5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridine-2-carbonitrile (810 mg, 3.7 mmol), 10 % Pd/C (Degussa type E101, 50% water by wt, 300 mg), and trifluoroacetic acid (4 mL) in
- 20 methanol (50 mL) to a pressure vessel. Pressurize the vessel to 40 psi with hydrogen for 0.25 h. Filter the mixture through Celite® and wash the cake with warm ethanol followed by DCM under a nitrogen atmosphere. Concentrate *in vacuo* to obtain the crude product as a trifluoroacetic acid salt. Prepare the free base with SCX ion chromatography, then
- 25 purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (20:1) to obtain the title compound (676 mg, 82%). GC-MS *m/z*: 220 (M⁺).

Preparation 101
2-Aminomethyl-5-fluoro-pyridine



5
2-Bromo-5-fluoro-pyridine: Cool 48% hydrobromic acid (44 mL, 4.4 equiv.) in an ice/acetone bath to -5°C , then add 2-amino-5-fluoropyridine (10.0 g, 89.2 mmol, 1.0 equiv.) portion wise over 10 min and maintain the temperature below 5°C throughout addition. Add bromine (14 mL, 3 equiv.) at 0°C over 2 h and maintain the temperature at
 10 0°C throughout the addition. Stir the mixture for 30 min, then add a solution of sodium nitrite (15.4 g) in water (30 mL) via addition funnel over 2 h and maintain the temperature below 0°C throughout the addition. Stir the mixture for 30 min., then add a solution of NaOH (34 g) in water (34 mL) over 1 h and maintain the temperature below 10°C . Stir the mixture for 3 min. Extract with diethyl ether (5 x 250 mL), dry the combined organic
 15 extracts over Na_2SO_4 and concentrate *in vacuo* to give the desired intermediate (12.1 g, 77%).


(5-Fluoro-pyridin-2-yl)-methanol: At -78°C under nitrogen, add *n*-butyllithium (2.5 M in hexane, 16.4 mL, 40.9 mmol) via syringe to a solution of 2-bromo-5-fluoro-pyridine
 20 (6.0 g, 34.1 mmol) in toluene (220 mL), while keeping the reaction temperature below -60°C . Stir the mixture at -78°C and then add DMF (3.4 mL, 44.3 mmol) and stir for 1 h at this temperature. Warm to -10°C and quench with methanol (10 mL). Concentrate the mixture to half of the volume *in vacuo*. Dilute with methanol (150 mL), cool the mixture to -78°C and add sodium borohydride (3.2 g, 85.2 mmol) portion wise over 5 min. Warm
 25 the mixture to ambient temperature and stir for 2 h. Quench with water (10 mL) and remove the organic solvent *in vacuo* to obtain an oil/water mixture. Extract with diethyl ether (3 x 100 mL), dry the combined organic extracts, wash with brine, dry and concentrate *in vacuo* to obtain the desired intermediate as an oil (3.9 g, 91%).

Methanesulfonic acid (5-fluoro-pyridin-2-yl)methyl ester: Add methanesulfonyl chloride (1.8 mL, 23.5 mmol) to a solution of (5-fluoro-pyridin-2-yl)-methanol (2.5 g, 19.7 mmol) and triethylamine (8.2 mL, 59.0 mmol) in DCM (150 mL) at 0°C under nitrogen. Stir the mixture for 30 min and concentrate *in vacuo*. Dilute with water (20 mL) and extract the mixture with EtOAc (3 x 50 mL). Combine the organic extracts and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc to obtain the desired intermediate (2.2 g, 54%).

2-Aminomethyl-5-fluoro-pyridine: Dissolve methanesulfonic acid (5-fluoro-pyridin-2-yl)-methyl ester (1.5 g, 7.3 mmol) in DMF (5 mL) and add sodium azide (950 mg, 14.6 mmol). Stir the mixture for 30 min, then dilute with hexane/EtOAc (1:1, 50 mL). Wash the mixture with 10% aqueous NaCl (3 x 10 mL). Dry the combined organic extracts over Na₂SO₄ and remove half of the solvent *in vacuo*. Add EtOAc (20 mL) and a suspension of 10% Pd/C (200 mg) in EtOAc (2 mL). Stir the mixture for 1 h at ambient temperature in a pressurized vessel under 50 psi of hydrogen. Filter the slurry through Celite® and concentrate *in vacuo* to obtain 2-aminomethyl-5-fluoro-pyridine (613 mg, 60% yield, 80% purity by GC/MS). GC-MS *m/z*: 126 (M⁺).

Preparation 102

3-Aminomethyl-5-fluoro-pyridine




In a Parr Bottle add 2,6-dichloro-3-cyano-5-fluoropyridine (20 g, 0.105 mol), ethanol (336 mL), triethylamine (24 mL), and 5% Pd/C (4 g). Place on a Parr Shaker Apparatus under 60 psi hydrogen for 1 h at ambient temperature. Filter the reaction mixture and bubble ammonia gas into filtrate for 10 min. Add Raney® nickel (5.2 g) and place on a Parr Shaker Apparatus under 500 psi hydrogen for 18 h at 60-70°C. Filter the reaction mixture and concentrate *in vacuo*. Dissolve in methanol and add 1N hydrogen chloride in ether until form a precipitate. Cool in an ice bath, filter off the precipitate,

wash the solid several times with ether, and dry to give the title compound as the hydrochloride salt (12 g, 70%). MS (ES+) m/z : 127 (M+H)⁺. Dissolve the hydrochloride salt in water, add 0.1 N aqueous NaOH to adjust to pH 10, extract with DCM, dry the organic layer over Na₂SO₄, filter and concentrate to give the title compound.

5

Preparation 103

3-Aminomethyl-4-trifluoromethyl-pyridine




10

Add 4-trifluoromethyl-nicotinonitrile (1.0 g, 5.8 mmol) and ethanol wet Raney® activated nickel (0.2 g) to a Parr pressure vessel. Immediately add, at ambient temperature, 2B-ethanol (25 mL) previously saturated with ammonia gas and seal the vessel. Purge the reaction vessel with nitrogen, pressurize the reaction mixture with hydrogen (400 KPa), seal the vessel, agitate the reaction and heat to 40°C. Continue the reaction for 20 h then turn off the heat and allow the reaction mixture to cool to ambient temperature. Vent the excess hydrogen from the vessel and purge the vessel with nitrogen. Filter the reaction mixture to remove the Raney® nickel, wash with ethanol and concentrate in *vacuo*. Purify by SCX chromatography to give the title compound (560 mg, 55%). MS (ES+) m/z : 177 (M+H)⁺.

20

Preparation 104

2-Aminomethyl-6-fluoropyridine Dihydrochloride



25


3-Fluoropyridine-N-Oxide: Dissolve 3-fluoropyridine (2.5 g, 25.749 mmol) in anhydrous DCM (75 mL). Add *m*-CPBA (70% suspension, 12.696 g, 51.499 mmol) and stir at ambient temperature overnight. Wash the reaction mixture with saturated aqueous

NaHCO₃, dry the organic phase over Na₂SO₄, filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with DCM and DCM/methanol (97:3) to obtain the desired intermediate as a solid (1.413 g, 49%). MS (ES+) *m/z*: 115 (M+H)⁺.

- 5 **2-Cyano-3-fluoropyridine:** Dissolve 3-fluoropyridine-*N*-oxide (1.0 g, 8.687 mmol) in anhydrous acetonitrile (100 mL). Add triethylamine (1.319 g, 1.82 mL, 13.031 mmol), trimethylsilylcyanide (3.447 g, 4.63 mL, 34.749 mmol) and heat the mixture to reflux overnight. Cool to ambient temperature and concentrate *in vacuo*. Dissolve the residue in EtOAc and wash with saturated aqueous NaHCO₃. Dry the organic layer over Na₂SO₄,
10 filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 17:3) to give the desired intermediate as a solid (746 mg, 70%). GC-MS *m/z*: 122 (M⁺).

- 2-Aminomethyl-3-fluoropyridine dihydrochloride:** Dissolve 2-cyano-3-fluoropyridine
15 (300 mg, 2.457 mmol) in absolute ethanol (12 mL). Add 10% Pd/C (93 mg) and concentrated HCl (0.614 mL, 7.37 mmol). Hydrogenate at 40 psi overnight. Filter through Celite® and concentrate *in vacuo* to give the title compound as a solid (440 mg, 90%). MS (ES+) *m/z*: 127 (M+H)⁺.

20

Preparation 105**2-Aminomethyl-6-fluoropyridine Dihydrochloride**


- 25 **2-Cyano-6-fluoropyridine:** Dissolve 2,6-difluoropyridine (12 g, 104.2 mmol) in anhydrous DMSO (5 mL). Add a solution of sodium cyanide (1.3 g, 26.53 mmol) in DMSO (60 mL) over 12 h using a syringe pump. Heat the mixture to 100°C overnight. Cool to ambient temperature, dilute with EtOAc (500 mL), and wash with brine. Dry the organic phase over Na₂SO₄, filter, and concentrate *in vacuo*. Purify by chromatography
30 on silica gel eluting with hexane/EtOAc (1:0 and 4:1) to give the desired intermediate as a solid (723 mg, 22%). GC-MS *m/z*: 122 (M⁺).

2-Aminomethyl-6-fluoropyridine Dihydrochloride: Dissolve 2-cyano-6-fluoropyridine (300 mg, 2.46 mmol) in absolute ethanol (12 mL). Add 10% Pd/C (93 mg) and concentrated HCl (0.614 mL, 7.37 mmol). Hydrogenate at 40 psi overnight. Filter
5 through Celite® and concentrate to give the title compound as a solid (356 mg, 73%). MS (ES+) m/z : 127 (M+H)⁺.

Preparation 106


4-Aminomethyl-*N*-(pyridin-2-yl-methyl)-benzamide












10




Use the General Procedure 6-2, using 2-(aminomethyl)pyridine (181 mg, 0.172 mL, 1.67 mmol) and 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid (420 mg, 1.67
15 mmol) to give the title compound as a solid (427 mg, 100 %). MS (ES+) m/z : 242 (M+H)⁺.


The compounds of Preparations 107-117 may be prepared essentially as described in Preparation 106 by using 4-(*tert*-butoxycarbonylamino-methyl)-benzoic acid and the
20 appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.



Pre p.	NHR	Compound	Yield (%)	MS (ES+) or GC-MS
107		4-Aminomethyl- <i>N</i> -(thiophen-2-ylmethyl)-benzamide	100	247 (M+H) ⁺
108		4-Aminomethyl- <i>N</i> -(3-fluoropyridin-2-ylmethyl)-benzamide	58	259 (M) ⁺
109		4-Aminomethyl- <i>N</i> -(6-fluoropyridin-2-ylmethyl)-benzamide	98	259 (M) ⁺
110		4-Aminomethyl- <i>N</i> -(5-fluoropyridin-2-ylmethyl)-benzamide	67	259 (M) ⁺
111		4-Aminomethyl- <i>N</i> -(3-(trifluoromethyl)pyridin-2-ylmethyl)-benzamide	62	310 (M+H) ⁺
112		4-Aminomethyl- <i>N</i> -(4-(trifluoromethyl)pyridin-2-ylmethyl)-benzamide	76	309 (M) ⁺
113		4-Aminomethyl- <i>N</i> -(5-(trifluoromethyl)pyridin-2-ylmethyl)-benzamide	65	310 (M+H) ⁺
114		4-Aminomethyl- <i>N</i> -(2-(thiophen-2-yl)ethyl)-benzamide	100	261 (M+H) ⁺
115		4-Aminomethyl- <i>N</i> -(2-(pyridin-2-yl)ethyl)-benzamide	81	256 (M+H) ⁺
116		4-Aminomethyl- <i>N</i> -(2-(pyridin-3-yl)ethyl)-benzamide	97	256 (M+H) ⁺
117		4-Aminomethyl- <i>N</i> -(2-(pyridin-4-yl)ethyl)-benzamide	96	256 (M+H) ⁺

Preparation 118**(±)-1-(3-Fluorophenyl)ethylamine**

5 Add sodium cyanoborohydride (452 mg, 7.2 mmol) to a solution of 3-fluoroacetophenone (500 mg, 3.6 mmol) and ammonium acetate (2.8 g, 36 mmol) in methanol (11 mL). Stir the mixture for 96 h at ambient temperature under a nitrogen atmosphere. Adjust to pH 2 with 2M hydrogen chloride in diethyl ether. Concentrate the
10 slurry *in vacuo*, dilute the residue with DCM and wash with 5N aqueous NaOH followed by saturated aqueous NaHCO₃. Dry the organic layer, concentrate *in vacuo* to half of the volume, and load the solution onto a SCX column (pre-wash column with methanol followed by DCM, then elute with 2M ammonia in methanol). Concentrate the fractions
15 to half of the volume to remove ammonia, add excess of 2M hydrogen chloride in diethyl ether and concentrate to obtain the hydrochloride salt (70:30 mixture of title compound and dimer). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (20:1) to obtain the title compound (323 mg, 51%). MS (ES+) *m/z*: 140 (M+H)⁺

Preparation 119**1-(3-Fluorophenyl)ethylamine, Isomer 2**

25 Set-up flask equipped with condenser, mechanical stirrer and addition funnel. Add 3-fluoroacetophenone (25 g, 0.18 mol) and formic acid (4.2 g, 0.09 mol) via addition funnel to a flask containing formamide (32.6 g, 0.72 mol) at 140°C over 15 min, and then heat the mixture to 160°C. Add formic acid successively (4.2 g, 0.5 equiv.) via addition funnel to the flask every hour for 4 h while maintaining the reaction temperature at

160°C. Cool the reaction mixture, extract with toluene (3 x 100 mL), and concentrate the organic layer *in vacuo*. Add aqueous HCl (37%, 40 mL) to the residue and heat to reflux for 2 h. Cool to ambient temperature and wash the aqueous mixture with toluene (2 x 100 mL), then basify the aqueous mixture with 5N aqueous NaOH (120 mL). Extract the
5 basic mixture with EtOAc (3 x 100 mL), dry the combined organic extracts over Na₂SO₄ and filter. Acidify the filtrate with 2M hydrogen chloride in diethyl ether to pH 2 and concentrate *in vacuo* to a solid. Suspend the solid in diethyl ether, filter and wash with diethyl ether. Dry the solid in a vacuo-oven at 50°C to obtain (±)-1-(3-fluorophenyl)ethylamine hydrochloride (21.5 g, 68%). MS (ES+) *m/z*: 140 (M+H)⁺.

10


Dissolve (±)-1-(3-fluorophenyl)ethylamine hydrochloride (42.5 g, 0.24 mol) in THF (520 mL) and saturated aqueous NaHCO₃ (430 mL). Add di-*tert*-butyl-dicarbonate (69 g, 0.31 mol) and stir for 16 h at ambient temperature. Separate the organic layer, dilute with EtOAc (300 mL) and wash with 2N aqueous NaOH (1 x 400 mL) and water (2
15 x 200 mL). Concentrate the organic layer *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain (±)-*N*-[1-(3-fluorophenyl)ethyl]-carbamic acid *tert*-butyl ester (56 g, 97%). GC-MS *m/z*: 183 [(M-C₄H₉)⁺].

Separate the racemic mixture of (±)-*N*-[1-(3-fluorophenyl)ethyl]-carbamic acid
20 *tert*-butyl ester by normal phase chiral chromatography (Chiralcel OD 8 x 34 cm, elute with 95:5, heptane/isopropanol). Using the General Procedure 1-4, deprotect the desired isomer [20.7 g, >95% ee (Chiralcel OD, 4.6 x 250 mm, eluent: 95:5 heptane/isopropanol with 0.2% DMEA, 1.0 mL/min)] to obtain the title compound (9.4 g, 78%). MS (ES+) *m/z*: 140 (M+H)⁺.

25

Preparation 120

(±)-1-(2-Fluorophenyl)ethylamine




30

Add sodium cyanoborohydride (1.8 g, 29 mmol) to a solution of 2-fluoroacetophenone (2.0 g, 14.5 mmol) and ammonium acetate (11.2 g, 145 mmol) in methanol (45 mL). Stir the mixture for 20 h at ambient temperature under a nitrogen atmosphere. Adjust the mixture to pH 1 with 2M hydrogen chloride in diethyl ether. Concentrate the slurry *in vacuo*, dilute the residue with DCM and wash with 5N aqueous NaOH. Dry the organic layer, concentrate carefully, as the amine is volatile, under reduced pressure to one third of the volume, and load the material onto an SCX column (pre-wash column with methanol, followed by DCM, elute with 2M ammonia in methanol). Concentrate the fraction to one half of the volume to remove the ammonia, then add excess 2M hydrogen chloride in diethyl ether and concentrate to obtain the hydrochloride salt. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (20:1) to obtain the title compound (280 mg, 13%). MS (ES+) m/z : 140 (M+H)⁺.

Preparation 121


15

1-(2-Fluorophenyl)ethylamine, Isomer 1



Use a method similar to the General Procedure 6-3, using 2-fluoroacetophenone (1.4 g, 9.9 mmol) and (*R*)-(+)-2-methyl-2-propanesulfinamide (1.0 g, 8.2 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc/2M ammonia in methanol (90:9:1 to 50:45:5). Add 4M hydrogen chloride in dioxane to obtain the title compound as the hydrochloride (600 mg, 35%). MS (ES+) m/z : 140 (M+H)⁺. Dissolve the hydrochloride in an aqueous solution of cesium carbonate (1.5 equiv.) and extract with toluene to obtain the free base.

The compounds of Preparations 122-141 may be prepared essentially as described in Preparation 121 by using (*R*)-(+)-2-methyl-2-propanesulfinamide or (*S*)-(-)-2-methyl-2-propanesulfinamide and the appropriate acetophenone. Overall yields and mass spectrum data are shown in the Table below.




Prep.	R	Compound	Yield (%)	MS (ES+) or GC-MS
122	3-CN	1-(3-Cyanophenyl)ethylamine, Isomer 1	37	130 (M+H-NH ₃) ⁺
123	3-CN	1-(3-Cyanophenyl)ethylamine, Isomer 2	49	130 (M+H-NH ₃) ⁺
124	4-CN	1-(4-Cyanophenyl)ethylamine, Isomer 1	49	130 (M+H-NH ₃) ⁺
125	4-CN	1-(4-Cyanophenyl)ethylamine, Isomer 2	49	130 (M+H-NH ₃) ⁺
126	2-Cl	1-(2-Chlorophenyl)ethylamine, Isomer 1	25	156 (M+H) ⁺
127	3-Cl	1-(3-Chlorophenyl)ethylamine, Isomer 1	68	156 (M+H) ⁺
128	3-CF ₃	1-(3-Trifluoromethylphenyl)-ethylamine, Isomer 1	40	190 (M+H) ⁺
129	4-CF ₃	1-(4-Trifluoromethylphenyl)-ethylamine, Isomer 2	70	190 (M+H) ⁺
130	3-Cl,4-F	1-(3-Chloro-4-fluorophenyl)-ethylamine, Isomer 1	66	174 (M+H) ⁺
131	3-Cl-4-F	1-(3-Chloro-4-fluorophenyl)-ethylamine, Isomer 2	68	174 (M+H) ⁺
132	2,3-diF	1-(2,3-Difluorophenyl)-ethylamine, Isomer 1	20	141 (M+H-NH ₃) ⁺
133	2,3-diF	1-(2,3-Difluorophenyl)-ethylamine, Isomer 2	45	141 (M+H-NH ₃) ⁺
134	2,4-diF	1-(2,4-Difluorophenyl)-ethylamine, Isomer 1	58	158 (M+H) ⁺
135	2,4-diF	1-(2,4-Difluorophenyl)-ethylamine, Isomer 2	49	158 (M+H) ⁺
136	3,5-diF	1-(3,5-Difluorophenyl)-ethylamine, Isomer 1	26	158 (M+H) ⁺

Prep.	R	Compound	Yield (%)	MS (ES+) or GC-MS
137	3,5-diF	1-(3,5-Difluorophenyl)-ethylamine, Isomer 2	83	158 (M+H) ⁺
138	3,4-diF	1-(3,4-Difluorophenyl)-ethylamine, Isomer 1	67	158 (M+H) ⁺
139	3,4-diF	1-(3,4-Difluorophenyl)-ethylamine, Isomer 2	77	158 (M+H) ⁺
140	3,4,5-triF	1-(3,4,5-Trifluorophenyl)-ethylamine, Isomer 2	20	176 (M+H) ⁺
141	3,5-diCF ₃	1-(3,5-bis-trifluoromethylphenyl)-ethylamine, Isomer 2	49	258 (M+H) ⁺
142	2-OCF ₃	1-(2-Trifluoromethoxyphenyl)-ethylamine, Isomer 2	47	ND
143	2-Me	1-(2-Methyl)-ethylamine, Isomer 1	13	136 (M ⁺)


ND = Not determined

Preparation 144

(±)-1-(2,5-Difluorophenyl)ethylamine



Slurry 2',5'-difluoroacetophenone (0.9 g, 5.76 mmol), ammonium acetate (4.44 g, 57.5 mmol) and sodium cyanoborohydride (755 mg, 12 mmol) in anhydrous methanol (25 mL) and stir for 18 h at ambient temperature. Acidify with 5N aqueous HCl (5 mL), dilute, extract with ethyl ether (3 x 150 mL), basify aqueous layer with 5N aqueous NaOH, extract with DCM (3 x 75 mL), wash the organic layer with brine, dry over MgSO₄, filter and concentrate *in vacuo*. Purify by SCX chromatography to give a mixture of (±)-1-(2,5-difluorophenyl)ethylamine and bis-[1-(±)-2,5-difluorophenyl]ethylamine (total 400 mg, crude weight). MS (ES+) *m/z*: 158 (M+H)⁺ and *m/z*: 298 (M+H)⁺.

Preparation 145**(±)-1-(3,5-Difluoro-4-methoxyphenyl)ethylamine**


5

Slurry 3',5'-difluoro-4'-methoxyacetophenone (1.0 g, 5.0 mmol), ammonium acetate (4.14 g, 50 mmol) and sodium cyanoborohydride (630 mg, 20 mmol) in anhydrous methanol (35 mL) and stir for 18 h at ambient temperature. Acidify with 1N aqueous HCl (5 mL), dilute, extract with ethyl ether (3 x 150 mL), basify aqueous with 1N aqueous NaOH, extract with DCM (3 x 50 mL), wash the organic extracts with brine, dry over MgSO₄, filter and concentrate *in vacuo*. Purify by SCX chromatography to give crude the title compound as a yellow oil (380 mg).

10

Preparations 146 and 147

15

1-(4-Phenoxyphenyl)-ethylamine, Isomer 1 and Isomer 2

20


Mix 4-phenoxyacetophenone (5.3 g, 25 mmol), ammonium acetate (14.5 g, 187.5 mmol) and sodium cyanoborohydride (3.2 g, 50 mmol) in anhydrous methanol (200 mL). Stir for 18 h at ambient temperature. Acidify with 1N aqueous HCl (10 mL), dilute, extract with ethyl ether (3 x 150 mL), dry over MgSO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting sequentially with hexane/EtOAc (4:1, 1:1 and 0:1) and EtOAc/methanol (1:1) to give (±)-1-(4-phenoxyphenyl)-ethylamine (1.6 g, 30%). Dissolve the racemate (1.1 g, 5.2 mmol) in DCM (100 mL), add triethylamine (1.6 mL, 11.4 mmol) followed by di-*tert*-butyl-dicarbonate (1.7 g, 7.8 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give (±)-α-methyl-(4'-

25

phenoxy)-benzylamino]carbamic acid *tert*-butyl ester as an off-white solid (1.3 mg, 81%). Separate via chiral chromatography (heptane/isopropanol/DMEA 95:5:0.2, 4.6 x 250 mm Chiralpak AD, 1 mL/min, UV detector at 260 nm) to give [α -methyl-(4'-phenoxy)benzylamino]carbamic acid *tert*-butyl ester, isomer 1 (315 mg, chiral HPLC: t_R = 7.35 min; 99.1% ee) and [α -methyl-(4'-phenoxy)benzyl-aminocarbamic acid *tert*-butyl ester, isomer 2 (400 mg, chiral HPLC: t_R = 8.7 min; 97.2% ee). Dissolve [α -methyl-(4'-phenoxy)benzylamino]carbamic acid *tert*-butyl ester isomer 1 or isomer 2 in DCM/trifluoroacetic acid (1:1, 20 mL) to give, after solvent evaporation and chromatography over SCX column, 1-(4-phenoxyphenyl)-ethylamine, isomer 1 (Preparation 146) and 1-(4-phenoxyphenyl)-ethylamine, isomer 2 (Preparation 147). MS (ES+) m/z : 214 (M+H)⁺.

Preparation 148

(5-Fluoro-indan-1-yl)amine, Isomer 1



Use a method similar to the General Procedure 6-3 to react 5-fluoro-indan-1-one (1.5 g, 9.9 mmol) and (*R*)-(+)-2-methyl-2-propanesulfinamide (1.0 g, 8.3 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (5:2). Add 4M hydrogen chloride in dioxane to obtain the title compound as the hydrochloride (254 mg, 16%). MS (ES+) m/z : 152 (M+H)⁺. Dissolve the hydrochloride in an aqueous solution of cesium carbonate (1.5 equiv.) and extract with toluene to obtain the free base.

Preparation 149

1-Phenyl-cyclopropylamine




Dissolve 1-phenyl-cyclopropanecarboxylic acid (2.5 g, 15.4 mmol) in a mixture of sulfuric acid (12.5 mL) and DCM (25 mL). Add sodium azide (2.3 g, 35.4 mmol) by small portions at ambient temperature. Heat the reaction mixture at 50°C for 8 h, cool to 0°C and slowly add 2M aqueous NaOH until pH 11. Extract the reaction mixture with DCM (3 x 100 mL), combine the organic extracts and dry over anhydrous Na₂SO₄. Evaporate the solvent and purify by chromatography on silica gel eluting with DCM and DCM/2M ammonia in methanol (9:1) to obtain the title compound as a brown oil (1.1 g, 54%). MS (ES+) *m/z*: 134 (M+H)⁺.

10

Preparation 150

1-(2,4-Dichlorophenyl)-cyclopropylamine




15

Use a method similar to Preparation 149, using 1-(2,4-dichlorophenyl)-cyclopropanecarboxylic acid (3.5 g, 15.4 mmol), to obtain the title compound as a yellow oil (1.0 g, 32%). MS (ES+) *m/z*: 203 (M+H)⁺.

20

Preparation 151

4-Methylamino-benzo[1,3]dioxole



25

Benzo[1,3]dioxol-4-yl-methanol: Dissolve benzo[1,3]dioxole-4-carbaldehyde (2.0 g, 13.3 mmol) in anhydrous THF (30 mL) and treat with sodium borohydride (0.5 g, 13.3 mmol) at 0°C. Stir the reaction mixture for 30 min at ambient temperature and quench with water (30 mL). Extract the reaction mixture with DCM (3 x 10 mL), combine the

organic extracts and dry over anhydrous Na_2SO_4 . Remove the solvent to obtain the desired intermediate as a colorless oil (1.9 g, 94%).


5 **4-Chloromethyl-benzo[1,3]dioxole:** Dissolve benzo[1,3]dioxol-4-yl-methanol (1.9 g, 12.5 mmol) in thionyl chloride (3 mL, 41.1 mmol) and reflux the reaction mixture for 1 h. Concentrate *in vacuo* to obtain the desired intermediate as a yellow oil (1.9 g, 91%) that was used without further purification. GC-MS m/z : 170 (M^+).

10 **4-Methylamino-benzo[1,3]dioxole:** Dissolve 4-chloromethyl-benzo[1,3]dioxole (1.9 g, 11.1 mmol) in methanol (5 mL), cool the solution to 0°C and saturate with anhydrous ammonia for 15 min. Keep the reaction mixture at 0°C for 18 h. Evaporate the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.6 g, 36%). GC-MS m/z : 151 (M^+).

15

Preparation 152

6-Bromomethyl-benzothiazole



20 **Benzothiazole-6-carboxylic acid methyl ester:** Add 1-methyl-3-nitro-1-nitrosoguanidine (5.0 g, 33.9 mmol) to a mixture of diethyl ether (20 mL) and 1N aqueous NaOH (20 mL) at ambient temperature. Separate the organic layer and add it slowly to a solution of benzothiazole-6-carboxylic acid (1.0 g, 5.58 mmol) in THF (50 mL) at 0°C . Evaporate the solvent to obtain the desired intermediate as a yellow solid (1.1 g, 100%).
25 MS (ES+) m/z : 194 ($\text{M}+\text{H}$) $^+$.


Benzothiazol-6-yl-methanol: Add slowly a solution of benzothiazole-6-carboxylic acid methyl ester (0.5 g, 2.59 mmol) in anhydrous THF (10 mL) to a suspension of lithium

aluminum hydride (0.1 g, 2.85 mmol) in anhydrous THF (20 mL) at -10°C and stir for 20 min at -10°C . Treat the reaction mixture with 2N aqueous NaOH until a granular precipitate starts to form and filter through a pad of Celite®. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1, 7:3, 3:2 and 1:1) to obtain the desired intermediate as a yellow oil (0.4 g, 99%). MS (ES+) m/z : 166 (M+H)⁺.

6-Bromomethyl-benzothiazole: Dissolve benzothiazol-6-yl-methanol (0.4 g, 2.55 mmol) in diethyl ether (10 mL) and add slowly a solution of phosphorus tribromide (0.7 g, 2.55 mmol) in diethyl ether (5 mL). Stir the reaction mixture for 2 h at ambient temperature, wash with brine, dry the organic phase over anhydrous Na_2SO_4 , evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1) to obtain the title compound as a white solid (0.5 g, 86%). MS (ES+) m/z : 229 (M+H)⁺.

Preparation 153

6-Bromomethyl-2-cyclohexyl-benzothiazole



Cyclohexanecarboximidic acid ethyl ester, hydrochloride: Combine cyclohexanecarbonitrile (1.0 g, 9.20 mmol), ethanol (0.4 g, 9.20 mmol) and 4N hydrogen chloride in dioxane (8 mL) and stir the reaction mixture for 17 h at ambient temperature. Evaporate the solvent and triturate the residue with diethyl ether to obtain the desired intermediate as a white solid (1.4 g, 80%).

2-Cyclohexyl-6-methyl-benzothiazole: Combine 2-amino-5-methyl-benzenethiol zinc salt (1.0 g, 2.91 mmol, prepared as described in *Synth. Commun.* 1980, 10, 167-173),

cyclohexanecarboximidic acid ethyl ester hydrochloride (1.1 g, 5.82 mmol), methanol (20 mL) and reflux the reaction mixture for 17 h. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a white solid (1.15 g, 85%).

5


6-Bromomethyl-2-cyclohexyl-benzothiazole: Combine 2-benzyl-6-methyl-benzothiazole (0.6 g, 2.42 mmol), NBS (0.5 g, 2.54 mmol), AIBN (40 mg, 0.24 mmol), carbon tetrachloride (10 mL) and reflux for 3 h. Cool the reaction mixture to ambient temperature, dilute with chloroform and wash with water. Dry the organic extracts over anhydrous Na₂SO₄, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the title compound as a white solid (0.4 g, 53%). MS (ES+) *m/z*: 311 (M+H)⁺.

10

Preparation 154

15

6-Bromomethyl-2-phenyl-benzothiazole



6-Methyl-2-phenyl-benzothiazole: Combine 2-amino-5-methyl-benzenethiol zinc salt (1.0 g, 2.91 mmol, prepared as described in *Synth. Commun.* 1980, 10, 167-173), ethyl benzimidate hydrochloride (1.1 g, 5.82 mmol), methanol (20 mL), and reflux the reaction mixture for 17 h. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a white solid (1.1 g, 85%). MS (ES+) *m/z*: 226 (M+H)⁺.

25


6-Bromomethyl-2-phenyl-benzothiazole: Combine 6-methyl-2-phenyl-benzothiazole (0.2 g, 0.98 mmol), NBS (0.2 g, 1.02 mmol), AIBN (20 mg, 0.10 mmol), carbon tetrachloride (5 mL) and reflux for 3 h. Cool the reaction mixture to ambient temperature, dilute with chloroform and wash with water. Dry the organic extracts over anhydrous Na₂SO₄, concentrate and purify by chromatography on silica gel eluting with

30

hexane/EtOAc (1:0, 9:1, 8:2 and 7:3) to obtain the title compound as a white solid (0.2 g, 69%).

Preparation 155


2-Benzyl-6-bromomethyl-benzothiazole



2-Phenyl-acetimidic acid ethyl ester, hydrochloride: Combine benzyl cyanide (1.0 g, 8.50 mmol), ethanol (0.4 g, 8.50 mmol) and 4N hydrogen chloride in dioxane (8 mL) and stir the reaction mixture at ambient temperature for 17 h. Evaporate the solvent and triturate the residue with diethyl ether to obtain the desired intermediate as a white solid (1.7 g, 100%).

2-Benzyl-6-methyl-benzothiazole: Combine 2-amino-5-methyl-benzenethiol zinc salt (1.0 g, 2.91 mmol, prepared as described in *Synth. Commun.* 1980, 10, 167-173), 2-phenyl-acetimidic acid ethyl ester hydrochloride (1.16 g, 5.82 mmol), methanol (20 mL) and reflux the reaction mixture for 17 h. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a white solid (1.0 g, 72%). MS (ES+) m/z : 240 ($\text{M}+\text{H}$)⁺.

2-Benzyl-6-bromomethyl-benzothiazole: Combine 2-benzyl-6-methyl-benzothiazole (0.6 g, 2.51 mmol), NBS (0.5 g, 2.63 mmol), AIBN (40 mg, 0.25 mmol), carbon tetrachloride (10 mL) and reflux for 3 h. Cool the reaction mixture to ambient temperature, dilute with chloroform and wash with water. Dry the combined organic extracts over anhydrous Na_2SO_4 , evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the title compound as a white solid (0.2 g, 69%). MS (ES+) m/z : 319 ($\text{M}+\text{H}$)⁺.

Preparation 156**5-Bromomethyl-benzoxazole**

5


5-Methyl-benzoxazole: Combine 2-amino-4-methyl-phenol (1.0 g, 8.12 mmol), [(dimethylaminomethylene-aminomethylene)dimethylammonium chloride (Gold's reagent) (1.6 g, 9.91 mmol), anhydrous 1,4-dioxane (25 mL) and reflux for 17 h. Cool the reaction mixture to ambient temperature, evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to obtain the desired intermediate as a yellow oil (0.7 g, 65%).

10

5-Bromomethyl-benzoxazol: Combine 5-methyl-benzoxazole (0.5 g, 3.75 mmol), NBS (0.7 g, 3.93 mmol), AIBN (60 mg, 0.37 mmol), chloroform (10 mL) and reflux for 1 h. Cool the reaction mixture to ambient temperature, dilute with chloroform and wash with water. Dry the organic extracts over anhydrous Na₂SO₄, evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1 and 7:3) to obtain the title compound as a white solid (0.1 g, 13%).

15

20

Preparation 157**5- Methylamino-2-phenyl-benzoxazole**

25

2-(Phenyl-benzoxazol-5-ylmethyl)-carbamic acid 2-trimethylsilylanyl-ethyl ester:


Combine (2-phenyl-benzoxazol-5-yl)-acetic acid (1.0 g, 3.95 mmol), triethylamine (0.5 g, 4.34 mmol), and anhydrous toluene (20 mL), heat to reflux and slowly add

diphenylphosphoryl azide (1.2 g, 4.15 mmol) in anhydrous toluene (8 mL). Continue to reflux for 3 h, cool to ambient temperature, add 2-trimethylsilylethanol (0.9 g, 7.89 mmol) to the reaction mixture and continue to reflux for 3 h. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1 and 7:3) to obtain the desired intermediate as a yellow solid (0.4 g, 26%).

5-Methylamino-2-phenyl-benzoxazole: Dissolve (2-phenyl-benzoxazol-5-yl-methyl)-carbamic acid 2-trimethylsilanyl-ethyl ester (0.4, 0.99 mmol) in anhydrous THF (5 mL) and treat with 1M tetrabutylammonium fluoride in THF (1.5 mL, 1.54 mmol). Heat the mixture at reflux for 30 min, evaporate the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.1 g, 27%).

Preparation 158

4-Aminomethyl-1-methylindole




1-Methylindole-4-carbonitrile: Add slowly a solution of indole-4-carbonitrile (1.0 g, 7.04 mmol) in anhydrous DMF (5 mL) to a suspension of sodium hydride (60% dispersion in mineral oil, 0.6 g, 8.64 mmol) in anhydrous DMF (2 mL) at 0°C and warm the reaction mixture to ambient temperature. Add iodomethane (0.7 mL, 10.6 mmol) and stir the reaction for 1 h at ambient temperature. Dilute the reaction mixture with 1M aqueous NH₄OH (30 mL) and extract with diethyl ether (3 x 10 mL). Combine the organic extracts, dry over anhydrous Na₂SO₄, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1 and 7:3) to obtain the desired intermediate as a yellow oil (1.0 g, 87%). GC-MS *m/z*: 156 (M⁺).

4-Aminomethyl-1-methylindole: Dissolve 1-methylindole-4-carbonitrile (1.0 g, 6.18 mmol) in anhydrous THF (10 mL) and add slowly to 1M lithium aluminum hydride in THF (12.4 mL, 12.37 mmol) at ambient temperature. Heat the reaction mixture at 50°C for 17 h and cool to ambient temperature. Quench the reaction mixture with water until a

granular precipitate starts to form and filter through a pad of Celite®. Evaporate the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.9 g, 91%). GC-MS m/z : 160 (M^+).

5

Preparation 159**6-Aminomethyl-1-methylindole**

- 10 **1-Methylindole-6-carbonitrile:** Add slowly a solution of indole-6-carbonitrile (1.0 g, 7.04 mmol) in anhydrous DMF (5 mL) to a suspension of sodium hydride (60% dispersion in mineral oil, 0.6 g, 14.1 mmol) in anhydrous DMF (2 mL) at 0°C and warm the reaction mixture to ambient temperature. Add iodomethane (0.7 mL, 1.06 mmol) and stir the reaction mixture for 1 h at ambient temperature. Dilute the reaction mixture with
- 15 1M aqueous NH_4OH (30 mL) and extract with diethyl ether (3 x 10 mL). Combine the organic layers, dry over anhydrous Na_2SO_4 , remove the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 4:1 and 7:3) to obtain the desired intermediate as a yellow oil (1.0 g, 87%). MS (ES^+) m/z : 156 ($M+\text{H}$)⁺.
- 20 **6-Aminomethyl-1-methylindole:** Dissolve 1-methylindole-6-carbonitrile (0.97 g, 6.18 mmol) in anhydrous THF (10 mL) and add slowly to 1M lithium aluminum hydride in THF (1.24 mL, 1.24 mmol) at ambient temperature. Heat the reaction mixture at 50°C for 17 h and cool to ambient temperature. Quench the reaction mixture with water until a granular precipitate starts to form and filter through a pad of Celite®. Evaporate the
- 25 solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.9 g, 91%). GC-MS m/z : 160 (M^+).

Preparation 160**6-Aminomethyl-benzofuran**


5

Dissolve benzofuran-6-carbonitrile (0.5 g, 3.28 mmol) in anhydrous THF (10 mL) and add slowly to 1M lithium aluminum hydride in THF (6.56 mL, 6.56 mmol) at ambient temperature. Heat the reaction mixture at 50°C for 17 h and cool to ambient temperature. Quench the reaction mixture with water until a granular precipitate starts to form and filter through a pad of Celite®. Evaporate the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.4 g, 79%).

10

Preparation 161**4-Aminomethyl-benzofuran**

15




Benzofuran-4-carbonitrile: Combine 4-bromo-benzofuran (1.0 g, 5.07 mmol), copper(I) cyanide (0.9 g, 10.2 mmol), anhydrous DMF (16 mL) and reflux for 17 h. Cool the reaction mixture to ambient temperature, treat with 50% (v/v) aqueous ethylenediamine (25 mL). Extract the reaction mixture with diethyl ether (3 x 15 mL), combine the organic extracts, wash with brine (15 mL) and dry over anhydrous Na₂SO₄. Evaporate the solvent and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1) to obtain the desired intermediate as a colorless oil (0.3 g, 39%).

20
25

4-Aminomethyl-benzofuran: Dissolve benzofuran-4-carbonitrile (0.3 g, 1.96 mmol) in anhydrous THF (5 mL) and add slowly to 1M lithium aluminum hydride in THF (3.91 mL, 3.91 mmol) at ambient temperature. Heat the reaction mixture at 50°C for 5 h and

cool to ambient temperature. Quench the reaction mixture with water until a granular precipitate starts to form and filter through a pad of Celite®. Evaporate the solvent and purify by SCX chromatography to obtain the title compound as a brown oil (0.4 g, 79%). GC-MS m/z : 147 (M^+).


5

Preparation 162**4-Aminomethyl-benzo[*b*]thiophene**

10

Add lithium aluminum hydride (1M solution in THF, 7.5 mL) to benzo[*b*]thiophene-4-carbonitrile (prepared as described in WO 0168653) (0.6 g, 3.8 mmol) at 0°C in THF (38 mL). After 17 h at ambient temperature, cool to 0°C and add sequentially water (1.89 mL), 2N aqueous NaOH (1.89 mL) and water (2.69 mL). Filter the solids and evaporate the filtrate to obtain the crude amine. Purify by SCX chromatography. Rinse the column with methanol, add a solution of the crude amine in methanol, wash the column with methanol and then elute with 1N ammonia in methanol. Concentrate to give the title compound (0.57 g, 93%). GC-MS m/z : 163 (M^+).

15

Preparation 163**6-Aminomethyl-benzo[*b*]thiophene**

20

Benzo[*b*]thiophen-6-carbonitrile: Heat copper(I) cyanide (0.84 g, 9.4 mmol) and 6-bromobenzo[*b*]thiophene (prepared as described in WO 01/23381) (1.0 g, 4.7 mmol) at 160°C for 13 h. Cool the mixture to 0°C, add 33% aqueous ethylenediamine (20 mL) and dilute with ether. Wash the organic mixture with brine, dry over Na₂SO₄ and evaporate.

25

Purify by chromatography on silica gel eluting with EtOAc/hexane (0:1 to 1:3) to give the desired intermediate (0.58 g, 78%). GC-MS m/z : 159 (M^+).

6-Aminomethyl-benzo[*b*]thiophene: Add 1M lithium aluminum hydride in THF (7.3 mL) to benzo[*b*]thiophene-6-carbonitrile (0.6 g, 3.6 mmol) at 0°C in THF (36 mL). After 15 h at ambient temperature, cool to 0°C and add sequentially water (1.82 mL), 2N aqueous NaOH (1.82 mL) and water (2.60 mL). Filter the solid and evaporate the filtrate to obtain the crude amine. Purify by SCX chromatography. Rinse the column with methanol, add a solution of the crude amine in methanol, wash the column with methanol and then elute with 1N ammonia in methanol. Concentrate *in vacuo* to give the title compound (0.55 g, 92%).

Preparation 164

8-Bromomethyl-quinoline



Combine 8-methyl-quinoline (1.0 g, 6.99 mmol), NBS (1.3 g, 7.13 mmol), benzoyl peroxide (6.0 mg, 0.03 mmol), carbon tetrachloride (30 mL) and reflux for 17 h. Cool the reaction mixture to ambient temperature and evaporate the solvent. Dissolve the residue in chloroform (30 mL), wash the organic solution with saturated aqueous NaHCO₃ (2 x 10 mL), brine (10 mL) and dry over anhydrous Na₂SO₄. Evaporate the solvent and purify by chromatography on silica gel eluting with DCM to obtain the title compound as a white solid (1.3 g, 83%). MS (ES+) m/z : 223 ($M+H$)⁺.

Preparation 165


2-Aminomethyl-quinoline



Combine quinoline-2-carbonitrile (0.2 g, 1.29 mmol), Raney® 3201 nickel (slurry in water, 0.05 g), 2N ammonia in methanol (10 mL) and hydrogenate at 50 psi for 15 min. Filter the reaction mixture through a pad of Celite®, remove the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.2 g, 98%). MS (ES+) m/z : 159 (M+H)⁺.

Preparation 166


3-Aminomethyl-quinoline Dihydrochloride




Combine quinoline-3-carbonitrile (1.0 g, 6.49 mmol), 10% Pd/C (0.2 g), 5% TFA in methanol (100 mL) and hydrogenate at 30 psi for 2 h. Filter the reaction mixture through a pad of Celite® and evaporate the solvent. Dissolve the residue in ethanol (10 mL), treat with 1N hydrogen chloride in diethyl ether (5 mL) and allow the mixture to stand at 5°C for 18 h. Filter the precipitate, wash with ethanol and dry under *vacuo* to obtain the title compound as a white solid (0.6 g, 53%).

Preparation 167

2-Aminomethyl-isoquinoline Dihydrochloride



Combine isoquinoline-3-carbonitrile (1.0 g, 6.49 mmol), 10% Pd/C (0.2 g), 5% TFA in methanol (95 mL) and hydrogenate at 30 psi for 17 h. Filter the reaction mixture through a pad of Celite® and evaporate the solvent. Dissolve the residue in ethanol (10 mL), treat with 1N hydrogen chloride in diethyl ether (5 mL) and allow to stand at 5 °C for 18 h. Filter the precipitate, wash with ethanol and dry under *vacuo* to obtain the title compound as a white solid (0.6 g, 55%).

Preparation 168**6-Aminomethyl-quinoline**


5

6-Quinolinecarboxamide: Combine 6-quinolinecarboxylic acid (2.0 g, 11.6 mmol), 1,1-carbonyldiimidazol (3.8 g, 23.45 mmol) in DCM (50 mL) and stir at ambient temperature for 1 h. Saturate the reaction mixture with anhydrous ammonia and continue to stir for 1 h. Quench the reaction mixture with water (100 mL) and extract with chloroform (3 x 50 mL). Combine the organic extracts, dry over anhydrous Na₂SO₄ and evaporate the solvent to obtain the desired intermediate as a white solid (1.6 g, 78%).

6-Quinolinecarbonitrile: Dissolve 6-quinolinecarboxamide (1.5 g, 8.95 mmol) in DCM (50 mL), add triethylamine (2.7 g, 26.8 mmol) and cool the reaction mixture to 0°C. Add trifluoroacetic acid anhydride (2.4 g, 11.16 mmol) to the reaction mixture and stir for 10 min at 0 °C. Quench the reaction mixture with water (20 mL) and separate the organic layer. Extract aqueous layer with DCM (2 x 15 mL). Combine the organic extracts and dry over anhydrous Na₂SO₄. Evaporate the solvent to obtain the desired intermediate as a white solid (1.0 g, 73%). GC-MS *m/z*: 154 (M⁺).

6-Aminomethyl-quinoline: Combine 6-quinolinecarbonitrile (1.0 g, 6.49 mmol), Raney® 3201 nickel (slurry in water, 0.2 g), 2N ammonia in methanol (20 mL) and hydrogenate at 50 psi for 1 h. Filter the reaction mixture through a pad of Celite®, remove the solvent and purify by SCX chromatography to obtain the title compound as a yellow oil (0.8 g, 78%).

Preparation 169

(±)-2-(1-Aminoethyl)-5-methylthiophene

5

(±)-2-(1-Hydroxyethyl)-5-methylthiophene: Add sodium borohydride (270 mg, 7.13 mmol) to a solution of 2-acetyl-5-methylthiophene (1.0 g, 7.13 mmol) in methanol (40 mL). Stir the mixture for 1 h at room temperature. Remove the solvent *in vacuo* and partition the residue between water and DCM. Separate the organic phase, dry over Na_2SO_4 , filter and concentrate to obtain the desired intermediate as an oil (0.995 g, 98%) that was used without further purification. GC-MS m/z 142 (M^+).

(±)-2-(1-Azidoethyl)-5-methylthiophene: Add DBU (1.228 g, 1.2 mL, 8.07 mmol) to a solution of (±)-2-(1-hydroxyethyl)-5-methylthiophene (0.955 g, 6.72 mmol) and diphenylphosphoryl azide (2.22 g, 1.74 mL, 8.07 mmol) in anhydrous toluene. Stir at room temperature for 18 h. Dilute the mixture with EtOAc and wash with water and 0.5N aqueous HCl. Dry the organic phase over Na_2SO_4 , filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 19:1) to obtain the desired intermediate as an oil (0.875 g, 78%). GC-MS m/z 167 (M^+).

20


(±)-2-(1-Aminoethyl)-5-methylthiophene: Add lithium aluminum hydride (29 mg, 0.72 mmol) to a solution of (±)-2-(1-azidoethyl)-5-methylthiophene (100 mg, 0.59 mmol) in anhydrous THF (5 mL). Stir at room temperature overnight. Work-up the mixture with EtOAc and water. Filter the mixture over Celite®. Separate and wash the organic phase with brine. Dry over Na_2SO_4 , filter and concentrate *in vacuo*. Purify by SCX chromatography. Rinse with DCM/methanol (1:1), load the crude mixture in methanol and elute sequentially with methanol and 1N ammonia in methanol to obtain the title compound as an oil (80 mg, 95%). GC-MS m/z 141 (M^+).

30

Preparations 170 and 171

1-(5-Phenyl-thiophen-2-yl)ethylamine, Isomer 1 and

1-(5-phenyl-thiophen-2-yl)ethylamine, Isomer 2



5

N-[(5-Phenylthiophen-2-yl)-methylene]-2-methylpropanesulfinamide: To a solution of 5-phenyl-2-thiophenecarboxaldehyde (1.25 g, 6.64 mmol) in anhydrous THF (50 mL), add titanium(IV) ethoxide (3.03 g, 2.78 mL, 13.28 mmol) and (R)-(+)-2-methyl-2-propanesulfinamide (0.965 g, 7.968 mmol) under nitrogen. Heat the reaction at 80°C overnight. Cool the mixture to room temperature and dilute with EtOAc. Add water and filter the resulting precipitate over Celite®. Separate and dry the organic phase over Na₂SO₄, filter and concentrate *in vacuo* to obtain the desired intermediate as a yellow solid (1.93 g, 100% yield) that was used without purification.

15

N-[1-(5-Phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 1) and N-[1-(5-phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 2): Add slowly methyllithium (8.1 mL, 12.92 mmol, 1.6 M solution in ether) to a solution of N-[(5-phenylthiophen-2-yl)-methylene]-2-methylpropanesulfinamide (1.883 g, 6.46 mmol) in anhydrous THF (50 mL) at -40°C. Warm the reaction to -20°C and stir for 2 h. Warm to 0°C and stir for an additional 2 h. Add saturated aqueous NH₄Cl and extract with EtOAc. Dry the organic phase over Na₂SO₄, filter and concentrate *in vacuo*. Purify by

20

chromatography on silica gel eluting with hexane/EtOAc (7:3 and 1:1) to obtain *N*-[1-(5-phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 1) (575 mg, 30% yield) and *N*-[1-(5-phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 2) (847 mg, 44% yield).

5

1-(5-Phenyl-thiophen-2-yl)ethylamine (Isomer 1, Preparation 170): Add 4N hydrogen chloride in dioxane (0.837 mL, 3.349 mmol) to a stirred solution of *N*-[1-(5-phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 1) (515 mg, 1.675 mmol) in methanol (8 mL) at room temperature. Stir for 2 h and remove the solvent *in vacuo* to obtain a solid that was washed with ethyl ether. Dissolve the solid in DCM and wash with saturated aqueous NaHCO₃. Dry the organic phase over Na₂SO₄, filter and concentrate *in vacuo* to obtain the desired intermediate (236 mg, 69% yield).

10


1-(5-Phenyl-thiophen-2-yl)ethylamine (Isomer 2, Preparation 171): Add 4N hydrogen chloride in dioxane (1.112 mL, 4.449 mmol) to a stirred solution of *N*-[1-(5-phenylthiophen-2-yl)ethyl]-2-methylpropanesulfinamide (Isomer 2) (684 mg, 2.225 mmol) in methanol (10 mL) at room temperature. Stir for 2 h and remove the solvent *in vacuo* to obtain a solid that was washed with ethyl ether. Dissolve the solid in DCM and wash with saturated aqueous NaHCO₃. Dry the organic phase over Na₂SO₄, filter and concentrate *in vacuo* to obtain the desired intermediate (347 mg, 77% yield).

20

Example 49

6-(2-Benzoylamino-ethylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride


25





Dissolve 6-(2-amino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (70 mg, 0.208 mmol) in DCM (4 mL). Add benzoyl chloride (24 μ L, 0.208 mmol), and triethylamine (44 μ L, 0.312 mmol) and stir at ambient temperature for 24 h under nitrogen atmosphere. Dilute with DCM and add 1M aqueous HCl. Extract the aqueous layer with DCM. Dry the organic layer over MgSO₄ and concentrate in *vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 7:3 and 1:1) to obtain 6-(2-benzoylamino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.

Use a method similar to the General Procedure 1-1, using 6-(2-benzoylamino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound (77 mg, 90% overall). HPLC: t_R = 2.64 min (20–80% of Solvent B in 7.5 min. Solvent A: water, 0.1% TFA. Solvent B: acetonitrile, 0.1% TFA. Column: C18 Metachem, 5 micron, 4.6x50).

Examples 50-52 may be prepared essentially as described in Example 49 by using 6-(2-amino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine or 6-(3-amino-propylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate benzoyl chloride. Overall yields and MS (ES⁺) data are shown in the Table below.




Ex.	NH-CO-R	n	Compound	Yield (%)	MS (ES ⁺) <i>m/z</i>
50		2	7-Chloro-6-[2-(2-fluorobenzoylamino)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	40	362 (M+H) ⁺

Ex.	NH-CO-R	n	Compound	Yield (%)	MS (ES+) <i>m/z</i>
51		3	6-(3-Benzoylamino-propylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	90	ND
52		3	7-Chloro-6-[3-(2-fluorobenzoylamino)-propylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	40	376 (M+H) ⁺

ND = Not determined

Example 53

7-Chloro-6-{2-[(pyridine-3-carbonyl)-amino]-ethylamino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Dissolve nicotinic acid (28.2 mg, 0.23 mmol) in DCM (3 mL). Add EDC (40 mg, 0.208 mmol), HOBT (28.1 mg, 0.208 mmol) and stir at ambient temperature for 10 min. Add 6-(2-amino-ethylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (70 mg, 0.208 mmol) and stir at ambient temperature for 10 hr. Dilute with DCM, add water and extract the aqueous layer three times with DCM. Wash combined organic extracts with 1*N* aqueous NaOH, and brine. Dry the organic layer over MgSO₄, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 1:1, 3:7 and 1:9) to obtain 7-chloro-6-{2-[(pyridine-3-carbonyl)-amino]-ethylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.

Use a method similar to the General Procedure 1-1, using 7-chloro-6-{2-[(pyridine-3-carbonyl)-amino]-ethylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the free base of the title compound. Use a method similar to

the General Procedure 2-2 to give the title compound as a solid (92 mg, 98%). HPLC: t_R = 1.38 min (20–80% of Solvent B in 7.5 min. Solvent A: water, 0.1% TFA. Solvent B: acetonitrile, 0.1% TFA. Column: C18 Metachem, 5 micron, 4.6x50).

Example 54

7-Chloro-6-[3-(3-phenyl-ureido)-propylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Combine phenyl isocyanate (15 μ L, 0.137 mmol) and 6-(3-amino-propylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (48 mg, 0.137 mmol) in DCM and stir for 16 h. Concentrate, add DCM, filter and collect the solid to obtain 7-chloro-6-[3-(3-phenyl-ureido)-propylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (18 mg, 28%).

Use a method similar to the General Procedure 1-1, using 7-chloro-6-[3-(3-phenyl-ureido)-propylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound (14 mg, 23%). MS (ES+) m/z : 373 (M+H)⁺.

Example 55


6-(2-Phenoxy-ethylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the General Procedure 5-1, using 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (100 mg, 0.23 mmol) and phenoxyethylamine (63 mg, 0.4 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (85:15) followed by SCX chromatography, 6-(2-phenoxyethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil. MS (ES+) *m/z*: 379 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 6-(2-phenoxyethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (75 mg, 0.19 mmol). Purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (ES+) *m/z*: 283 (M+H)⁺.

Examples 56-61 may be prepared essentially as described in Example 55 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step1 (General Procedure 5-1) and MS (ES+) data are shown in the Table below.




20

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
56		7-Chloro-6-phenethylamino-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	47	301 (M+H) ⁺
57		7-Chloro-6-(3-fluorophenethylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	55	319 (M+H) ⁺
58		7-Chloro-6-[(thiazol-2-yl)methylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	21	294 (M+H) ⁺

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
59		7-Chloro-6-[(2-methyl-thiazol-4-yl)methylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	16	308 (M+H) ⁺
60		7-Chloro-6-(2-pyridin-2-yl-ethylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	86	302 (M+H) ⁺
61		7-Chloro-6-(2-thiophen-2-yl-ethylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	78	ND

ND = Not determined

Example 62

5 7-Chloro-6-[(2-ethoxyethyl)amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate


10 Use a method similar to the General Procedure 5-1, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.47 mmol) and 2-ethoxyethyl amine (105 μ L, 1.0 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (95:5) and additional SCX chromatography, 7-chloro-6-[(2-ethoxyethyl)amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (32 mg, 19%). MS (ES+) *m/z*: 365 (M+H)⁺.

15

20 Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[(2-ethoxyethyl)amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (30 mg, 0.08 mmol). Purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as an oil (23.8 mg, 75% over 2 steps). MS (ES+) *m/z*: 269 (M+H)⁺.

Examples 63-68 may be prepared essentially as described in Example 62 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-1), optical rotations and MS (ES⁺) data are shown in the Table below.


5



Ex.	NH-R	Compound	Yield (%)	MS (ES ⁺) <i>m/z</i> .	[α] ²⁰ _D (c, solvent)
63		7-Chloro-6-[2-(1-propoxy)ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	57	283 (M+H) ⁺	-
64		7-Chloro-6-[2-(2-propoxy)ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	75	283 (M+H) ⁺	-
65		6-(2-Benzyloxy-ethylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	37	331 (M+H) ⁺	-
66		(<i>R</i>)-6-(2-Benzyloxy-1-methyl-ethylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	15	345 (M+H) ⁺	ND
67		(<i>R</i>)-6-(2-Phenoxy-1-methyl-ethylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	15	331 (M+H) ⁺	+54.7° (c 0.5, CH ₃ OH)
68		(<i>R</i>)-6-[2-(4-Fluorobenzyloxy)-1-methyl-ethylamino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	69	363 (M+H) ⁺	+22.6° (c 0.5, CH ₃ OH)

ND = Not determined

Example 69

6-(2-Fluorobenzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

5

Use a method similar to the General Procedure 5-1, using 3-(2,2,2-trifluoroacetyl)-6-trifluoromethylsulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (100 mg, 0.26 mmol) and 2-fluorobenzylamine (88 μ L, 0.77 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (9:1), 6-(2-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (45 mg, 48%). MS (ES+) *m/z*: 367 (M+H)⁺.

10


Use a method similar to the General Procedure 1-1 to deprotect 6-(2-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (40 mg, 0.11 mmol). Purify by SCX chromatography to give the free base of the title compound as a yellow oil (28 mg, 94 %). Use a method similar to the General Procedure 2-2 to give the title compound as an off-white solid (29 mg, 95%). MS (ES+) *m/z*: 271 (M+H)⁺.

15

20

Example 70 may be prepared essentially as described in Example 69 by using 3-(2,2,2-trifluoroacetyl)-6-trifluoromethylsulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2,6-difluorobenzylamine. The yield for the Step 1 (General Procedure 5-1) and MS (ES+) data are shown in the Table below.


25

Ex.	Structure	Compound	Yield (%)	MS (ES+) m/z
70		6-(2,6-Difluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	69	289 (M+H) ⁺

Example 71

7-Chloro-6-(2-fluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

5




Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 2-fluorobenzyl amine. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 and 4:1) to give 7-chloro-6-(2-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow solid. MS (ES+) m/z : 401 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(2-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Purify by SCX chromatography to give the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to give the title compound as a light yellow solid. MS (ES+) m/z : 305 (M+H)⁺.

20

Examples 72-80 may be prepared essentially as described in Example 71 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. MS (ES⁺) data are shown in the Table below.




5

Ex.	R	Compound	MS (ES ⁺) <i>m/z</i>
72	3-F	7-Chloro-6-(3-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	305 (M+H) ⁺
73	4-F	7-Chloro-6-(4-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	305 (M+H) ⁺
74	2,3-diF	7-Chloro-6-(2,3-difluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	323 (M+H) ⁺
75	3,4-diF	7-Chloro-6-(3,4-difluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	323 (M+H) ⁺
76	3,5-diF	7-Chloro-6-(3,5-difluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	323 (M+H) ⁺
77	3,4,5-triF	7-Chloro-6-(3,4,5-trifluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	341 (M+H) ⁺
78	3-CF ₃	7-Chloro-6-(3-trifluoromethylbenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	355 (M+H) ⁺
79	3,5-diCF ₃	7-Chloro-6-[3,5-bis(trifluoromethyl)benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	423 (M+H) ⁺
80	4-O(CH ₂) ₂ N(CH ₃) ₂	7-Chloro-6-[4-[2-(<i>N,N</i> -dimethylamino)ethoxy]benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	374 (M+H) ⁺

Example 81

6-(4-*tert*-Butylbenzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5


Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (300 mg, 0.7 mmol) with 4-(*tert*-butyl)benzyl amine (375 μ L, 2.1 mmol). Purify by
10 chromatography on silica gel eluting with hexane/EtOAc (95:5) followed by SCX chromatography to give 6-(4-*tert*-butylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil (240 mg, 78%). MS (ES+) *m/z*: 439 (M+H)⁺.

15

Use a method similar to the General Procedure 1-1 to deprotect 6-(4-*tert*-butylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (235 mg, 0.54 mmol). Purify by SCX chromatography to give the free
base of the title compound (161 mg, 87%). Use a method similar to the General Procedure
2-1 to give the title compound as an off-white gum (190 mg, 88%). MS (ES+) *m/z*: 343
20 (M+H)⁺.

25


Examples 82-88 may be prepared essentially as described in Example 81 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. MS (ES+) data are shown in the Table below.



Ex.	R	Compound	MS (ES+) <i>m/z</i>
82	3- <i>t</i> -Bu	6-(3- <i>tert</i> -Butylbenzylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	343 (M+H) ⁺
83	4-OCF ₃	7-Chloro-6-(4-trifluoromethoxybenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	371 (M+H) ⁺
84	4-F,3-CF ₃	7-Chloro-6-[(4-fluoro-3-trifluoromethyl)benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	373 (M+H) ⁺
85	4-F,3-OCH ₃	7-Chloro-6-[(4-fluoro-3-methoxy)benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	321 (M+H) ⁺
86	4-Ph	7-Chloro-6-(4-phenylbenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	363 (M+H) ⁺
87	4-OPh	7-Chloro-6-(4-phenoxybenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	379 (M+H) ⁺
88	4-SO ₂ CH ₃	7-Chloro-6-(4-methanesulfonylbenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	365 (M+H) ⁺

Example 89

- 5 7-Chloro-6-(4-cyanobenzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-1 to react 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (504 mg, 1.2 mmol), 4-cyanobenzylamine (476 mg, 3.6 mmol), palladium(II) acetate (29 mg, 0.1 mmol), BINAP (148 mg, 0.2 mmol) and cesium carbonate (540 mg, 1.7 mmol) in toluene (5 mL). Purify by chromatography on silica gel eluting with isohexane/EtOAc (1:0 to 1:1) to give 7-chloro-6-(4-cyanobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a white gum (108 mg, 22%). MS (ES+) *m/z*: 408 (M+H)⁺.

Use a method similar to the General Procedure 1-2 to deprotect 7-chloro-6-(4-cyanobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (98 mg, 0.2 mmol). Purify by preparative liquid chromatography eluting with a gradient of water/acetonitrile (19:1 to 1:19) to give the free base of the title compound (31 mg, 42%). MS (ES+) *m/z*: 312 (M+H)⁺. Use a method similar to the General Procedure 2-1, using 7-chloro-6-(4-cyanobenzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (31 mg, 0.1 mmol) to give the title compound as a beige solid (41 mg, 95%). MS (ES+) *m/z*: 312 (M+H)⁺.

Example 90

7-Chloro-6-(3-phenyl-benzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.3 g, 0.706 mmol) with 3-phenyl-benzylamine (0.388 g, 2.117 mmol) using


palladium(II) acetate (32 mg, 0.141 mmol), tris(dibenzylideneacetone)dipalladium(0) (65 mg, 0.070 mmol), BINAP (264 mg, 0.424 mmol) and cesium carbonate (460 mg, 1.412 mmol) in toluene (12 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 19:1) to give 7-chloro-6-(3-phenyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (0.257 g, 79%). MS (ES⁺) *m/z*: 459 (M+H)⁺.

Use a method similar to the General Procedure 1-2, using 7-chloro-6-(3-phenyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (237 mg, 0.516 mmol), to give the free base of the title compound as an oil (188 mg, 100%) that was used without further purification.

Use a method similar to the General Procedure 2-1, using 7-chloro-6-(3-phenyl-benzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (188 mg, 0.518 mmol) to give the title compound as a white solid (191 mg, 77%). MS (ES⁺) *m/z*: 363 (M+H)⁺.

Example 91

7-Chloro-6-(4-chlorobenzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




20

Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (700 mg, 1.6 mmol) with 4-chlorobenzylamine (354 mg, 2.5 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) and then SCX chromatography to give 7-chloro-6-(4-chlorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (459 mg, 69%). MS (ES⁺) *m/z*: 417 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(4-chlorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give the free base of the title compound. MS (ES+) *m/z*: 321 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.


Examples 92-98 may be prepared essentially as described in Example 91 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3) and MS (ES+) data are shown in the Table below.










Ex.	R	Compound	Yield (%)	MS (ES+) <i>m/z</i>	
92	3-Cl	7-Chloro-6-(3-chlorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	45	321 (M+H) ⁺	
93	3-Cl,4-F	7-Chloro-6-(3-chloro-4-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	90	339 (M+H) ⁺	
94	2-Cl,4-F	7-Chloro-6-(2-chloro-4-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	75	339 (M+H) ⁺	
95	3-OCH ₃	7-Chloro-6-(3-methoxybenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	84	316 (M+H) ⁺	
96	2-F,4-CH ₃	7-Chloro-6-(2-fluoro-4-methylbenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	53	319 (M+H) ⁺	
97	3-OCF ₃	7-Chloro-6-(3-trifluoromethoxybenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	85	371 (M+H) ⁺	
98	3-Cl,4-OCH ₃	7-Chloro-6-(3-chloro-4-methoxybenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	100	351 (M+H) ⁺	

Examples 99-106 may be prepared essentially as described in Example 91 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3) and MS (ES⁺) data are shown in the Table below.


5



Ex.	R	Compound	Yield (%)	MS (ES ⁺) <i>m/z</i>	
99		7-Chloro-6-(4-benzyloxy-benzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	87	393 (M+H) ⁺	
100		7-Chloro-6-[4-(3,3-dimethyl-2-oxobutoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	20	401 (M+H) ⁺	
101		7-Chloro-6-[4-(2,2-dimethylpropoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	23	373 (M+H) ⁺	
102		7-Chloro-6-[4-(2-cyclohexylethoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	61	413 (M+H) ⁺	
103		7-Chloro-6-[4-(1 <i>H</i> -pyrazol-1-yl)benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	36	353 (M+H) ⁺	
104		7-Chloro-6-[4-(pyridin-3-yloxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	42	380 (M+H) ⁺	
105		6-(4-Benzylthio-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	21	409 (M+H) ⁺	

Example 106

7-Chloro-6-(2-fluoro-4-phenoxy-benzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate



5


Using a method similar to the General Procedure 5-3, couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.1 g, 2.5 mmol) with 2-fluoro-4-phenoxy-benzylamine (550 mg, 2.5 mmol). Purify by
10 chromatography on silica gel eluting with hexane/EtOAc (9:1) and then SCX chromatography to obtain 7-chloro-6-(2-fluoro-4-phenoxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. MS (ES+) *m/z*: 493 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(2-fluoro-4-phenoxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-
15 benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give the free base of the title compound (468 mg, 47% overall). MS (ES+) *m/z*: 397 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

20

Example 107


7-Chloro-6-[2-fluoro-4-(3'-fluorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



25

Use a method similar to the Example 106, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (426 mg, 1.0 mmol) and 2-fluoro-4-(3'-fluorophenoxy)-benzylamine (340 mg, 1.4 mmol) to give the free base of the title compound (162 mg, 39%). MS (ES+) *m/z*: 415 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Examples 108-121 may be prepared essentially as described in Example 107 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3) and MS (ES+) data are shown in the Table below.




Ex.	R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
108	2-F	7-Chloro-6-[4-(2'-fluorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	44	397 (M+H) ⁺
109	3-F	7-Chloro-6-[4-(3'-fluorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	23	397 (M+H) ⁺
110	4-F	7-Chloro-6-[4-(4'-fluorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	50	397 (M+H) ⁺
111	3-Cl	7-Chloro-6-[4-(3'-chlorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	45	413 (M+H) ⁺
112	3,5-diF	7-Chloro-6-[4-(3',5'-difluorophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	36	415 (M+H) ⁺
113	4-CH ₃	7-Chloro-6-[4-(4'-methylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	54	393 (M+H) ⁺

Ex.	R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
114	3-CH ₃	7-Chloro-6-[4-(3'-methylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	45	393 (M+H) ⁺
115	2-CH ₃	7-Chloro-6-[4-(2'-methylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	54	393 (M+H) ⁺
116	3- ⁱ Pr	7-Chloro-6-[4-(3'-isopropylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	49	421 (M+H) ⁺
117	2- ⁱ Pr	7-Chloro-6-[4-(2'-isopropylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	40	421 (M+H) ⁺
118	2-CN	7-Chloro-6-[4-(2'-cyanophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	79	404 (M+H) ⁺
119	3-CN	7-Chloro-6-[4-(3'-cyanophenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	37	404 (M+H) ⁺
120	2-CF ₃	7-Chloro-6-[4-(2'-trifluoromethylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	30	447 (M+H) ⁺
121	3-CF ₃	7-Chloro-6-[4-(3'-trifluoromethylphenoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	37	447 (M+H) ⁺

Example 122

7-Chloro-6-[4-(3'-cyanobenzoyloxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate.


5






Mix 7-chloro-6-(4-hydroxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (150 mg, 0.38 mmol), 3-cyanobenzyl bromide (90 mg, 0.46 mmol), powdered potassium carbonate (105 mg, 0.76 mmol), powdered potassium iodide (6.6 mg, 0.04 mmol) and acetone (30 mL). Stir and heat to reflux under nitrogen for 16 hr. Dilute with acetone, filter, concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 4:1) to obtain 7-chloro-6-[4-(3'-cyanobenzyloxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (72.4 mg, 37%). MS (ES+) *m/z* 514 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[4-(3'-cyanobenzyloxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (95:5) to give the free base of the title compound (42 mg, 71%). MS (ES+) *m/z*: 418 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Examples 123-126 may be prepared essentially as described in Example 122 by using 7-chloro-6-(4-hydroxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate bromide. Overall yields and MS (ES+) data are shown in the Table below.




Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i> (M+H) ⁺
123		7-Chloro-6-[4-(3'-fluorobenzyloxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	75	411 (M+H) ⁺

Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
124		7-Chloro-6-[4-(2-oxo-2-phenylethoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	45	421 (M+H) ⁺
125		7-Chloro-6-[4-(2-oxo-2-(4-fluorophenyl)ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	17	439 (M+H) ⁺
126		7-Chloro-6-[4-(2-oxo-2-piperidin-1-ylethoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	44	428 (M+H) ⁺

Example 127


7-Chloro-6-[3-chloro-4-(3,3-dimethyl-2-oxo-butoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Use a method similar to the General Procedure 4-1 to react 7-chloro-6-(3-chloro-4-hydroxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (438 mg, 1.01 mmol) and 1-bromopinacolone (217 mg, 1.21 mmol). Purify by chromatography on silica gel eluting with EtOAc/hexane (1:4) to give 7-chloro-6-[3-chloro-4-(3,3-dimethyl-2-oxo-butoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil (441 mg, 82%). MS (ES+) *m/z*: 531 (M+H)⁺.


Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[3-chloro-4-(3,3-dimethyl-2-oxo-butoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (441 mg, 0.83 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (93:7) to give the free base of the title compound (278 mg, 95%). MS (ES+) *m/z*: 435 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound.

Example 128 may be prepared essentially as described in Example 127, using 7-chloro-6-(3-chloro-4-hydroxy-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and benzyl bromide. The overall yield and MS (ES+) data are shown in the Table below.

Ex.	Structure	Compound	Yield (%)	MS (ES+) <i>m/z</i>
128		7-Chloro-6-(3-chloro-4-benzyloxy-benzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	64	427 (M+H) ⁺

Example 129

(±)-7-Chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-3, to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (851 mg, 2.0 mmol) and (±)-4-(1-phenyl-ethoxy)-benzylamine (721 mg, 2.6 mmol). Purify by chromatography on silica gel eluting with EtOAc/hexane (1:8) to give (±)-7-chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (702 mg, 69%). MS (ES+) *m/z*: 503 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect (±)-7-chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (702 mg, 1.40 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (92:8) to give the free base of the title compound (368 mg, 65 %). MS (ES+) *m/z*: 407 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Examples 130 and 131

(-)-7-Chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (+)-7-Chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Separate the two enantiomers of Example 129 by chiral HPLC [Chiralcel OJ-H column, acetonitrile/methanol (20:80) with 0.2% DMEA; flow rate 1 mL/min; Isomer 1: *t_R*=5.0 min, Isomer 2: *t_R*=6.5 min].

Use a method similar to the General Procedure 2-1 to prepare the succinate of each enantiomer: (-)-7-chloro-6-[4-(1-phenyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate, [α]_D²⁰ -17.4° (c 0.5, CH₃OH), and (+)-7-chloro-6-[4-(1-

phenyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate, $[\alpha]^{20}_{\text{D}}$ +18.2° (c 0.5, CH₃OH).

Example 132


5 7-Chloro-6-[4-(3,3-dimethylbutoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Mesylate



10 Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (426 mg, 1.0 mmol) and 4-(3,3-dimethylbutoxy)-benzylamine (325 mg, 1.5 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) and then SCX chromatography to obtain 7-chloro-6-[4-(3,3-dimethylbutoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. MS (ES+) *m/z*: 483 (M+H)⁺.


20 Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[4-(3,3-dimethylbutoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give the free base of the title compound (161 mg, 42% overall). MS (ES+) *m/z*: 387 (M+H)⁺. Use a method similar to the General Procedure 2-4 to obtain the title compound.

25 Example 133 may be prepared essentially as described in Example 132, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-cyclohexylmethoxy-benzylamine. The overall yield and MS (ES+) data are shown in the Table below.

Ex.	Structure	Compound	Yield (%)	MS (ES+) <i>m/z</i>
133		7-Chloro-6-(4-cyclohexylmethoxy-benzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Mesylate	27	399 (<i>M</i> + <i>H</i>) ⁺

Example 134

7-Chloro-6-(3-pyrrolidinyl-benzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate



Use a method similar to the General Procedure 5-1, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (300 mg, 0.7 mmol) and 3-(pyrrolidin-1-yl)benzylamine (300 mg, 1.7 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (19:1, 9:1, 4:1 and 3:2), 7-chloro-6-(3-pyrrolidinyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (195 mg, 62%). MS (ES+) *m/z*: 452 (*M*+*H*)⁺.

15

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(3-pyrrolidinyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (195 mg, 0.43 mmol). Purify by SCX chromatography to give the free base of the title compound (136 mg, 89%). Use a method similar to the General Procedure 2-1, using 7-chloro-6-(3-pyrrolidinyl-benzylamino)-2,3,4,5-tetrahydro-1*H*-

20

benzo[*d*]azepine (130 mg, 0.37 mmol), to give the title compound as an off-white gum (111 mg, 61%). MS (ES+) *m/z*: 356 (M+H)⁺.


Example 135

5 6-(4-Methoxybenzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

Use a similar method to the General Procedure 1-1, using 6-(4-methoxybenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-
10 benzo[*d*]azepine (0.1 g, 0.24 mmol) to give the free base of the title compound. Use a similar method to the General Procedure 2-2 to give the title compound (75 mg, 80%). HRMS calcd for C₁₈H₂₁ClN₂O 317.1421, found 317.1410.

Example 136

15 7-Chloro-6-[4-(2,2,3,3-tetrafluoropropoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-
benzo[*d*]azepine Succinate




20 Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (500 mg, 1.2 mmol) with 4-(2,2,3,3-tetrafluoropropoxy)-benzylamine (835 mg, 3.5 mmol) in toluene (10 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) followed by SCX chromatography [pre-wash column with methanol
25 followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to obtain 7-chloro-6-[4-(2,2,3,3-

tetrafluoropropoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (600 mg, 99%).

5 Use a method similar to the the General Procedure 1-3 to deprotect 7-chloro-6-[4-(2,2,3,3-tetrafluoropropoxy)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (600 mg, 1.2 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound (390 mg, 62 %). MS (ES+) *m/z*: 417 (M+H)⁺.

10

Examples 137-138 may be prepared essentially as described in Example 136 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.




15

Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
137		7-Chloro-6-[4-(2,2,3,3,3-pentafluoropropoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	45	435 (M+H) ⁺
138		7-Chloro-6-[4-(2,2,2-trifluoro-1,2-dimethyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	66	413 (M+H) ⁺

Examples 139 and 140

20 (-)-7-Chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (+)-7-Chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (500 mg, 1.2 mmol) with (±)-4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamine (515 mg, 2.3 mmol) in toluene (10 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM; load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to give (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (530 mg, 90%). GC-MS *m/z*: 494 (M^+).

Use a method similar to the General Procedure 1-3 to deprotect (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (520 mg, 1.1 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to give (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Use a method similar to the General Procedure 2-1 to obtain (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate.

Separate the two enantiomers of (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine succinate by normal phase chiral chromatography (Chiralpak AD 8x30 cm, elute with 85:15 heptane/3A ethanol with 0.2% DMEA).

Use a method similar to the General Procedure 2-1 to obtain (-)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate [137 mg, 71% recovery, 98% ee (Chiralpak AD, 4.6x150 mm, eluent: 85:15 heptane/isopropanol with 0.2% DMEA, 0.6 mL/min)]. MS (ES+) *m/z*: 399 (M+H)⁺.

5 $[\alpha]_D^{20} -7.9^\circ$ (c 0.5, MeOH).


Use a method similar to the General Procedure 2-1 to obtain (+)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate [133 mg, 69% recovery, 97% ee (Chiralpak AD, 4.6x150 mm, eluent: 85:15 heptane/isopropanol with 0.2% DMEA, 0.6 mL/min)]. MS (ES+) *m/z*: 399 (M+H)⁺.

10 $[\alpha]_D^{20} +9.2^\circ$ (c 0.5, MeOH).

Example 141

6-(4-Acetyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

15



Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.47 mmol) with 4-(2-methyl-[1,3]dioxolan-2-yl)-benzylamine (prepared by following the procedure described in *J. Med. Chem.* 1978, 21, 507) (182 mg, 0.94 mmol).

20 Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 19:1 and 9:1) to give 6-{4-(2-methyl-[1,3]dioxolan-2-yl)benzylamino}-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (150 mg, 68%). GC-MS *m/z* 468 (M⁺).

25


Dissolve 6-{4-(2-methyl-[1,3]dioxolan-2-yl)benzylamino}-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (150 mg, 0.32 mmol) in methanol (5 mL) and add 1*N* aqueous HCl (1 mL). Stir the solution at ambient temperature for 2 h. Remove the solvent, dissolve the residue in DCM and wash with saturated aqueous NaHCO₃. Dry the organic phase over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 17:3 and 4:1) to obtain 6-(4-acetylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (107 mg, 79%). GC-MS *m/z* 424 (*M*⁺).

10 Use a method similar to the General Procedure 1-2, using 6-(4-acetylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (100 mg, 0.23 mmol), to give the free base of the title compound as an oil (76 mg, 99%) that was used without further purification.

15 Use a method similar to the General Procedure 2-1, using 6-(4-acetylbenzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (76 mg, 0.23 mmol), to give the title compound as a white solid (102 mg, 97%). MS (ES⁺) *m/z*: 329 (*M*+H)⁺.

Example 142

20 6-(3-Acetylbenzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




25 Use a method similar to Example 141, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-(2-methyl-[1,3]dioxolan-2-yl)-benzylamine (prepared by following the procedure described in *J. Med. Chem.* 2000, 43, 3315), to give the title compound as a solid. MS (ES⁺) *m/z*: 329 (*M*+H)⁺.

Example 143

7-Chloro-6-[4-(1-hydroxyiminoethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate

5



Add hydroxylamine hydrochloride (19 mg, 0.27 mmol) and pyridine (0.04 mL, 0.54 mmol) to a solution of 6-(4-acetylbenzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (115 mg, 0.27 mmol) in ethanol (10 mL). Heat the mixture to reflux for 2 h. Remove the solvent *in vacuo* and partition the residue between DCM and 0.1N aqueous HCl. Dry the organic phase over Na₂SO₄, filter and concentrate. Dissolve the oil into the minimum amount of ether and add hexane to precipitate the solid. Filter to obtain 7-chloro-6-[4-(1-hydroxyiminoethyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a solid (112 mg, 94%) that was used without further purification. MS (ES+) *m/z*: 440 (M+H)⁺.


Use a method similar to the General Procedure 1-2, using 7-chloro-6-[4-(1-hydroxyiminoethyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 0.23 mmol), to give 7-chloro-6-[4-(1-hydroxyiminoethyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (61 mg, 78%) that was used without further purification.

Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(1-hydroxyiminoethyl)benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (58 mg, 0.17

mmol) to give the title compound as a white solid (68 mg, 87%). MS (ES+) m/z : 344 (M+H)⁺.

Example 144


5 6-(4-Benzoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate



10 Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (272 mg, 0.64 mmol) with 4-(aminomethyl)benzophenone (prepared by following the procedure described in *J. Biol. Chem.* 1993, 268 (19), 14230) (270 mg, 1.3 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1, 17:3 and 4:1) to give 6-(4-benzoyl-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (300 mg, 96%).

20 Use a method similar to the General Procedure 1-2, using 6-(4-benzoyl-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (80 mg, 0.16 mmol), to give 6-(4-benzoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (47 mg, 73%) that was used without further purification.


Use a method similar to the General Procedure 2-1, using 6-(4-benzoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (45 mg, 0.11 mmol), to give the title compound as a white solid (37 mg, 63%). MS (ES+) m/z : 391 (M+H)⁺.

Example 145**7-Chloro-6-[4-(1-hydroxyiminobenzyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

Add hydroxylamine hydrochloride (52 mg, 0.75 mmol) and pyridine (0.1 mL) to a solution of 6-(4-benzoyl-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (91 mg, 0.19 mmol) in ethanol (10 mL). Heat the mixture to reflux overnight. Remove the solvent *in vacuo* and partition the residue between DCM and 0.1N aqueous HCl. Dry the organic phase over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 4:1 and 3:1) to give 7-chloro-6-[4-(1-hydroxyiminobenzyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a mixture of E/Z isomers (93 mg, 99%).

Use a method similar to the General Procedure 1-2, using 7-chloro-6-[4-(1-hydroxyiminobenzyl)benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (97 mg, 0.19 mmol), to give 7-chloro-6-[4-(1-hydroxyiminobenzyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (68 mg, 87%) that was used without further purification.

Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(1-hydroxyiminobenzyl)benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (65 mg, 0.16 mmol), to give the title compound as a white solid (67 mg, 80%). MS (ES+) *m/z*: 406 (M+H)⁺.


Example 146**7-Chloro-6-[4-(pyridin-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

5

Use a method similar to the General Procedure 5-3, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (178 mg, 0.426 mmol) and a solution of 4-(pyridin-4-yl)-benzylamine (116 mg, 0.63 mmol) in THF/toluene (1:1, 8 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 7:3 and 1:1) to give 7-chloro-6-[4-(4-pyridin-4-yl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (120 mg, 63%). MS (ES+) m/z : 460 (M+H)⁺.

15 Use a method similar to the General Procedure 1-2, using 7-chloro-6-[4-(pyridin-4-yl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (153 mg, 0.33 mmol), to give 7-chloro-6-[4-(pyridin-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (110 mg, 91%) that was used without further purification. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[4-(pyridin-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (105 mg, 0.289 mmol) to give the title compound as a white solid (123 mg, 88%). MS (ES+) m/z : 364 (M+H)⁺.


25 Examples 147-149 may be prepared essentially as described in Example 146 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.



Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
147		7-Chloro-6-[4-(pyridin-2-yl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	32	364 (M+H) ⁺
148		7-Chloro-6-[4-(1,2,3-thiadiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	23	371 (M+H) ⁺
149		7-Chloro-6-[4-(2-methylthiazol-4-yl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	22	384 (M+H) ⁺

Example 150

- 5 (-)-7-Chloro-6-[4-(4-phenyl-4,5-dihydro-1*H*-imidazol-2-yl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Mix 7-chloro-6-(4-cyanobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200mg, 0.49 mmol, 1.0 equiv.), 1-(*R*)-phenyl-ethane-1,2-diamine (600 mg, 4.4 mmol, prepared as described in *J. Org. Chem.* 1997, 62, 3586) and *p*-toluenesulfonic acid monohydrate (102 mg, 0.53 mmol) in a sealed tube equipped with a magnetic stirrer. Heat the mixture to 200°C for 16 h. Cool the mixture to ambient temperature. Dilute with DCM (50 mL) and wash with saturated aqueous NaHCO₃ (10 mL). Collect the organic fraction and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (98:2 to 80:20).

Use a method similar to the General Procedure 2-3 to give title compound as the hydrochloride. Use reverse phase HPLC [Column: Symmetry C18, 10x300 mm, flow = 25 mL/min, water with 0.1% TFA / Acetonitrile (9:1 to 2:3)] followed by SCX chromatography to obtain the free base of the title compound. Use a method similar to the General Procedure 2-3 to obtain the title compound (38 mg, 16%). MS (ES+) *m/z*: 431 (M+H)⁺. [α]_D²⁰ -20° (c 0.5, MeOH).

Example 151

7-Chloro-6-[4-(1-methyl-1*H*-imidazol-2-yl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (455 mg, 1.1 mmol) with 4-(1-methyl-1*H*-imidazol-2-yl)-benzylamine (240 mg, 1.3

mmol) in toluene (8 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to obtain 7-chloro-6-[4-(1-methyl-1*H*-imidazol-2-yl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (429 mg, 93%). MS (ES+) *m/z*: 463 (M+H)⁺.

Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-[4-(1-methyl-1*H*-imidazol-2-yl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound (350 mg, 73 %). MS (ES+) *m/z*: 367 (M+H)⁺.

Example 152

7-Chloro-6-(4-ethanesulfonyl-benzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Use a method similar to the General Procedure 5-2, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.2 g, 0.35 mmol) and 4-ethanesulfonyl-benzylamine (0.2 g, 1.06 mmol) to give 7-chloro-6-(4-ethanesulfonyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to

form the hydrochloride salt. Purify by reverse phase preparative HPLC (Zorbax SB-Phenyl 21.2x250 mm, 5 micron, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm) to obtain the title compound as a white solid (57 mg, 36%).


5 MS (ES+) m/z : 379 (M+H)⁺.

Example 153 may be prepared essentially as described in Example 152, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 4-(2-propanesulfonyl)-benzylamine. The overall yield and MS (ES+) data are shown in the Table below.

Ex.	Structure	Compound	Yield (%)	MS (ES+) m/z
153		7-Chloro-6-[4-(2-propanesulfonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	11	393 (M+H) ⁺

Example 154

15 7-Chloro-6-(4-methoxycarbonyl-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




20 Treat 4-aminomethyl-benzoic acid methyl ester hydrochloride (0.2 g, 0.71 mmol) with K₂CO₃ (1.0 g, 0.71 mmol) in a mixture of toluene/water (1:1, 2 mL). Separate the organic layer, dry over anhydrous Na₂SO₄ and use as a toluene solution for the next step.

Use a method similar to the General Procedure 5-2, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.1 g, 0.24 mmol) and 4-aminomethyl-benzoic acid methyl ester (0.2 g, 0.71 mmol) to give 7-chloro-6-(4-methoxycarbonyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the title compound as a white solid (20 mg, 18%). MS (ES+) *m/z*: 345 (M+H)⁺.


Example 155

6-(4-Carboxy-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Combine 7-chloro-6-(4-methoxycarbonyl-benzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (70 mg, 0.16 mmol), potassium carbonate (0.87 g, 6.3 mmol), methanol (2 mL), water (2 mL) and heat at 50°C for 3 h. Purify by SCX chromatography to obtain 6-(4-carboxy-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil.

Use a method similar to the General Procedure 2-2 to form the hydrochloride salt. Purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm] to obtain the title compound as a white solid (30 mg, 46%). MS (ES+) *m/z*: 331 (M+H)⁺.

Example 156**7-Chloro-6-(4-methylcarbamoyl-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5

Combine 3-(*tert*-butoxycarbonyl)-6-(4-carboxy-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.1 g, 0.3 mmol), methylamine hydrochloride (31 mg, 0.46 mmol), triethylamine (0.1 g, 0.9 mmol), HATU (0.2 g, 0.5 mmol), anhydrous DMF (3 mL) and stir at ambient temperature for 17 h. Partition the reaction mixture between brine (5 mL) and diethyl ether (5 mL), separate the organic layer and dry over anhydrous Na₂SO₄. Evaporate the solvent to obtain 3-(*tert*-butoxycarbonyl)-7-chloro-6-(4-methylcarbamoyl-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (0.1 g, 93%). MS (ES⁺) *m/z*: 344 (M+H-Boc)⁺.


15

Use a method similar to the General Procedure 1-5 and purify the residue by SCX chromatography to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to form the hydrochloride salt. Purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm] to obtain the title compound as a white solid (0.9 g, 65%). MS (ES⁺) *m/z*: 344 (M+H)⁺.

20

Examples 157-158 may be prepared essentially as described in Example 156 by using 3-(*tert*-butoxycarbonyl)-6-(4-carboxy-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate amine. Overall yields and MS (ES⁺) data are shown in the Table below.


25



Ex.	R	R'	Compound	Yield (%)	MS (ES+) <i>m/z</i>
157	Me	Me	7-Chloro-6-(4-dimethylcarbamoyl-benzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	51	358 (M+H) ⁺
158	<i>i</i> -Pr	H	7-Chloro-6-(4-isopropylcarbamoyl-benzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	56	372 (M+H) ⁺

Example 159


- 5 6-(4-*tert*-Butylcarbamoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



- 10 Use a method similar to the General Procedure 5-2, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.2 g, 0.35 mmol) and 4-aminomethyl-*N*-*tert*-butyl-benzamide (0.2 g, 1.06 mmol), to give 6-(4-*tert*-butylcarbamoyl-benzylamino)-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to form the hydrochloride salt and purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm] to obtain the title compound as a white solid (65 mg, 41%). MS (ES+) m/z : 386 (M+H)⁺.


Examples 160-161 may be prepared essentially as described in Example 159 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.



Ex.	R	R'	Compound	Yield (%)	MS (ES+) m/z
160	<i>t</i> -Bu	Me	6-(4- <i>tert</i> -Butylcarbamoyl-3-fluorobenzylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	48	404 (M+H) ⁺
161	<i>n</i> -Pr	Me	7-Chloro-6-[3-fluoro-4-(<i>N</i> -methyl- <i>N</i> -propyl-carbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	48	404 (M+H) ⁺

Example 162

7-Chloro-6-[4-(cyclohexylaminocarbonyl)-3-fluoro-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Use a method similar to the General Procedure 5-2 to react 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (500 mg, 1.17 mmol) with 4-aminomethyl-*N*-cyclohexyl-2-fluoro-benzamide (441 mg, 1.76 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1, 7:1 and 5:1) to give 7-chloro-6-[4-(cyclohexylaminocarbonyl)-3-fluoro-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.


Use a method similar to the General Procedure 1-3 and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 20:1, 10:1 and 7:1) followed by reverse phase semi-prep HPLC [SymmetryPrep C18, 7 μ m, 19x300 mm column eluting with acetonitrile/0.1 % trifluoroacetic acid in water (1:9 to 8:2) at 20 mL/min] and SCX chromatography to give the free base of the title compound.

Use a method similar to the General Procedure 2-1 to give the title compound as a yellow solid (97 mg, 15%). MS (ES+) *m/z*: 430 (M+H)⁺.

Example 163

7-Chloro-6-[4-(2,2,2-trifluoroethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate


5









10 Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.59 mmol) with 4-aminomethyl-*N*-(2,2,2-trifluoroethyl)-benzamide (273 mg, 1.17 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1, 7:1 and 5:1) to give 7-chloro-3-(2,2,2-trifluoroacetyl)-6-[4-(2,2,2-trifluoroethyl-aminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.

15 Use a method similar to the General Procedure 1-3 and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 20:1, 10:1 and 7:1) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (191 mg, 61%). MS (ES+) *m/z*: 412 (M+H)⁺.

20 Examples 164-177 may be prepared essentially as described in Example 163 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.




Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
164		7-Chloro-6-[4-(3,3,3-trifluoropropylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	38	426 (M+H) ⁺
165		7-Chloro-6-[4-(2,2,3,3,3-pentafluoropropylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	41	462 (M+H) ⁺
166		(±)-7-Chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	46	426 (M+H) ⁺
167		(±)-7-Chloro-6-[4-(1-methyl-3,3,3-trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	28	440 (M+H) ⁺
168		7-Chloro-6-[4-(cyclopentylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	55	398 (M+H) ⁺
169		7-Chloro-6-[4-(cyclohexylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	82	412 (M+H) ⁺
170		7-Chloro-6-[4-(cycloheptylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	65	426 (M+H) ⁺
171		6-[4-(Benzylaminocarbonyl)-benzylamino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	33	420 (M+H) ⁺
Ex.	NH-R	Compound	Yield (%)	MS (ES+)

				<i>m/z</i>
172		7-Chloro-6-[4-(3,4-difluoro-benzylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	55	456 (<i>M</i> + <i>H</i>) ⁺
173		7-Chloro-6-[4-(1-methyl-1-phenyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	12	448 (<i>M</i> + <i>H</i>) ⁺
174		(±)-7-Chloro-6-[4-(1-methyl-2-phenyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	36	448 (<i>M</i> + <i>H</i>) ⁺
175		7-Chloro-6-[4-(<i>p</i> -tolylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	60	420 (<i>M</i> + <i>H</i>) ⁺
176		7-Chloro-6-[4-(4-chloro-phenylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	28	440 (<i>M</i> + <i>H</i>) ⁺
177		7-Chloro-6-[4-(tetrahydro-pyran-4-yl-aminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	13	414 (<i>M</i> + <i>H</i>) ⁺

Examples 178 and 179

(-)-7-Chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (+)-7-Chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Dissolve (±)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (472 mg, 1.11 mmol) in DCM (50 mL) and add di-*tert*-butyl-dicarbonate (300 mg, 1.34 mmol) and a solution of sodium carbonate (2 g) in water (50 mL). Stir the reaction at room temperature for 2 h then dilute with DCM, wash with water, dry over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) to give (±)-3-*tert*-butoxycarbonyl-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-benzo[*d*]azepine (330 mg, 57%).


- 10 Separate the two enantiomers by chiral HPLC [Chiralpak AD column, 8x30 cm, eluting with 0.2% DMEA in heptane/isopropanol (9:1)].

15 Use a method similar to the General Procedure 1-5 to deprotect the first eluting compound and purify by SCX chromatography to give (-)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Use a method similar to the General Procedure 2-1 to give (-)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate as a white solid (50 mg, 15%). MS (ES+) *m/z*: 426 (M+H)⁺; [α]_D²⁰ -3.3° (c 0.5, CH₃OH).

20 Use a method similar to the General Procedure 1-5 to deprotect the second eluting compound and purify by SCX chromatography to give (+)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Use a method similar to the General Procedure 2-1 to give (+)-7-chloro-6-[4-(2,2,2-trifluoro-1-methyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate as a white solid (55 mg, 16%). MS (ES+) *m/z*: 426 (M+H)⁺; [α]_D²⁰ +4.4° (c 0.5, CH₃OH).

Examples 180 and 181

- 30 (+)-7-Chloro-6-[4-(1-methyl-3,3,3-trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (-)-7-Chloro-6-[4-(1-methyl-3,3,3-trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Dissolve (±)-7-chloro-3-(2,2,2-trifluoroacetyl)-6-[4-(1-methyl-3,3,3-trifluoro-
 5 propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (985 mg,
 2.24 mmol) in DCM (50 mL) and add di-*tert*-butyl-dicarbonate (605 mg, 3.36 mmol) and
 a solution of sodium carbonate (2 g) in water (50 mL). Stir the mixture at room
 temperature for 1 h then dilute with DCM, wash with water, dry over Na₂SO₄, filter and
 concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1,
 10 5:1 and 3:1) to give (±)-3-*tert*-butoxycarbonyl-7-chloro-6-[4-(1-methyl-3,3,3-trifluoro-
 propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-benzo[d]azepine.

Separate the two enantiomers by chiral HPLC [Chiralpak AD column, 8x30 cm,
 eluting with heptane/isopropanol/0.2% DMEA in methanol (90:5:5)].

15 Use a method similar to the General Procedure 1-5 to deprotect the first eluting
 compound and purify by SCX chromatography to give (+)-7-chloro-6-[4-(1-methyl-3,3,3-
 trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine.
 Use a method similar to the General Procedure 2-1 to give (+)-7-chloro-6-[4-(1-methyl-
 20 3,3,3-trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-
 benzo[d]azepine succinate as a white solid (186 mg, 15%). MS (ES+) *m/z*: 440 (M+H)⁺;
 [α]_D²⁰ +6.5° (c 0.5, CH₃OH).


Use a method similar to the General Procedure 1-5 to deprotect the second eluting
 25 compound and purify by SCX chromatography to give (-)-7-chloro-6-[4-(1-methyl-3,3,3-
 trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine.
 Use a method similar to the General Procedure 2-1 to give (-)-7-chloro-6-[4-(1-methyl-

3,3,3-trifluoro-propylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate as a white solid (191 mg, 15%). MS (ES+) *m/z*: 440 (M+H)⁺; [α]²⁰_D -5.2° (c 0.5, CH₃OH).

5

Example 182

(*R*)-(+)-7-Chloro-6-[4-(1-phenyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



10


Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.59 mmol) with (*R*)-4-aminomethyl-*N*-(1-phenyl-ethyl)-benzamide (298 mg, 1.17 mmol) in toluene (15 mL). Purify by chromatography on silica gel eluting with
15 hexane/EtOAc (20:1, 10:1, 7:1 and 5:1) to give (*R*)-(+)-7-chloro-6-[4-(1-phenyl-ethylaminocarbonyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.

20

Use a method similar to the General Procedure 1-3 and purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (1:0, 20:1, 10:1 and 7:1) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a yellow solid (158 mg, 49%). MS (ES+) *m/z*: 434 (M+H)⁺; [α]²⁰_D +18.7° (c 0.5, CH₃OH).

Example 183

(*S*)-(-)-7-Chloro-6-[4-(1-phenyl-ethylaminocarbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the Example 182, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.59 mmol) and (*S*)-4-aminomethyl-*N*-(1-phenyl-ethyl)-benzamide (298 mg, 1.17 mmol) to give the title compound as a white solid (95 mg, 29%). MS (ES+) *m/z*: 434 (M+H)⁺; [α]_D²⁰ -20.1° (c 0.5, CH₃OH).

10

Example 184

7-Chloro-6-{4-[(2-thiophen-2-yl-ethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

15




Use a method similar to the General Procedure 5-3, react 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.588 mmol) with 4-aminomethyl-*N*-(2-thiophen-2-yl-ethyl)-benzamide (306











mg, 1.176 mmol) using palladium(II) acetate (26 mg, 0.118 mmol),
tris(dibenzylideneacetone)dipalladium(0) (53 mg, 0.059 mmol), BINAP (220 mg, 0.353
mmol) and cesium carbonate (383 mg, 1.176 mmol) in dioxane (6 mL). Purify by
chromatography on silica gel eluting with hexane/EtOAc (1:0, 7:3 and 1:1) to give 7-
5 chloro-6-{4-[(2-thiophen-2-yl-ethyl)-carbamoyl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-
2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (233 mg, 91%). MS (ES+) *m/z*: 535
(M+H)⁺.

Use a method similar to the General Procedure 1-2, using 7-chloro-6-{4-[(2-
10 thiophen-2-yl-ethyl)-carbamoyl]-benzylamino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-
tetrahydro-1*H*-benzo[*d*]azepine (223 mg, 0.416 mmol), to give 7-chloro-6-{4-[(2-
thiophen-2-yl-ethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as
an oil (145 mg, 79%) that was used without any further purification.

Use a method similar to the General Procedure 2-1, using 7-chloro-6-{4-[(2-
15 thiophen-2-yl-ethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
(145 mg, 0.330 mmol), to give the title compound as a solid (123 mg, 67%). MS (ES+)
m/z: 440 (M+H)⁺.


Examples 185-194 may be prepared essentially as described in Example 184 by
20 using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-
1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are
shown in the Table below.



Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
185		7-Chloro-6-{4-[(thiophen-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	46	426 (M+H) ⁺
186		7-Chloro-6-{4-[(pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	49	421 (M+H) ⁺
187		7-Chloro-6-{4-[(3-trifluoromethyl-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	39	489 (M+H) ⁺
188		7-Chloro-6-{4-[(4-trifluoromethyl-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	26	489 (M+H) ⁺
189		7-Chloro-6-{4-[(5-trifluoromethyl-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	29	489 (M+H) ⁺
190		7-Chloro-6-{4-[(3-fluoro-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	37	439 (M+H) ⁺
191		7-Chloro-6-{4-[(5-fluoro-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	51	439 (M+H) ⁺
192		7-Chloro-6-{4-[(6-fluoro-pyridin-2-ylmethyl)-carbamoyl]-benzylamino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	54	439 (M+H) ⁺
193		7-Chloro-6-[4-(2-pyridin-3-yl-ethylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	46	435 (M+H) ⁺
194		7-Chloro-6-[4-(2-pyridin-4-yl-ethylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	27	435 (M+H) ⁺

Example 195

7-Chloro-6-[4-(2-pyridin-2-yl-ethylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



5


Use a method similar to the General Procedure 5-3 to react 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (200 mg, 0.471 mmol) and 4-aminomethyl-N-(2-pyridin-2-yl-ethyl)-benzamide (241 mg, 0.942 mmol) using palladium(II) acetate (21 mg, 0.094 mmol),
10 tris(dibenzylideneacetone)dipalladium(0) (43 mg, 0.047 mmol), BINAP (176 mg, 0.283 mmol) and cesium carbonate (307 mg, 0.942 mmol) in dioxane (5 mL). Purify by chromatography on silica gel eluting with hexane and hexane/EtOAc/DCM/methanol (7:1:1:1) to give 7-chloro-6-[4-(2-pyridin-2-yl-ethylcarbamoyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (107 mg, 43%). MS
15 (ES+) m/z : 531 (M+H)⁺.

Use a method similar to the General Procedure 1-2, using 7-chloro-6-[4-(2-pyridin-2-yl-ethylcarbamoyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (107 mg, 0.202 mmol), to give 7-chloro-6-[4-(2-pyridin-2-yl-ethylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (85 mg, 97%) that was used without any further purification.
20

Use a method similar to the General Procedure 2-2, using 7-chloro-6-[4-(2-pyridin-2-yl-ethylcarbamoyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (85 mg, 0.195 mmol), to give the title compound as a solid (103 mg, 97 %). MS (ES+) m/z : 435 (M+H)⁺.
25

Example 196

7-Chloro-6-[4-(piperidine-1-carbonyl)-benzylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Using a method similar to the General Procedure 5-2, react 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (500 mg, 1.17 mmol) with 4-(piperidin-1-ylcarbonyl)-benzylamine (308 mg, 1.41 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1, 7:1 and 5:1) to give 7-chloro-6-[4-(piperidine-1-carbonyl)-benzylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.

15


Use a method similar to the General Procedure 1-3 and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 20:1, 10:1 and 7:1) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as a yellow solid (284 mg, 47%). MS (ES+) *m/z*: 398 (M+H)⁺.

20

Example 197

7-Chloro-6-[2-(cyclohexylaminocarbonyl-pyridin-5-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate

5




10 Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (348 mg, 0.82 mmol) with 5-aminomethyl-pyridine-2-carboxylic acid cyclohexylamide (200 mg, 0.86 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1, 7:1 and 5:1) to give 7-chloro-6-[2-(cyclohexylaminocarbonyl-pyridin-5-ylmethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as oil.

15 Use a method similar to the General Procedure 1-3 and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (1:0, 20:1, 10:1 and 7:1) to give the free base of the title compound.

20 Use a method similar to the General Procedure 2-1 to give the title compound as a yellow solid (147 mg, 34%). MS (ES+) m/z : 413 (M+H)⁺.


Example 198 may be prepared essentially as described in Example 197, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 5-aminomethyl-pyridine-2-carboxylic acid 4-fluoro-benzylamide.

25 The overall yield and MS (ES+) data are shown in the Table below.

Ex.	Structure	Compound	Yield (%)	MS (ES+) m/z
198		7-Chloro-6-[2-(4-fluoro-benzylaminocarbonyl)-pyridin-5-ylmethyl]-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	28	439 (M+H) ⁺

Example 199

7-Chloro-6-(4-*tert*-butylthiocarbamoyl-benzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



Combine 6-(4-*tert*-butylcarbamoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo-[d]azepine (0.3 g, 0.67 mmol), 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent) (0.3, g, 0.67 mmol) and anhydrous 1,4-dioxane (10 mL) in a sealed tube and heat at 100°C for 5 h. Cool the reaction mixture to ambient temperature, evaporate the solvent and purify the residue by SCX chromatography to obtain 6-(4-*tert*-butylthiocarbamoyl-benzylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil.


15

Use a method similar to the General Procedure 2-2 to form the hydrochloride salt and purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:9) over 30 min, detector at 230 nm] to obtain the title compound as a yellow solid (0.2 g, 63%). MS (ES+) m/z : 403 (M+H)⁺.

20

Example 200

(S)-(-)-7-Chloro-6-[1-(4-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate



5

Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (7.0g, 16.4mmol) with (S)-1-(4-fluorophenyl)ethylamine (6.9 g, 49.3 mmol) in toluene (175 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to give 7-chloro-6-[1-(S)-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3.96 g, 58%). GC-MS m/z : 414 (M^+).


15

Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-[1-(S)-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3.92 g, 9.5 mmol) and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 80:20) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 and crystallize the solid from ethanol and methyl-*t*-butyl ether. Filter and dry the solid in a vacuum oven at 60°C overnight to obtain the title compound (3.4 g, 83 %). MS (ES+) m/z : 319 ($M+H$)⁺; $[\alpha]_D^{20}$ -102.8° (c 0.5, MeOH).

25

Examples 201-209 may be prepared essentially as described in Example 200 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-

1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-2), optical rotation and MS (ES⁺) data are shown in the Table below.




5

Ex.	R	Compound	Yield (%)	$[\alpha]^{20}_D$ (c, solvent)	MS
201	4-F	(<i>R</i>)-(+)-7-Chloro-6-[1-(4-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	69	+89.2° (c 0.5, MeOH)	319 (<i>M</i> + <i>H</i>) ⁺
202	2-F	(+)-7-Chloro-6-[1-(2-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	62	+105° (c 0.5, MeOH)	319 (<i>M</i> + <i>H</i>) ⁺
203	4-CN	(+)-7-Chloro-6-[1-(4-cyanophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	60	+142.1° (c 0.5, MeOH)	326 (<i>M</i> + <i>H</i>) ⁺
204	4-CN	(-)-7-Chloro-6-[1-(4-cyanophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	52	-149.3° (c 0.5, MeOH)	326 (<i>M</i> + <i>H</i>) ⁺
205	2,3-diF	(+)-7-Chloro-6-[1-(2,3-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	14	+99.3° (c 0.5, MeOH)	337 (<i>M</i> + <i>H</i>) ⁺
206	2,3-diF	(-)-7-Chloro-6-[1-(2,3-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	80	-107.9° (c 0.5, MeOH)	337 (<i>M</i> + <i>H</i>) ⁺
207	2,4-diF	(+)-7-Chloro-6-[1-(2,4-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	94	+101.4° (c 0.5, MeOH)	337 (<i>M</i> + <i>H</i>) ⁺
208	2,4-diF	(-)-7-Chloro-6-[1-(2,4-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	96	-107.9° (c 0.5, MeOH)	337 (<i>M</i> + <i>H</i>) ⁺

Ex.	R	Compound	Yield (%)	$[\alpha]^{20}_D$ (c, solvent)	MS
209	3,5-diCF ₃	(-)-7-Chloro-6-[1-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	99	-93° (c 0.5, MeOH)	437 (M+H) ⁺

Example 210


(+)-7-Chloro-6-[(2-trifluoromethoxy-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Oxalate



Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.15 g, 0.35 mmol) with 1-(2-trifluoromethoxyphenyl)-ethylamine Isomer 2 at 90°C for 15 h. Use a method similar to the General Procedure 1-2 and purify by reverse phase preparative HPLC to give the free base of the title compound. Use a method similar to the General Procedure 2-5 to give the title compound (27 mg, 16 %). HPLC t_R = 4.2 min (Chiralpak AD 4.6x150 mm, 3 micron column, 1.0 mL/min of 94.8/5/0.2 heptane/ethanol/dimethylethylamine isocratic; detector is at 225 nm); HRMS calcd for C₁₉H₂₀ClF₃N₂O 385.1294, found 385.1285; $[\alpha]^{20}_D$ +95.4° (c 0.5, MeOH).

Example 211

(±)-7-Chloro-6-[1-(3-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




5
10
15
20
Add palladium(II) acetate (27 mg, 0.12 mmol), BINAP (146 mg, 0.24 mmol), cesium carbonate (270 mg, 0.8 mmol) and (±)-1-(3-fluorophenyl)-ethylamine (230 mg, 1.6 mmol) to a solution of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.6 mmol) in toluene (9 mL). Degas the slurry and fill with nitrogen. Heat the mixture to 95°C for 16 h. Add additional palladium(II) acetate (0.1 equiv.) and BINAP (0.2 equiv.) and continue heating the reaction for an additional 24 h. Cool the mixture, dilute with EtOAc (50 mL) then filter through Celite®. Concentrate the filtrate and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) followed by SCX chromatography to obtain (±)-7-chloro-6-[1-(3-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (138 mg, 56%). GC-MS *m/z*: 414 (*M*⁺).

25
Use a method similar to the General Procedure 1-3 to deprotect (±)-7-chloro-6-[1-(3-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (132 mg, 0.3 mmol) and purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (99:1 to 90:10) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound (98 mg, 70 %). MS (ES⁺) *m/z*: 319 (*M*+H)⁺.

Example 212

(+)-7-Chloro-6-[1-(3-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5

Separate the two enantiomers of (±)-7-chloro-6-[1-(3-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate by normal phase chromatography (Chiralpak AD 2x25 cm, elute with 95:5 heptane/isopropanol with 0.2 % DMEA).


10

Use a method similar to the General Procedure 2-1 to obtain the title compound [23 mg, 30% recovery, 99% ee (Chiralpak AD, 4.6x250 mm, eluent: 95:5 heptane/isopropanol, with 0.2% DMEA, 1.0 mL/min)]. MS (ES+) *m/z*: 319 (M+H)⁺; [α]_D²⁰ +64° (c 0.5, MeOH).

15

Example 213

(-)-7-Chloro-6-[1-(3-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




20

Add tris(dibenzylideneacetone)dipalladium(0) (3.4 g, 3.8 mmol), BINAP (4.7 g, 7.5 mmol), cesium carbonate (8.6 g, 26.3 mmol) and 1-(3-fluorophenyl)-ethylamine Isomer 2 (5.8 g, 41.3 mmol) to a solution of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (8.0 g, 18.8 mmol) in toluene (225 mL). Degas the slurry and fill with nitrogen. Heat the mixture to 95 °C for 8 h. Add additional tris(dibenzylideneacetone)dipalladium(0) (0.1 equiv.), and BINAP (0.2 equiv.). Continue heating the reaction for an additional 16 h. Cool the mixture, dilute with EtOAc (200 mL) then filter thru Celite®. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) followed by SCX chromatography to obtain 7-chloro-6-[1-(3-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (6.0 g, 78%). GC-MS *m/z*: 414 (*M*⁺).

Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-[1-(3-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (6.0 g, 14.4 mmol). Purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (99:1 to 90:10) to give the free base of the title compound. Use a method similar to the General Procedure 2-1 and crystallize the solid from ethanol and methyl-*t*-butyl ether. Filter and dry the solid under vacuum at 60°C overnight to obtain the title compound [5.3 g, 84 % yield, 99% ee (Chiralpak AD, 4.6x250 mm, eluent: 95:5 heptane/EtOH, with 0.2% DMEA, 1.0 mL/min)]. MS (ES⁺) *m/z*: 319 (*M*+*H*)⁺; [α]_D²⁰ -90.6° (c 0.5, MeOH).

Example 214

(±)-7-Chloro-6-[1-(2-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (250 mg, 0.6 mmol) with (±)-1-(2-fluorophenyl)-ethylamine (206 mg, 1.5 mmol) in toluene (5 mL). Purify the residue by chromatography on silica gel eluting with
5 hexane/EtOAc (9:1 to 1:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to obtain (±)-7-chloro-6-[1-(2-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (86 mg, 35%). GC-MS *m/z*: 414 (M^+).

10

Use a method similar to the General Procedure 1-3 to deprotect (±)-7-chloro-6-[1-(2-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (85 mg, 0.2 mmol) and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10) to give the free base of the title
15 compound. Use a method similar to the General Procedure 2-1 to give the title compound (70 mg, 80 %). MS (ES+) *m/z*: 319 ($M+H$)⁺.

20

Examples 215-216 may be prepared essentially as described in Example 214 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-1), optical rotation and MS (ES+) data are shown in the Table below.




Ex.	R	Compound	Yield (%)	$[\alpha]_D^{20}$ (c, solvent)	MS (ES+) m/z
215	3-CN	(+)-7-Chloro-6-[1-(3-cyanophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	58	+100.7° (c 0.5, MeOH)	326 (M+H) ⁺
216	3-CN	(-)-7-Chloro-6-[1-(3-cyanophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	90	-109.7° (c 0.5, MeOH)	326 (M+H) ⁺

Example 217

(S)-(-)-7-Chloro-6-(1-phenyl-ethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate


5



Add palladium(II) acetate (396 mg, 1.8 mmol), BINAP (2.2 g, 3.5 mmol), cesium carbonate (8.0 g, 24.6 mmol), and 1S-(-)-methylbenzylamine (6.4 g, 52.9 mmol) to a solution of 7-chloro-6-trifluoromethanesulfonyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (7.5 g, 17.6 mmol) in toluene (173 ml). Degas the slurry and fill with nitrogen. Heat the mixture to 95°C for 16 h. GC/MS shows some starting material still present after 16 h, so add additional palladium(II) acetate (0.1 equiv.), BINAP, and 1S-(-)-methylbenzylamine (1.0 equiv.). Continue heating the reaction for an additional 24 h. Cool the mixture, dilute with EtOAc (250 ml) then filter through Celite®. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc/methanol (84:15:1) followed by SCX chromatography to give (S)-7-chloro-6-(1-phenyl-ethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (4.38 g, 63%). GC-MS m/z : 396 (M^+).

Use a method similar to the General Procedure 1-1 to deprotect (*S*)-7-chloro-6-(1-phenyl-ethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (4.3 g, 10.8 mmol). Purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (99/1 to 80/20) to give the free base of the title compound. Use a method
 5 similar to the General Procedure 2-1 and crystallize the solid from ethanol and methyl-*t*-butyl ether. Filter and dry the solid in a vacuum oven at 70°C overnight to obtain the title compound (3.6 g, 80%). MS (ES+) *m/z*: 301 (M+H)⁺. [α]_D²⁰ -95.6° (c 0.5, MeOH).

Examples 218-227 may be prepared essentially as described in Example 217 by
 10 using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1, optical rotation or enantiomeric excess (determined by chiral HPLC) and MS (ES+) data are shown in the Table below.



15


Ex.	R	Compound	Yield (%)	[α] _D ²⁰ (c, solvent) or ee (%)	MS (ES+) <i>m/z</i>
218	H	(<i>R</i>)-(+)-7-Chloro-6-(1-phenyl-ethylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	47	+100.5° (c 0.5, MeOH)	301 (M+H) ⁺
219	4-CF ₃	(+)-7-Chloro-6-[1-(4-trifluoromethyl-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	55	+95.7° (c 0.5, MeOH)	369 (M+H) ⁺
220	3-CF ₃	7-Chloro-6-[1-(3-trifluoromethyl-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate, Isomer 1	90	95% ee	369 (M+H) ⁺

Ex.	R	Compound	Yield (%)	$[\alpha]^{20}_D$ (c, solvent) or ee (%)	MS (ES+) m/z
221	3,4-diF	7-Chloro-6-[1-(3,4-trifluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Succinate, Isomer 1	28	94 % ee	337 (M+H) ⁺
222	3,4-diF	(+)-7-Chloro-6-[1-(3,4-trifluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Succinate	81	+89.0° (c 0.5, MeOH)	337 (M+H) ⁺
223	3,4,5-triF	7-Chloro-6-[1-(3,4,5-trifluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Succinate, Isomer 2	40	ND	355 (M+H) ⁺
224	3-OCH ₃	7-Chloro-6-[1-(3-methoxyphenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Hydrochloride, Isomer 1	53	ND	331 (M+H) ⁺
225	4-OCH ₃	7-Chloro-6-[1-(4-methoxyphenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Hydrochloride, Isomer 1	53	>99 % ee	331 (M+H) ⁺
226	4-OPh	7-Chloro-6-[1-(4-phenoxyphenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Succinate, Isomer 1	27	ND	393 (M+H) ⁺
227	4-OPh	7-Chloro-6-[1-(4-phenoxyphenyl)-ethylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[d]azepine Succinate, Isomer 2	27	ND	393 (M+H) ⁺

ND = Not determined

Example 228

(-)-7-Chloro-6-[1-(3-chloro-4-fluoro-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




5

Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (426 mg, 1.0 mmol) with 1-(3-chloro-4-fluoro-phenyl)-ethylamine Isomer 1 (226 mg, 1.3 mmol). Purify by chromatography on silica gel eluting with EtOAc/hexane (1:7) to give 7-chloro-6-[1-(3-chloro-4-fluoro-phenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (293 mg, 65%).

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(3-chloro-4-fluoro-phenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (293 mg, 0.65 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to give the free base of the title compound as an oil (157 mg, 68%). MS (ES+) *m/z*: 353 (M+H)⁺. Use a method similar to preparation E-1 to convert the free base to the title compound. $[\alpha]_D^{20} -115.9^\circ$ (c 0.5, MeOH).

Examples 229-235 may be prepared essentially as described in Example 228 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3), optical rotation and MS (ES+) data are shown in the Table below.


25



Ex.	R	Compound	Yield (%)	$[\alpha]^{20}_D$ (c, solvent)	MS
229	3-Cl	(+)-7-Chloro-6-[1-(3-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	17	+119.6° (c 0.5, CH ₃ OH)	335 (M+H) ⁺
230	2-Cl	(+)-7-Chloro-6-[1-(2-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	30	+45.0° (c 0.5, CH ₃ OH)	335 (M+H) ⁺
231	4-CH ₃	(R)-(+)-7-Chloro-6-(1-p-tolylethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	57	+107° (c 0.5, MeOH)	315 (M+H) ⁺
232	4-CH ₃	(S)-(-)-7-Chloro-6-(1-p-tolylethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	54	-97.2° (c 0.5, MeOH)	315 (M+H) ⁺
233	3-Cl,4-F	(+)-7-Chloro-6-[1-(3-chloro-4-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	84	+115.0° (c 0.5, CH ₃ OH)	353 (M+H) ⁺
234	3,5-diF	(-)-7-Chloro-6-[1-(3,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	50	-97.6° (c 0.5, MeOH)	337 (M+H) ⁺
235	3,5-diF	(+)-7-Chloro-6-[1-(3,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	41	+91.0° (c 0.5, MeOH)	337 (M+H) ⁺

Example 236

(±)-7-Chloro-6-[1-(4-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5


Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (852 mg, 2.0 mmol) and (±)-4-chloro-(α-methyl)benzylamine (622 mg, 4.0 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain (±)-7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (326 mg, 38%). MS (ES+) *m/z*: 431 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect (±)-7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give the free base of the title compound (61 mg, 100%). MS (ES+) *m/z*: 335 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

20

Examples 237 and 238

(-)-7-Chloro-6-[1-(4-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (+)-7-Chloro-6-[1-(4-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Submit (\pm)-7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (326 mg, 0.76 mmol) to chiral chromatography (Chiralpak AD, 4.6x150 mm, eluting with heptane/ethanol (9:1) with 0.2% DMEA, 1 mL/min) to provide the two enantiomers: 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (102 mg, t_R = 5.25 min) and 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (110 mg, t_R = 6.40 min).


Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (Example 237, 82 mg, 100%). MS (ES+) m/z : 335 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound. $[\alpha]^{20}_D$ -127.7° (c 0.5, CH₃OH).

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to give 7-chloro-6-[1-(4-chlorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (Example 238, 68 mg, 78%). MS (ES+) m/z : 335 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound. $[\alpha]^{20}_D$ +133.6° (c 0.5, CH₃OH).

Examples 239 and 240

7-Chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate Isomer 1, and 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate Isomer 2

5



Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (550 mg, 1.27 mmol) and crude (±)-α-methyl-(2',5'-difluoro)benzylamine (400 mg).

Separate the two enantiomers by chiral chromatography (eluent: 75:20:5 heptane/isopropanol/methanol, 4.6x250 mm Chiralpak AD, 1 mL/min, uv 260 nm) to obtain 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 [150 mg, 29%; chiral HPLC: *t_R* = 4.5 min; MS (ES+) *m/z*: 433 (M+H)⁺] and 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 [130 mg, 25%; chiral HPLC: *t_R* = 5.5 min; MS (ES+) *m/z*: 433 (M+H)⁺], both as opaque oils which solidify upon standing to off-white waxy solids.

20


Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (140 mg, 0.32 mmol). Purify by SCX chromatography to give 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (102 mg, 95%) as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the Isomer 1 of the title compound (130 mg, 95%) as an off-white solid. MS (ES+) *m/z*: 337 (M+H)⁺.

25

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (125 mg, 0.29 mmol). Purify by SCX chromatography to give 7-chloro-6-[1-(2,5-difluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (87.7 mg, 90%) as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the Isomer 2 of the title compound (117 mg, 99%) as an off-white solid. MS (ES+) *m/z*: 337 (M+H)⁺.

Example 241

(-)-7-Chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (300 mg, 0.7 mmol) and crude α -methyl-(3',5'-difluoro-4'-methoxy)benzylamine (380 mg). Purify by chromatography on silica gel eluting with hexane/EtOAc (95:5) followed by chiral chromatography [heptane/isopropanol/dimethylethylamine (90:10:0.2), 4.6x250 mm Chiralpak AD, 1 mL/min, uv 250 nm] to give 7-chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 [59 mg, 18% yield, 99% ee, chiral HPLC: *t*_R = 6.0 min; MS (ES-) *m/z*: 461 (M-H)⁻] and 7-chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 [50 mg, 15% yield, 99% ee, chiral HPLC: *t*_R = 7.7 min; MS (ES-) *m/z*: 461 (M-H)⁻]. Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (50

mg, 0.14 mmol). Purify by SCX chromatography to give 7-chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (35 mg, 70%) as a yellow oil. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[1-(3,5-difluoro-4-methoxy-phenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 2 (35 mg, 0.10 mmol), to give the title compound (44 mg, 97%) as an off-white powder. MS (ES+) *m/z*: 367 (M+H)⁺; [α]_D²⁰ -107.0° (c 0.5, CH₃OH).

Example 242


(+)-7-Chloro-6-[(2-methylphenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Oxalate



Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.15 g, 0.35 mmol) with (*R*)-1-(2-methyl)-ethylamine (162 mg, 1.2 mmol) at 90°C for 17 h. Deprotect according to the General Procedure 1-2. Purify by reverse phase preparative HPLC and form the oxalate salt according to the General Procedure 2-5 to give the title compound (72 mg, 51 %). HPLC *t_R* = 4.0 min (Chiralpak AD 4.6x150 mm, 3 micron column, 1.0 mL/min of 89.8:10:0.2 heptane/isopropanol/DMEA, isocratic; detector is at 225 nm); HRMS calcd for C₁₉H₂₃ClN₂ 315.1628, found 315.1623. [α]_D²⁰ +67.2° (c 0.5, CH₃OH).

Example 243

(+)-7-Chloro-6-(indan-1-ylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5

Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.5 mmol) with (*R*)-1-aminoindan (188 mg, 1.4 mmol) in toluene (5 mL).

10 Purify by chromatography on silica gel eluting with hexane / EtOAc (9:1 to 1:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to give 7-chloro-6-(indan-1-ylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (129 mg, 67%). GC-MS *m/z*: 408 (*M*⁺).


15

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-(indan-1-ylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (125 mg, 0.3 mmol) and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 80:20) to give the free base of the title compound. Use a method
20 similar to the General Procedure 2-1 to give the title compound (104 mg, 78 %). MS (ES⁺) *m/z*: 313 (*M*+H)⁺. [α]_D²⁰ +73.9° (c 0.5, MeOH).

Example 244

(+)-7-Chloro-6-(5-fluoro-indan-1-ylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate

5



Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
10 (210 mg, 0.5 mmol) with 5-fluoro-indan-ylamine Isomer 1 (161 mg, 1.1 mmol) in toluene (10 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) followed by SCX chromatography to obtain 7-chloro-6-[1-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]- 3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (616 mg, 99%).


15

Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-(5-fluoro-indan-ylamine)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (200 mg, 0.5 mmol). Purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (99/1 to 90/10) to give the free base of the title
20 compound. Use Preparation E-1 to give the title compound (140 mg, 66 %). MS (ES+) *m/z*: 331 (M+H)⁺. [α]_D²⁰ + 80.0° (C, 0.5, MeOH)

Example 245

(±)-7-Chloro-6-(2,3-dihydro-benzofuran-3-ylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

5



Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.15 g, 0.35 mmol) with 2,3-dihydro-benzofuran-3-ylamine (prepared as described in WO 0069816) (0.14 g, 1.1 mmol) at 90°C for 18 h.


Use a method similar to the General Procedure 1-2 and purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 4.6x150 mm, 5 micron column, 1 mL/min of 0.1% TFA in water/ACN (9:1 to 1:9) over 30 min, detector at 230 and 254 nm].

Use a method similar to the General Procedure 2-1 to give the title compound (4.3 mg, 3%). HRMS calcd for C₁₈H₁₉ClN₂O 315.1264, found 315.1256.

20

Example 246

7-Chloro-6-(indan-2-yl-amino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-3, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (426 mg, 1.0 mmol) and 2-aminoindane (400 mg, 3.0 mmol), to give 7-chloro-6-(indan-2-yl-amino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a slightly yellow oil (354 mg, 86%). MS (ES+) *m/z*: 409 (M+H)⁺.

Using a method similar to the General Procedure 1-1, deprotect 7-chloro-6-(indan-2-yl-amino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (354 mg, 0.87 mmol) to obtain 7-chloro-6-(indan-2-yl-amino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a pale-yellow oil (166 mg, 61%). MS (ES+) *m/z*: 313 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound.

Example 247

(-)-7-Chloro-6-[(*N*-methyl)-1-phenylethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Dissolve (-)-7-chloro-6-(1-phenyl-ethylamine)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (192 mg) in DCE (5 mL) and add acetic acid (0.33 mL, 5.8 mmol), formaldehyde (37% solution; 0.5 mL) and sodium triacetoxyborohydride (570 mg, 2.7 mol) and stir the reaction at ambient temperature for 16 h. Dilute the reaction with DCM and wash with 1*N* aqueous NaOH. Dry the organic layers over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (20:1, 10:1 and 5:1) to give (-)-7-chloro-6-(methyl-1-phenylethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.

Use a method similar to the General Procedure 1-3 to deprotect (-)-7-chloro-6-(methyl-1-phenylethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound
5 as a white solid (176 mg, 85%). MS (ES+) m/z : 315 (M+H)⁺. $[\alpha]^{20}_D$ -5.4° (c 0.5, CH₃OH).

Example 248

7-Chloro-6-[(N-methyl)-benzylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate

10




Dissolve 6-benzylamino-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (330 mg, 0.86 mmol) in DCM (3 mL) and add triethylamine (250 μ L, 1.8 mmol) followed by di-*tert*-butyl-dicarbonate (260 mg, 1.2 mmol). Stir at ambient temperature for 1 h. Pour the mixture into water (250 mL), extract with DCM (3x25 mL) and concentrate *in vacuo* to give, after chromatography on silica gel eluting with hexane/EtOAc (9:1), 6-benzylamino-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a colorless oil (260 mg, 78%).
20

Dissolve 6-benzylamino-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (50 mg, 0.11 mmol) in acetonitrile (3 mL) and add a solution of formaldehyde in water (37%, 85 μ L, 0.97 mmol) followed by sodium cyanoborohydride (16.5 mg, 0.26 mmol). Heat the solution to reflux 1 h, cool to ambient temperature, add glacial acetic acid (0.25 mL) and stir 72 h. Pour the mixture into water (100 mL) containing methanol (1 mL), extract with DCM (3x20 mL), wash the organic extracts with brine, dry over MgSO₄, filter and concentrate *in vacuo*. Dissolve the resulting residue in DCM (5 mL), and add trifluoroacetic acid (2 mL). Stir for 2 h at ambient
25

temperature and evaporate the solvent. Purify by SCX chromatography. Use a method similar to the General Procedure 2-1 to give the title compound (45 mg, 95%). MS (ES+) m/z : 301 (M+H)⁺.


- 5 Example 249 may be prepared essentially as described in Example 248 by using 7-chloro-6-(3-fluorobenzylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. The overall yield and MS (ES+) data are shown in the Table below.

Ex.	Structure	Compound	Yield (%)	MS (ES+) m/z
249		7-Chloro-6-[(<i>N</i> -methyl)-3-fluorobenzylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	85	319 (M+H) ⁺

10

Example 250

7-Chloro-6-(1-phenyl-cyclopropylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




15

- Use a method similar to the General Procedure 5-2 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.2 g, 0.47 mmol) with 1-phenyl-cyclopropylamine (0.2 g, 1.41 mmol) using tris(dibenzylideneacetone)dipalladium(0) (43.0 mg, 0.05 mmol), BINAP (0.1 g, 0.15 mmol) and cesium carbonate (0.3 g, 0.97 mmol) at 90°C for 17 h to obtain 7-chloro-6-(1-phenyl-cyclopropylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.
- 20

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the title compound as a white solid (85 mg, 33%).


- 5 Example 251 may be prepared essentially as described in Example 250 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 1-(2,4-dichlorophenyl)-cyclopropylamine. The overall yield (3 steps) is shown in the Table below.

Ex.	Structure	Compound	Yield (%)
251		7-Chloro-6-[1-(2,4-dichlorophenyl)-cyclopropylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	19

10

Example 252

(±)-7-Chloro-6-(2,3-dihydro-benzofuran-3-yl-methylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate



15

Use a method similar to the General Procedure 5-2 to couple 2,3-dihydro-benzofuran-3-yl-methylamine (prepared as described in WO 0069816) (0.14 g, 1.1 mmol) with 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.15 g, 0.35 mmol) at 90°C for 18 h.


- 20 Use a method similar to the General Procedure 1-2 to deprotect 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

Purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 4.6x150 mm 5 micron column, 1 mL/min of 1% TFA in water/ACN (9:1 to 1:9) over 30 min, detector at 230 and 254 nm]. Use a method similar to the General Procedure 2-1 to give the title compound (4.3 mg, 3%).

5

Example 253

7-Chloro-6-[(2,3-dihydrobenzo[*b*]furan-5-yl)-methylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



10

Suspend commercially available 2,3-dihydrobenzo[*b*]furan-5-yl-methylamine hydrochloride (1.0 g, 5.4 mmol) in DCM (100 mL). Add 1N aqueous NaOH (15 mL) and stir until all solids dissolve. Add two spatulas of NaCl. Stir the mixture and extract twice with DCM. Combine the organic layers, dry over Na₂SO₄, and concentrate in *vacuo* to obtain 2,3-dihydrobenzo[*b*]furan-5-yl-methylamine (650 mg, 81%). MS (ES⁺) *m/z*: 133 (M+H-NH₃)⁺.

15

Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (426 mg, 1.0 mmol) with 5-aminomethyl-2,3-dihydrobenzo[*b*]furane (223 mg, 1.5 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain 7-chloro-6-[(2,3-dihydrobenzo[*b*]furan-5-yl)-methylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (244 mg, 58%). MS (ES⁺) *m/z*: 425 (M+H)⁺.


20

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[(2,3-dihydrobenzo[*b*]furan-5-yl)-methylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia

25



in methanol (95:5) to give the free base of the title compound (105 mg, 32%). MS (ES+) m/z : 329 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

- 5 Examples 254-260 may be prepared essentially as described in Example 253 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3) and MS (ES+) data are shown in the Table below.



10


Ex.	NH-R	Compound	Yield (%)	MS (ES+) m/z
254		(±)-7-Chloro-6-[C-(3-methyl-2,3-dihydro-benzofuran-5-yl)-methylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	50	343 (M+H) ⁺
255		(±)-7-Chloro-6-[C-(3-methyl-2,3-dihydro-benzofuran-6-yl)-methylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	66	343 (M+H) ⁺
256		7-Chloro-6-[C-(3,3-dimethyl-2,3-dihydro-benzofuran-6-yl)-methylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	57	357 (M+H) ⁺
257		7-Chloro-6-[C-(3,3-dimethyl-2,3-dihydro-benzofuran-5-yl)-methylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	64	357 (M+H) ⁺
258		7-Chloro-6-[C-(2,2-dimethyl-3-oxo-2,3-dihydro-benzofuran-5-yl)-methylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate	47	371 (M+H) ⁺

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
259		7-Chloro-6-[C-(2,2-dimethyl-3-oxo-2,3-dihydro-benzofuran-6-yl)-methylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	67	371 (M+H) ⁺
260		7-Chloro-6-[(2,2-dimethyl-chroman-6-yl)-methylamino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	24	371 (M+H) ⁺

Example 261


7-Chloro-6-(naphthalen-2-yl-methylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

5



Use a method similar to the General Procedure 5-2 to couple 2-aminomethylnaphthalene (prepared as described in WO 9509159) (0.17 g, 1.1 mmol) with 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.15 g, 0.35 mmol) at 90°C for 18 h.


Use a method similar to the General Procedure 1-2 to give the free base of the title compound. HRMS calcd for C₂₁H₂₁ClN₂ 337.1471, found 337.1461. Use a method similar to the General Procedure 2-1 to give the title compound (104 mg, 66 % overall).

Example 262**7-Chloro-6-[(quinolin-6-yl-methyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride**

Use a method similar to the General Procedure 5-2, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.2 g, 0.35 mmol) and 6-aminomethyl-quinoline (0.2 g, 1.06 mmol) with tris(dibenzylideneacetone)dipalladium(0) (32.0 mg, 0.04 mmol), BINAP (44.0 mg, 0.07 mmol) and cesium carbonate (0.2 g, 0.71 mmol) at 90°C for 17 h, to obtain 7-chloro-6-[(quinolin-6-yl-methyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to form the hydrochloride salt and purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron column, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm) to obtain the title compound as a white solid (50 mg, 56% overall). MS (ES+) *m/z*: 338 (M+H)⁺.


Examples 263-266 may be prepared essentially as described in Example 262 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.



Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
263		7-Chloro-6-[(isoquinolin-3-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	63	338 (M+H) ⁺
264		7-Chloro-6-[(quinolin-3-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	35	338 (M+H) ⁺
265		7-Chloro-6-[(quinolin-2-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	20	338 (M+H) ⁺
266		7-Chloro-6-[(2-phenyl-benzoxazol-6-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	15	404 (M+H) ⁺

Example 267

- 5 6-[(Benzofuran-6-ylmethyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



- 10 Use a method similar to the General Procedure 5-2, using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.2 g, 0.35 mmol) and 6-aminomethyl-benzofuran (0.2 g, 1.06 mmol) with

tris(dibenzylideneacetone)dipalladium (0) (32.0 mg, 0.04 mmol), BINAP (88.0 mg, 0.11 mmol) and cesium carbonate (0.2 g, 0.71 mmol) at 90°C for 17 h, to obtain 6-[(benzofuran-6-yl-methyl)-amino]-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.


5

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the title compound as a white solid (72 mg, 46% overall). MS (ES⁺) *m/z*: 327 (M+H)⁺.

10

Examples 268-271 may be prepared essentially as described in Example 267 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES⁺) data are shown in the Table below.


15



Ex.	NH-R	Compound	Yield (%)	MS (ES ⁺) <i>m/z</i>
268		6-[(Benzo[1,3]dioxol-4-yl-methyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	54	331 (M+H) ⁺
269		6-[(Benzo[1,3]dioxol-5-yl-methyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	55	331 (M+H) ⁺
270		6-(Benzo[<i>b</i>]thiophen-4-yl-methylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	73	343 (M+H) ⁺
271		6-(Benzo[<i>b</i>]thiophen-6-yl-methylamino)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	48	343 (M+H) ⁺

Example 272

6-[(Benzothiazol-6-yl-methyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Oxalate




5

Using a method similar to the General Procedure 5-4, combine 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.1 g, 0.35 mmol), 6-bromomethyl-benzothiazole (80 mg, 0.35 mmol), and potassium carbonate (47.0 mg, 0.35 mmol) in anhydrous DMF (1 mL) in a sealed tube. Heat at 150°C for 3 h to obtain 6-[(benzothiazol-6-yl-methyl)-amino]-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-5 to obtain the title compound as a white solid (25 mg, 16% overall). MS (ES+) *m/z*: 344 (M+H)⁺.

Example 273

20 7-Chloro-6-[(quinolin-8-yl-methyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




Using a method similar to the General Procedure 5-4, combine 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*] azepine (0.1 g, 0.35 mmol), 8-bromomethyl-quinoline (83.6 mg, 0.038 mmol), cesium carbonate (0.2 g, 0.68 mmol) and anhydrous acetonitrile (1 mL) in a sealed tube and heat at 50°C for 12 h to obtain 7-chloro-6-[(quinolin-8-yl-methyl)-amino]-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to form the hydrochloride salt and purify by reverse phase preparative HPLC [Zorbax SB-Phenyl 21.2x250 mm, 5 micron column, 22 mL/min of 0.1% HCl in water/acetonitrile (9:1 to 1:1) over 30 min, detector at 230 nm) to obtain the title compound as a white solid (13 mg, 8% overall). MS (ES+) *m/z*: 338 (M+H)⁺.

15

Example 274

7-Chloro-6-[(2-cyclohexyl-benzothiazol-6-yl-methyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




20

Using a method similar to the General Procedure 5-4, combine 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*] azepine (60 mg, 0.21 mmol), 6-bromomethyl-2-cyclohexyl-benzothiazole (0.1 g, 0.31 mmol), potassium carbonate (58 mg, 0.42 mmol) and anhydrous toluene (2 mL) in a sealed tube and heat at 100°C for 72 h

to obtain 7-chloro-6-[(2-cyclohexyl-benzothiazol-6-yl-methyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

- 5 Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the title compound as a white solid (40 mg, 35% overall). MS (ES+) *m/z*: 427 (M+H)⁺.

- 10 Examples 275-277 may be prepared essentially as described in Example 274 by using 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate bromide. Overall yields and MS (ES+) data are shown in the Table below.




15

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
275		7-Chloro-6-[(2-phenyl-benzothiazol-6-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	39	420 (M+H) ⁺
276		6-[(2-Benzyl-benzothiazol-6-yl-methyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	36	453 (M+H) ⁺
277		6-[(Benzoxazol-6-yl-methyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	7	328 (M+H) ⁺

Example 278

7-Chloro-6-[(1-methyl-indol-4-yl-methyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate




5



Using a method similar to the General Procedure 5-1, couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.1 g, 0.24 mmol) with 4-aminomethyl-1-methylindole (0.1 g, 0.71 mmol) to obtain 7-chloro-6-[(1-methyl-indol-4-yl-methyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil.

Use a method similar to the General Procedure 1-1 to obtain the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-1 to obtain the title compound as a white solid (0.1 g, 91% overall). MS (ES+) *m/z*: 340 (M+H)⁺.

Examples 279-280 may be prepared essentially as described in Example 278 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.




20

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
279		7-Chloro-6-[(1-methyl-indol-6-yl-methyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	42	340 (M+H) ⁺
280		6-[(Benzofuran-6-ylmethyl)-amino]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	46	327 (M+H) ⁺

Example 281

7-Chloro-6-(pyridin-2-ylmethylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride


5



10 Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (500 mg, 1.17 mmol) with pyridin-2-ylmethylamine (254 mg, 2 equiv.) using palladium acetate (0.1 equiv.), BINAP (0.3 equiv.) and cesium carbonate (1.4 equiv.) in toluene (5 mL). Purify the residue by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1, 3:1, and 1:1) to give 7-chloro-6-(pyridin-2-ylmethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil.


15 Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-(pyridin-2-ylmethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by SCX chromatography followed by silica gel chromatography eluting with DCM/2M ammonia in methanol (1:0, 40:1, 20:1 and 10:1) to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to give the
20 title compound as an off white solid (207 mg, 55% overall). MS (ES+) *m/z*: 288 (M+H)⁺.

Example 282 may be prepared essentially as described in Example 281 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and pyridin-4-ylmethylamine. The overall yield and MS (ES+) data are shown in the Table below.

Ex.	NH-R	Compound	Yield (%)	MS (ES+) m/z
282	 (HCl) _x	7-Chloro-6-(pyridin-4-ylmethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	28	288 (M+H) ⁺

Example 283

(±)-7-Chloro-6-[(1-pyridin-4-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (400 mg, 0.94 mmol) and (±)-1-pyridin-4-yl-ethylamine (prepared as described in *Bull. Kor. Chem. Soc.* 1998, 19 (8), 891-893) (172 mg, 1.41 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 4:1 and 1:1) to give (±)-7-chloro-6-[(1-pyridin-4-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

Use a method similar to the General Procedure 1-1 to give the free base of the title compound (73 mg, 26%). Use a method similar to the General Procedure 2-1, using (±)-


7-chloro-6-[(1-pyridin-4-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (73 mg, 0.243 mmol), to give the title compound (31 mg, 31%). MS (ES+) *m/z*: 302 (M+H)⁺.

- Examples 284-287 may be prepared essentially as described in Example 283 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. The yields for the Step 1 (General Procedure 5-3) and MS (ES+) data are shown in the Table below.



10

Ex.	NH-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
284		7-Chloro-6-(5-fluoro-pyridin-3-ylmethylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	88	306 (M+H) ⁺
285		7-Chloro-6-(6-trifluoromethyl-pyridin-3-yl-methylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	83	356 (M+H) ⁺
286		7-Chloro-6-(4-trifluoromethyl-pyridin-3-yl-methylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	60	356 (M+H) ⁺
287		7-Chloro-6-[(6-trifluoromethyl-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	84	356 (M+H) ⁺


Example 288**7-Chloro-6-[(5-fluoro-pyridin-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

Use a method similar to the General Procedure 5-1 to couple 2-aminomethyl-5-fluoro-pyridine (230 mg, 1.8 mmol) and a solution of 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (500 mg, 1.2 mmol) in toluene (4 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) followed by SCX chromatography to give 7-chloro-6-[(5-fluoro-pyridin-2-ylmethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (302 mg, 64%). GC-MS m/z : 402 (M^+).

Dissolve 7-chloro-6-[(5-fluoro-pyridin-2-ylmethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (297 mg, 0.74 mmol) in ethanol (5 mL). Add 5N aqueous NaOH (10 equiv.) and stir for 1 h at ambient temperature. Concentrate *in vacuo* and purify by SCX chromatography followed by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 9:1) to obtain the free base of the title compound. Use a method similar to the General Procedure 2-1 and crystallize the solid from methanol and diethyl ether. Dry the solid in a vacuum oven at 60°C overnight to obtain the title compound (181 mg, 58%). MS (ES+) m/z : 306 ($M+H$)⁺.

Example 289

7-Chloro-6-{{5-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethyl}-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



5

Use a method similar to the General Procedure 5-2 to couple 7-chloro-6-trifluoromethanesulfonyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (370 mg, 0.9 mmol) with 2-aminomethyl-5-(2,2,2-trifluoroethoxy)-pyridine (180 mg, 0.9 mmol) in toluene (8 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1 and 3:1) followed by SCX chromatography [pre-wash column with methanol followed by DCM, load material dissolved in DCM, then elute with DCM/2M ammonia in methanol (1:1) and concentrate *in vacuo*] to obtain 7-chloro-6-{{5-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethyl}-amino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.


15



Use a method similar to the General Procedure 1-3 to deprotect 7-chloro-6-{{5-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethyl}-amino}-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel elutin with DCM/2M ammonia in methanol (99/1 to 90/10) to obtain the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound (184 mg, 42 %). MS (ES+) *m/z*: 386 (M+H)⁺.

20

Examples 290-291 may be prepared essentially as described in Example 289 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.


25



Ex.	O-R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
290		7-Chloro-6- {[5-(2,2,2-trifluoro-1,1-dimethyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	48	414 (M+H) ⁺
291		(±)-7-Chloro-6- {[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepin Succinate	49	400 (M+H) ⁺

Examples 292 and 293


- 5 (-)-7-Chloro-6- {[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate and (+)-7-Chloro-6- {[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Separate the two enantiomers of (\pm)-7-chloro-6-{{[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate by normal phase chiral HPLC (Chiralcel OD 8x35 cm, elute with 4:1 heptane/3A-ethanol with 0.2 % DMEA). Purify each enantiomer by chromatography on silica gel eluting with DCM/2M ammonia in methanol (20:1). Use a method similar to the General Procedure 2-1 to obtain the title compounds: (-)-7-Chloro-6-{{[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate (Example 292, 75 mg, 38%), 95% ee [Chiralpak AD, 4.6x150 mm, eluent: 85/15 heptane/3A ethanol with 0.2% DMEA, 0.6 mL/min]; MS (ES+) *m/z*: 400 (M+H)⁺. [α]_D²⁰ -12.1° (c 0.5, MeOH). (+)-7-Chloro-6-{{[5-(2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-2-ylmethyl]-amino}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate (Example 293, 72 mg, 37%), 93% ee [Chiralpak AD, 4.6x150 mm, eluent: 85/15 heptane/3A ethanol with 0.2% DMEA, 0.6 mL/min]. MS (ES+) *m/z*: 400 (M+H)⁺. [α]_D²⁰ +7.4° (c 0.5, MeOH).

Example 294

(\pm)-7-Chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.47 mmol) with (\pm)-1-thiophen-2-yl-ethylamine (prepared as described in *J. Amer. Chem. Soc.* 1942, 64, 477-479) (200 mg, 1.57 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1) to give (\pm)-7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (126 mg, 67%).

Use a method similar to the General Procedure 1-1, using (\pm)-7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (126 mg, 0.313 mmol), to give the free base of the title compound (73 mg, 77%). Use a method similar to the General Procedure 2-1, using (\pm)-7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (73 mg, 0.241 mmol) to give the title compound (100 mg, 50% overall). MS (ES+) *m/z*: 307 (M+H)⁺.

Example 295

(+)-7-Chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate, Isomer 1




Separate the two enantiomers of (\pm)-7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine by chiral preparative HPLC (Chiralpak AD, 8x30 cm; eluent: 9:1 heptane/isopropanol with 0.2% DMEA; flow: 350 mL/min at 240 nm (UV), ~650 mg load] to obtain 7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1, ee=100% [Analytical Column: Chiralpak AD, 4.6x250mm; eluent: 9:1 heptane/isopropanol with 0.2% DMEA; flow: 1 mL/min at 250nm (UV)].

Use a method similar to the General Procedure 1-1, using 7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1, to give 7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[(1-thiophen-2-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (73 mg, 0.241 mmol) to give the title compound (100 mg, 98%). MS (ES+) *m/z*: 307 (M+H)⁺. [α]_D²⁰ +115.0° (c 0.5, MeOH).

Example 296

(±)-7-Chloro-6-[1-(5-methylthiophen-2-yl)ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

5




Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (96 mg, 0.227 mmol) with (±)-2-(1-aminoethyl)-5-methylthiophene (48 mg, 0.34 mmol) using palladium(II) acetate (10 mg, 0.0454 mmol), BINAP (60 mg, 0.0908 mmol) and cesium carbonate (148 mg, 0.454 mmol) in toluene (10 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 19:1) to give (±)-7-chloro-6-[1-(5-methylthiophen-2-yl)ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (47 mg, 50%). GC-MS *m/z* 416 (M^+).

Use a method similar to the General Procedure 1-2, using (±)-7-chloro-6-[1-(5-methylthiophen-2-yl)ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (47 mg, 0.113 mmol) to give (±)-7-chloro-6-[1-(5-methylthiophen-2-yl)ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (30 mg, 83%) that was used without further purification. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (36 mg, 88%). MS (ES+) *m/z*: 321 ($M+H$)⁺.

Example 297

(+)-7-Chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

5




Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (0.328 g, 0.773 mmol) with 1-(5-phenyl-thiophen-2-yl)ethylamine Isomer 1 (0.236 g, 1.16 mmol) using palladium(II) acetate (69 mg, 0.309 mmol), tris(dibenzylideneacetone)-dipalladium(0) (142 mg, 0.155 mmol), BINAP (578 mg, 0.928 mmol) and cesium carbonate (504 mg, 1.546 mmol) in toluene (10 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 19:1) to give 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (89 mg, 34%).

Use a method similar to the General Procedure 1-2, using 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (89 mg, 0.186 mmol) to give 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (65 mg, 92%) as an oil that was used without further purification. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Isomer 1 (65 mg, 0.17 mmol), to give the title compound as a white solid (58 mg, 68%). MS (ES⁺) *m/z*: 383 (M+H)⁺; [α]_D²⁰ +159.0° (c 0.5, MeOH).

Example 298

(-)-7-Chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate



5

Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.484 g, 1.138 mmol) with 1-(5-phenyl-thiophen-2-yl)ethylamine Isomer 2 (0.347 g, 1.71 mmol) using palladium(II) acetate (102 mg, 0.45 mmol), tris(dibenzylideneacetone)-dipalladium(0) (209 mg, 0.228 mmol), BINAP (851 mg, 1.366 mmol) and cesium carbonate (741 mg, 2.276 mmol) in toluene (12 mL). Purify by chromatography on silica gel eluting with hexane:EtOAc (1:0 and 19:1) to give 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Isomer 2 (247 mg, 63 %).

15


Use a method similar to the General Procedure 1-2, using 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Isomer 2 (247 mg, 0.516 mmol) to give 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Isomer 2 (184 mg, 93%) as an oil that was used without further purification. Use a method similar to the General Procedure 2-1, using 7-chloro-6-[1-(5-phenyl-thiophen-2-yl)-ethylamino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Isomer 2 (184 mg, 0.48 mmol) to give the title compound as a white solid (200 mg, 83%). MS (ES+) m/z : 383 (M+H)⁺; $[\alpha]_D^{20}$ -196.5° (c 0.5, MeOH).

25

Example 299

(±)-7-Chloro-6-[(1-thiophen-3-yl-ethyl)-amino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate


5



Use a method similar to the General Procedure 5-3 to couple 7-chloro-3-(2,2,2-
10 trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
(200 mg, 0.47 mmol) with (±)-1-thiophen-3-yl-ethylamine (prepared as described in *J.*
Heterocycl. Chem. 1988, 25, 1571-1581) (90 mg, 0.70 mmol). Purify by chromatography
on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1) to give (±)-7-chloro-6-(1-
15 thiophen-3-yl-ethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-
benzo[*d*]azepine (100 mg, 53%).

Use a method similar to the General Procedure 1-1, using (±)-7-chloro-6-(1-
thiophen-3-yl-ethylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-
benzo[*d*]azepine (100 mg, 0.248 mmol), to give the free base of the title compound (74
20 mg, 98%). Use a method similar to the General Procedure 2-1, using (±)-7-chloro-6-(1-
thiophen-3-yl-ethylamino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (74 mg, 0.242 mmol)
to give the title compound (108 mg, 54% overall). MS (ES+) *m/z*: 307 (M+H)⁺.


25

Example 300**7-Chloro-6-[(5-methylfuran-2-ylmethyl)-amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5

Combine 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 0.24 mmol), 2-(di-*tert*-butylphosphino)-biphenyl (6.8 mg, 0.023 mmol), tris(dibenzylideneacetone)dipalladium (11 mg, 0.012 mmol) and potassium phosphate (70 mg, 0.33 mmol) in a pressure tube and degas. Dissolve the mixture in dry toluene (2 mL) and degas. Add a solution of 5-methylfurfurylamine (30 mg, 0.27 mmol) in toluene (1 mL) and degas. Stir at 90°C for 24 h. Cool to ambient temperature, dilute with ethyl ether and filter through Celite®. Concentrate and purify by chromatography on silica gel eluting with hexane/EtOAc (20:1). Remove the solvent and add 7M ammonia in methanol (4 mL). Stir at ambient temperature for 24 h. Concentrate and purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-2 to obtain the title compound as a solid (56 mg, 66%). MS (ES+) *m/z*: 291 (M+H)⁺.

Examples 301-302 may be prepared essentially as described in Example 300 by using 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.




Ex.	R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
301	4-Cl	7-Chloro-6-[[3-(4-chlorophenyl)-isoxazol-5-ylmethyl]-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	30	389 (M+H) ⁺
302	4-OMe	7-Chloro-6-[[3-(4-methoxyphenyl)-isoxazol-5-ylmethyl]-amino]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	54	384 (M+H) ⁺

Example 303

5

7-Chloro-6-(thiazol-5-ylmethyl-amino)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



- 10 **Thiazole-5-carbaldehyde:** Add DMSO slowly to a solution of oxalyl chloride (1.6 g, 13 mmol) in anhydrous DCM (30 mL) under nitrogen at -78°C and stir for 10 min. Add dropwise a solution of 5-hydroxymethylthiazole (1.15 g, 10 mmol) in DCM (10 mL) and stir the mixture for 40 min. Add triethylamine and stir for 5 min and then quench the

reaction with water. Extract the mixture three times with ether, combine the organic extracts, wash with brine, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (2:5) to give thiazole-5-carbaldehyde (337 mg, 29%).

5

3-(tert-Butoxycarbonyl)-7-chloro-6-(thiazol-5-ylmethyleamino)-2,3,4,5-tetrahydro-

1H-benzo[d]azepine: Dissolve 6-amino-7-chloro-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (285 mg, 0.97 mmol) in methanol (10 mL). Add 7N ammonia in methanol (10 mL) and stir overnight at ambient temperature. Concentrate *in vacuo* and dissolve the residue in THF (10 mL). Add saturated aqueous NaHCO₃ (5 mL) and di-*tert*-butyl-dicarbonate (254 mg, 1.16 mmol). Stir the reaction mixture at ambient temperature for 4 h. Dilute the mixture with water, extract three times with EtOAc, combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo* to give crude material. Mix thiazole-5-carbaldehyde (165 mg, 1.45 mmol) with above crude residue (0.97 mmol, assuming 100% conversion), acetic acid (87 mg, 1.45 mmol) and 1,2-dichloroethane (10 mL). Stir at ambient temperature for 20 min. Add sodium triacetoxymethylborohydride and stir under nitrogen overnight. Quench the reaction with saturated aqueous NaHCO₃, separate the organic layer and extract the aqueous layer three times with DCM. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to afford the desired intermediate as a yellow oil (228 mg, 60% three steps). MS (ES+) *m/z*: 392 (M+H)⁺.

10

15

20

3-(*t*-Butoxycarbonyl)-7-chloro-6-(thiazol-5-ylmethyl-amino)-2,3,4,5-tetrahydro-1H-

benzo[d]azepine: Dissolve 3-(*t*-butoxycarbonyl)-7-chloro-6-(thiazol-5-ylmethyleamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (228 mg, 0.58 mmol) in methanol (10 mL), add sodium borohydride (263 mg, 7 mmol) and reflux for 28 h. Cool to ambient temperature, dilute with EtOAc and add slowly water. Separate the organic layer, extract the aqueous layer three times with EtOAc. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc/hexane (1:3) to give the desired intermediate as a colorless oil (134 mg, 58%). MS (ES+) *m/z*: 394 (M+H)⁺.

25


30

7-Chloro-6-(thiazol-5-ylmethyl-amino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

Hydrochloride: Use a method similar to the General Procedure 1-6 to deprotect 3-(*tert*-butoxycarbonyl)-7-chloro-6-(thiazol-5-ylmethyl-amino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (134 mg, 0.34 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to give 7-chloro-6-(thiazol-5-ylmethyl-amino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (90 mg, 90%). MS (ES+) m/z : 294 (M+H)⁺. Use a method similar to the General Procedure 2-2 to obtain the title compound.

Example 304

7-Chloro-6-[(3-pyridyl)amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.7 mmol) with 3-aminopyridine (75 mg, 0.85 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give 7-chloro-6-[(3-pyridyl)amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an off-white solid (20 mg, 8%). MS (ES+) m/z : 370 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-6-[(3-pyridyl)amino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (20 mg, 0.05 mmol). Purify by SCX chromatography to give 7-chloro-6-[(3-pyridyl)amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (15 mg, 99%). Use a method similar to the General Procedure 2-1, using 7-chloro-6-[(3-pyridyl)amino]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (15.1 mg, 0.05 mmol), to give the title compound as a light yellow solid (20 mg, 97%). MS (ES+) m/z : 319 (M+H)⁺.


Example 305**7,9-Dichloro-6-(3,4-difluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride**

5




Dissolve 7-dichloro-6-(3,4-difluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (150 mg, 0.36 mmol) in anhydrous toluene (20 mL). Add
10 *N*-chlorosuccinimide (140 mg, 1 mmol) and heat at 60°C for 4 h. Cool to room temperature, pour reaction mixture into water (250 mL) and extract with EtOAc (3x50 mL). Wash combined organic extracts with water, brine, dry over Na₂SO₄, filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give 7,9-dichloro-6-(3,4-difluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (110 mg, 67%). MS (ES+) *m/z*: 453 (M+H)⁺.
15

Use a method similar to the General Procedure 1-1 to deprotect 7,9-dichloro-6-(3,4-difluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (120 mg, 0.26 mmol). Purify by SCX chromatography to give 7,9-dichloro-6-(3,4-difluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow
20 oil (81 mg, 88%). Use a method similar to the General Procedure 2-2, using 7,9-dichloro-6-(3,4-difluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (75 mg, 0.21 mmol), to give the title compound as a yellow gum (80 mg, 96%). MS (ES+) *m/z*: 357 (M+H)⁺.

Example 306**7-Chloro-9-fluoro-6-(3-fluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

Use a method similar to the General Procedure 5-1 to couple 7-chloro-9-fluoro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (130 mg, 0.3 mmol) with 3-fluorobenzylamine (100 μ L, 0.89 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 and 4:1) followed by SCX chromatography to give 7-chloro-9-fluoro-6-(3-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (35 mg, 28%). MS (ES+) m/z : 401 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect 7-chloro-9-fluoro-6-(3-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (32 mg, 0.08 mmol). Purify by SCX chromatography to give 7-chloro-9-fluoro-6-(3-fluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (10 mg, 45%). Use a method similar to the General Procedure 2-1, using 7-chloro-9-fluoro-6-(3-fluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (10 mg, 0.033 mmol), to give the title compound as a light yellow solid (14 mg, 97%). MS (ES+) m/z : 323 (M+H)⁺.


Example 307**7-Fluoro-6-(4-fluorobenzylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

5

Use a method similar to the General Procedure 5-1 to couple 7-chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine (250 mg, 0.61 mmol) with 4-fluorobenzylamine (92 mg, 1.2 equiv.) using palladium(II) acetate (0.1 equiv.), BINAP (0.3 equiv.) and cesium carbonate (1.4 equiv.) in toluene (5 mL). Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1, 5:1, 3:1 and 1:1) to give 7-fluoro-6-(4-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil.

Use a method similar to the General Procedure 1-3 to deprotect 7-fluoro-6-(4-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Purify by SCX chromatography to give the free base of the title compound. Use a method similar to the General Procedure 2-1 to give the title compound as an off white solid (14 mg, 6%). MS (ES+) m/z : 289 (M+H)⁺.


20

Example 308**6-Benzylamino-7-cyano-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

Use a method similar to the General Procedure 5-1 to couple 7-cyano-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (125 mg, 0.3 mmol) with benzylamine (0.1 mL, 0.9 mmol) using palladium(II) acetate (7 mg, 0.03 mmol), BINAP (37 mg, 0.06 mmol) and cesium carbonate (137 mg, 0.4 mmol) in toluene (3 mL). Purify by chromatography on silica gel eluting with heptane/EtOAc (4:1 to 1:1) to give 6-benzylamino-7-cyano-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a clear oil (60 mg, 54%). MS (ES+) *m/z*: 374 (M+H)⁺.


Use a method similar to the General Procedure 1-2, using 6-benzylamino-7-cyano-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (56 mg, 0.15 mmol), to give 6-benzylamino-7-cyano-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a clear oil (38 mg, 93%). MS (ES+) *m/z*: 278 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound as a white powder (39 mg, 71%). MS (ES+) *m/z*: 278 (M+H)⁺.

Examples 309-310 may be prepared essentially as described in Example 308 by using 7-cyano-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriate amine. Overall yields and MS (ES+) data are shown in the Table below.



20

Ex.	R	Compound	Yield (%)	MS (ES+) <i>m/z</i>
309	4-F	7-Cyano-6-(4-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	46	296 (M+H) ⁺
310	2-F	7-Cyano-6-(2-fluorobenzylamino)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	43	296 (M+H) ⁺


Example 311**6-(3-Fluorobenzylamino)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

5

Use a method similar to the General Procedure 5-1 to couple 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (110 mg, 0.24 mmol) and 3-fluorobenzyl amine (90 μ L, 0.7 mmol).

- 10 Purify by chromatography on silica gel eluting with hexane/EtOAc (95:5) followed by SCX chromatography to give 6-(3-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (55 mg, 53%). MS (ES+) m/z : 435 (M+H)⁺.

- 15 Use a method similar to the General Procedure 1-1 to deprotect 6-(3-fluorobenzylamino)-3-(2,2,2-trifluoroacetyl)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (55 mg, 0.13 mmol). Purify by SCX chromatography to give 6-(3-fluorobenzylamino)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (34 mg, 81%). Use a method similar to the General Procedure 2-1 to give the title
- 20 compound as an off-white solid (33 mg, 72%). MS (ES+) m/z : 339 (M+H)⁺.

Example 312**(S)-(-)-6-[1-(4-Fluorophenyl)-ethylamino]-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**


25

Use a method similar to the General Procedure 5-3 to couple 3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-7-trifluoromethyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (430 mg, 0.94 mmol) with (*S*)-1-(4-fluorophenyl)ethylamine (195 mg, 1.40 mmol). Purify by chromatography on silica gel eluting with EtOAc/hexane (1:8) to give (*S*)-6-[1-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-7-trifluoromethyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (279 mg, 66%). MS (ES+) *m/z*: 449 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect (*S*)-6-[1-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-7-trifluoromethyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (279 mg, 0.62 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (94:6) to obtain (*S*)-6-[1-(4-fluorophenyl)-ethylamino]-7-trifluoromethyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil (190 mg, 87%). MS (ES+) *m/z*: 353 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound. [α]_D²⁰ -96.7° (c 0.5, MeOH).

Example 313

(*S*)-7-Ethyl-6-[1-(4-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




Use a method similar to the General Procedure 5-3 to couple 7-ethyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (335 mg, 0.8 mmol) and (*S*)-1-(4-fluorophenyl)ethylamine (557 mg, 4.0 mmol). Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 17:3) to give (*S*)-7-ethyl-6-[1-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (127 mg, 39%). MS (ES+) *m/z*: 409 (M+H)⁺.

Use a method similar to the General Procedure 1-1 to deprotect (*S*)-7-ethyl-6-[1-(4-fluorophenyl)-ethylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (93:7) to give (*S*)-7-ethyl-6-[1-(4-fluorophenyl)-ethylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (70 mg, 72%). MS (ES+) *m/z*: 313 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Example 314

7-Propyl-6-[(2-thienyl)methylamino]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



Use a method similar to the General Procedure 5-1 to couple 7-propyl-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-(aminomethyl)-thiophene. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 and 4:1) to give 7-propyl-6-[(2-thienyl)methylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow solid. MS (ES+) *m/z*: 397 (M+H)⁺.

20

Use a method similar to the General Procedure 1-1 to deprotect 7-propyl-6-[(2-thienyl)methylamino]-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Purify by SCX chromatography to give the free base of the title compound as a yellow oil. Use a method similar to the General Procedure 2-2 to give the title compound as a light yellow solid. MS (ES+) *m/z*: 301 (M+H)⁺.

25


General Procedure 7

Dissolve the appropriate substituted 3-*tert*-butoxycarbonyl-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 equiv) in methanol (0.1-0.2 M solution). Add potassium hydroxide (32 equiv.) and heat the mixture at 50°C for 2-8 h. Cool the
 5 reaction to ambient temperature and add the appropriate halide (1.0-5.0 equiv.). Stir the mixture at ambient temperature for 0.5-16 h. Remove the solvent *in vacuo* and partition the residue between DCM and water. Extract the aqueous phase with DCM, combine the organic extracts, dry over Na₂SO₄, filter and concentrate. Purify by chromatography in silica gel eluting with hexane/EtOAc mixtures to obtain the desired compound.

10

Preparation 172

3-*tert*-Butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



15

7-Chloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:


Place 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (64.3 g, 219 mmol) in acetone (450 mL) and water (200 mL) with K₂CO₃ (91.8 g, 664 mmol) and dimethylthiocarbamoyl chloride (31.5 g, 255 mmol). Stir at ambient temperature for 1.25 h. Add additional dimethylthiocarbamoyl chloride (3 g, 24 mmol) and stir for an additional 1.75 h at ambient temperature. Add more dimethylthiocarbamoyl chloride (0.7 g, 5.7 mmol) and water (150 mL) to the mixture and stir for 0.5 h at ambient temperature. Slowly add water (500 mL) to the
 20 reaction over 2 h to promote crystallization and stir the resulting slurry at ambient
 25 temperature for 1.5 h. Collect the solid by filtration to give the desired intermediate (76 g, 91%).

3-tert-Butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Dissolve 7-chloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (155 g, 407 mmol) in diphenyl ether (1500 mL) and heat to 250°C for 2.5 h. Cool the reaction and dilute with methanol (308 mL). Add 1N aqueous NaOH (616 mL) and stir at 60°C for 4 h. Cool the reaction to ambient temperature and extract between DCM (3 x 500 mL) and water (500 mL). Combine the organic extracts and add to 1N aqueous HCl (1 L). Stir the reaction at ambient temperature for 0.25 h then wash with hexane (5 x 400 mL). Adjust the pH of the aqueous layer to 7.0 with 5N aqueous NaOH and mix the aqueous solution with DCM (2.5 L). Cool the mixture in an ice bath and add K₂CO₃ (169 g, 1221 mmol) and di-*t*-butyl dicarbonate (67.5 g, 390 mmol) and stir the reaction at ambient temperature for 0.5 h. Add di-*t*-butyl dicarbonate (16.35 g, 75 mmol) and stir for 0.3 h at ambient temperature. Add di-*t*-butyl dicarbonate (0.1 g, 0.46 mmol) and stir for 0.25 h at ambient temperature. Concentrate the mixture *in vacuo* to remove the volatiles and warm to 45°C. Seed the mixture with a small amount of the title compound and stir for 1 h at 45°C. Cool the reaction in an ice bath and stir for an additional 2 h. Collect the resultant solid by filtration and rinse with cold hexane (100 mL). Concentrate the filtrate *in vacuo*, recrystallize from DCM/heptane, and isolate the solids by filtration. Combine the solids and dry *in vacuo* to give the title compound as a white crystalline solid (142 g, 91%). MS (ES+) *m/z* 385 (M+H)⁺.

Preparation 173

3-tert-Butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-tert-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine



7-Chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-

benzo[d]azepine:

To a solution of 6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.961 g, 3.71 mmol) in toluene (30 mL) at 70 °C, add diisobutylamine (52 µL, 0.30 mmol) followed by slow addition of neat sulfonyl chloride (343 µL, 4.27 mmol). Stir for 1 h at 70 °C and concentrate *in vacuo*. Dilute the residue with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to afford a 4:1 mixture of 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a white solid (1.07 g, 98%).

7-Chloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

To a mixture of 4:1 7-chloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.513 g, 1.75 mmol) in anhydrous dioxane (10 mL) under nitrogen, add dimethylthiocarbonyl chloride (0.432 g, 3.50 mmol), 4-dimethylaminopyridine (21 mg, 0.18

mmol) and triethylamine (731 μ L, 5.24 mmol) and heat under reflux overnight. Cool the reaction mixture to ambient temperature and dilute with water, extract three times with EtOAc, dry over anhydrous Na_2SO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (17:1) to afford a mixture of 4:1 7-chloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (0.64 g, 95%)


7-Chloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Heat the mixture of 4:1 7-chloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.630 g, 1.66 mmol) in diphenyl ether (4.5 mL) at 250 $^{\circ}\text{C}$ for 4 h under nitrogen. Cool to ambient temperature. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3) to give a mixture of 4:1 7-chloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (0.54 g, 85%).

3-tert-Butoxycarbonyl-7-chloro-6-dimethylcarbamoylethio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-tert-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylethio-2,3,4,5-tetrahydro-1H-benzo[d]azepine: To the mixture of 4:1 7-chloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 7,9-dichloro-6-dimethylcarbamoylethio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.536 g, 1.47 mmol) in methanol (7 mL), add aqueous potassium carbonate (0.812 g, 5.88 mmol in 1.5 mL of water). Stir for 5 h at ambient temperature, add di-tert-butyl dicarbonate (418 mg, 1.91 mmol) and stir for an additional 30 min. Dilute with EtOAc and water. Separate the layers and extract the aqueous layer three times with EtOAc. Dry over anhydrous Na_2SO_4 , and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3) to give a mixture of 4:1 3-tert-butoxycarbonyl-7-chloro-6-dimethylcarbamoylethio-2,3,4,5-tetrahydro-1H-

benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a white solid (0.52 g, 96%).

Preparation 174


5 7-Bromo-3-*tert*-butoxycarbonyl-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



10 Use a method similar to the Preparation 172, using 7-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the title compound.

Preparation 175

15 3-*tert*-Butoxycarbonyl-6-dimethylcarbamoylthio-7-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



7-Bromo-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Add potassium carbonate (10.214 g, 73.9 mmol) to a solution of 7-bromo-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (5.0 g, 14.8 mmol) in acetone (50 mL) and stir for 10 min. Add methyl iodide (4.2 g, 1.5 mL, 29.6 mmol) and stir the mixture overnight at room temperature. Remove the solvent *in vacuo* and partition the residue between water and DCM. Extract the aqueous phase twice with DCM. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo* to obtain the desired intermediate as a solid (5.15 g, 99%). MS (ES+) *m/z*: 352 (M+H)⁺.

6-Methoxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Add potassium carbonate (5.65 g, 40.91 mmol), tetrakis(triphenylphosphine)palladium (1.576 g, 1.363 mmol) and trimethylboroxine (2.053 g, 2.3 mL, 16.35 mmol) to a solution of 7-bromo-6-methoxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (4.8 g, 13.63 mmol) in dimethylformamide (40 mL) under nitrogen. Heat the mixture to 115°C for 6 h. Add water and extract the aqueous phase twice with EtOAc. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 19:1) to obtain the desired intermediate as a solid (3.23 g, 83%). GC-MS *m/z* 287 (M⁺).

6-Hydroxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Add borontribromide (21.6 mL, 1.0 M solution in DCM) to a solution of 6-methoxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (3.1 g, 10.8 mmol) in DCM (200 mL) at 0°C under nitrogen. Warm to room temperature and stir overnight. Dilute with DCM and wash with water. Dry the organic layer over Na₂SO₄, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a solid (2.74 g, 93%). MS (ES+) *m/z*: 274 (M+H)⁺.

6-Dimethylthiocarbamoyloxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Dissolve 6-hydroxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.0 g, 3.66 mmol) in acetone (50 mL). Add potassium

carbonate (1.517 g, 10.98 mmol) and dimethylthiocarbamoyl chloride (0.904 g, 7.32 mmol). Heat the mixture at reflux overnight. Remove the solvent *in vacuo* and partition the residue between water and DCM. Dry the organic phase over Na₂SO₄, filter and concentrate. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a solid (1.18 g, 90%). MS (ES+) *m/z*: 361 (M+H)⁺.

6-Dimethylcarbamoylthio-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Dissolve 6-dimethylthiocarbamoyloxy-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.15 g, 3.19 mmol) in diphenyl ether (20 mL) and heat to 265°C for 3 h in a sealed tube. Cool the reaction to room temperature. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1 and 7:3) to obtain the desired intermediate as a solid (1.10 g, 96%). MS (ES+) *m/z*: 361 (M+H)⁺.


3-tert-Butoxycarbonyl-6-dimethylcarbamoylthio-7-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Dissolve 6-dimethylcarbamoylthio-7-methyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.048 g, 2.9 mmol) in methanol (40 mL). Add a solution of potassium carbonate (1.6 g, 11.6 mmol) in water (10 mL). Stir at room temperature overnight. Remove the solvent and partition the residue between water and DCM. Extract the aqueous phase twice with DCM. Combine the organic extracts, dry over Na₂SO₄, filter and concentrate. Dissolve the residue (0.756 g, 2.86 mmol) in DCM (50 mL). Add triethylamine (0.579 g, 0.8 mL, 2.0 equiv) and di-*tert*-butyl dicarbonate (0.624 g, 2.86 mmol) and stir at room temperature overnight. Dilute with DCM and wash with water. Dry the organic phase over Na₂SO₄, filter and concentrate to obtain the title compound as foam (1.038 g, 99%). MS (ES+) *m/z*: 264 (M+H-Boc)⁺.

Preparation 176

3-*tert*-Butoxycarbonyl-7-cyano-6-dimethylcarbamoylsulfanyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine

5

**7-Cyano-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:**

10 Add dimethylthiocarbamoyl chloride (197 mg, 1.58 mmol) to a stirred solution of 7-cyano-6-hydroxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (150 mg, 0.53 mmol), DMAP (6 mg, 0.05 mmol) and dry triethylamine (300 μ L) in dry 1,4-dioxane (5 mL) under an atmosphere of nitrogen and heat at 120 $^{\circ}$ C for 6 h. Cool and continue stirring for 2 days at ambient temperature. Dilute with EtOAc, wash with 1N aqueous HCl, water, saturated aqueous Na₂CO₃ and brine. Dry over

15 MgSO₄ then concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc:heptane (0:1 to 3:10) to give the desired intermediate as a white solid (158 mg, 81%).

7-Cyano-6-dimethylcarbamoylsulfanyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-

20 **1*H*-benzo[*d*]azepine:** Heat a round bottom flask containing a solution of 7-cyano-6-dimethylthiocarbamoyloxy-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (786 mg, 2.12 mmol) in diphenyl ether (21 mL) in a preheated oil bath at 230 $^{\circ}$ C for 2 h. Cool and purify by chromatography on silica gel eluting with EtOAc:heptane (0:1 to 1:1) to give the desired intermediate as a yellow foam (740 mg,

94%). ^1H NMR (300 MHz, CDCl_3) δ 7.60-7.56 (d, 1H), 7.36-7.30 (d, 1H), 3.88-3.68 (m, 4H), 3.34-3.03 (m, 10H).


3-tert-Butoxycarbonyl-7-cyano-6-dimethylcarbamoylsulfanyl-2,3,4,5-tetrahydro-1H-

5 **benzo[d]azepine:** Add potassium carbonate (4.13 g, 30 mmol) to a stirred solution of 7-cyano-6-dimethylcarbamoylsulfanyl-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (740 mg, 2.0 mmol) in methanol (40 mL)/water (15 mL) and stir for 1.5 h. Add DCM (10 mL), di-*tert*-butyl dicarbonate (480 mg, 2.2 mmol) and stir at ambient temperature for 3 days. Concentrate *in vacuo* and dilute with DCM, wash with water and
10 extract with DCM. Combine the organic layers, wash with brine, dry over MgSO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with EtOAc:heptane (0:1 to 1:1) to give the title compound as a colourless foam (370 mg, 50%). ^1H NMR (300 MHz, CDCl_3) δ 7.52 (d, J 8 Hz, 1H), 7.29 (d, J 8 Hz, 1H), 3.69-3.48 (m, 4H), 3.26-3.02 (m, 10H), 1.45 (s, 9H).

15

Preparation 177

(*S*)-3-*tert*-Butoxycarbonyl-7-chloro-6-(5-oxo-tetrahydro-furan-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine




20

To a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[d]azepine (137 mg, 0.356 mmol) in methanol (2 mL) add potassium hydroxide pellets (640 mg, 11.4 mmol) and heat for 3 h at 50 °C. Cool to ambient
25 temperature, add saturated aqueous NH_4Cl , extract three times with EtOAc, dry over anhydrous Na_2SO_4 , and concentrate *in vacuo*. Dissolve the crude thiophenol thus obtained in dry DMF (2 mL), and add with stirring sodium hydride (18 mg, 0.713 mmol,

95% dispersion), followed by (*S*)-(+)-dihydro-5-(*p*-tolylsulfonyloxymethyl)-2-(3*H*)-furanone (144 mg, 0.533 mmol). Continue stirring overnight at ambient temperature, then dilute cautiously with EtOAc and cold saturated aqueous NH₄Cl. Extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:3) to give the title compound as a colorless oil.

Preparation 178

5-Chloromethyl-3-methyl-[1,2,4]oxadiazole








10

Add with stirring hydroxylamine (50 % in water, 25.0 mL, 0.380 mol) to a solution of acetonitrile (5.0 mL, 95.0 mmol) and ethanol (500 mL). Heat at 70 °C for 18 h. Concentrate *in vacuo* to provide crude *N*-hydroxyacetamidine (7.0 g, 100 %).

15 Add slowly with stirring vinyl chloroacetate (2.1 mL) to *N*-hydroxyacetamidine (*J. Org. Chem.* 1971, 36, 1306-1307) (1.00 g, 13.5 mmol) and heat at 90 °C for 5 h. Cool to ambient temperature, dilute with DCM, wash with aqueous 1N aqueous NaOH, dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to give the title compound (904 mg, 50%).

20 The compounds of Preparation 179-182 were prepared essentially as described in Preparation 178.

Prep.	Structure	Compound
179		3- <i>tert</i> -Butyl-5-chloromethyl-[1,2,4]oxadiazole
180		5-Chloromethyl-3-propyl-[1,2,4]oxadiazole
181		5-Chloromethyl-3-(4-chloro-phenyl)-[1,2,4]oxadiazole
182		2-(5-Chloromethyl-[1,2,4]oxadiazol-3-yl)-pyridine

Preparation 183**2-Bromomethyl-6-chloropyridine**

5 Heat a mixture of 2-chloro-6-methylpyridine (5.46 g, 42.8 mmol), NBS (8.38 g, 47.08 mmol), and benzoyl peroxide (500 mg, 2.06 mmol) in carbon tetrachloride (80 mL) for 20 h at 85 °C. Cool to ambient temperature, filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/toluene (4:3) to provide the title
10 compound as a white solid (3.64 g, 41%).

Preparation 184**3-Bromo-2-bromomethyl-pyridine**

15 Heat a mixture of 3-bromo-2-methylpyridine (*J. Med. Chem.* 1987, 30, 871-880) (2.7 g, 15.8 mmol), NBS (3.10 g, 17.42 mmol), and benzoyl peroxide (190 mg, 0.78 mmol) in carbon tetrachloride (50 mL) overnight at 85 °C. Cool to ambient temperature,
20 filter, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with toluene to provide the title compound as a white solid (1.81 g, 45%).


Preparation 185**2-Bromo-6-bromomethyl-pyridine**

25

Use a method similar to the Preparation 184, using 2-bromo-6-methylpyridine, to give the title compound.

Preparation 186

5-Bromo-2-bromomethylpyridine




2-Hydroxymethyl-5-bromopyridine: Dissolve 2,5-dibromopyridine (10 g, 42 mmol) in toluene (500 mL) and cool to -78°C . Add 2.5M *n*-butyllithium in hexane (20.3 mL, 50.6 mmol) and stir the mixture for 7 h at the same temperature. Add DMF (4.2 mL, 54.87 mmol) and stir for 1 h. Warm the solution to 0°C and add sodium borohydride (3.2 g, 84.42 mmol). Stir the mixture at ambient temperature for 3 h. Dilute with EtOAc and saturated aqueous NH_4Cl . Separate the layers and extract the aqueous layer three times with EtOAc. Dry over anhydrous Na_2SO_4 , filter and concentrate *in vacuo*. Recrystallization from hexane/EtOAc (9:1) gives the desired intermediate as a white solid (5.3 g, 66%).

5-Bromo-2-bromomethyl-pyridine : Dissolve 2-hydroxymethyl-5-bromopyridine (5.21 g, 27.7 mmol) in 48% aqueous hydrobromic acid (20 mL). Heat the mixture at 150°C for 2 h. Cool to ambient temperature and remove excess hydrobromic acid under vacuum. Dilute with water, add cautiously saturated aqueous NaHCO_3 and extract three times with EtOAc. Dry over anhydrous Na_2SO_4 , filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the title compound as pink oil (6.0 g, 87%) that crystallizes in the freezer.

Preparation 187

2-Chloromethyl-3-methylpyridine Hydrochloride



2-Hydroxymethyl-3-methylpyridine: Heat a mixture of 3-methylpicolinic acid (1.0 g, 7.3 mmol), potassium carbonate (4.1 g, 29.7 mmol), and iodomethane (4.4 g, 31.0 mmol) in acetone (35 mL) overnight under reflux. Filter, wash the residue with EtOAc, and concentrate *in vacuo*. Pass through a short plug of silica gel eluting with hexane/EtOAc (1:1) to provide 2-methoxycarbonyl-3-methylpyridine as a pale yellow liquid (630 mg, 57%). To a solution of 2-methoxycarbonyl-3-methylpyridine in anhydrous THF (10 mL) at 0 °C, add with stirring a solution of 1M lithium aluminum hydride in THF (5 mL, 5 mmol), and continue stirring for 30 min at 0 °C. Allow the mixture to warm to ambient temperature and quench cautiously with 0.5M aqueous NaOH. Heat the mixture at 60 °C for 40 min, cool to ambient temperature, extract with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:3) to give the desired intermediate (90 mg, 18%).


2-Chloromethyl-3-methylpyridine hydrochloride: To 2-hydroxymethyl-3-methylpyridine (90 mg, 0.73 mmol) in dry DCM (10 mL) at ambient temperature, add with stirring thionyl chloride (0.53 mL, 7.3 mmol). Continue stirring overnight, concentrate *in vacuo*, and azeotrope three times with chloroform. Triturate the residue with dry ether, filter, and dry under vacuum to obtain the title compound as a beige solid (130 mg, 100%).

Preparation 188

2-Chloromethyl-6-methylpyridine




Add with stirring a solution of thionyl chloride (0.77 mL, 10.6 mmol) in dry DCM (20 mL) to 2-hydroxymethyl-6-methylpyridine (1.0 g, 8.12 mmol) in dry DCM (20 mL) at 0 °C. Continue stirring at 0 °C for 1.25 h. Quench with isopropanol and concentrate *in vacuo*. Dissolve the residue in DCM, wash with saturated aqueous NaHCO₃, dry over anhydrous Na₂SO₄, and concentrate *in vacuo* to give the title compound. MS (ES+) *m/z* 142 (M+H)⁺.

Preparation 189**5-Butyl-2-chloromethylpyridine Hydrochloride**

5


Use a method similar to the Preparation 187, using fusaric acid, to give the title compound. MS (APCI+) m/z 184 (M+H)⁺.

Preparation 190**6-Bromomethylnicotinonitrile**

10

Use a method similar to the Preparation 184, using 5-cyano-2-methylpyridine, to give the title compound.


15

Preparation 191**5-Bromomethyl-pyridine-2-carbonitrile**

20

Use a method similar to the Preparation 184, using 5-methyl-picolinonitrile (*J. Chem. Soc.* 1962, 2637-2658), to give the title compound.


Preparation 192



Use the chlorination method described in Preparation 187, using 2-hydroxymethyl-3-trifluoromethylpyridine, to give the title compound. MS (APCI+) m/z 196 (M+H)⁺.

Preparation 193


2-Chloromethyl-3-methoxypyridine



- 2-Hydroxymethyl-3-methoxypyridine:** Heat a mixture of 3-hydroxypicolinic acid (5.3 g, 38 mmol), potassium carbonate (15.8 g, 114 mmol), and iodomethane (9.6 mL, 153 mmol) in acetone (100 mL) and DMF (10 mL) overnight at 60°C. Cool the reaction mixture to ambient temperature, pour into brine, extract three times with ethyl ether, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Pass through a short plug of silica gel eluting with ether to provide 3-methoxy-2-methoxycarbonylpyridine as a pale yellow liquid (6.3 g, 100%). To a solution of 3-methoxy-2-methoxycarbonylpyridine (2.34 g, 14.0 mmol) in dry THF (25 mL) add slowly with stirring a solution of 1M lithium aluminum hydride in THF (10 mL, 10 mmol) and continue stirring overnight at ambient temperature. Quench cautiously with sodium sulfate decahydrate, filter under suction and rinse the solids with additional THF. Concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (3:1) to provide the desired intermediate as a white solid (350 mg, 18%).


2-Chloromethyl-3-methoxypyridine: Use a method similar to the Preparation 188, using 2-hydroxymethyl-3-methoxypyridine, to give the title compound. MS (APCI+) m/z 158 (M+H)⁺.

5

Preparation 194**2-Chloromethyl-6-methoxypyridine Hydrochloride**

10 **2-Hydroxymethyl-6-methoxypyridine:** To 6-methoxy-pyridine-2-carbaldehyde (*J. Org. Chem.* 1990, 55, 69-73) (11.0 g, 80.3 mmol) in wet THF (200 mL) add portion wise with stirring sodium borohydride (3.0 g, 79mmol) and continue stirring for 1 h at ambient temperature. Add brine, extract the reacton mixture twice with EtOAc, dry the organic layer over anhydrous Na₂SO₄ and concentrate *in vacuo*. Pass the residue through a small
15 plug of silica gel eluting with hexane/EtOAc (3:1) to provide the desired intermediate as a clear liquid (9.0 g, 81%).

2-Chloromethyl-6-methoxypyridine hydrochloride: Use the chlorination method described in Preparation 187, using 2-hydroxymethyl-6-methoxypyridine, to give the title
20 compound as a pale yellow solid. MS (APCI+) m/z 158 (M+H)⁺.

Preparation 195**3-Bromomethyl-6-chloro-pyridazine**

25

Use a method similar to the Preparation 184, using 3-chloro-6-methylpyridazine, to give the title compound as a red-orange liquid that darkens on standing.

Preparation 196**(±)-2-(1-Chloroethyl)-3-cyanothiophene**

2-Acetyl-3-cyanothiophene: Heat a stirred solution of 2-acetyl-3-bromothiophene (1.49 g, 7.29 mmol) (*Chem. Pharm. Bull.* 2000, 48, 1558-1566) in dry NMP (72 mL) for 10 h at 150 °C in the presence of copper cyanide (3.26 g, 36.5 mmol). Dilute the mixture with water, extract three times with diethyl ether, dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1) to give the desired intermediate as a dark oil (1.1 g, 99%).


(±)-2-(1-Hydroxyethyl)-3-cyanothiophene: Use a method similar to the reduction procedure described in Preparation 194, using 2-acetyl-3-cyanothiophene, to give the desired intermediate as dark oil.

(±)-2-(1-Chloroethyl)-3-cyanothiophene: Use a method similar to the Preparation 188, using (±)-2-(1-hydroxyethyl)-3-cyanothiophene, to give the title compound as dark oil. Use the crude material without further purification.

Preparation 197**(±)-2-(1-Bromoethyl)-pyridine**

To (±)-2-(1-hydroxyethyl)-pyridine (*Bull. Chem. Soc. Jpn.* 1990, 63, 461-465) (10.0 g, 81.3 mmol) in DCM (120 mL) at 0° C, add with stirring triphenylphosphine (22.39 g, 85.365 mmol) followed by NBS (15.2 g, 85.4 mmol) in portions. Warm the reaction mixture to ambient temperature and continue stirring for 3 h. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (19:1) to give the title compound.

Preparation 198

(±)-2-(1-Chloroethyl)-6-methylpyridine Hydrochloride


5

(±)-2-(1-Hydroxyethyl)-6-methylpyridine: To 6-methylpyridine-2-carboxaldehyde (2.0 g, 16.5 mmol) in dry THF (55 mL) at 0 °C under nitrogen, add a solution of 3M methyl magnesium bromide in ether (6.0 mL, 18.0 mmol,) dropwise with stirring. After 1 h at 0°C, quench with saturated aqueous NH₄Cl, extract three times with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to give the desired intermediate (crude, 2.3 g).

(±)-2-(1-Chloroethyl)-6-methylpyridine hydrochloride: To the crude 2-(1-hydroxyethyl)-6-methylpyridine (1.6 g, 11.7 mmol) in dry DCM (15 mL) add with stirring thionyl chloride (2.0 mL, 27 mmol) and continue stirring overnight. Concentrate *in vacuo*, azeotrope three times with dry chloroform and dry under high vacuum to provide the title compound as a tan solid (1.9 g, 85%). MS (APCI+) *m/z* 156 (M+H)⁺.

20

Preparation 199

(R)-Methanesulfonic acid 1-(6-methyl-pyridin-2-yl)-ethyl ester


(±)-1-(6-Methyl-pyridin-2-yl)-ethanol: Use a method similar to the Preparation 198 (Step 1), using 6-methyl-2-pyridinecarboxaldehyde and methylmagnesium bromide, to give the desired intermediate.

25

- (R)-1-(6-Methyl-pyridin-2-yl)-ethanol:** Stir a mixture of 1-(6-methyl-pyridin-2-yl)-ethanol (2.9 g, 21 mmol), 4A molecular sieves powder (3 g), vinyl acetate (6 mL) and lipase *Candida Antarctica* acrylic resin (0.87 g) in *i*-Pr₂O (40 mL) at ambient temperature overnight (*J. Org. Chem.* 1998, 63, 2481-2487; *Synlett* 1999, 41-44). Remove the solid residue by filtration. Evaporate the volatile substances and purify by chromatography eluting with hexane/EtOAc (7:3 to 1:1) to give the faster eluting (*R*)-acetic acid 1-(6-methyl-pyridin-2-yl)-ethyl ester as colorless oil (1.9 g, 50%), and the slower eluting (*S*)-alcohol as light yellow oil (1.258 g, 43%). Dissolve (*R*)-acetic acid 1-(6-methyl-pyridin-2-yl)-ethyl ester (1.72 g, 9.62 mmol) in methanol (50 mL) and add potassium carbonate (5.3 g, 38.5 mmol) in water (10 mL). Stir the mixture at ambient temperature for 4 h. Dilute with brine, extract three times with EtOAc, dry over anhydrous Na₂SO₄, filter through a short pad of silica gel and concentrate *in vacuo* to give the desired intermediate as a colorless oil (1.17 g, 89%).
- (R)-Methanesulfonic acid 1-(6-methyl-pyridin-2-yl)-ethyl ester:** To a stirred solution of (*R*)-1-(6-methyl-pyridin-2-yl)-ethanol (175 mg, 1.28 mmol) and triethylamine (355 µl, 2.56 mmol) in DCM (5 mL) at 0°C add methanesulfonyl chloride (148 µl, 1.92 mmol). Stir at 0 °C for 30 min and quench the reaction mixture with saturated aqueous NaHCO₃ at the same temperature. Extract the mixture three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (8:2) to give the title compound as a colorless oil (274 mg, 100%).

Preparation 200

(±)-2-(1-Bromoethyl)-3-methyl-pyridine



- (±)-1-(3-Methyl-pyridin-2-yl)-ethanol:** Dissolve *N,N*-dimethylethanolamine (70.45 mmol) in hexane (90 mL) at 0°C, add 2.5M *n*-butyl lithium in hexane (140.9 mmol,) and stir for 30 min at this temperature. Add a solution of 3-picoline (35.23 mmol) in hexane


(10 mL) and continue stirring at 0° C for 1 h. Cool the resulting mixture to -78° C, add acetaldehyde (70.45 mmol) and continue stirring at -78° C for 1 h. Dilute with water, warm to ambient temperature, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography eluting with hexane/EtOAc (85:15) to give the desired intermediate as a light yellow oil.

(±)-2-(1-Bromoethyl)-3-methyl-pyridine: Use a method similar to the Preparation 197, using 1-(3-fluoro-pyridin-2-yl)-ethanol, to give the title compound.

10

Array-44


(±)-2-[1-Methanesulfonyloxy-(2,2,2-trifluoroethyl)]pyridine



(±)-2-[1-Hydroxy-(2,2,2-trifluoroethyl)]-pyridine: To a stirred solution of 2-pyridine carboxaldehyde (2.09 g, 19.5 mmol) and (trifluoromethyl)trimethylsilane (3.33 g, 23.4 mmol) in THF (30 mL) at 0° C add 1M tetrabutylammonium fluoride in THF (956 µl, 0.956 mmol). Continue stirring for 30 min at 0° C and then at ambient temperature for 2 h. Add 1M aqueous HCl (20 mL) and stir 2 h at ambient temperature. Dilute with aqueous 1M aqueous NaOH to pH 8, extract the mixture three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography eluting with hexane/EtOAc (8:2) to give the desired intermediate as a yellow oil (3.22 g, 93%).

(±)-2-[1-Methanesulfonyloxy-(2,2,2-trifluoroethyl)]pyridine: Use a method similar to the Preparation 199 (Step 3), using (±)-2-[1-hydroxy-(2,2,2-trifluoroethyl)]pyridine, to give the title compound.

Preparation 202 Array-45
(±)-2-(1-Bromopropyl)pyridine




5

(±)-1-Pyridin-2-yl-propan-1-ol: To a stirred solution of 2-pyridine carboxaldehyde (4.0 g, 37.34 mmol) in THF (50 mL) at 0° C, add 3M ethyl magnesium bromide in ether (18.7 mL, 56.0 mmol), continue stirring for 30 min at 0° C and then at ambient temperature for 2 h. Add water (200 mL), extract three times with EtOAc, dry over anhydrous Na₂SO₄,
10 filter through a short pad of silica gel and concentrate *in vacuo* to give the desired intermediate as a yellow oil (3.39 g, 66%).

(±)-2-(1-Bromopropyl)pyridine: Use a method similar to the Preparation 197, using 1-pyridin-2-yl-propan-1-ol, to give the title compound.

15

Preparation 203
(±)-1-Pyridazin-3-yl-ethanol



20

3-(1-Ethoxyvinyl)pyridazine: Heat pyridazine-3-chloride (WO 0107416) (2 g, 17.5 mmol) with tributyl-(1-ethoxyvinyl)tin (7.1 mL, 21.1 mmol) and dichlorobis(triphenylphosphine)palladium(II) (1.1 g, 1.6 mmol) in DMF (18 mL) at 110° C for 13 h. Cool the mixture, dilute with ether (175 mL) and add a solution of potassium fluoride (5.43 g, 94 mmol) in water (10 mL). After 1 h, filter the mixture
25 through Celite®, and wash the filtrate with brine. Dry the combined organic extracts over Na₂SO₄ and evaporate. Purify by chromatography on silica gel eluting with EtOAc:hexane (0:1 to 6:4) to obtain the desired intermediate (1.7 g, 65%). HPLC *t_R*=3.7


min (Zorbax Eclipse XBD-C8 4.6 x 150 mm 5 micron column, 1.5 mL/min of 90/10 to 10/90 0.1% TFA in water/acetonitrile over 10 min. Detector is at 230 and 254 nm.).

1-Pyridazin-3-yl-ethanone: Stir 3-(1-ethoxyvinyl)pyridazine (1.7 g, 11.3 mmol) in acetone (6.3 mL) and 2.5N aqueous HCl (3.1 mL) for 2 h at ambient temperature and evaporate. Dissolve the residue in DCM and wash the organic layer with saturated aqueous NaHCO₃, dry the organic layer over Na₂SO₄ and evaporate to obtain the desired intermediate (1.4 g, 99%). HPLC t_R =1.9 min (Zorbax Eclipse XBD-C8 4.6 x 150 mm 5 micron column, 1.5 mL/min of 90/10 to 10/90 0.1% TFA in water/acetonitrile over 10 min. Detector is at 230 and 254 nm.).

(±)-1-Pyridazin-3-yl-ethanol: To 1-pyridazin-3-yl-ethanone (1.4 g, 11.2 mmol) in methanol (112 mL) add sodium borohydride (0.85 g, 22.5 mmol) at 0 °C and stir for 1 h at ambient temperature. Evaporate the mixture and purify by chromatography on silica gel eluting with EtOAc:hexane (1:1 to 1:0) and methanol:EtOAc (0:1 to 1:9) to obtain the title compound (1.3 g, 93%).

Preparation 204

(R)-(-)-1-(2-Pyridinyl)ethanol methanesulfonate ester



(R)-1-(Pyridin-2-yl)-ethanol: Stir a mixture of (±)-1-(pyridin-2-yl)-ethanol (21.2 mmol), 4A molecular sieves powder (3 g), vinyl acetate (6 mL) and lipase Candida Antarctica acrylic resin (0.87 g) in *i*-Pr₂O (40 mL) at ambient temperature overnight (*J. Org. Chem.* 1998, 63, 2481-2487; *Synlett* 1999, 41-44). Remove the solid residue by filtration. Evaporate the volatile substances and purify by chromatography eluting with hexane/EtOAc (7:3 to 1:1) to give the faster eluting (*R*)-acetic acid 1-(pyridin-2-yl)-ethyl ester as colorless oil (50%) and the slower eluting (*S*)-alcohol as light yellow oil (43%). Dissolve (*R*)-acetic acid 1-(pyridin-2-yl)-ethyl ester (9.620 mmol) in methanol (50 mL)

and add potassium carbonate (38.48 mmol) in water (10 mL). Stir the mixture at ambient temperature for 4 h. Dilute with brine, extract three times with EtOAc, dry over anhydrous Na₂SO₄, filter through a short pad of silica gel and concentrate *in vacuo* to give the desired intermediate as a colorless oil (89%).

5


(R)-(-)-1-(2-Pyridinyl)ethanol methanesulfonate ester: To a stirred solution of (R)-1-(pyridin-2-yl)-ethanol (1.28 mmol) and triethylamine (2.56 mmol) in DCM (5 mL) at 0°C add methanesulfonyl chloride (1.92 mmol). Stir at 0°C for 30 min and quench the reaction mixture with saturated aqueous NaHCO₃ at the same temperature. Extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give the title compound as a colorless oil (100 %). MS (APCI+) *m/z* 202 (M+H)⁺; [α]_D²⁵ = -73.5° (c 1, CHCl₃).

10

Preparation 205

15

(±)-1-(4-Fluorophenyl)ethyl bromide



Method A: Add carbon tetrabromide (646 mg, 1.95 mmol) to a solution of triphenylphosphine (511 mg, 1.95 mmol) and (±)-4-fluoro-α-methylbenzyl alcohol (260 mg, 1.86 mol) in dry DMF (20 mL) at 0°C under nitrogen. Stir the reaction for 2 h to give the title compound. No further purification required.

20

Method B: Add HBr (460 μL of 48% w/w in water, 4.28 mmol) to a solution of (±)-4-fluoro-α-methylbenzyl alcohol (300 mg, 2.14 mmol) in dry DCM (10 mL) at ambient temperature under an atmosphere of nitrogen. Stir for 2.5 h. Reduce volume *in vacuo* to give the title compound. Dilute with DCM (1 mL) and use without further purification.

25


Preparation 206**(±)-2-(1-Bromoethyl)benzonitrile**

5

Use a method similar to the Preparation 184, using 2-ethylbenzonitrile, to give the title compound as a clear liquid.

Preparation 207**1-(4-Bromomethylphenyl)-3,3-dimethylbutan-1-one**

10



(±)-3,3-Dimethyl-1-*p*-tolylbutan-1-ol: To a stirred solution of 4-methylbenzaldehyde (1.51 g, 12.6 mmol) in THF (30 mL) at 0° C, add neopentyl magnesium chloride (33.0 mL, 16.34 mmol, 0.5-1M in ether) and continue stirring at 0 ° C for 1 h. Dilute with saturated aqueous NH₄Cl, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (95:5) to give the desired intermediate as a colorless oil (2.15 g, 89%).

20


3,3-Dimethyl-1-*p*-tolylbutan-1-one: To a stirred solution of (±)-3,3-dimethyl-1-*p*-tolylbutan-1-ol (2.15 g, 11.3 mmol) in hexane (30 mL) add manganese dioxide (2.94 g, 33.8 mmol) and heat the mixture overnight at 65° C. Cool to ambient temperature, filter the manganese salts, and concentrate *in vacuo* to give the desired intermediate as a colorless oil (2.2 g, 100%).

25

1-(4-Bromomethylphenyl)-3,3-dimethylbutan-1-one: Use a method similar to the Preparation 184, using 3,3-dimethyl-1-*p*-tolylbutan-1-one, to give the title compound.

Preparation 208

1-(4-Bromomethylphenoxy)-3,3-dimethylbutan-2-one



5

1-(4-Hydroxymethylphenoxy)-3,3-dimethylbutan-2-one: Mix potassium carbonate (2.764 g, 20 mmol), 4-hydroxy-benzyl alcohol (1.49 g, 12 mmol) in absolute ethanol (100 mL), add 1-bromopinacolone (1.791 g, 10 mmol) dropwise. Heat the mixture under reflux for 12 h. Add water to dissolve the solid, and remove most of the ethanol *in vacuo*.


10 Extract the mixture with EtOAc three times. Combine the organic layers, wash with brine, dry over Na₂SO₄, filter and concentrate. Purify the residue by chromatography on silica gel eluting with EtOAc:hexane (1:2) to provide the desired intermediate as a colorless oil (1.08 g, 48%). MS (ES+) *m/z*: 205 (M+H-H₂O)⁺.

15 **1-(4-Bromomethylphenoxy)-3,3-dimethylbutan-2-one:** Add phosphorous tribromide (1.45 g, 5.34 mmol) slowly to a solution of 1-(4-hydroxymethyl-phenoxy)-3,3-dimethylbutan-2-one (1.08 g, 4.85 mmol) in anhydrous THF under nitrogen at 0 °C. Stir at 0 °C for 1 h and then raise to ambient temperature. Stir overnight. Dilute with EtOAc, wash with saturated aqueous NaHCO₃, brine, dry over Na₂SO₄, filter and concentrate.

20 Purify the residue by chromatography on silica gel eluting with EtOAc:hexane (1:6) to provide the title compound (1.152 g, 83%). MS (ES+) *m/z*: 205 (M-Br)⁺.

Preparation 209

1-(4-Bromomethyl-3-chlorophenoxy)-3,3-dimethylbutan-2-one



5

3-Chloro-4-hydroxybenzyl alcohol: Add a solution of DIBAL-H in toluene (1.0 M, 35 mL) to a solution of methyl 3-chloro-4-hydroxybenzoate (1.9 g, 10 mmol) at 0 °C under nitrogen. Stir the reaction at 0 °C and gradually warm to ambient temperature overnight. Quench the reaction with slow addition of 0.1N aqueous HCl; add more acid to break the gel-like solid to two clear layers. Separate the organic layer, and extract the aqueous layer with EtOAc three times. Combine the organic layers, wash with brine, dry over Na₂SO₄, filter and concentrate to give a white solid. MS (ES-) *m/z* 157 (M-H)⁻.


10

1-(4-Bromomethyl-3-chlorophenoxy)-3,3-dimethylbutan-2-one: Use a method similar to the Preparation 208 to convert 3-chloro-4-hydroxy-benzyl alcohol to the title compound (1.144 g, 64% two steps). MS (ES+) *m/z* 319.0 (M+H)⁺.

15

Preparation 210

1-Bromomethyl-4-(2,2-dimethyl-propoxy)-benzene



20

1-(2,2-Dimethyl-propoxy)-4-methyl-benzene: To a solution of *p*-cresol (526 mg, 4.87 mmol) in THF (50 mL), add with stirring diisopropyl azodicarboxylate (2.16 mL, 10.7

mmol) followed by triphenylphosphine (306 mg, 11.7 mmol) and neopentyl alcohol (5.15 g, 58.4 mmol). Heat at 60 °C for 3 h, cool to ambient temperature and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc to give the desired intermediate as a colorless oil.


5

1-Bromomethyl-4-(2,2-dimethyl-propoxy)-benzene: Use a method similar to the Preparation 184, using 1-(2,2-dimethyl-propoxy)-4-methylbenzene, to give the title compound.

10

Preparation 211

1-Bromomethyl-2-methanesulfonylbenzene




15 **(2-Methanesulfonylphenyl)methanol:** To a stirred solution of 2-methanesulfonylbenzoic acid (2.7 g, 13.5 mmol) in dry THF (60 mL) at 0 °C, add a solution of borane in THF (27.0 mL, 0.5 M, 13.5 mmol). Allow the mixture to warm to ambient temperature and continue stirring for 2 days. Quench the excess borane by slow addition of methanol, add brine, extract three times with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to provide the crude desired intermediate as a clear, thick oil (2.4 g, 97 %).

20 **1-Bromomethyl-2-methanesulfonylbenzene:** To a stirred solution of (2-methanesulfonyl-phenyl)methanol (735 mg, 3.99 mmol) in dry DCM (2 mL) at 0 °C, add a solution of 1M phosphorous tribromide in DCM (6.0 mL, 6.0 mmol) and continue stirring for 1 h. Dilute with saturated aqueous NaHCO₃, extract three times with ethyl ether, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (12:1) to provide the title compound as a white solid (950 mg, 97 %).

Preparation 212

1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene



- 5 **Methanesulfonic acid 3,3,3-trifluoro-2-methyl-2-trifluoromethyl-propyl ester:** To 2,2-bis(trifluoromethyl)propanol (4.34 g, 22.1 mmol) in DCM (100 mL) at 0 °C add with stirring triethylamine (6.2 mL, 44 mmol) followed by methanesulfonyl chloride (2.6 mL, 33 mmol). After 15 min at 0 °C dilute with water and extract three times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to give the crude desired
- 10 intermediate as a yellow oil (6.16 g, 100 %).


- 1-Methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene:** In a sealed tube dissolve 4-methylbenzenethiol (4.13 g, 33.2 mmol) in DMF (20 mL) at ambient temperature. Add portionwise with stirring sodium hydride (899 mg, 37.5 mmol)
- 15 followed by tetrabutylammonium iodide (82 mg, 0.22 mmol) and a solution of methanesulfonic acid 3,3,3-trifluoro-2-methyl-2-trifluoromethylpropyl ester (6.16 g, 22.5 mmol) in DMF (10 mL). Stir at 150 °C overnight, cool the mixture to ambient temperature and dilute cautiously with water. Extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel
- 20 eluting with hexane to give the desired intermediate as a yellow oil (4.5 g, 62 %).

1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene:

Use a method similar to the Preparation 184, using 1-methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene, to give the title compound.

Preparation 213

1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfinyl)-benzene



5

1-Methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfinyl)-benzene:

To 1-methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene (4.5 g, 14.9 mmol) in acetic acid (15 mL) at ambient temperature, add with stirring aqueous hydrogen peroxide (15 mL, 30% in water) and stir for 1 h. Dilute the reaction with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the desired intermediate as a colorless oil (4.125 g, 88 %).

10

1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfinyl)-


benzene: To 1-methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfinyl)-benzene (4.13 g, 13.0 mmol) in carbon tetrachloride (50 mL) add NBS (2.31 g, 13.0 mmol), benzoyl peroxide (314 mg, 1.30 mmol) and stir overnight at reflux. Cool to ambient temperature, dilute with water and extract three times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the title compound as colorless oil (2.3 g, 55 %).

20

Preparation 214

1-Bromomethyl-4-(2,2-dimethylpropane-1-sulfonyl)benzene

25




1-(2,2-Dimethyl-propane-1-sulfonyl)-4-methyl-benzene: In a sealed tube, dissolve *p*-toluenesulfinic acid sodium salt (5.71 g, 32.1 mmol) in DMF (20 mL) and water (10 mL). Add *neo*-pentyl bromide (6.3 mL, 48 mmol) and tetrabutylammonium iodide (592 mg, 1.60 mmol) and heat the mixture at 145 °C overnight. Cool the reaction to ambient temperature, dilute with water and extract 3 times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the desired intermediate as a colorless oil (3.3 g, 45 %).

1-Bromomethyl-4-(2,2-dimethylpropane-1-sulfonyl)benzene: Use a method similar to the Preparation 213 (Step 2), using 1-(2,2-dimethylpropane-1-sulfonyl)-4-methylbenzene, to give the title compound.

Preparation 215


1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfonyl)-benzene



1-Methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfonyl)benzene:

To 1-methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)benzene (3.47 g, 11.49 mmol) in trifluoroacetic acid (15 mL) at ambient temperature add with stirring aqueous hydrogen peroxide (15 mL, 30% in water) and stir for 1 h. After removing trifluoroacetic acid *in vacuo*, dilute with saturated aqueous NaHCO₃. Extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the desired intermediate as a colorless oil (2.8 g, 74 %).

1-Bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfonyl)-benzene: Use a method similar to the Preparation 213 (Step 2), using 1-methyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfonyl)benzene, to give the title compound.

Preparation 216**1-Bromomethyl-4-(4'-trifluoromethyl)-phenylsulfonylbenzene**


5

1-Methyl-4-(4-trifluoromethyl)-phenylthio-benzene: Heat a mixture of 4-methylbenzenethiol (7.67 g, 61.8 mmol), 1-bromo-4-trifluoromethyl-benzene (4.63 g, 20.6 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione (379 mg, 2.06 mmol), cesium carbonate (20.1 g, 61.8 mmol) and CuCl (102 mg, 1.03 mmol) in NMP (30 mL) at 150° C for 3 h. Cool the mixture to ambient temperature, dilute with water, extract three times with EtOAc, dry the organic layer over anhydrous Na₂SO₄, and concentrate *in vacuo*. Recrystallize the residue from hexane/EtOAc to give the desired intermediate as a white solid (3.87 g, 70%).

1-Bromomethyl-4-(4-trifluoromethyl)-phenylsulfonyl-benzene: Use a method similar to the Preparation 215, using 1-methyl-4-(4-trifluoromethyl)-phenylthiobenzene, to give the title compound.

Preparation 217**1-(4-Bromomethylbenzenesulfonylmethyl)-2,4-difluorobenzene**


20



Use a method similar to the Preparation 214, using 2,4-difluorobenzyl bromide, to give the title compound.

Preparation 218


1-Bromomethyl-4-cyclohexylmethanesulfonyl-benzene



Use a method similar to the Preparation 214, using cyclohexylmethyl bromide, to give the title compound.

Preparation 219

Methyl 4-bromomethyl-2-fluorobenzoate




Methyl 2-fluoro-4-methyl-benzoate: Mix 1-bromo-2-fluoro-4-methylbenzene (15 g, 79.4 mmol), palladium acetate (712 mg, 3.17 mmol), 1,3-bis(diphenylphosphino)-propane (2.94 g, 7.14 mmol), triethylamine (16.1 g, 159 mmol) in methanol (150 mL) and DMF (100 mL). Degas the mixture under vacuo and pressurize to 65 psi with carbon monoxide. Stir the reaction at 110 °C for 2 days. Remove methanol *in vacuo*, dilute the mixture with water, and extract three times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give the desired intermediate as a white solid (7.40 g, 55%).

Methyl 4-bromomethyl-2-fluoro-benzoate: Use a method similar to the Preparation 184, using methyl 2-fluoro-4-methylbenzoate, to give the title compound as a white solid.


Preparation 220

4-Chloromethyl-*N*-cyclohexylbenzamide
















To 4-chloromethylbenzoyl chloride (1.03 g, 5.47 mmol) in DCM (20 mL) at 0 °C, add with stirring triethylamine (0.839 mL, 6.02 mmol) followed by cyclohexylamine (0.688 mL, 6.02 mmol), and continue stirring for 15 min. Dilute the reaction mixture with aqueous 1M hydrochloric acid, extract three times with EtOAc, wash with water and saturated aqueous NaHCO₃. Dry the combined organic extracts over anhydrous Na₂SO₄ and concentrate *in vacuo* to give the title compound as a white solid (1.31 g, 95%).

The compounds of Preparations 221-235 may be prepared essentially as described in Preparation 220 by using 4-chloromethylbenzoyl chloride and the appropriate amine.



Prep.	NH-R	Compound
221		4-Chloromethyl- <i>N</i> -(2,2-dimethylpropyl)-benzamide
222		<i>N</i> -tert-Butyl-4-chloromethylbenzamide


Prep.	NH-R	Compound
223		4-Chloromethyl- <i>N</i> -cyclohexylmethyl-benzamide
224		4-Chloromethyl- <i>N</i> -(4-trifluoromethyl-benzyl)-benzamide
225		4-Chloromethyl- <i>N</i> -(2,3,4-trifluoro-benzyl)-benzamide
226		4-Chloromethyl- <i>N</i> -(3,4-difluoro-benzyl)-benzamide
227		4-Chloromethyl- <i>N</i> -(2-fluoro-4-trifluoromethyl-benzyl)-benzamide
228		<i>N</i> -(3,5-Bis-trifluoromethyl-benzyl)-4-chloromethyl-benzamide
229		4-Chloromethyl- <i>N</i> -(4-fluoro-2-trifluoromethyl-benzyl)-benzamide
230		(<i>S</i>)-4-Chloromethyl- <i>N</i> -(1-cyclohexyl-ethyl)-benzamide
231		(<i>R</i>)-4-Chloromethyl- <i>N</i> -(1-cyclohexyl-ethyl)-benzamide
232		(<i>S</i>)-4-Chloromethyl- <i>N</i> -[1-(4-fluoro-phenyl)-ethyl]-benzamide

Prep.	NH-R	Compound
233		(R)-4-Chloromethyl-N-[1-(4-fluorophenyl)-ethyl]-benzamide
234		(S)-4-Chloromethyl-N-[1-(4-chlorophenyl)-ethyl]-benzamide
235		(R)-4-Chloromethyl-N-[1-(4-chlorophenyl)-ethyl]-benzamide

Preparation 236

2-(2-Iodoethoxy)propane

5




Methanesulfonic acid 2-isopropoxyethyl ester: To a stirred solution of 2-isopropoxyethanol (2.0 mL, 17.37 mmol) in DCM (100 mL) at ambient temperature add methanesulfonyl chloride (1.48 mL, 18.08 mmol). Add triethylamine (2.70 mL, 19.37 mmol) slowly followed by DMAP (catalytic). Continue stirring overnight and concentrate *in vacuo*. Add diethyl ether and filter. Wash the filtrate with aqueous 1N aqueous HCl, brine, and saturated aqueous NaHCO₃. Dry over anhydrous MgSO₄ and concentrate *in vacuo* to give the desired intermediate (2.97 g, 94%).


15

2-(2-Iodoethoxy)propane: To a stirred solution of methanesulfonic acid 2-isopropoxyethyl ester (2.95 g, 16.2 mmol) in acetone (200 mL) at ambient temperature add sodium iodide (7.28 g, 19.4 mmol) and continue stirring overnight. Concentrate *in vacuo*, add diethyl ether and filter, and concentrate *in vacuo* to give the title compound as a pale yellow liquid (3.12 g, 90%).


20

Preparation 237**(*R*)-Toluene-4-sulfonic Acid Tetrahydrofuran-3-yl Ester**

5 To (*R*)-tetrahydro-furan-3-ol (2.0 g, 22.7 mmol), triethylamine (3.8 mL, 27.3 mmol), DMAP (277 mg, 2.26 mmol), and silver oxide (5.26 g, 22.7 mmol) in dry DCM (30 mL) at 0 °C under nitrogen, add portion wise with stirring *p*-toluenesulfonyl chloride (4.76 g, 25.0 mmol). Warm to ambient temperature overnight, filter from silver salts, and
10 concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:1) to give the title compound as a clear liquid (4.7 g, 85%).


Preparation 238**(*S*)-Toluene-4-sulfonic Acid Tetrahydrofuran-3-yl Ester**

15 Use a method similar to the Preparation 237, using (*S*)-tetrahydro-furan-3-ol, to give the title compound as a clear liquid.

Preparation 239**2-(2-Bromoethyl)-pyridine Hydrobromide**

25 Use a method similar to the bromination procedure described in Preparation 186 (Step 2), using 2-pyridineethanol, to give the title compound. Recrystallize from 2-propanol to give a light brown solid.

Preparation 240


5-(3-Bromopropyl)-3-*tert*-butyl-[1,2,4]oxadiazole

4-Bromobutyric acid vinyl ester: To 4-bromobutyric acid (1.0 g, 6.0 mmol) in vinyl acetate (54 mL) add with stirring palladium(II) acetate (188 mg, 0.84 mmol) and continue stirring overnight at ambient temperature. Filter and concentrate *in vacuo* to provide the crude desired intermediate.

5-(3-Bromopropyl)-3-*tert*-butyl-[1,2,4]oxadiazole: Use a method similar to the Preparation 178, using 4-bromobutyric acid vinyl ester, to give the title compound.

Preparation 241

1-Bromomethyl-2-fluoro-4-phenoxybenzene



2-(4-Bromo-2-fluoro-benzyloxy)-tetrahydro-pyran: Mix under nitrogen atmosphere 4-bromo-2-fluorobenzyl alcohol, (4.1 g, 20 mmol), dihydropyran (2 g, 24 mmol), *p*-toluenesulfonic acid monohydrate (100 mg, 0.52 mmol), and anhydrous DCM (70 mL). Stir for 16 h at ambient temperature. Dilute with DCM, wash sequentially with saturated aqueous NaHCO_3 then brine. Separate the organic layer, dry over Na_2SO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 9:1) to obtain the desired intermediate as a clear oil (4.36 g, 75%). MS (ES+) m/z : 312 ($\text{M}+\text{Na}$)⁺.


2-(2-Fluoro-4-phenoxy-benzyloxy)-tetrahydro-pyran: Mix under argon atmosphere 2-(4-bromo-2-fluorobenzyloxy)-tetrahydropyran (2.9 g, 10 mmol), phenol (1.9 g, 20 mmol),
5 2,2,6,6-tetramethylheptane-3,5-dione (184.3 mg, 1.0 mmol), cesium carbonate (6.5 g, 20 mmol) and anhydrous NMP (20 mL). Degas the flask and fill with argon. Add copper(I) chloride (495 mg, 5 mmol) quickly. Degas the flask three times then fill with argon. Heat at 120 °C for 3 h. Cool to ambient temperature. Dilute with EtOAc and filter. Concentrate *in vacuo* and purify by chromatography on silica gel to obtain the desired
10 intermediate (2.05 g, 68%). MS (ES+) *m/z*: 325 (M+Na)⁺.

(2-Fluoro-4-phenoxy-phenyl)-methanol: Mix under nitrogen atmosphere 2-(2-fluoro-4-phenoxy-benzyloxy)-tetrahydro-pyran (2.05g, 6.8 mmol), methanol (60 mL) and *p*-toluenesulfonic acid monohydrate (260 mg, 1.35 mmol). Stir at ambient temperature for
15 16 h. Dilute with EtOAc. Wash with saturated aqueous NaHCO₃. Separate the organic layer, dry over Na₂SO₄ and concentrate *in vacuo* to give the desired intermediate (1.41 g, 95%). MS (ES+) *m/z*: 201 (M-OH)⁺.

1-Bromomethyl-2-fluoro-4-phenoxy-benzene: Dissolve under nitrogen atmosphere (2-fluoro-4-phenoxyphenyl)-methanol (1.41 g, 6.5 mmol) in anhydrous THF (60 mL). Cool to 0 °C in an ice bath. Add phosphorous tribromide (2.11 g, 7.8 mmol). Stir at cold for 1 h, then remove the ice bath and stir at ambient temperature for 16 h. Quench the reaction with saturated aqueous NaHCO₃. Extract aqueous phase three times with EtOAc. Combine organic fractions, wash with brine, dry over Na₂SO₄ and concentrate *in vacuo*.
20 Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1). Evaporate the solvent to obtain the title compound (1.31 g, 72%).
25

Preparation 242

3-*tert*-Butoxycarbonyl-7-chloro-6-(4-hydroxymethyl-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



5

3-*tert*-Butoxycarbonyl-6-(4-carboxy-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:

To a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 g, 2.6 mmol) in methanol (15 mL) under nitrogen, add with stirring potassium hydroxide (4.5 g, 80.3 mmol) at ambient temperature. Heat at 55-60°C for 2 h, cool to ambient temperature, and add methyl 4-bromomethylbenzoate (1.2 g, 5.2 mmol). TLC after 20 min shows formation of product; however, after 4 h at ambient temperature both TLC and LC/MS indicate complete hydrolysis of the ester and the carbamate. Dilute with saturated aqueous NH₄Cl, extract three times with EtOAc, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Dissolve the crude material in THF (10 mL), treat with di-*tert*-butyl-dicarbonate (2 equiv) and saturated aqueous NaHCO₃ (10 mL), and stir overnight. Extract three times with EtOAc, dry over anhydrous MgSO₄ and concentrate *in vacuo* to give the desired intermediate as an oil that was used without purification [2.32 g, 50% purity with (Boc)₂O]. MS (ES+) *m/z* 348 (M+H-Boc)⁺.

20

3-*tert*-Butoxycarbonyl-7-chloro-6-(4-hydroxymethyl-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:

To a solution of 3-*tert*-butoxycarbonyl-6-(4-carboxybenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.85 g, 50% purity, 2.06 mmol) in anhydrous THF (40 mL) under nitrogen, add with stirring 1M borane in THF (4.2 mL) at 0 °C. Warm to ambient temperature and stir 2-3 h. Quench by the careful addition of water (3 mL), dilute with saturated aqueous NaHCO₃, extract three times with ethyl ether,


25

dry over anhydrous MgSO_4 , and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (5:1) to provide the title compound as a white solid (485 mg, 54 %).

5

Preparation 243

3-*tert*-Butoxycarbonyl-7-chloro-6-(4-methanesulfonylmethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



10

3-*tert*-Butoxycarbonyl-7-chloro-6-(4-methanesulfonyloxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: To a stirred solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(4-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (170 mg, 0.391 mmol) in anhydrous DCM under nitrogen, add methanesulfonyl chloride (33 μL , 0.426 mmol) and triethylamine (61 μL , 0.44 mmol) and continue stirring for 2 h. Dilute with water (5 mL) and extract three times with DCM. Wash the combined organic extracts with brine, dry over anhydrous Na_2SO_4 , and concentrate *in vacuo* to obtain the desired intermediate that was used without purification.

15

20

3-*tert*-Butoxycarbonyl-6-(4-bromomethylbenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Dissolve the crude 3-*tert*-butoxycarbonyl-7-chloro-6-(4-methanesulfonyloxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in anhydrous acetone (3 mL), treat with anhydrous lithium bromide (335 mg, 3.89 mmol) and continue stirring overnight. Add water, extract the reaction mixture three times with ethyl ether, wash with brine, dry over anhydrous MgSO_4 , and concentrate *in vacuo* to obtain the desired intermediate that was used without purification.

25


3-tert-Butoxycarbonyl-7-chloro-6-(4-methanesulfonylmethyl-benzylthio)-2,3,4,5-

tetrahydro-1H-benzo[d]azepine: To the crude 3-tert-butoxycarbonyl-6-(4-bromomethyl-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine in anhydrous DMF (1 mL) under nitrogen, add with stirring sodium methanesulfinate (400 mg, 3.9 mmol), and
5 continue stirring for 30 min at ambient temperature followed by 2 h at 40 °C. Add water, extract three times with EtOAc, wash with brine, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (3:1) to give a clear oil that solidifies on standing to a white solid (118 mg, 61%).

10

Preparation 244

6-(4-Bromo-3-fluorobenzylthio)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine



15 **1-Bromo-4-bromomethyl-2-fluorobenzene:** Use a method similar to the Preparation 184, using 4-bromo-3-fluorotoluene, to give the desired intermediate as a white solid.


6-(4-Bromo-3-fluorobenzylthio)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-

1H-benzo[d]azepine: Use a method similar to the Preparation 177, using 3-tert-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 1-bromo-4-bromomethyl-2-fluorobenzene, to give the title compound as a white solid.

20

Preparation 245

(±)-3-*tert*-Butoxycarbonyl-7-chloro-6-(1-methoxycarbonyl-1-phenyl-methylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



5

(±)-3-*tert*-Butoxycarbonyl-6-(1-carboxy-1-phenyl-methylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:


To a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.23 g, 3.2 mmol) in methanol (20 mL) under nitrogen, add with stirring potassium hydroxide (5.36 g, 95.5 mmol) at ambient temperature. Heat at 55-60 °C for 2 h, cool to ambient temperature, and add methyl α-bromophenylacetate (600 μL, 3.81 mmol). After 30 min, dilute with saturated aqueous NH₄Cl, extract three times with EtOAc, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Dissolve the crude material in THF (10 mL), treat with di-*tert*-butyl-dicarbonate (2 equiv) and saturated aqueous NaHCO₃ (10 mL), and stir overnight. Extract three times with EtOAc, dry over anhydrous MgSO₄ and concentrate *in vacuo* to give the desired intermediate as an oil that is used without purification (1.1 g, 77%).

(±)-3-*tert*-Butoxycarbonyl-6-(1-methoxycarbonyl-1-phenyl-methylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Treat a solution of 3-*tert*-butoxycarbonyl-6-(1-carboxy-1-phenyl-methylthio)-7-chloro-2,3,4,5-tetrahydrobenzo[*d*]azepine (200 mg, 0.447 mmol) in anhydrous DMF (2 mL) with methyl iodide (317 mg, 2.237 mmol) and potassium carbonate (310 mg, 2.237 mmol) for 1.5 h at ambient temperature. Add water and extract the aqueous phase three times with EtOAc. Dry the organic phase over MgSO₄ and concentrate to obtain the title compound that was used without purification.

25

Preparation 246

6-(3-Bromo-4-chloro-benzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



5

2-Bromo-4-bromomethyl-1-chloro-benzene: Use a method similar to the Preparation 184, using 3-bromo-4-chlorotoluene, to give the desired intermediate.


6-(3-Bromo-4-chloro-benzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-

1*H*-benzo[*d*]azepine: Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylsulfanyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-bromo-4-bromomethyl-1-chloro-benzene, to give the title compound.

15

Preparation 247

3-*tert*-Butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine



20

3-tert-Butoxycarbonyl-7-chloro-6-(5-methoxycarbonyl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine:


Dissolve 3-tert-butoxycarbonyl-6-(5-bromopyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (2.13 g, 4.40 mmol), palladium acetate (35 mg, 0.156 mmol), 1,1'-bis(diphenylphosphino)ferrocene (150 mg, 0.271 mmol) and triethylamine (1.30 mL) in methanol (10 mL) and DMF (5 mL). Degas and then heat under a balloon filled with carbon monoxide at 75 °C for 10 h. Remove methanol *in vacuo*, and dilute the mixture with water. Extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrated *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (7:1) to give the desired intermediate as a clear oil (1.86 g, 91%). MS (APCI+) *m/z* 463 (M+H)⁺, 363 (M+H-Boc)⁺.

3-tert-Butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

Dissolve 3-tert-butoxycarbonyl-7-chloro-6-(5-methoxycarbonyl-pyridin-2-ylmethylthio)-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.86 g, 4.03 mmol) in methanol (25 mL). Add 1M aqueous lithium hydroxide (12 mL) and stir at ambient temperature overnight. Remove methanol *in vacuo*, and dilute the mixture with cold 0.5M aqueous HCl to pH 4. Add brine and extract three times with EtOAc. Dry over anhydrous Na₂SO₄, and concentrate *in vacuo* to give the title compound as an off-white solid (1.78 g, 95%). MS (APCI+) *m/z* 449 (M+H)⁺, 349 (M+H-Boc)⁺.

Preparation 248

6-(4-Bromo-thiophen-2-ylmethylthio)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine




3-Bromo-5-bromomethyl-thiophene: Use the bromination procedure described in Preparation 211 (Step 2), using (3-bromothiophen-2-yl)methanol (*Synthesis* 1983, 1, 73-75), to give the desired intermediate as a light brown liquid.

- 5 **6-(4-Bromo-thiophen-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine:** Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-bromo-5-bromomethyl-thiophene, to give the title compound as a gum.

10

Example 315

7-Chloro-6-(2-isopropoxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



15


- To a 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.52 mmol) in methanol (5 mL) under nitrogen, add potassium hydroxide (0.9 g, 16.1 mmol) at ambient temperature. When the mixture becomes homogenous, heat at 55-60 °C for 2-3 h, until TLC shows the disappearance of starting material. Cool to ambient temperature, add aqueous saturated ammonium chloride, extract three times with diethyl ether, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Dissolve the crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in anhydrous THF (5 mL) under nitrogen and add with stirring 1.0 M potassium *t*-butoxide in THF (1.0 mL) at ambient temperature. After 10 min, add 2-(2-iodoethoxy)propane (223 mg, 1.04 mmol), and allow the reaction to continue overnight. Dilute with aqueous saturated ammonium chloride, extract the mixture three times with diethyl ether, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with
- 20
- 25
- 30

hexane/EtOAc (12:1) to provide 3-*tert*-butoxycarbonyl-7-chloro-6-(2-isopropoxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a clear oil (127 mg, 63 %). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 300 (M+H)⁺.

5

Example 316

(±)-7-Chloro-6-(1-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



10


Use a method similar to the General Procedure 7, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (±)-2-(1-bromoethyl)-pyridine to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as a white solid. MS (APCI+) *m/z*: 319 (M+H)⁺.

15

Example 317

(-)-7-Chloro-6-(1-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate.

20




Separate the enantiomers of (\pm)-7-chloro-6-(1-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine by chiral normal phase chromatography (Chiralpak AD 8x30 cm column, eluting with 0.2% DMEA in methanol). Take the second eluting isomer and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (100:1 to 80:20).

Use the General Procedure 2-1 to give the title compound as a white solid (4.27 g, 33%). MS (ES+) *m/z*: 319 (M+H)⁺; ee = 99.4%; [α]_D²⁰ -179° (c 0.5, CH₃OH).

Example 318


(-)-7-Chloro-6-(1-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the General Procedure 7, except that the alkylation is conducted at 0° C, to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with (*R*)-(-)-1-(2-pyridinyl)ethanol methanesulfonate ester. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (APCI+) *m/z*: 319 (M+H)⁺; ee = 98.6% [Chiral HPLC: Chiralpak AD-H 0.46x15 cm column, eluting with 15:85 ethanol/heptane].

Example 319


(\pm)-7-Chloro-6-[1-(6-methylpyridin-2-yl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 315, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (±)-2-(1-chloroethyl)-6-methylpyridine hydrochloride to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as a tan solid. MS (ES+) *m/z*: 333 (M+H)⁺.

Example 320 :


7-Chloro-6-[1-(6-methylpyridin-2-yl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride, Isomer 1



Use a method similar to the Preparation 177, except that the alkylation is conducted at 0° C, to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with (*R*)-methanesulfonic acid 1-(6-methylpyridin-2-yl)-ethyl ester. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 333 (M+H)⁺; ee >97%, *t_R* = 6.53 min. (Chiral HPLC: Chiralpak OJ 120Å 4.6x250 mm, 45 °C; eluent: 20% isopropanol with 0.05% triethylamine in SFC, flow rate 2 mL/min, UV detector at 234 nm).

Example 321

(±)-7-Chloro-6-[1-(3-methylpyridin-2-yl)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



5


Use a method similar to the Preparation 177 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine with (±)-2-(1-bromoethyl)-3-methyl-pyridine. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 333 (M+H)⁺.

10

Example 322

(-)-7-Chloro-6-[1-(3-methylpyridin-2-yl)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

15




Separate the enantiomers of (±)-7-chloro-[1-(3-methyl-pyridin-2-yl)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine by chiral normal phase chromatography (Chiralpak AD 8x30 cm column, eluting with 85:15 heptane:0.2% DMEA in ethanol). Take the second eluting isomer and purify by SCX column chromatography.

20

Use the General Procedure 2-2 to give the title compound as a white solid (60 mg, 43%). MS (ES+) m/z : 333 (M+H)⁺; $[\alpha]_D^{20}$ -232° (c 0.5, CH₃OH).

Example 323

5 (±)-7-Chloro-6-(2,2,2-trifluoro-1-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




10 Use a method similar to the Preparation 177 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine with (±)-2-[1-methanesulfonyloxy-(2,2,2-trifluoroethyl)]-pyridine. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) m/z : 373 (M+H)⁺.

15

Example 324

(±)-7-Chloro-6-(1-pyridin-2-yl-propylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



20


Use method similar to the Preparation 177 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine with (±)-2-(1-

bromopropyl)pyridine. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) m/z : 333 (M+H)⁺.

5

Example 325

(±)-7-Chloro-6-[1-(pyridazin-3-yl)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Oxalate



10

Dissolve (±)-1-pyridazin-3-yl-ethanol (38 mg, 0.31 mmol) in thionyl chloride (0.14 mL) at 0°C and stir for 1 h at ambient temperature. Evaporate the mixture, add toluene and evaporate again. Treat this residue with the thiolate prepared from 7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine-3-carboxylic acid *tert*-butyl ether (0.1 g, 0.25 mmol) according to the General Procedure 7 in the presence of potassium carbonate (0.3 g, 2.25 mmol) in DMF (3 mL) at 80°C for 16 h.


15

Use a method similar to the General Procedure 1-5, basic work-up, and a method similar to the General Procedure 2-5 to give the title compound (38 mg, 37%). HRMS calcd for C₁₆H₁₉ClN₃S 320.0988, found 320.0970.

20

Example 326

(+)-7-Chloro-6-[1-(pyridazin-3-yl)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Oxalate




25

Dissolve (\pm)-1-pyridazin-3-yl-ethanol (0.29 g, 2.35 mmol) in thionyl chloride (1.0 mL) at 0°C and stir for 1 h at ambient temperature. Evaporate the mixture, add toluene and evaporate again. Treat this residue with the thiolate prepared from 7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ether (0.72 g, 1.88 mmol) according to the General Procedure 7 in the presence of potassium carbonate (2.60 g, 18.8 mmol) and tetrabutylammonium iodide (7 mg, 0.02 mmol) in DMF (20 mL) at 80 °C for 28 h. Separate the enantiomers by preparative HPLC (Waters Symmetry C18 4.6 x 150 mm 3.5 micron column, 1 mL/min of 90:10 to 50:50:0.1% TFA in water:ACN over 25 min. Detector is at 254 nm) to obtain 3-*tert*-butoxycarbonyl-7-chloro-6-[1-(pyridazin-3-yl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, isomer 1.

Use a method similar to the General Procedure 1-5, basic work-up, and a method similar to the General Procedure 2-5 to give the title compound (56 mg, 7%). HPLC t_R = 3.0 min (Chiralpak AD-H 4.6x150 mm, 3 micron column, 1.0 mL/min of 99.8:0.2 methanol/dimethylethylamine isocratic; detector at 225 nm); HRMS calc'd for $C_{16}H_{19}ClN_3S$ 320.0988, found 320.1001. $[\alpha]_D^{20}$ +160° (c 0.5, CH_3OH).

Example 327

7-Chloro-6-(pyridazin-3-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



React 3-chloromethyl-pyridazine (prepared as described in WO 99/54333, WO 98/49166) (1.8 g, 11.0 mmol) with 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (2.2 g, 5.7 mmol)


according to the General Procedure 7 in the presence of tetrabutylammonium iodide (0.1 g, 0.27 mmol) at ambient temperature for 3 h.

5 Use a method similar to the General Procedure 1-4 to give the title compound as a tan powder (1.9 g, 98 %): HRMS calcd for $C_{15}H_{16}ClN_3S$ 306.0832, found 306.0829.

Example 328

7-Chloro-6-(6-chloro-pyridazin-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

10




15

Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-bromomethyl-6-chloropyridazine to give 3-*tert*-butoxycarbonyl-7-chloro-6-(6-chloro-pyridazin-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Use a method similar to the General Procedure 1-4 to give the title compound as an off-white powder. MS (APCI+) m/z : 340 ($M+H$)⁺.

Example 329


20 7-Chloro-6-[6-(2,2-dimethylpropoxy)-pyridazin-3-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



To a stirred solution of neopentyl alcohol (105 mg, 1.19 mmol) in THF (5 mL) at ambient temperature add sodium hydride (31 mg, 95%, 1.19 mmol) and continue stirring for 3 h at ambient temperature. Add a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(6-chloro-pyridazin-3-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (315 mg, 0.59 mmol) in THF (1 mL) and continue stirring overnight at ambient temperature and then at 60°C for 1 h. Dilute with water, extract the reaction mixture three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (6:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[6-(2,2-dimethyl-propoxy)-pyridazin-3-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a clear oil (81 mg, 28%). MS (APCI+) *m/z*: 492 (M+H)⁺, 392 (M+H-Boc)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a white powder. MS (APCI+) *m/z*: 392 (M+H)⁺, *m/z*: 322 (M+H-C₅H₁₁)⁺.

Example 330

7-Chloro-6-(thiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




To a 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[*d*]azepine (108 mg, 0.281 mmol) in methanol (3 ml), add potassium hydroxide pellets (504 mg, 9.0 mmol) and heat the mixture 2 h at 50 °C. Cool the reaction to ambient temperature, add 2-chloromethylthiophene (186 μ L, 1.406 mmol), and continue stirring for 30 min. Dilute

with EtOAc and water. Separate the layers and extract the aqueous layer three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (19:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(thiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-benzo[*d*]azepine as a colorless oil (36 mg, 31%).

Use a method similar to the General Procedure 1-5, using 3-*tert*-butoxycarbonyl-7-chloro-6-(thiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-benzo[*d*]azepine to give, after basic workup and a method similar to the General Procedure 2-2, the title compound as a white solid. MS (ES+) *m/z*: 310 (M+H)⁺.

Example 331


(±)-7-Chloro-6-(3-cyanothiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Trifluoroacetate



Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (±)-2-(1-chloroethyl)-3-cyanothiophene to give, after deprotection using a method similar to the General Procedure 1-5, the title compound as a white solid. MS (APCI+) *m/z*: 349 (M+H)⁺.

Example 332**7-Chloro-6-(5-methylisoxazol-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5



To a 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine (200 mg, 0.521 mmol) in methanol (3.3 mL) under nitrogen add potassium hydroxide (0.9 g, 16.1 mmol) at ambient temperature. When the mixture becomes homogenous, heat at 55-60°C for 2-3 h, until TLC shows the disappearance of starting material. Cool to ambient temperature, add 3-(chloromethyl)-5-methylisoxazole (82 mg, 0.62 mmol) and continue stirring for 30 min.


15 Add aqueous saturated ammonium chloride, extract the mixture three times with diethyl ether, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Treat a solution of the crude material so obtained in DCM (2 mL) with 2M hydrogen chloride in ether (excess) and continue stirring until TLC shows consumption of the starting material. Concentrate *in vacuo*, purify by preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol,

20 and convert to the hydrochloride by following a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 309 (M+H)⁺.

Example 333

7,9-Dichloro-6-(5-methylisoxazol-3-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

5




Obtain the free base of the title compound as a minor product from Example 332, after preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol. Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 343 (M+H)⁺.

10

Example 334

7-Chloro-6-(2-methylthiazol-4-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

15




Use a method similar to the Example 332, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-chloromethyl-2-methylthiazole hydrochloride to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (APCI+) *m/z*: 325 (M+H)⁺.

20

Example 335

6-(4-Bromothiophen-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

5




Use a method similar to the General Procedure 1-4, using 6-(4-bromothiophen-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to
10 give the title compound as a white solid. MS (APCI+) *m/z*: 390 (M+H)⁺.

Example 336

7-Chloro-6-(4-cyanothiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

15




Degas a stirred solution of 6-(4-bromothiophen-2-ylmethylthio)-3-*tert*-
butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (183 mg, 0.37 mmol),
20 zinc cyanide (50 mg, 0.42 mmol) and tetrakis(triphenylphosphine) palladium(0) (30 mg,
0.026 mmol) in dry DMF. Purge with dry nitrogen, and heat at 120°C for 6 h. Dilute with
water, extract three times with EtOAc, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1) to give
3-*tert*-butoxycarbonyl-7-chloro-6-(4-cyanothiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-

1*H*-benzo[*d*]azepine as an oil (85 mg, 52%). MS (APCI+) *m/z*: 335 (M+H-Boc)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (APCI+) *m/z*: 335 (M+H)⁺.

5

Example 337

7-Chloro-6-([1,2,4]-oxadiazol-3-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10







Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-chloromethyl-1,2,4-oxadiazole to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z* 296 (M+H)⁺.

15

Examples 338-343 may be prepared essentially as described in Example 337 using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted 5-chloromethyl-1,2,4-oxadiazole or 4-chloromethyl-thiazole. MS (ES+) data are included in the Table below.


20



Ex.	SR	Compound	MS (ES+) <i>m/z</i>
338		7-Chloro-6-(3-methyl-[1,2,4]oxadiazol-5-ylmethylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	310 (<i>M</i> + <i>H</i>) ⁺
339		6-(3- <i>tert</i> -Butyl-[1,2,4]oxadiazol-5-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	352 (<i>M</i> + <i>H</i>) ⁺
340		7-Chloro-6-(3-propyl-[1,2,4]oxadiazol-5-ylmethylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	338 (<i>M</i> + <i>H</i>) ⁺
341		7-Chloro-6-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-ylmethylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	406 (<i>M</i> + <i>H</i>) ⁺
342		7-Chloro-6-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-ylmethylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	373 (<i>M</i> + <i>H</i>) ⁺
343		7-Chloro-6-[2-(4-trifluoromethylphenyl)-thiazol-4-ylmethylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	455 (<i>M</i> + <i>H</i>) ⁺

Example 344

7-Chloro-6-(pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride



5


Using a method similar to the General Procedure 7, react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylaminocarbonylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine (8 g, 20.8 mmol) with 2-picolyl chloride hydrochloride (3.41 g, 20.8 mmol). Dilute the reaction mixture with diethyl ether and filter the precipitate. Concentrate the filtrate *in vacuo*, dissolve the residue in diethyl ether (100 mL) and add 1N aqueous HCl (100 mL). Stir the mixture for 16 h at ambient temperature. Separate, wash the aqueous layer with diethyl ether, adjust the pH of the aqueous layer to 12 with sodium hydroxide and extract with diethyl ether. Dry over Na₂SO₄ and concentrate *in vacuo* to give the free base of the title compound. Use the General Procedure 2-2 to give the title compound as a white solid (4.91 g, 78%). MS (ES⁺) *m/z*: 305 (M+H)⁺.

15

Example 345

7-Chloro-6-(pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate

20




Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1 equiv.) in methanol (0.1-0.4 M) and add potassium hydroxide (8-20 equiv.). Stir at 60°C for 4-24 h. Cool the reaction mixture in an ice bath, add picolyl chloride hydrochloride (1-3 equiv.) and stir the mixture at ambient
5 temperature for 16-24 h. Add a volume of toluene approximately equal to the volume of the reaction mixture and concentrate the resulting mixture to approximately ½ the resulting total volume and repeat this process once more. Add water until all solids dissolve and separate the layers. Dry the organic layer over Na₂SO₄ and filter. Heat the solution (containing about 0.25-0.40 M of free base of the title compound) to 50-75°C
10 and then optionally seed with previously formed crystals of the title compound. Add succinic acid (1-1.3 equivalents) in isopropyl alcohol (0.25-0.40M solution) to the solution over 5-45 min. Cool the solution to 20-25°C over 1-3 h and filter, rinsing with a solution of toluene/isopropyl alcohol (1:1). Dry the resulting solid under vacuum at 50-70°C/5 Torr to give the title compound as a white solid, mp 159-160 °C. Anal. Calc'd
15 for C₂₀H₂₃ClN₂O₄S: C, 56.80; H, 5.48; N, 6.62. Found: C, 56.56; H, 5.41; N, 6.57.

Example 346

7,9-Dichloro-6-(pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

20



Obtain as minor product from the reaction of the 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-
25 benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[*d*]azepine with 2-bromomethylpyridine hydrobromide, using a method similar to the General Procedure 7. Treat a solution of the crude mixture in DCM

with 4M hydrogen chloride in dioxane (excess) overnight. Concentrate *in vacuo* and purify by preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol. Use a method similar to the General Procedure 2-2 to give the title compound as an off-white solid. MS (APCI+) m/z : 339 (M+H)⁺.

5

Example 347

7-Chloro-6-(2-fluorobenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




10

To a mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[d]azepine (102 mg, 0.267 mmol) in methanol (2 ml), add potassium hydroxide pellets (450 mg, 8.02 mmol) and heat the mixture 3 h at 60 °C. Cool to ambient temperature, add aqueous saturated ammonium chloride solution, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Dissolve the crude thiophenol thus obtained in dry DCM (2 mL) under nitrogen, and add DBU (80 μ L, 0.54 mmol) and 2-fluorobenzyl bromide (65 μ L, 0.54 mmol) with stirring. Stir overnight at ambient temperature, dilute with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(2-fluorobenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (31 mg, 25%). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) m/z : 322 (M+H)⁺.

25

Example 348

7-Chloro-6-(pyridin-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




Use a method similar to the Example 347, using 3-*tert*-butoxycarbonyl-7-chloro-
5 6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-(bromomethyl)pyridine hydrobromide to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 305 (M+H)⁺.

10

Example 349

7-Chloro-6-(5-fluoropyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate



15

Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (527 mg, 1.4 mmol) and potassium hydroxide (1.1 g, 20.5 mmol) in methanol (10 mL) and heat the solution to reflux for 2 h. Cool the reaction mixture to ambient temperature and remove the solvent *in vacuo*. Slurry the residue with
20 EtOAc (50 ml), and wash the slurry with a saturated NH₄Cl. Collect and dry the organic phase over Na₂SO₄, remove the solvent under reduced pressure to obtain the intermediate thiophenol as an oil. Dissolve the oil in DMSO (10 ml), add triethylamine (1.1 ml, 8.2 mmol) and methanesulfonic acid 5-fluoro-pyridin-2-ylmethyl ester (500mg, 2.4 mmol).


Heat the reaction mixture to 60 °C for 1 h. Monitor the reaction by HPLC and TLC.

Cool the reaction to ambient temperature, add 1:1 hexane/EtOAc (80 ml) and wash the organic layer with a 5% NaCl (3 X 30 ml). Collect the organic layer, concentrate, and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1 to 1:1) to obtain
5 3-*tert*-butoxycarbonyl-7-chloro-6-(5-fluoro-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (519 mg, 89%). MS (ES+) *m/z*: 423 (M+H)⁺.

Use the General Procedure 1-4 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-(5-fluoro-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (510 mg, 1.2
10 mmol). Purify by SCX chromatography followed by chromatography on silica gel eluting with DCM/2M ammonia in methanol (99:1 to 90:10). Use the General Procedure 2-1 to give the title compound (370 mg, 70%). MS (ES+) *m/z*: 323 (M+H)⁺.

Example 350

15 7-Chloro-6-(6-chloropyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




20 Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-bromomethyl-6-chloropyridine hydrochloride to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as an off-white solid. MS (APCI+) *m/z*: 339 (M+H)⁺.





25

Examples 351-360 may be prepared essentially as described in Example 350 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted chloromethylpyridine,

bromomethylpyridine or chloromethylquinoline. MS (ES+) data are included in the Table below.




Ex.	SR	Compound	MS (ES+ or APCI+)
351		7-Chloro-6-(6-chloro-pyridin-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	339 (M+H) ⁺
352		6-(5-Bromo-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	385 (M+H) ⁺
353		6-(3-Bromo-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	385 (M+H) ⁺
354		6-(6-Bromo-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	385 (M+H) ⁺
355		7-Chloro-6-(3-methyl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	319 (M+H) ⁺
356		7-Chloro-6-(5-cyano-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	330 (M+H) ⁺

Ex.	SR	Compound	MS (ES+ or APCI+)
357		7-Chloro-6-(6-cyano-pyridin-3-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	330 (M+H) ⁺
358		7-Chloro-6-(6-trifluoromethyl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	373 (M+H) ⁺
359		7-Chloro-6-(3-trifluoromethyl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	373 (M+H) ⁺
360		7-Chloro-6-(quinolin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	355 (M+H) ⁺

Example 361

7-Chloro-6-(3-methoxypyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

5




Use a method similar to the Example 315, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 2-chloromethyl-3-

10

methoxypyridine to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as a white solid (71 mg). MS (APCI+) m/z : 335 (M+H)⁺.

Example 362

- 5 7-Chloro-6-(6-methoxypyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




- 10 Use a method similar to the Example 330, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 2-chloromethyl-6-methoxypyridine hydrochloride to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as a white solid (120 mg). MS (APCI+) m/z : 335 (M+H)⁺.

15

Example 363

- 20 6-(5-Butylpyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




20

Use a method similar to the Example 315, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 5-butyl-2-chloromethylpyridine hydrochloride to give the title compound as a white solid. MS (APCI⁺) *m/z*: 330 (M+H)⁺.

5

Example 364

7-Chloro-6-[5-(3-methylbutyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



10


To 6-(5-bromo-pyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (219 mg, 0.452 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (18 mg, 0.022 mmol) under dry nitrogen add with stirring a solution of 0.5M 3-methylbutylzinc bromide in THF (4.6 mL, 2.3 mmol). Degas, purge with dry nitrogen, and stir overnight at ambient temperature. Dilute with EtOAc, wash with water, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (5:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[5-(3-methylbutyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (160 mg, 75%). MS (APCI⁺) *m/z*: 475 (M+H)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a tan solid. MS (APCI⁺) *m/z*: 375 (M+H)⁺.

15

20

Example 365


7-Chloro-6-[5-(2,2-dimethylpropyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



5

To a stirred solution of 1.0 M neopentyl magnesium chloride in diethyl ether (50 mL, 50 mmol) at -78°C under nitrogen, add via syringe a solution of 0.5 M zinc chloride in THF (100 mL, 50 mmol). Warm gradually to ambient temperature and transfer via syringe of this solution (25 mL, ~ 8.33 mmol) to a stirred solution of 3-*tert*-butoxycarbonyl-6-(5-bromo-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.62 mmol) in THF (2 mL) at ambient temperature. Add dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (50 mg, 0.061 mmol) and heat at 65°C for 6 h. Cool to ambient temperature, dilute with EtOAc, wash with water, dry over anhydrous MgSO_4 and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (6:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[5-(2,2-dimethyl-propyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (69 mg, 24%). MS (APCI+) m/z : 501 ($\text{M}+\text{H}$)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a white powder. MS (APCI+) m/z : 375 ($\text{M}+\text{H}$)⁺.

20

Example 366**7-Chloro-6-(5-cyclohexylpyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**


5

To a mixture of 6-(5-bromopyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (146 mg, 0.30 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (12 mg, 0.015 mmol) under dry nitrogen add with stirring a solution of 0.5 M cyclohexylzinc bromide in THF (3.0 mL, 1.5 mmol). Degas, purge with dry nitrogen, and stir overnight at 60 °C. Cool to ambient temperature, dilute with EtOAc, wash with water, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (5:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(5-cyclohexylpyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (46 mg, 32%). MS (APCI+) *m/z*: 487 (M+H)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (APCI+) *m/z*: 387 (M+H)⁺.

15

Example 367

7-Chloro-6-(5-cyclopentylpyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate



5


Use a method similar to the Example 366 to react 6-(5-bromo-pyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with a solution of cyclopentylzinc bromide in THF. Use a method similar to the General Procedure 1-4, basic workup, and a method similar to the General Procedure 2-1 to give the title compound as a tan solid. MS (APCI+) *m/z*: 373 (M+H)⁺.

10

Example 368

7-Chloro-6-(5-cyclohexylmethylpyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

15




Use a method similar to the Example 366 to react 6-(5-bromo-pyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with cyclohexylmethylzinc bromide. Use a method similar to the General Procedure 1-5,

20

basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) m/z : 401 (M+H)⁺.

Example 369

5 7-Chloro-6-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




10 In a sealed tube, add tris(dibenzylideneacetone)dipalladium(0) (3.44 mg, 0.00376 mmol) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (4.98 mg, 0.00752 mmol) to a mixture of 6-(5-bromopyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (242 mg, 0.501 mmol), sodium *tert*-butoxide (96 mg, 1.0 mmol), 18-crown-6 (13 mg, 0.050 mmol) and piperidine (496 μ L, 5.01 mmol) in toluene
15 (3 mL). Flush the mixture with nitrogen and heat overnight. Cool to ambient temperature, dilute with water and extract three times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil
20 (179 mg, 73%).

Use a method similar to the General Procedure 1-5, using 3-*tert*-butoxycarbonyl-7-chloro-6-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give, after basic workup and a method similar to the General
25 Procedure 2-2, the title compound as a yellow solid. MS (ES+) m/z : 388 (M+H)⁺.

Example 370

7-Chloro-6-(5-pyrrolidin-1-yl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




5

Use a method similar to the Example 369, using 6-(5-bromopyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine and pyrrolidine to give the title compound as a pale yellow solid. MS (ES+) m/z : 374 (M+H)⁺.

10

Example 371

6-(5-Azepan-1-yl-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




15

Use a method similar to the Example 369, using 6-(5-bromopyridin-2-ylmethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine and homopiperidine to give the title compound as a yellow solid. MS (ES+) m/z 402 (M+H)⁺.

20

Example 372

7-Chloro-6-(3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl-5'-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Use a method similar to the Example 369, using 3-*tert*-butoxycarbonyl-7-chloro-6-(6-chloropyridin-3-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and piperidine, to give the title compound as a white solid. MS (ES+) *m/z*: 388 (M+H)⁺.

10

Example 373

7-Chloro-6-[5-(4-fluorophenylethynyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Dissolve 3-*tert*-butoxycarbonyl-6-(5-bromopyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 g, 2.07 mmol), tetrakis(triphenylphosphine) palladium(0) (120 mg, 0.104 mmol), cuprous iodide (20 mg, 0.105 mmol), triethylamine

(2.60 mL) and 1-ethynyl-4-fluorobenzene (500 mg, 4.16 mmol) in DMF (8 mL). Degas the mixture, purge with nitrogen, and heat at 65 ° C for 3 days. Dilute the mixture with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (50:1) to give
5 3-*tert*-butoxycarbonyl-7-chloro-6-[5-(4-fluorophenylethynyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a tan foam (1.02 g, 95%). MS (APCI+) *m/z*: 523 (M+H)⁺, 423 (M+H-Boc)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a tan powder. MS (APCI+) *m/z*: 423 (M+H)⁺.

10

Example 374

(*Z*)-7-Chloro-6-{5-[2-(4-fluorophenyl)vinyl]-pyridin-2-ylmethylthio}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride)




15

Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-[5-(4-fluorophenylethynyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.0 g, 1.9 mmol), Lindlar catalyst (240 mg), and quinoline (0.8 mL) in methanol (30 mL). Degas, purge with nitrogen, and stir under a balloon of hydrogen for 36 h. Filter the mixture and wash the catalyst with
20 additional methanol. Concentrate the filtrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (8:1) to give (*Z*)-3-*tert*-butoxycarbonyl-7-chloro-6-{5-[2-(4-fluoro-phenyl)-vinyl]-pyridin-2-ylmethylthio}-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a clear oil (630 mg, 63%). MS (APCI+) *m/z*: 525 (M+H)⁺, 425 (M+H-Boc)⁺. Use a method similar to the General Procedure 1-4 to give the title
25 compound as a pale yellow solid. MS (APCI+) *m/z*: 425 (M+H)⁺.

Example 375

7-Chloro-6-[5-(2-fluoro-4-trifluoromethylbenzylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




5

Dissolve 3-*tert*-butoxycarbonyl-6-(5-carboxypyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.67 mmol) in DMF (5.0 mL). Treat successively with HATU (305 mg, 0.802 mmol), *N,N*-diisopropylethylamine (140 μ L, 0.804 mmol) and 2-fluoro-4-(trifluoromethyl)benzylamine (260 mg, 1.34 mmol). Stir overnight at 40° C. Dilute the mixture with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (3:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[5-(2-fluoro-4-trifluoromethyl-benzylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a foam (409 g, 98%). Use a method similar to the General Procedure 1-4 to give, after basic work-up and a method similar to the General Procedure 2-1, the title compound as an off-white solid. MS (APCI+) *m/z*: 524 (M+H)⁺.

15

Example 376

7-Chloro-6-[5-(2,2-dimethylpropylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




20

Use a method similar to the Example 375, using 3-*tert*-butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and neopentylamine, to give the title compound as an off-white solid. MS (APCI+) *m/z*: 418 (M+H)⁺.

5

Example 377

7-Chloro-6-[5-(4-fluoro-benzylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




10

Use a method similar to the Example 375, using 3-*tert*-butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-fluorobenzylamine, to give the title compound as an off-white solid. MS (APCI+) *m/z*: 456 (M+H)⁺.

15

Example 378

7-Chloro-6-[5-(cyclohexylmethylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




20

Use a method similar to the Example 375, using 3-*tert*-butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and aminomethylcyclohexane to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (APCI+) *m/z*: 444 (M+H)⁺.

5

Example 379

6-(5-*tert*-Butylcarbamoyl-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the Example 375, using 3-*tert*-butoxycarbonyl-6-(5-carboxy-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and *tert*-butylamine to give, after deprotection by the General Procedure 1-4, the title compound as an off-white solid. MS (APCI+) *m/z*: 404 (M+H)⁺.

15

Example 380


7-Chloro-6-(4-trifluoromethoxybenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



20

To a 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (102 mg, 0.27 mmol) in methanol (1.7 mL) under nitrogen, add potassium hydroxide (0.9 g, 16.1 mmol) at ambient temperature. When the mixture becomes homogenous, heat at 55-60 °C for 2-3 h, until TLC shows the disappearance of starting material. Cool to ambient temperature, add aqueous saturated ammonium chloride solution, extract three times with diethyl ether, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Dissolve the crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in anhydrous DCM (2 mL) under nitrogen. Add with stirring DBU (80 µL, 0.532 mmol) and 4-(trifluoromethoxy)benzyl bromide (77 µL, 0.53 mmol) at ambient temperature and allow the reaction to continue overnight. Dilute with aqueous saturated ammonium chloride solution, extract three times with diethyl ether, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Treat a solution of the crude 3-*tert*-butoxycarbonyl-7-chloro-6-(4-trifluoromethoxy-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in DCM (2 mL) with 2M hydrogen chloride in ether (excess) and continue stirring until TLC shows consumption of starting material. Concentrate *in vacuo* and triturate the obtained solid with ether/pentane (10:90). Purify by preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol and convert to the hydrochloride by following a method similar to the General Procedure 2-2 to give the title compound as a white solid (48 mg, 43%). MS (APCI+) *m/z*: 388 (M+H)⁺.


Examples 381-383 may be prepared essentially as described in Example 380 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl bromide. Example 382 may be purified after deprotection by preparative reverse phase HPLC [Column: YMC ODS-AQ 120Å 20x250mm [S10-20µm], eluent: gradient from 95:5 to 5:95 A/B, flow rate: 15 mL/min; solvent A: water, 0.1% TFA, 1% isopropanol; solvent B: acetonitrile, 0.05% TFA, 1% isopropanol]. MS (ES+) data are included in the Table below.



Ex.	R	Compound	MS (ES+) <i>m/z</i>
381	2-Cl	7-Chloro-6-(2-chloro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	338 (M+H) ⁺
382	2-CN	7-Chloro-6-(2-cyano-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	329 (M+H) ⁺
383	4-Ph	7-Chloro-6-(4-phenyl-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	380 (M+H) ⁺


Example 384

- 5 7-Chloro-6-(4-fluoro-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate



- 10 Use a method similar to the Example 380 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 4-fluorobenzyl bromide. Purify by preparative reverse phase HPLC [Column: YMC ODS-AQ 120Å 20 x 250mm [S10-20μm], eluent: gradient from 95:5 to 5:95 A/B, flow rate: 15 mL/min; solvent A: water, 0.1% TFA, 1% isopropanol; solvent B: acetonitrile, 0.05% TFA, 1% isopropanol] to give the title compound as a white solid. MS (ES+) *m/z*: 322
- 15 (M+H)⁺.

Examples 385-386 may be prepared essentially as described in Example 384 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl bromide. MS (ES⁺) data are included in the Table below.




5

Ex.	R	Compound	MS (ES ⁺) <i>m/z</i>
385	4-Cl	7-Chloro-6-(4-chloro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	338 (M+H) ⁺
386	4-CN	7-Chloro-6-(4-cyano-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	329 (M+H) ⁺

Example 387

7-Chloro-6-(3,4-dichlorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Trifluoroacetate

10




To a 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (200 mg, 0.521 mmol) in methanol (3.3 mL) under nitrogen add potassium hydroxide (0.9 g, 16.07 mmol) at

15

ambient temperature. When the mixture becomes homogenous, heat at 55-60°C for 2-3 h, until TLC shows the disappearance of starting material. Cool to ambient temperature, add aqueous saturated ammonium chloride solution, extract three times with diethyl ether, dry over anhydrous MgSO_4 , and concentrate *in vacuo*. Dissolve the crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in anhydrous DCM (5 mL) under nitrogen. Add PS-DIEA (Argonaut, 3.83 mmol/g, 410 mg, 1.57 mmol) and 3,4-dichlorobenzyl bromide (100 μL , 0.586 mmol) at ambient temperature and allow the reaction to continue overnight. Filter the reaction mixture from the resin and rinse with DCM (2 mL), methanol (2 mL), DCM (2 mL), and methanol (2 mL). Concentrate *in vacuo*. Treat a solution of the crude 3-*tert*-butoxycarbonyl-7-chloro-6-(3,4-dichloro-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in DCM (2 mL) with a 2M hydrogen chloride in ether (excess) and continue stirring until TLC shows consumption of starting material. Concentrate *in vacuo* and triturate the obtained solid with ether:pentane (10:90). Purify by preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; Solvent A: 10 mM aqueous ammonium carbonate, Solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min) to give the title compound as a white solid (97 mg, 38%). MS (APCI+) m/z : 374 ($\text{M}+\text{H}$)⁺.


Examples 388-393 may be prepared essentially as described in Example 387 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl bromide. MS (ES+) data are included in the Table below.



Ex.	R	Compound	MS (ES+ or APCI+)
388	3-Cl	7-Chloro-6-(3-chloro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	338 (M+H) ⁺
389	3-F	7-Chloro-6-(3-fluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	322 (M+H) ⁺
390	3,4-diF	7-Chloro-6-(3,4-difluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	340 (M+H) ⁺
391	3,5-diF	7-Chloro-6-(3,5-difluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	340 (M+H) ⁺
392	3,4,5-triF	7-Chloro-6-(3,4,5-trifluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	358 (M+H) ⁺
393	3-OCF ₃	7-Chloro-6-(3-trifluoromethoxybenzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Trifluoroacetate	388 (M+H) ⁺

Example 394

5 7,9-Dichloro-6-(3-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Trifluoroacetate




10 Obtain as minor product from the reaction of the 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[*d*]azepine with 3-fluorobenzyl bromide, using a method similar

to the Example 387. Deprotect and isolate the title compound as a white solid after preparative reverse phase HPLC. MS (ES+) m/z : 356 (M+H)⁺.

Example 395


- 5 7,9-Dichloro-6-(3,4,5-trifluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Trifluoroacetate



- 10 Obtain as minor product from the reaction of the 4:1 mixture of 3-*tert*-
butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-
benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-
2,3,4,5-tetrahydro-benzo[*d*]azepine with 3,4,5-trifluorobenzyl bromide, using a method
similar to the Example 387. Deprotect and isolate the title compound as a white solid
15 after preparative reverse phase HPLC. MS (APCI+) m/z : 392 (M+H)⁺.

Example 396


- 7-Chloro-6-(2-nitro-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



- 20 Use a method similar to the Example 387, using 3-*tert*-butoxycarbonyl-7-chloro-
6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-nitrobenzyl
bromide to give, after chromatography eluting with hexane/EtOAc (10:1) and

deprotection by the General Procedure 1-4, the title compound as an off-white powder.
MS (APCI+) m/z : 349 (M+H)⁺.

5 Examples 397-399 may be prepared essentially as described in Example 396 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl bromide. MS (ES+) data are included in the Table below.




Ex.	R	Compound	MS (ES+ or APCI+)
397	2-OCF ₃	7-Chloro-6-(2-trifluoromethoxybenzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	388 (M+H) ⁺
398	3-OPh	7-Chloro-6-(3-phenoxybenzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	396 (M+H) ⁺
399	3,5-diCF ₃	7-Chloro-6-(3,5-bis(trifluoromethyl)benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	440 (M+H) ⁺

10

Example 400

7,9-Dichloro-6-(3,5-bis-trifluoromethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride (2148393)




15

Obtain as minor product from the reaction of the 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[*d*]azepine with 3,5-bis-trifluoromethylbenzyl bromide, using a method similar to the Example 396. Deprotect the crude mixture and purify by preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; solvent A: 10 mM aqueous ammonium carbonate; solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 474 (M+H)⁺.

Example 401


7-Chloro-6-(2,6-difluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 330, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2,6-difluorobenzyl bromide to give, after deprotection by the General Procedure 1-4, the title compound.

Example 402

7-Chloro-6-(2-trifluoromethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Use a method similar to the Example 347 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 2-trifluoromethylbenzyl bromide. Use a method similar to the General Procedure 1-4 to give the title compound as a waxy tan solid. MS (APCI+) m/z : 372 (M+H)⁺.

5

Example 403

7-Chloro-6-(4-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-benzo[*d*]azepine
Hydrochloride




10

Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and methyl 4-(bromomethyl)benzoate to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) m/z : 362 (M+H)⁺.

15

Example 404

7-Chloro-6-(3-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



20


Use a method similar to the Example 347 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with methyl 3-(bromomethyl)benzoate. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-2 to give the title compound.

5 MS (APCI+) m/z : 362 (M+H)⁺.

Example 405

7-Chloro-6-(2-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

10



Use a method similar to the Example 347, using the 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-benzo[*d*]azepine with methyl 2-(bromomethyl)benzoate. Use a method similar to the General Procedure 1-4 and purify by preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; solvent A: 10 mM aqueous ammonium carbonate, solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min).


15 Use a method similar to the General Procedure 2-2, to give the title compound as a white solid. MS (ES+) m/z : 362 (M+H)⁺.

20

Example 406

7,9-Dichloro-6-(2-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

5




Obtain the free base of the title compound as a minor product from Example 405, after preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; solvent A: 10 mM aqueous ammonium carbonate; solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (ES+) m/z : 396 (M+H)⁺.

10

Example 407

15

6-(4-Benzoylbenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride



Use a method similar to the Example 380 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine with 4-(bromomethyl)benzophenone. Purify by preparative reverse phase HPLC (Column:


20

Xterra Prep RP18 19x250mm; Solvent A: 10 mM aqueous ammonium carbonate, Solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (ES+) m/z : 408 (M+H)⁺.

5

Example 408

7-Chloro-6-[4-(3,3-dimethyl-2-oxo-butoxy)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate



10

Use a method similar to the General Procedure 7, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine (577 mg, 1.5 mmol) and 1-(4-bromomethylphenoxy)-3,3-dimethylbutan-2-one (556 mg, 1.95 mmol) to give, after chromatography on silica gel eluting with EtOAc/hexane (1:5), 3-*tert*-butoxycarbonyl-7-chloro-6-[4-(3,3-dimethyl-2-oxo-butoxy)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a colorless oil (669 mg, 86%). MS (ES+) m/z : 518 (M+H)⁺.

15


Use a method similar to the General Procedure 1-5 to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-[4-(3,3-dimethyl-2-oxo-butoxy)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (669 mg, 1.29 mmol). Purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (92:8) to give the free base of the title compound as a colorless oil (349 mg, 64%). MS (ES+) m/z : 418 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound.

20

25

Example 409

7-Chloro-6-[3-chloro-4-(3,3-dimethyl-2-oxo-butoxy)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate




5

Use a method similar to the Example 408, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 1-(4-bromomethyl-3-chlorophenoxy)-3,3-dimethylbutan-2-one to give the title compound. MS (ES⁺) *m/z*:

10 452 (M+H)⁺.**Example 410**

7-Chloro-6-(4-methanesulfonylmethyl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




15

Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-7-chloro-6-(4-methanesulfonylmethyl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give the title compound as a white solid. MS (ES⁺) *m/z*: 396 (M+H)⁺.

20

Example 411

7-Chloro-6-(5-chloro-thiophen-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




5

Use a method similar to the Example 387, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-chloro-5-(chloromethyl)thiophene to give, after hydrochloride formation by the General Procedure
2-2, the title compound as a brown solid. MS (APCI+) *m/z*: 344 (M+H)⁺.

10

Example 412

7-Chloro-6-(pyridin-4-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




15

Use a method similar to the Example 387, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-bromomethylpyridine hydrobromide to give, after hydrochloride formation by the General
Procedure 2-2, the title compound as a white solid. MS (APCI+) *m/z*: 305 (M+H)⁺.

20

Example 413


7-Chloro-6-(6-methyl-pyridin-2-ylmethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride



Use a method similar to the Example 387, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 2-chloromethyl-6-methylpyridine to give, after chromatography on silica gel eluting with hexane/EtOAc (4:1) and deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 319 (M+H)⁺.

Example 414

7-Chloro-6-[3-fluoro-4-(3-methylbutyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




To 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.210 mg, 0.42 mmol) and dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct (17 mg, 0.021 mmol) add 0.5 M 3-methylbutylzinc bromide in THF (4.2 mL, 2.10 mmol). Degas, purge

with dry nitrogen, and stir overnight at 80 °C. Cool to ambient temperature, dilute with EtOAc, wash with water, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[3-fluoro-4-(3-methylbutyl)-benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (85 mg, 42%). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 392 (M+H)⁺.

Example 415


7-Chloro-6-(4-cyclohexylmethyl-3-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate



Use a method similar to the Example 414 to react 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with (cyclohexyl)methylzinc bromide. Use a method similar to the General Procedure 1-4, basic work-up, and a method similar to the General Procedure 2-1, to give the title compound as a white solid. MS (ES+) *m/z*: 418 (M+H)⁺.

Example 416

7-Chloro-6-(4-cyclohexyl-3-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



5


Use a method similar to the Example 414, using 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and cyclohexylzinc bromide. Use a method similar to the General Procedure 1-4, basic work-
up, and a method similar to the General Procedure 2-1, to give the title compound as a
white solid. MS (ES+) *m/z*: 404 (M+H)⁺.

10

Example 417

7-Chloro-6-(2,5'-difluoro-2'-methoxybiphenyl-4-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-
benzo[*d*]azepine Hydrochloride


15



Degas a stirred mixture of 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (212 mg, 0.424 mmol), 5-fluoro-2-methoxybenzene boronic acid (108 mg, 0.636 mmol), potassium carbonate (292 mg, 2.12 mmol), triphenylphosphine (11 mg, 0.0424 mmol) and bis(triphenylphosphine)-palladium(II) chloride (15 mg, 0.0212 mmol) in dioxane (3 mL) and water (1 mL). Purge with dry nitrogen and heat at 100 °C for 5 h. Cool to ambient temperature, add water, extract three times with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/ EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(2,5'-difluoro-2'-methoxy-biphenyl-4-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as yellow oil (216 mg, 93%). Use a method similar to the General Procedure 1-4 to give the title compound as a yellow foam. MS (ES+) *m/z*: 446 (M+H)⁺.

Example 418


7-Chloro-6-(2'-chloro-2-fluorobiphenyl-4-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 417, using 2-chlorophenylboronic acid to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 432 (M+H)⁺.

Example 419

7-Chloro-6-(3-fluoro-4-piperidin-1-yl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




5

In a sealed tube, add tris(dibenzylideneacetone)dipalladium (13 mg, 0.014 mmol) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (19 mg, 0.029 mmol) to a mixture of 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (957 mg, 1.91 mmol), sodium *tert*-butoxide (367 mg, 3.83 mmol), 18-crown-6 (50 mg, 0.191 mmol) and piperidine (944 μ l, 9.57 mmol) in toluene (10 mL). Flush the mixture with nitrogen and heat overnight. Cool to ambient temperature, dilute with water and extract three times with EtOAc. Dry over anhydrous Na₂SO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(3-fluoro-4-piperidin-1-yl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a yellow oil (511 mg, 33%). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 405 (M+H)⁺.

Example 420

7-Chloro-6-(3-fluoro-4-pyrrolidin-1-yl-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

5




Use a method similar to the Example 419 to react 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with pyrrolidine.

10 Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 391 (M+H)⁺.

Example 421

6-(4-Azepan-1-yl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

15




Use a method similar to the Example 419 to react 6-(4-bromo-3-fluorobenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with homopiperidine. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 419 (M+H)⁺.

5

Example 422

7-Chloro-6-(4-chloro-3-pyrrolidin-1-yl-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine hydrochloride



10


Use a method similar to the Example 419, using 6-(3-bromo-4-chloro-benzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and pyrrolidine to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 407 (M+H)⁺.

15

Example 423

7-Chloro-6-(4-cyclohexylmethoxybenzylthio)-3-*tert*-butoxycarbonyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

20



Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-(chloromethyl)phenyl acetate to give 6-(4-acetoxybenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a white solid.


5

To 6-(4-acetoxybenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (532 mg, 1.15 mmol) in methanol (8 mL) at ambient temperature add with stirring a solution of potassium carbonate (796 mg, 5.77 mmol) in water (4 mL) and stir the mixture for 2 h. Dilute with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. To a portion of the crude phenol thus obtained (204 mg, 0.487 mmol) in THF (5 mL), add with stirring diisopropyl azodicarboxylate (216 µL, 1.71 mmol) followed by triphenylphosphine (306 mg, 1.17 mmol) and cyclohexylmethanol (619 mg, 5.42 mmol). Heat at 60°C for 3 h, cool to ambient temperature and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(4-cyclohexylmethoxy-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colorless oil (176 mg, 70%). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 416 (M+H)⁺.

20

Example 424

7-Chloro-6-(4-cycloheptyloxybenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




25

Use a method similar to the Example 423 to react 6-(4-acetoxybenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with cycloheptanol. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 416 (M+H)⁺.

5

Example 425

7-Chloro-6-[4-(2,2-dimethylpropoxy)-benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the Preparation 177 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 1-bromomethyl-4-(2,2-dimethylpropoxy)-benzene. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 390 (M+H)⁺.

15

Example 426

7-Chloro-6-(2-methanesulfonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




20

Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 1-bromomethyl-2-methanesulfonyl-benzene to give, after deprotection by the General Procedure 1-4, the title compound and as a white solid. MS (APCI+) *m/z*: 382 (M+H)⁺.

5

Example 427

7-Chloro-6-(4-methanesulfonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the Example 380, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-methylsulfonylbenzyl bromide to give, after hydrochloride formation by the General Procedure 2-2, the title compound as a white solid. MS (ES+) *m/z*: 382 (M+H)⁺.

15

Example 428


7-Chloro-6-[4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfinyl)benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride







20

To 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (723 mg, 1.88 mmol) in methanol (10 mL) add potassium hydroxide pellets (3.34 g, 60.2 mmol) and stir mixture at 50 °C for 2 h. Cool to ambient temperature, add aqueous saturated ammonium chloride, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo* to give the crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine. Dissolve the compound in DMF (5 mL), add cesium carbonate (920 mg, 2.82 mmol) and 1-bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethyl-propane-1-sulfinyl)-benzene (824 mg, 2.071 mmol) and stir 2 h at ambient temperature. Dilute with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-[4-(3,3,3-trifluoro-2-methyl-2-trifluoromethyl-propane-1-sulfinyl)-benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a yellow oil (986 mg, 83%). Use a method similar to the General Procedure 1-4 to give the title compound as a white foam. MS (ES+) *m/z*: 530 (M+H)⁺.

Examples 429-432 may be prepared essentially as described in Example 428 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with the appropriately substituted benzyl bromide. MS (ES+) data are included in the Table below.




Ex.	SO ₂ R	Compound	MS (ES+ or APCI+)
429		7-Chloro-6-[4-(2,2-dimethyl-propane-1-sulfonyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	438 (M+H) ⁺
430		7-Chloro-6-[4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropane-1-sulfonyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	546 (M+H) ⁺
431		7-Chloro-6-[4-(4-trifluoromethyl-benzenesulfonyl)-benzylthio]-1,2,4,5-tetrahydro-benzo[d]azepine Hydrochloride	512 (M+H) ⁺
432		7-Chloro-6-(4-cyclohexylmethanesulfonyl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	464 (M+H) ⁺

Example 433

7-Chloro-6-[4-(2,4-difluoro-phenylmethanesulfonyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate


5



10 Use a method similar to the Example 428 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine with 1-(4-bromomethyl-benzenesulfonylmethyl)-2,4-difluoro-benzene. Use a method similar to the General Procedure 1-4, basic work-up, and a method similar to the General Procedure 2-1, to give the title compound as a white solid. MS (ES+) *m/z*: 494 (M+H)⁺.

Example 434

7-Chloro-6-[4-(3,3,3-trifluoro-2-methyl-2-trifluoromethylpropylthio)-benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




5

Use a method similar to the Example 428 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 1-bromomethyl-4-(3,3,3-trifluoro-2-methyl-2-trifluoromethyl-propylthio)-benzene. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-1, to give the title compound as a white solid. MS (APCI⁺) *m/z*: 514 (M+H)⁺.

15

Example 435

7-Chloro-6-[4-(3,3-dimethylbutyryl)-benzylthio]-1,2,4,5-tetrahydro-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 428 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with


20

1-(4-bromomethylphenyl)-3,3-dimethylbutan-1-one. Use a method similar to the General Procedure 1-4, basic workup, and a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI⁺) *m/z*: 402 (M+H)⁺.

5

Example 436

(±)-7-Chloro-6-[1-(2-cyanophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (±)-2-(1-bromoethyl)benzonitrile to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (APCI⁺) *m/z*: 343 (M+H)⁺.

15

Example 437

(-)-7-Chloro-6-[1-(2-cyanophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



20

Dissolve (±)-7-chloro-6-[1-(2-cyanophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine succinate (326 mg, 1.0 mmol) in DCM (5 mL) and pyridine (0.4 mL, 5 mmol). Add di-*tert*-butyl-dicarbonate (270 mg, 1.2 mmol) and stir the mixture for 16 h at ambient temperature. Wash the mixture with 5N aqueous NaOH and saturated aqueous


25

NaHCO₃ successively. Collect the organic layer and concentrate *in vacuo*. Purify the residue by chromatography on silica gel eluting with hexane/EtOAc (1:1) to obtain (±)-3-*tert*-butoxycarbonyl-7-chloro-6-[1-(2-cyanophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (393 mg, 93%). Separate the enantiomers of (±) 3-*tert*-butoxycarbonyl-7-chloro-6-[1-(2-cyanophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine by
5 chiral normal phase chromatography (Chiralpak AD 8x30 cm column, eluting with heptane/isopropylamine, 95:5).

Take the second eluting isomer and deprotect using the General Procedure 1-5.
10 Purify with SCX chromatography. Use a method similar to the General Procedure 2-2 to obtain the title compound (125 mg, 37%). MS (ES+) *m/z*: 343 (M+H)⁺. [α]_D²⁰ -112° (c 0.5, CH₃OH).

Examples 438 and 439

15 6-[4-(2-Butyl-2*H*-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride and 6-[4-(1-Butyl-1*H*-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



4-Acetylbenzyl bromide: Use a method similar to the Preparation 184, using 4-methylacetophenone, to give the desired intermediate as a white solid.

6-(4-Acetylbenzylthio)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-

- 5 **benzo[d]azepine:** Use a method similar to the Example 380, using 3-tert-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 4-acetylbenzyl bromide to give, after chromatography eluting with hexane/EtOAc (15:1), the desired intermediate as a white solid. MS (APCI+) m/z 346 (M+H-Boc)⁺.

10

3-tert-Butoxycarbonyl-7-chloro-6-[4-(3-dimethylaminoacryloyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine: Heat a solution of 6-(4-acetylbenzylthio)-3-tert-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.0 g, 2.2 mmol) in toluene (10 mL) at 110 °C overnight in the presence of tert-butoxy-bis(dimethylamino)-methane (1.0 mL, 4.84 mmol). Concentrate *in vacuo* to provide the desired intermediate as a dark oil (1.2 g, 100%). MS (APCI+) m/z 401 (M+H-Boc)⁺.

15

6-[4-(1-Butyl-1H-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1H-

- 20 **benzo[d]azepine Hydrochloride:** To a stirred mixture of 3-tert-butoxycarbonyl-7-chloro-6-[4-(3-dimethylaminoacryloyl)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (240 mg, 0.475 mmol), butylhydrazine oxalate (102 mg, 0.574 mmol), sodium carbonate (55 mg, 0.444 mmol) in water (8 mL) and methanol (10 mL) add acetic acid (ca. 3-6 drops) to pH 5. Heat overnight at 70 °C. Concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (10:1) to give a mixture of the
- 25 desired intermediates, 3-tert-butoxycarbonyl-6-[4-(2-butyl-2H-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (65 mg, 32%), MS (APCI+) m/z : 426 (M+H-Boc)⁺ and 3-tert-butoxycarbonyl-6-[4-(1-butyl-1H-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (100 mg, 50%), MS (APCI+) m/z : 426 (M+H-Boc)⁺.

30

Use a method similar to the General Procedure 1-4, using 3-tert-butoxycarbonyl-6-[4-(2-butyl-2H-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1H-


benzo[*d*]azepine, to give 6-[4-(2-butyl-2*H*-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (Example 438) as a white solid. MS (APCI+) *m/z*: 426 (M+H)⁺.

- 5 Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-6-[4-(1-butyl-1*H*-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give 6-[4-(1-butyl-1*H*-pyrazol-3-yl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (Example 439) as a white solid. MS (APCI+) *m/z*: 426 (M+H)⁺.

10

Example 440

6-(4-*tert*-Butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



15

3-*tert*-Butoxycarbonyl-7-chloro-6-(3-fluoro-4-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Use a method similar to the Example 428, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and methyl 4-bromomethyl-2-fluorobenzoate, to give the desired intermediate as a white solid.

20


3-*tert*-Butoxycarbonyl-6-(4-carboxy-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: Heat a stirred solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(3-fluoro-4-methoxycarbonylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (3.56 g, 7.44 mmol) in THF (50 mL) and water (40 mL) overnight at 65 °C in the presence of potassium hydroxide (8.30 g, 148.77 mmol). Cool the mixture to 0 °C, add slowly a 1N

25





solution of hydrochloric acid until pH 5. Extract three times with EtOAc, dry over anhydrous Na₂SO₄ and concentrate *in vacuo* to provide the desired intermediate as a white solid (3.5 g, 99%).

- 5 **6-(4-*tert*-Butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride:** To a solution of 3-*tert*-butoxycarbonyl-6-(4-carboxy-3-fluoro-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.1 g, 2.36 mmol) in DMF (7 mL), add *tert*-butylamine (12.05 g, 165.2 mmol), EDC (1.81 g, 9.44 mmol) and HOBT (1.44g, 10.62 mmol) and stir in a sealed tube at 70 °C overnight. Dilute with
 10 EtOAc, wash with water, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-6-(4-*tert*-butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a clear oil. MS (APCI+) *m/z*: 421 (M+H)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as a white powder. MS (APCI+)
 15 *m/z*: 421 (M+H)⁺.

Examples 441-447 may be prepared essentially as described in Example 440 by reacting 3-*tert*-butoxycarbonyl-6-(4-carboxy-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine with the appropriate amine. MS (ES+) data are included
 20 in the Table below.




Ex.	N-R	R'	Compound	MS (ES+ or APCI+)
441	N-(<i>n</i> -Pr)	H	7-Chloro-6-(3-fluoro-4- <i>n</i> -propylcarbamoyl-benzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	407 (M+H) ⁺
442	N-(<i>i</i> -Bu)	H	6-(4- <i>iso</i> -Butylcarbamoyl-3-fluoro-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride	421 (M+H) ⁺

Ex.	N-R	R'	Compound	MS (ES+ or APCI+)
443	N-(<i>n</i> -Pr)	<i>n</i> -Pr	7-Chloro-6-(4-dipropylcarbamoyl-3-fluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	449 (M+H) ⁺
444		H	7-Chloro-6-[3-fluoro-4-(4-fluoro-benzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	473 (M+H) ⁺
445		H	7-Chloro-6-(4-cyclohexylcarbamoyl-3-fluoro-benzylthio)-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	447 (M+H) ⁺
446		H	7-Chloro-6-[3-fluoro-4-(2-isobutyl-pyrrolidine-1-carbonyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	475 (M+H) ⁺
447		H	7-Chloro-6-{3-fluoro-4-[3-(4-fluoro-phenyl)-pyrrolidine-1-carbonyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine-Hydrochloride	513 (M+H) ⁺

Example 448

(*S*)-(+)-6-(4-*sec*-Butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

5



3-*tert*-Butoxycarbonyl-7-chloro-6-(4-chlorocarbonyl-3-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine: To a solution of 3-*tert*-butoxycarbonyl-6-(4-carboxy-

3-fluoro-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.95 g, 4.21 mmol) in DCM (20 mL) at 0 °C under nitrogen, add three drops of DMF and oxalyl chloride


10







(1.06 g, 8.41 mmol). Stir for 2 h and concentrate *in vacuo* to afford the desired intermediate as a yellow oil (1.93 g, 95%).

5 **(S)-3-tert-Butoxycarbonyl-6-(4-sec-butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** To a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(4-chlorocarbonyl-3-fluoro-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine (415 mg, 0.860 mmol) in DCM (10 mL), add (*S*)-(+)-*sec*-butylamine (1.0 g, 13.7 mmol) and stir at ambient temperature for 30 min. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give the desired
10 intermediate as a pale oil (352 mg, 79%). MS (APCI+) *m/z*: 421 (M+H-Boc)⁺.

(S)-(+)-6-(4-sec-Butylcarbamoyl-3-fluorobenzylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride: Use a method similar to the General Procedure 1-4, using (+)-3-*tert*-butoxycarbonyl-6-(4-*sec*-butylcarbamoyl-3-fluoro-benzylthio)-7-
15 chloro-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine, to give the title compound as a pale solid. MS (APCI+) *m/z*: 421 (M+H)⁺. [α]_D²⁰ +8.7° (c 0.5, CH₃OH).

Examples 449-454 may be prepared essentially as described in Example 448 by reacting 3-*tert*-butoxycarbonyl-6-(4-carboxy-3-fluoro-benzylthio)-7-chloro-2,3,4,5-
20 tetrahydro-1*H*-benzo[d]azepine with the appropriate amine. Optical rotation and MS (ES+) data are included in the Table below.




Ex.	NH-R	Compound	$[\alpha]^{20}_D$ (c, solvent)	MS (ES+) m/z
449		(<i>R</i>)-(-)-6-(4- <i>sec</i> -Butylcarbamoyl-3-fluoro-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	-7.0° (c 0.5, CH ₃ OH).	421 (M+H) ⁺
450		7-Chloro-6-[4-(2-chloro-benzylcarbamoyl)-3-fluoro-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	-	489 (M+H) ⁺
451		7-Chloro-6-[3-fluoro-4-(2-trifluoromethyl-benzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine-3-Hydrochloride	-	523 (M+H) ⁺
452		7-Chloro-6-[3-fluoro-4-(2-fluoro-4-trifluoromethyl-benzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	-	541 (M+H) ⁺
453		(<i>S</i>)-(-)-7-Chloro-6-{3-fluoro-4-[1-(4-fluoro-phenyl)-ethyl-carbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo-[<i>d</i>]azepine Hydrochloride	-25.8° (c 0.5, CH ₃ OH)	487 (M+H) ⁺
454		(<i>R</i>)-(+)-7-Chloro-6-{3-fluoro-4-[1-(4-fluoro-phenyl)-ethyl-carbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo-[<i>d</i>]azepine Hydrochloride	+24.9° (c 0.5, CH ₃ OH)	487 (M+H) ⁺

Example 455

7-Chloro-6-(3-fluoro-4-isobutylcarbamoyl-benzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate

5




Use a method similar to the Example 448 to react 3-*tert*-butoxycarbonyl-6-(4-carboxy-3-fluoro-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with isobutylamine. Use a method similar to the General Procedure 1-4, basic work-up, and a method similar to the General Procedure 2-1 to give the title compound as a white solid.

5 MS (ES+) *m/z*: 403 (M+H)⁺.

Example 456

7-Chloro-6-(4-cyclohexylcarbamoylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate

10













Use a method similar to the Preparation 177 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 4-chloromethyl-*N*-cyclohexylbenzamide. Use a method similar to the General Procedure 1-5, basic workup, and a method similar to the General Procedure 2-1 to give the title compound as a white solid. MS (ES+) *m/z*: 429 (M+H)⁺.

15

Examples 457-465 may be prepared essentially as described in Example 456 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl chloride. Optical rotation and MS (ES+) data are included in the Table below.


20



Ex.	NH-R	Compound	$[\alpha]^{20}_D$ (c, solvent)	MS (ES+ or APCI+)
457		7-Chloro-6-[4-(2-fluoro-4-trifluoromethyl-benzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-	523 (M+H) ⁺
458		[4-(3,5-Bis-trifluoromethyl-benzylcarbamoyl)-benzylthio]-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-	573 (M+H) ⁺
459		7-Chloro-6-[4-(4-fluoro-2-trifluoromethyl-benzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-	523 (M+H) ⁺
460		(<i>S</i>)-(+)-7-Chloro-6-[4-(1-cyclohexyl-ethylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	+11.2° (c 0.5, CH ₃ OH)	457 (M+H) ⁺
461		(<i>R</i>)-(-)-7-Chloro-6-[4-(1-cyclohexyl-ethylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-11.3° (c 0.5, CH ₃ OH)	457 (M+H) ⁺
462		(<i>R</i>)-(+)-7-Chloro-6-{4-[1-(4-fluoro-phenyl)-ethylcarbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	+2.2° (c 0.5, CH ₃ OH)	469 (M+H) ⁺
463		(<i>S</i>)-(-)-7-Chloro-6-{4-[1-(4-fluoro-phenyl)-ethylcarbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-1.6° (c 0.5, CH ₃ OH)	469 (M+H) ⁺
464		(<i>R</i>)-(-)-7-Chloro-6-{4-[1-(4-chloro-phenyl)-ethylcarbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	-5.8° (c 0.5, CH ₃ OH)	485 (M+H) ⁺
465		(<i>S</i>)-(+)-7-Chloro-6-{4-[1-(4-chloro-phenyl)-ethylcarbamoyl]-benzylthio}-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Succinate	+5.5° (c 0.5, CH ₃ OH)	485 (M+H) ⁺

Example 466


7-Chloro-6-[4-(2,2-dimethyl-propylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride








5

Use a method similar to the Example 456, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-chloromethyl-*N*-(2,2-dimethyl-propyl)-benzamide to give, after deprotection by a method similar to the
10 General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 417 (M+H)⁺.

Examples 467-471 may be prepared essentially as described in Example 466 by using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and the appropriately substituted benzyl chloride. MS (ES+) data are
15 included in the Table below.




Ex.	NH-R	Compound	MS (ES+) <i>m/z</i>
467		6-(4- <i>tert</i> -Butylcarbamoyl-benzylthio)-7-chloro-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	403 (M+H) ⁺
468		7-Chloro-6-[4-(cyclohexylmethylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	443 (M+H) ⁺
469		7-Chloro-6-[4-(4-trifluoromethylbenzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	505 (M+H) ⁺
470		7-Chloro-6-[4-(3,4-difluorobenzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	473 (M+H) ⁺
471		7-Chloro-6-[4-(2,3,4-trifluorobenzylcarbamoyl)-benzylthio]-2,3,4,5-tetrahydro-1 <i>H</i> -benzo[<i>d</i>]azepine Hydrochloride	491 (M+H) ⁺

Example 472

(±)-7-Chloro-6-(1-methoxycarbonyl-1-phenyl-methylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride

5




Use a method similar to the General Procedure 1-4, using (±)-3-*tert*-butoxycarbonyl-7-chloro-6-(1-methoxycarbonyl-1-phenyl-methylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the title compound as a white solid. MS (ES+) *m/z* 362 (M+H)⁺.

10

Example 473


(±)-7-Chloro-6-(2-hydroxy-1-phenyl-ethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride



To a stirred solution of (±)-3-*tert*-butoxycarbonyl-6-(1-carboxy-1-phenyl-methylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (220 mg, 0.447 mmol) in THF (10 mL) at 0° C, add a solution of 1M borane in THF (1.4 mL, 1.4 mmol). Continue stirring for 2 h at 0° C and then overnight at ambient temperature. Quench by slow addition of methanol, stir 1 h at ambient temperature and concentrate *in vacuo*. Add aqueous saturated ammonium chloride, extract three times with EtOAc, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with 19:1 DCM/saturated ammonia in methanol. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 334 (M+H)⁺.

Example 474

7,9-Dichloro-6-methoxycarbonylmethylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride




Obtain as minor product from the reaction of the 4:1 mixture of 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-*tert*-butoxycarbonyl-7,9-dichloro-6-dimethylcarbamoylthio-

2,3,4,5-tetrahydro-benzo[*d*]azepine with methyl bromoacetate, using a method similar to the Example 347. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z*: 320 (M+H)⁺.

5

Example 475

6-(4-Benzyloxybenzylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




10

Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (706 mg, 1.84 mmol) in methanol (20 mL). Add potassium hydroxide (3.5 g, 55 mmol) and heat the mixture at reflux for 3h. Cool to ambient temperature. Pour reaction in saturated aqueous NH₄Cl solution. Extract three times with EtOAc. Combine organic extracts, dry over Na₂SO₄ and concentrate *in vacuo* to obtain crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (602 mg, 100%). Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (282 mg, 0.9 mmol) in acetone (30 mL). Add 4-benzyloxybenzyl chloride (251 mg, 1.08 mmol), potassium carbonate (powder) (373 mg, 2.7 mmol) and potassium iodide (powder) (15 mg, 0.1 mmol) and reflux for 16 h. Cool the reaction to ambient temperature, dilute with acetone, filter and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (1:0 and 17:3) to give 6-(4-benzyloxybenzylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (309 mg, 67%). MS (ES+) *m/z*: 510 (M+H)⁺.

20


25

Use a method similar to the General Procedure 1-4 and purify by chromatography on silica gel eluting with DCM/2*M* ammonia in methanol (95:5) to obtain the free base of the title compound (230 mg, 92%). MS (ES+) *m/z*: 410 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Example 476**7-Chloro-6-[(2-fluoro-4-phenoxy)benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Succinate**

Use a method similar to the Example 475, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 1-bromomethyl-2-fluoro-4-phenoxybenzene to provide, after chromatography on silica gel eluting with
10 hexane/EtOAc (85:15), 3-*tert*-butoxycarbonyl-7-chloro-6-[(2-fluoro-4-phenoxy)-benzylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine (384 mg, 83%). MS (ES+) *m/z*: 414 (M-Boc+2H)⁺.

Use a method similar to the General Procedure 1-4 and purify by chromatography
15 on silica gel eluting with DCM/2M ammonia in methanol (95:5) to obtain the free base of the title compound (203 mg, 65%). MS (ES+) *m/z*: 414 (M+H)⁺. Use a method similar to the General Procedure 2-1 to obtain the title compound.

Example 477**7-Chloro-6-[2-(4-fluorophenyl)-2-oxo-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

Use a method similar to the Example 475, using crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-bromo-4'-fluoroacetophenone (239 mg, 1.1 mmol) to provide, after stirring at ambient temperature for 16 h and purification by chromatography on silica gel eluting with hexane/EtOAc (4:1), 3-*tert*-butoxycarbonyl-7-chloro-6-[2-(4-fluorophenyl)-2-oxo-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (38 mg, 9%).

Use a method similar to the General Procedure 1-5 and purify by chromatography on silica gel eluting with DCM/2M ammonia in methanol (95:5) to obtain the free base of the title compound (23 mg, 78%). MS (ES+) *m/z*: 350 (M+H)⁺. Use a method similar to the General Procedure 2-2 to obtain the title compound.

Example 478

7-Chloro-6-(2-hydroxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 347, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and methyl bromoacetate to give 3-*tert*-butoxycarbonyl-7-chloro-6-methoxycarbonylmethylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.


To a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-methoxycarbonylmethylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (750 mg, 1.94 mmol) in THF (25 mL) at -78 °C under nitrogen, add 1M DIBAL in toluene (5.0 mL, 5.0 mmol) dropwise with stirring. Warm to -30°C over 1 h and quench carefully with water. Extract with EtOAc, dry over anhydrous MgSO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (4:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (651 mg, 94%).

Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (190 mg, 0.531 mmol) to give the title compound as a white solid (105 mg, 67%). MS (ES+) *m/z*: 258 (M+H)⁺.

5

Example 479

7-Chloro-6-(3-methoxycarbonylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the Example 347, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and methyl 4-bromobutyrate to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 314 (M+H)⁺.

15

Example 480

7-Chloro-6-(4-methoxycarbonylbutylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




20

Use a method similar to the Example 387 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with methyl-5-bromovalerate. Purify by preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol. Use a method similar to the General Procedure 2-2 to give the title compound as a white solid. MS (APCI+) *m/z*: 328 (M+H)⁺.

25

Example 481

7,9-Dichloro-6-(4-methoxycarbonylbutylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




5

Obtain the free base of the title compound as a minor product from Example 480, after preparative TLC eluting with 19:1 DCM/saturated ammonia in methanol. Use a method similar to the General Procedure 2-2 to obtain the title compound as a pale yellow solid. MS (APCI+) *m/z*: 362 (M+H)⁺.

10

Example 482

7-Chloro-6-cyanomethylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate




15

Use a method similar to the Example 387 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with bromoacetonitrile. Purify by preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; Solvent A: 10 mM aqueous ammonium carbonate, Solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min) to give the title compound as a white solid. MS (APCI+) *m/z*: 253 (M+H)⁺.

20

Example 483

6-Cyanomethylthio-7,9-dichloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate




5

Obtain the title compound as a minor product from Example 482, after preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; solvent A: 10 mM aqueous ammonium carbonate, solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). MS (APCI+) *m/z*: 287 (M+H)⁺.

10

Example 484

(±)-7-Chloro-6-(1-cyanoethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



15


Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-bromopropionitrile to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 267 (M+H)⁺.

20

Example 485

(±)-7-Chloro-6-(1-cyanopropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride

5




To a stirred solution of 1.5M lithium diisopropylamide in cyclohexane (1.37 mL, 2.05 mmol) in dry THF (5 mL) at -78°C under dry nitrogen, add a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-cyanomethylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (600 mg, 1.70 mmol) in THF (5 mL) and continue stirring for 2 h. Rapidly transfer the above solution via cannula to a solution of ethyl iodide (13.2 g, 84.9 mmol) in THF (5 mL) and continue stirring for 1 h. Quench with aqueous saturated ammonium chloride solution, extract three times with EtOAc, dry over anhydrous Na_2SO_4 , and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give (±)-3-*tert*-butoxycarbonyl-7-chloro-6-(1-cyanopropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a pale oil (350 mg, 68%). Use a method similar to the General Procedure 1-4 to give the title compound as an off-white solid. MS (ES+) m/z : 281. ($\text{M}+\text{H}$)⁺.

20

Example 486

7-chloro-6-(1-cyano-1-methylethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




25

To a stirred solution of 3-*tert*-butoxycarbonyl-7-chloro-6-cyanomethylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]-azepine (300 mg, 0.85 mmol) in THF (5 mL) at 0°C, add potassium *tert*-butoxide (480 mg, 4.26 mmol) at ambient temperature. After 15 min, add methyl iodide (3.02 g, 21.31 mmol) and continue stirring overnight at ambient temperature. Concentrate *in vacuo* and purify by chromatography on silica gel eluting with hexane/EtOAc (9:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(1-cyano-1-methylethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (177 mg, 55%). MS (ES+) *m/z*: 282 (M+H-Boc)⁺. Use a method similar to the General Procedure 1-4 to give the title compound as an off-white solid. MS (ES+) *m/z*: 282 (M+H)⁺.

Example 487


7-Chloro-6-(4-cyanobutylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 387 to react 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 5-bromovaleronitrile. Purify by preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; Solvent A: 10 mM aqueous ammonium carbonate, Solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). Use a method similar to the General Procedure 2-2 to give the title compound as an off-white solid. MS (APCI+) *m/z*: 295 (M+H)⁺.

Example 488

7,9-Dichloro-6-(4-cyanobutylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Obtain the free base of the title compound as a minor product from Example 487, after preparative reverse phase HPLC (Column: Xterra Prep RP18 19x250mm; Solvent A: 10 mM aqueous ammonium carbonate, Solvent B: acetonitrile; 30-100% B over 20 minutes; flow rate 25 mL/min). Use a method similar to the General Procedure 2-2 to
5 obtain the title compound as a tan solid. MS (ES+) m/z : 329 (M+H)⁺.

Example 489

7-Chloro-6-(2-pyridin-2-yl-ethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Hydrochloride

10




15

Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 2-(2-bromoethyl)-pyridine hydrobromide to give, after deprotection using a method similar to the General Procedure 1-4, the title compound. MS (ES+) m/z 319 (M+H)⁺.

Example 490

6-[3-(3-*tert*-Butyl-[1,2,4]oxadiazol-5-yl)-propylthio]-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

20




25

Use a method similar to the Example 387, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 5-(3-bromopropyl)-3-*tert*-butyl-[1,2,4]oxadiazole to give, after deprotection using a method similar to the

General Procedure 1-4, the title compound as a white solid. MS (APCI+) m/z 380 (M+H)⁺.

Example 491


- 5 (-)-7-Chloro-6-(tetrahydrofuran-3-ylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



- 10 Use a method similar to the Example 332, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (*S*)-toluene-4-sulfonic acid tetrahydrofuran-3-yl ester to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as an off-white solid. MS (APCI+) m/z : 284 (M+H)⁺; $[\alpha]_D^{20}$ -28.0° (c 0.5, CH₃OH). ee = 97.8% [Chiral HPLC: Column: YMC
15 ODS-AQ 120Å 4.6x50 mm [S-3μm]; eluent: gradient from 95:5 to 5:95 A/B; solvent A: water, 0.01% HFBA, 1% isopropanol; solvent B: acetonitrile, 0.01% HFBA, 1% isopropanol; flow rate 2 mL/min].

Example 492

- 20 (+)-7-Chloro-6-(tetrahydrofuran-3-ylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




Use a method similar to the Example 332, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and (*R*)-toluene-4-sulfonic acid tetrahydro-furan-3-yl ester to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as an off-white solid. MS (APCI+) *m/z*: 284 (M+H); [α]_D²⁰ +32.5° (c 0.5, CH₃OH); ee = 95.7% [Chiral HPLC: Column: YMC ODS-AQ 120Å 4.6x50 mm. [S-3µm]; eluent: gradient from 95:5 to 5:95 A/B; solvent A: water, 0.01% HFBA, 1% isopropanol; solvent B: acetonitrile, 0.01% HFBA, 1% isopropanol; flow rate 2 mL/min].

10

Example 493

(±)-7-Chloro-6-(tetrahydrofuran-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




15

Use a method similar to the Example 330, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-(bromomethyl)tetrahydrofuran to give, after deprotection by the General Procedure 1-4, the title compound as white crystals. MS (APCI+) *m/z*: 298 (M+H)⁺.

20

Example 494

(±)-7-Chloro-6-(tetrahydropyran-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Use a method similar to the Example 330, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 2-(bromomethyl)tetrahydropyran to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (APCI+) *m/z*: 312 (M+H)⁺.

5

Example 495

(S)-(+)-7-Chloro-6-(5-oxo-tetrahydrofuran-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




10

Use a method similar to the General Procedure 1-4, using (S)-3-*tert*-butoxycarbonyl-7-chloro-6-(5-oxo-tetrahydrofuran-2-ylmethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the title compound as a white solid. MS (ES+) *m/z*: 312 (M+H)⁺. [α]_D²⁰ +78° (c 0.5, CH₃OH).

15

Example 496

7-Chloro-6-(3-dimethylcarbamoylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



20

Treat a solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(3-methoxycarbonylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (385 mg, 0.90 mmol) in dioxane/water (1:1, 3.5 mL) with lithium hydroxide (43.0 mg, 1.01 mmol) at 80 °C for 1.5 h. Cool to ambient temperature, add aqueous saturated ammonium chloride and brine,

25


extract three times with ethyl ether, dry over anhydrous MgSO_4 , and concentrate *in vacuo*. Dissolve the residue in DCM (3.5 mL) and add EDC (162 mg, 0.84 mmol), 1-hydroxybenzotriazole (91.0 mg, 0.67 mmol), triethylamine (0.20 mL, 1.35 mmol), and dimethylamine (0.700 mL, 1.35 mmol). Stir overnight at ambient temperature. Dilute
 5 with water, extract with ethyl ether, dry over anhydrous MgSO_4 , and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc/methanol 60:40:1 to give 3-*tert*-butoxycarbonyl-7-chloro-6-(3-dimethylcarbamoyl-propylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine.

10 Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-(3-dimethylcarbamoyl-propylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine in DCM (1 mL) at ambient temperature and add 4M hydrogen chloride in dioxane (200 μL , 0.8 mmol). Continue stirring until TLC shows consumption of starting material. Concentrate *in vacuo*, triturate the obtained solid with dry diethyl ether and dry at 50° C under high vacuum overnight to give the title compound
 15 as a hygroscopic white solid (45.0 mg, 57%). MS (ES+) m/z : 327 (M+H)⁺.

Example 497

7-Chloro-6-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-propylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate

20




Dissolve 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (2.0 g, 5.20 mmol) in methanol (58 mL) and add
 25 potassium hydroxide (9.36 g, 167 mmol). Heat at 50 °C for 2 h. Cool to ambient temperature, add aqueous saturated ammonium chloride and water, extract three times with EtOAc, dry over anhydrous Na_2SO_4 , and concentrate *in vacuo* to give 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.62 g, 5.20 mmol). Dissolve the crude 3-*tert*-butoxycarbonyl-7-chloro-6-mercapto-2,3,4,5-

tetrahydro-1*H*-benzo[*d*]azepine (1.40 g, 4.46 mmol) in dry DMF (49.8 mL) and add DBU (0.80 mL, 5.35 mmol) and 3-bromopropyl phthalimide (1.55 g, 5.80 mmol). Stir at ambient temperature for 3 h. Add aqueous saturated ammonium chloride and water. Extract twice with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify
 5 by chromatography on silica gel eluting with hexane/EtOAc (6:1) to give the free base of title compound (1.64 g, 74%).

Use a method similar to the General Procedure 1-5, to deprotect 3-*tert*-butoxycarbonyl-7-chloro-6-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propylthio]-2,3,4,5-
 10 tetrahydro-1*H*-benzo[*d*]azepine and purify by preparative reverse phase HPLC to give the title compound. MS (APCI+) *m/z* 401 (M+H)⁺.

Example 498

6-(3-Benzoylaminoethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
 15 Trifluoroacetate




Suspend 3-*tert*-butoxycarbonyl-7-chloro-6-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-propylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (1.20 g, 2.39 mmol) in ethanol
 20 (53.2 mL), add hydrazine (0.150 mL, 4.78 mmol) and heat at 65 °C for 2 h. Cool to ambient temperature, filter from precipitate, and concentrate *in vacuo* to provide the 6-(3-aminopropylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (861 mg, 97%). MS (APCI+) *m/z*: 371 (M+H)⁺.

To a solution of 6-(3-aminopropylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (46.7 mg, 0.126 mmol) in dry DCM (0.5 mL) at ambient temperature under nitrogen, add triethylamine (19.3 μ L, 0.139 mmol) and benzoyl chloride (16.1 μ L, 0.139 mmol). Stir at ambient temperature for 2.5 h. Add aqueous saturated ammonium chloride and water, extract three times with EtOAc, dry over anhydrous Na_2SO_4 , and concentrate *in vacuo*. Dissolve the residue in DCM (0.16 mL), add trifluoroacetic acid (44.6 μ L, 0.58 mmol) and stir for 18 h at ambient temperature. Concentrate *in vacuo* and purify by preparative HPLC [Column: YMC ODS-AQ 120Å 20x250mm [S10-20 μ m]; eluent: 95:5 to 5:95 A/B; solvent A: water, 0.1% TFA, 1% isopropanol; solvent B: acetonitrile, 0.05% TFA, 1% isopropanol; flow rate 20 mL/min] to give the title compound (7.0 mg, 12%). MS (APCI+) m/z 375 (M+H)⁺.

Example 499


6-[3-(3-Phenylureido)-propylthio]-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate



Use a method similar to the Example 498, using phenyl isocyanate, to give the title compound. MS (APCI+) m/z 390 (M+H)⁺.

Example 500


7-Chloro-6-[3-(4-trifluoromethylbenzoylamino)-propylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate



To a stirred solution of 4-trifluoromethylbenzoic acid (60.0 mg, 0.316 mmol) in anhydrous DMF (1.2 mL) at ambient temperature under nitrogen, add EDC (63.6 mg, 0.332 mmol), 1-hydroxybenzotriazole (44.8 mg, 0.332 mmol), 4-dimethylaminopyridine (40.5 mg, 0.332 mmol) and a solution of 6-(3-aminopropylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (123 mg, 0.332 mmol) in DCM (2 mL). Stir for 18 h at ambient temperature. Add water, extract twice with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Treat the residue with trifluoroacetic acid (0.272 mL, 0.640 mmol) in DCM (0.451 mL) at ambient temperature for 18 h. Concentrate *in vacuo* and purify by preparative reverse phase HPLC [Column: YMC ODS-AQ 120Å 20x250mm [S10-20µm]; eluent: 95:5 to 5:95 A/B; solvent A: water, 0.1% TFA, 1% isopropanol; solvent B: acetonitrile, 0.05% TFA, 1% isopropanol; flow rate 20 mL/min] to give the title compound as a white solid (31.0 mg, 18%). MS (APCI+) *m/z* 443 (M+H)⁺.

Example 501


7-Chloro-6-[3-(4-*tert*-butylbenzoylamino)-propylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate



Use a method similar to the Example 500, using 6-(3-aminopropylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and 4-*tert*-butyl benzoic acid to give the title compound as a white solid. MS (APCI+) *m/z* 431 (M+H)⁺.

Example 502

7-Chloro-6-(2-ethoxycarbonylamino-ethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Trifluoroacetate



5

Use a method similar to the Example 497, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and 3-bromoethyl phthalimide to give 6-(3-aminoethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine. MS (ES+) m/z 357 (M+H)⁺.

10


Use a method similar to the Example 498, using 6-(3-aminoethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine and ethyl chloroformate to give, after deprotection using a method similar to the General Procedure 1-5, the title compound as a white solid. MS (APCI+) m/z : 329 (M+H)⁺.

15

Example 503

7-Chloro-6-{2-[(pyridine-4-carbonyl)amino]-ethylthio}-2,3,4,5-tetrahydro-1H-benzo[d]azepine Trifluoroacetate

20




Use a method similar to the Example 500, using 6-(3-aminoethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and isonicotinic acid to give the title compound. MS (ES+) m/z : 362 (M+H)⁺.

5

Example 504

7-Chloro-6-[2-(cyclopropanecarbonylamino)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate




10

Use a method similar to the Example 498, using 6-(3-aminoethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and cyclopropanecarbonyl chloride to give, after deprotection using a method similar to the General Procedure 1-5, the title compound. MS (ES+) m/z : 325 (M+H)⁺.

15

Example 505

6-(2-Benzenesulfonylamino-ethylthio)-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Trifluoroacetate




20

Use a method similar to the Example 498, using 6-(3-amino-ethylthio)-3-*tert*-butoxycarbonyl-7-chloro-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and benzenesulfonyl chloride to give, after de protection using a method similar to the General Procedure 1-5, the title compound as a white solid. MS (APCI+) m/z : 397 (M+H)⁺.

25

Example 506

7-Chloro-6-(3-pyrrol-1-yl-propylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
Trifluoroacetate




5

Use a method similar to the Example 497, using 3-*tert*-butoxycarbonyl-7-chloro-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1H-benzo[d]azepine and *N*-(3-bromopropyl)pyrrole to give, after deprotection using a method similar to the General Procedure 1-5, the title compound as a white solid. MS (ES+) m/z : 321 (M+H)⁺.

10

Example 507

7-Chloro-6-[2-(2,2-dimethylpropionyloxy)-ethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride




15

To a stirred solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxyethylthio)-2,3,4,5-tetrahydrobenzo[d]azepine (85 mg, 0.238 mmol) in DCM (3 ml) at 0°C, add triethylamine (331 μ l, 2.381 mmol) followed by trimethylacetyl chloride (147 μ l, 1.190 mmol). Continue stirring for 15 min, dilute with water, extract three times with EtOAc, dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Deprotection by the General Procedure 1-5, basic workup, and by the General Procedure 2-2 give the title compound. MS (ES+) m/z 342 (M+H).

25

Example 508

7-Chloro-6-(2-cyclohexanecarbonyloxy-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




5

Use a method similar to the Example 507, using cyclohexanecarbonyl chloride, to give the title compound. MS (ES+) *m/z* 368 (M+H).

10

Example 509

7-Chloro-6-(3-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




15

Use a method similar to the Preparation 242, using 3-*tert*-butoxycarbonyl-7-chloro-6-(3-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 334 (M+H)⁺.

20

Example 510


7-Chloro-6-(2-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




Use a method similar to the Preparation 242, using 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give, after deprotection by the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 334 (M+H)⁺.

Example 511

7-Chloro-6-(4-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-7-chloro-6-(4-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the title compound as a white solid. MS (ES+) *m/z*: 334 (M+H)⁺.

Example 512**7-Chloro-6-(4-methoxymethylbenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

5


To a stirred solution of 3-*tert*-butoxycarbonyl-7-chloro-6-(4-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (133 mg, 0.306 mmol) in anhydrous DMF (2 mL) under nitrogen, add sodium hydride (60% dispersion, 13-15 mg, 0.375 mmol) at ambient temperature and continue stirring for 30 min. Add methyl iodide (80 mL, 1.28 mmol). After 15 min, dilute with water, extract three times with EtOAc, dry over anhydrous MgSO₄ and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (15:1) to give 3-*tert*-butoxycarbonyl-7-chloro-6-(4-methoxymethylbenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a clear oil, which crystallizes on standing to a white solid (87 mg, 63%), along with recovered starting material (22 mg, 17%). Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES⁺) *m/z*: 348 (M+H-Boc)⁺.

10

15

Example 513**7-Chloro-6-(3-methoxymethylbenzylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride**

20




Use a method similar to the Example 512, using 3-*tert*-butoxycarbonyl-7-chloro-6-(3-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the title compound as a white solid. MS (ES+) *m/z*: 348 (M+H).

5

Example 514

7-Chloro-6-(2-methoxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride




10

Use a method similar to the Example 512, using 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxymethylbenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine to give the title compound as a white solid. MS (ES+) *m/z*: 348 (M+H).

15

Example 515

7-Chloro-6-(2-methoxyethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine hydrochloride




20

Use a method similar to the Example 512, using 3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxy-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the title compound as a white solid. MS (ES+) *m/z*: 272 (M+H).

Example 516

7-Chloro-6-(4-methoxybutylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride



5


Use a method similar to the Example 478, using 3-*tert*-butoxycarbonyl-7-chloro-6-(3-methoxycarbonyl-propylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give 3-*tert*-butoxycarbonyl-7-chloro-6-(4-hydroxybutylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine. Use a method similar to the Example 512, using 3-*tert*-butoxycarbonyl-7-chloro-6-(4-hydroxybutylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give the title compound as a white solid. MS (ES+) m/z : 300 (M+H)⁺.

10

Example 517

(±)-7-Chloro-6-(2-methoxy-1-phenylethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine Hydrochloride

15




20

Use a method similar to the Example 512, using (±)-3-*tert*-butoxycarbonyl-7-chloro-6-(2-hydroxy-1-phenylethylthio)-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give, after deprotection by a method similar to the General Procedure 1-4, the title compound as an off-white solid. MS (ES+) m/z : 348 (M+H)⁺.

Example 518

(-)-7-Chloro-6-(2-methoxy-1-phenylethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride


5



Separate the enantiomers of (±)-7-chloro-6-(2-methoxy-1-phenyl-ethylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine by chiral normal phase chromatography (Chiralcel
10 OJ 8x33 cm column, eluting with 0.2% DMEA in ethanol/heptane, 40:60). Collect the second eluting isomer and use the General Procedure 2-2 to give the title compound as a white solid (76 mg, 29%). MS (ES+) *m/z*: 349 (M+H)⁺. [α]_D²⁰ -176° (c 0.5, CH₃OH).

Example 519

15 6-(4-Fluorobenzylthio)-7-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride




Use a method similar to the General Procedure 7, using 3-*tert*-butoxycarbonyl-6-dimethylcarbamoylthio-7-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (75 mg, 0.206
20 mmol) and 4-fluorobenzyl bromide (195 mg, 1.03 mmol) to give, after chromatography on silica gel eluting with hexane/EtOAc (1:0, 9:1 and 4:1), 3-*tert*-butoxycarbonyl-6-(4-fluorobenzylthio)-7-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as an oil (59 mg, 71%). MS (ES+) *m/z*: 302 (M+H-Boc)⁺.

Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-6-(4-fluorobenzylthio)-7-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (55 mg, 0.137 mmol) to give the title compound as a white solid (42 mg, 91%). MS (ES+) *m/z*: 285 (M+H)⁺.

5

Example 520

7-Cyano-6-(4-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




10

Use a method similar to the General Procedure 7, using 3-*tert*-butoxycarbonyl-7-cyano-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (123 mg, 0.33 mmol) and 4-fluorobenzyl bromide (204 mg, 1.64 mmol), to give 3-*tert*-butoxycarbonyl-7-cyano-6-(4-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colourless oil (118 mg, 87%). Use a method similar to the General Procedure 1-4, using 3-*tert*-butoxycarbonyl-7-cyano-6-(4-fluorobenzylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (118 mg, 0.286 mmol) to give, after basic work-up, the free base of the title compound (89 mg, 100%). MS (ES+) *m/z* 313 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound (123 mg, 100%). MS (ES+) *m/z* 313 (M+H)⁺.

20

Example 521

(±)-7-Cyano-6-[1-(4-fluorophenyl)ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Succinate




25

Use a method similar to the General Procedure 7, using 3-*tert*-butoxycarbonyl-7-cyano-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (171 mg, 0.46 mmol) and (±)-1-(4-fluorophenyl)ethyl bromide (377 mg, 1.85 mmol) to give, after
5 purification by chromatography on silica gel, (±)-3-*tert*-butoxycarbonyl-7-cyano-6-[1-(4-fluorophenyl)-ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine as a colourless oil (10.3 mg, 5.3%). MS (ES+) *m/z* 449 (M+Na)⁺, 465 (M+K)⁺.

Use a method similar to the General Procedure 1-5, using (±)-3-*tert*-
10 butoxycarbonyl-7-cyano-6-[1-(4-fluorophenyl)ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (10.3 mg, 0.024 mmol) to give, after basic work-up, the free base of the title compound (6.8 mg, 87%). MS (ES+) *m/z* 327 (M+H)⁺. Use a method similar to the General Procedure 2-1 to give the title compound as a white solid (9.3 mg, 87%). MS
15 (ES+) *m/z* 327 (M+H)⁺.

Example 522

7-Cyano-6-[1-(4-fluorophenyl)ethylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Succinate, Isomer 1




20

Separate the two enantiomers of (±)-7-cyano-6-[1-(4-fluorophenyl)ethylthio]-
2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine by chiral HPLC (Chiralpak AD-H 15cm x 4.6mm
column with a 5 μm packing size. Elute with heptane/ethanol (95:5) containing 0.2%
25 DEA at 0.5 mL/min with an injection volume of 10.00 μL).

Subject the first eluting isomer ($t_R = 17.2$ min, $ee > 99\%$) to the General Procedure 2-1 to afford the title compound as a white solid. MS (ES+) m/z 327 (M+H)⁺.

Example 523


5 7-Bromo-6-(3-ethoxycarbonylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



10 Use a method similar to the Preparation 177, using 3-*tert*-butoxycarbonyl-7-bromo-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and ethyl 4-bromobutyrate to give, after deprotection by a method similar to the General Procedure 1-4, the title compound. MS (ES+) m/z : 374 (M+H)⁺.

Example 524


15 7-Bromo-6-(3-dimethylcarbamoylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine
Hydrochloride



20 Use a method similar to the Example 523, using 7-bromo-3-*tert*-butoxycarbonyl-6-(3-ethoxycarbonylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine, to give the title compound as a white solid. MS (ES+) m/z : 373 (M+H)⁺.

Example 525


7-Bromo-6-(4-oxo-4-pyrrolidin-1-yl-butylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 523, using 7-bromo-3-*tert*-butoxycarbonyl-6-(3-ethoxycarbonylpropylthio)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine and pyrrolidine to give the title compound. MS (ES+) *m/z*: 397 (M+H)⁺.

Example 526


7-Bromo-6-[3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-propylthio]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



Use a method similar to the Example 497 to react 7-bromo-3-*tert*-butoxycarbonyl-6-dimethylcarbamoylthio-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine with 3-bromopropyl phthalimide. Use a method similar to the General Procedure 1-4 to give the title compound as a white solid. MS (ES+) *m/z* 445 (M+H)⁺.

Example 527

6-[2-(2,2-Dimethylpropionyloxy)-ethylthio]-7-trifluoromethyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine Hydrochloride



3-tert-Butoxycarbonyl-6-dimethylcarbamoylthio-7-trifluoromethyl-2,3,4,5-tetrahydro-benzo[d]azepine:

- To a stirred solution of 7-bromo-6-dimethylcarbamoylthio-3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (1.383 g, 3.254 mmol), in NMP (40 ml) add sodium trifluoromethyl acetate (3.54 g, 26.03 mmol), copper(I) iodide (2.47 g, 13.0 mmol) and heat the mixture at 180 °C for 4 h. Cool to ambient temperature. Dilute with EtOAc, water and remove the copper solid residue by filtration. Separate the layers of filtrate and extract the aqueous layer three times with EtOAc. Dry over anhydrous Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (6:1) to give the desired intermediate as a yellow oil (882 mg, 74%).

3-tert-Butoxycarbonyl-6-[2-(tert-butyl-dimethylsilyloxy)ethylthio]-7-

- trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine:** Use a method similar to the Preparation 177, using 3-tert-butoxycarbonyl-6-dimethylcarbamoylthio-7-trifluoromethyl-2,3,4,5-tetrahydro-benzo[d]azepine and (2-bromoethoxy)-tert-butyl-dimethylsilyl ether to give the desired intermediate.

3-tert-Butoxycarbonyl-6-(2-hydroxyethylthio)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine:

- Dissolve 6-[2-(tert-butyl-dimethyl-silyloxy)-ethylthio]-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (153 mg, 0.303 mmol) in THF (3 mL). Add 1.0 M tetrabutylammonium fluoride in THF (600 µL, 0.606 mmol,) and stir overnight. Dilute with water, extract three times with EtOAc, dry over anhydrous

Na₂SO₄, and concentrate *in vacuo*. Purify by chromatography on silica gel eluting with hexane/EtOAc (85:15) to give the desired intermediate.

6-[2-(2,2-Dimethylpropionyloxy)-ethylthio]-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-

- 5 **benzo[d]azepine hydrochloride:** Use a method similar to the Example 507, using 3-*tert*-butoxycarbonyl-6-(2-hydroxyethylthio)-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine to give, after deprotection using a method similar to the General Procedure 1-4, the title compound as a white solid. MS (ES+) *m/z*: 376 (M+H)⁺.

- 10 The compounds of the present invention are relatively selective for the 5-HT_{2C} receptor. The compounds of the present invention are particularly relatively selective for the 5-HT_{2C} receptor in comparison to other 5-HT receptor subtypes and specifically the 5-HT_{2A} and 5-HT_{2B} receptors. This selectivity is demonstrated in the following agonist activity assays and receptor binding assays.

15

Agonist Activity Assays (G alpha q-GTPγ[³⁵S] Binding Assays)

- The 5-HT₂ receptors are functionally coupled to specific G-proteins. Agonist activation of 5-HT₂ G-protein-coupled receptors results in the release of GDP from the α-subunit (G alpha q or G alpha i) of the G-protein and the subsequent binding of GTP. The
20 binding of the stable analog GTPγ[³⁵S] is an indicator of receptor activation (i.e. agonist activity).

- The G alpha q-GTPγ[³⁵S] binding assay is used to determine the *in vitro* potency (EC₅₀) and maximal efficacy (E_{max}, normalized to the 5-HT response) of a test compound
25 at the 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors. The area under the dose response curve (AUC) is also determined for each receptor subtype and used to measure the test compound's selectivity for the 5-HT_{2C} receptor over the 5-HT_{2A} and 5-HT_{2B} receptors, expressed as Selectivity Ratios (AUC 2C/2A and AUC 2C/2B, respectively). The Selectivity Ratios allow the assessment of selectivity based on both potency and efficacy.
30 A selectivity measure that incorporates both potency and efficacy at the 5-HT_{2C} receptor, as compared to the 5-HT_{2A} and 5-HT_{2B} receptors, is considered important due to the adverse events associated with 5-HT_{2A} and 5-HT_{2B} agonist activity (see introduction).

Membrane Preparation: Grow AV12 cells stably transfected with the human 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C} receptors in suspension, harvest by centrifugation, wash the cell pellet with phosphate buffered saline, pH 7.4, pellet the cells again, remove the supernatant, freeze the cell pellet on dry ice and store at -70°C. Thaw stock cell pellet and resuspend in 50mM Tris, pH 7.4, aliquot into 1-2 mL volumes and refreeze at -70°C for subsequent assays. (As is appreciated in the art, optimal cell quantities used per aliquot will vary with the individual transfected cell line used. In one embodiment, 5-HT_{2A} and 5-HT_{2C} transfected cells are typically used at about 6×10^8 cells per aliquot, while 5-HT_{2B} cells are typically used at about 7.5×10^8 cells per aliquot).

On the day of assay, thaw membranes, wash the membranes with assay buffer (50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 100 mM NaCl, and 0.2 mM EDTA), resuspend in assay buffer and incubate for 10 min. at 37°C to hydrolyze any residual endogenous 5-HT. Wash the membranes again with assay buffer, and resuspend in assay buffer at a concentration to provide aliquots of about $1-4 \times 10^6$ cell equivalents per well (typically about $1-2 \times 10^6$ cell equivalents for assays with 5-HT_{2A} or 5-HT_{2C} receptor assays, and about $3-4 \times 10^6$ cell equivalents for assays with 5-HT_{2B} receptor assays). Homogenize the cells with a tissue grinder and use the homogenate directly in the assay as described below.

G alpha q-GTP[³⁵S] Binding Assays: The immunoadsorption scintillation proximity assay (ISPA) of [³⁵S]-GTPγS binding to G alpha q is modified from published conditions (DeLapp et al, JPET 289 (1999) 946-955). Dissolve test compounds in DMSO and dilute in assay buffer to provide a range of concentrations to generate a concentration response curve. In wells of a 96 well microtiter plate, mix diluted test compound, GDP (0.1 μM final concentration), and [³⁵S]-GTPγS (between 0.5 and 1.0 nM final concentration). Add an aliquot of membranes to the incubation mixture and mix the plates to initiate agonist stimulation of the nucleotide exchange (200 μl final volume). Incubate the microtiter plates for 30 min. at room temperature. Quench the incubation with IGEPAL® CA-630 detergent (0.27% final concentration). Add affinity purified polyclonal rabbit anti-G alpha q antibody (about 1-2 μg per well), and anti-rabbit Ig

scintillation proximity assay beads (Amersham; about 1.25 mg per well; 300 µl final volume). Seal the plates and incubate the mixture for 3 h at room temperature. Centrifuge the microtiter plates briefly to pellet beads. Quantitate the GTPγ[³⁵S] binding by microtiter plate scintillation spectrometry (Wallac Trilux MicroBeta™ scintillation counter).

Data Analysis: For each concentration response curve for a test compound at a given receptor, analyze the data with GraphPad Prism™ software (v3.02; GraphPad Software, San Diego, CA) running on a personal computer with MicroSoft Windows OS®, using nonlinear regression analysis curve fitting to determine the EC₅₀ and E_{max} (normalized to 5-HT control curves). Determine the Area Under the agonist concentration-response Curve (AUC) with GraphPad Prism™ by the trapezoidal method.

To calculate the Selectivity Ratios, first, determine the AUC for the test compound for each receptor subtype as described above. Second, normalize the AUC's at each receptor subtype relative to the AUC determined for 5-HT at that receptor. The normalized AUC for a test compound at a given receptor is therefore expressed as a percentage of the AUC determined for 5-HT at that receptor. For example:

$$5HT_{2A} \text{ Normalized AUC} = a = \frac{(\text{AUC}_{\text{test compound at } 5HT_{2A} \text{ receptor}})}{(\text{AUC}_{5-HT \text{ at } 5HT_{2A} \text{ receptor}})} \times 100\%$$

$$5HT_{2B} \text{ Normalized AUC} = b = \frac{(\text{AUC}_{\text{test compound at } 5HT_{2B} \text{ receptor}})}{(\text{AUC}_{5-HT \text{ at } 5HT_{2B} \text{ receptor}})} \times 100\%$$

$$5HT_{2C} \text{ Normalized AUC} = c = \frac{(\text{AUC}_{\text{test compound at } 5HT_{2C} \text{ receptor}})}{(\text{AUC}_{5-HT \text{ at } 5HT_{2C} \text{ receptor}})} \times 100\%$$

Third, calculate the Selectivity Ratios for the test compound as follows:

$$\text{Selectivity Ratio for } 5-HT_{2C} \text{ receptor}/5-HT_{2A} \text{ receptor (AUC } 2C/2A) = c/a$$

$$\text{Selectivity Ratio for } 5-HT_{2C} \text{ receptor}/5-HT_{2B} \text{ receptor (AUC } 2C/2B) = c/b$$

For reference purposes, the AUC 2C/2A and AUC 2C/2B for 5-HT are each 1.0. Likewise, the ratios for mCPP (*meta*-chlorophenylpiperazine) are tested and are found to be 2.1 and 2.1 respectively.

Representative compounds of the present invention are tested in the G alpha q-GTP γ [³⁵S] assays for the 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors essentially as described above and are found to be a highly potent and selective agonists of the 5-HT_{2C} receptor, with EC₅₀'s typically less than or equal to 200 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than 1.5. Preferred compounds are those with EC₅₀'s less than or equal to 100 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than or equal to 2.0. More preferred are those with EC₅₀'s less than or equal to 50 nM, and AUC 2C/2A and AUC 2C/2B ratios greater than or equal to 3.0.

10 **Ligand Binding Assays**

The ligand binding affinity of the compounds of the present invention to the 5-HT_{2C} receptor subtype is measured essentially as described by Waincott (Waincott, *et al.*, *Journal of Pharmacology and Experimental Therapeutics*, 276:720-727 (1996)). Data is analyzed by nonlinear regression analysis on the concentration response curves using the four parameter logistic equation described by DeLean (DeLean, *et al.*, *Molecular Pharmacology*, 21, 5-16 (1982)). IC₅₀ values are converted to K_i values using the Cheng-Prusoff equation (Cheng, *et al.*, *Biochem. Pharmacol.*, 22, 3099-3108 (1973)).

Representative compounds of the present invention are tested essentially as described above and are found to have excellent affinity for the 5-HT_{2C} receptor, with K_i's typically less than or equal to about 200 nM. Preferred compounds are those with K_i's of less than or equal to about 100 nM. More preferred are those with K_i's less than or equal to 50 nM.

Affinities for other receptor subtypes can readily be determined by slight modification of the above described radioligand receptor binding assay using cells transfected with the desired receptor in place of cells transfected with the 5-HT_{2C} receptor subtype and using an appropriate radioligand. The binding affinities for representative compounds of the present invention for a variety of receptors are determined in such assays and the compounds are found to have surprisingly higher affinity for the 5-HT_{2C} receptor. Affinity for the 5-HT_{2C} receptor is found to be significantly higher than for other 5-HT receptor subtypes, and notably higher than the 5-HT_{2A} and 5-HT_{2B} receptor

subtypes. Preferred compounds are those with IC_{50} 's equal to or greater than 300 nM for the alpha 1 and alpha 2 adrenergic receptors and equal to or greater than 500 nM for D_1 and D_2 dopaminergic receptors. More preferred compounds are those with IC_{50} 's equal to or greater than 1000 nM for the alpha 1 and alpha 2 adrenergic receptors and the D_1 and D_2 dopaminergic receptors. Still more preferred are those compounds with IC_{50} 's equal to or greater than 3000 nM for the alpha 1 and alpha 2 adrenergic receptors and the D_1 and D_2 dopaminergic receptors.

For the above in vitro assays, exemplified compounds are assayed and found to have either an EC_{50} or a K_i value of equal to or less than 50 nM, and to have AUC 2C/2A and AUC 2C/2B ratios of greater than or equal to 2.0. Exemplified compounds are assayed and found to have alpha 1 and alpha 2 adrenergic receptor IC_{50} 's equal to or greater than 300 nM, and D_1 and D_2 dopaminergic receptor IC_{50} 's equal to or greater than 500 nM.

Rat feeding assays

The ability of the compounds of the present invention to treat obesity is demonstrated by testing in acute and chronic rat feeding assays.

Animals: Obtain male Long-Evans rats (Harlan Sprague-Dawley, Indianapolis, IN) that are approximately one hundred-days old and have been maintained on a calorie rich diet since weaning (TD 95217, 40% calories from fat; Teklad, Madison, WI). House the rats individually with a 12 h:12 h light:dark cycle (lights on from about 22:00 h to about 10:00 h) and maintain rats on the same diet (TD 95217) with free access to water, for about 1-2 weeks to acclimate the rats to the environment. Dose rats orally with vehicle (10% acacia with 0.15% saccharin in water) once daily for at least 1 day (typically 1-2 days) to acclimate the rats to the procedures. Randomize the rats into groups so each group has similar mean body weights.

Calorimetric Acute Feeding Assay: At approximately 8:00 h on the day of assay, weigh each rat and transfer to individual chambers of an open circuit calorimetry system (Oxymax, Columbus Instruments International Corporation; Columbus, OH), with free

access to food (pre-weighed) and water, and begin measuring VO_2 and VCO_2 . At approximately 10:00 h, dose rats orally with vehicle or test compound, return them to their calorimetry chambers, and continue measuring VO_2 and VCO_2 at regular time intervals (approximately hourly). At approximately 8:00 h the following day, measure rat
5 body weight and the remaining food, assuming the difference in weight of food is equal to the mass of food consumed. Calculate the 24 h energy expenditure (EE) and respiratory quotient (RQ) essentially as described in Chen, Y. and Heiman, M. L., *Regulatory Peptide*, 92:113-119 (2000). EE during light photoperiod is indicative of the resting metabolic rate and RQ is indicative of the fuel source the animal utilizes (pure
10 carbohydrate metabolism gives an RQ of about 1.0, pure fat metabolism gives an RQ of about 0.7, mixed carbohydrate and fat metabolism gives intermediate values for RQ). Calculate EE as the product of calorific value (CV) and VO_2 per body weight (kg); where $\text{CV} = 3.815 + 1.232 \cdot \text{RQ}$, and RQ is the ratio of CO_2 produced (VCO_2) to O_2 consumed (VO_2). Caloric intake is calculated as (mass of 24 h food intake in grams) x
15 (physiological fuel value of the diet in kilocalorie/g) per kg of body weight.

Acute Feeding Assay with a selective 5-HT_{2C} receptor antagonist: The above calorimetric acute feeding assay is conducted with the following modifications. Open circuit calorimetry systems are not used and only the 24 h periodic food intake and body weight
20 are measured. Three groups of rats are used with the first group receiving a subcutaneous dose of saline (0.5 mL) about 15 minutes prior to the oral dose of vehicle, the second group receiving a subcutaneous dose of saline (0.5 mL) about 15 minutes prior to the oral dose of test compound in vehicle, and the third group receiving a subcutaneous injection of a selective 5-HT_{2C} receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole (3 mg/Kg, in 35% cyclodextrin,
25 0.5 mL), about 15 min. prior to the oral dose of test compound in vehicle.

Chronic Feeding Assay: At between approximately 8:00 h and 10:00 h on day one of the assay, weigh and orally dose each rat with vehicle or test compound and return the animal
30 to its home cage, with free access to food (pre-weighed) and water. For each of days 2-15, at between approximately 8:00 h and 10:00 h, measure rat body weight and the weight of food consumed in the last 24 h period, and administer daily oral dose of test compound

or vehicle. On days -2 and 15 measure total fat mass and lean mass by nuclear magnetic resonance (NMR) using an EchoMRI™ system (Echo Medical Systems, Houston Texas). (See Frank C. Tinsley, Gersh Z. Taicher, and Mark L. Heiman, "Evaluation of a New Quantitative Magnetic Resonance (QMR) Method for Mouse Whole Body Composition Analysis", Obesity Research, submitted May 1, 2003.)

Representative compounds of the present invention are tested in acute and chronic feeding assays essentially as described above. In the acute assays, the compounds are found to significantly reduce 24 h food intake, which effect is blocked by pre-administration of the 5-HT_{2C} receptor antagonist. The compounds also are found to dose-dependently reduce RQ without significantly changing the energy expenditure during the light photo-period. Thus the compounds are found to reduce caloric intake and increase the proportion of fuel deriving from fat utilization, without significantly changing the resting metabolic rate. In the chronic assay, the compounds are found to significantly decrease cumulative food intake and cumulative body weight change in a dose-dependent manner compared to control animals. The decrease in body weight is found to be due to loss of adipose tissue while lean body mass is not changed.

The ability of the 5-HT_{2C} receptor agonists of the present invention to treat obsessive/compulsive disorder is demonstrated by testing in a variety of in vivo assays as follows:

Marble burying assay

Marble burying in mice has been used to model anxiety disorders including obsessive-compulsive disorders (OCD) due to ethological study of the behavior (e.g. Gyertyan I. "Analysis of the marble burying response: Marbles serve to measure digging rather than evoke burying", *Behavioural Pharmacology* 6: 24-31, (1995)) and due to the pharmacological effects of clinical standards (c.f., Njung'E K. Handley SL. "Evaluation of marble-burying behavior as a model of anxiety", *Pharmacology, Biochemistry & Behavior*. 38: 63-67, (1991)); Borsini F., Podhorna J., and Marazziti, D. "Do animal models of anxiety predict anxiolytic effects of antidepressants?", *Psychopharmacology* 163: 121-141, (2002)). Thus, drugs used in the treatment of generalized anxiety in

humans (e.g. benzodiazepines) as well as compounds used to treat OCD (e.g. SSRIs like fluoxetine) decrease burying.

House experimentally-naïve male, NIH Swiss mice (Harlan Sprague-Dawley,
5 Indianapolis, IN) weighing between 28-35 g in groups of 12 for at least three days prior to testing in a vivarium with 12 h light and dark cycles. Conduct experiments during the light cycle in a dimly lit experimental testing room. Dose mice with vehicle or test compound and, after a specified pretreatment interval (generally 30 min.), place each mouse individually on a rotorod (Ugo Basile 7650) operating at a speed of 6
10 revolutions/min. and observe for falling. After 2 min. on the rotorod, place the mice individually in a 17 x 28 x 12 cm high plastic tub with 5 mm sawdust shavings on the floor that are covered with 20 blue marbles (1.5 cm diameter) placed in the center. After 30 min., count the number of marbles buried (2/3 covered with sawdust). Assess the test compound's effect on marble burying with Dunnett's test and the effect on rotorod
15 performance by Fisher's exact test.

Clinically effective standard compounds suppress marble burying at doses that are devoid of motor-impairing effects as measured on the rotorod. The *in vivo* efficacy of
5HT_{2C} compounds at the 5HT_{2C} receptor is confirmed by the prevention of effects of the
20 5HT_{2C} agonists on marble burying by co-administration of the 5HT_{2C} receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole.

Representative compounds of the present invention are assayed in the marble
25 burying assay essentially as described and are surprisingly found to reduce burying behavior in the test mice. The reduction of burying behavior is found to be blocked by co-administration of the 5-HT_{2C} antagonist. In contrast to the compounds of the present invention, the anxiolytic compound chlordiazepoxide and the antipsychotic compound chlorpromazine decrease marble burying only at doses that also disrupt rotorod
30 performance.

Nestlet Shredding

Mice naturally will construct nests of material available in their living environment. Since this behavior is obsessive in nature, it has been used to model OCD (Xia Li, Denise Morrow and Jeffrey M. Witkin, "Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying", Psychopharmacology, submitted July 14, 2003). House experimentally-naïve male, NIH Swiss mice (Harlan Sprague-Dawley, Indianapolis, IN) weighing between 28-35 g in groups of 12 for at least three days prior to testing in a vivarium with a 12 h light/dark cycle. Conduct experiments during the light cycle in an experimental room with normal overhead fluorescent lighting. Dose mice with vehicle or test compound and after a specified pretreatment interval (generally 30 min.), place the mice individually in a 17 x 28 x 12 cm high plastic tub with about 5 mm sawdust shavings on the floor along with a pre-weighed multi-ply gauze pad (51 mm square). After 30 min., weigh the remainder of the gauze pad not removed by the mouse. Determine the weight of the gauze used for nestlet construction by subtraction. Compare the results for test compound treated mice to the results for vehicle control treated mice with Dunnett's test.

Clinically effective OCD treatment standard compounds suppress nestlet shredding at doses that are devoid of motor-impairing effects as measured by the rotorod test. The *in vivo* efficacy of 5HT_{2C} compounds at the 5HT_{2C} receptor is confirmed by the prevention of effects of the 5HT_{2C} agonists on nestlet shredding by co-administration of the 5HT_{2C} receptor antagonist, 6-chloro-5-methyl-N-{2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole.

Representative compounds of the present invention are assayed essentially as described above and are surprisingly found to suppress nestlet shredding at doses that are devoid of motor-impairing effects as measured by the rotorod test.

In contrast to the compounds of the present invention, the anxiolytic chlordiazepoxide and the psychomotor stimulant *d*-amphetamine decreases nestlet shredding only at doses that produce motoric side effects (depression or stimulation, respectively).

Schedule-Induced Polydipsia

Food-deprived rats exposed to intermittent presentations of food will drink amounts of water that are far in excess of their normal daily intake and in excess of their intake when given all of their food at one time (Falk JL. "Production of polydipsia in
5 normal rats by an intermittent food schedule", *Science* 133: 195-196, (1961)). This excessive behavior is persistent and has been used to model OCD.

Maintain Wistar rats on a food restricted diet (to maintain 85% free feeding weight), but with free access to water. Train the rats in a behavioral testing chamber to
10 press a lever to receive a food pellet under a fixed interval schedule, such that the rats are rewarded with a 45 mg food pellet the first time they press a lever after a 120 second interval has elapsed. The fixed interval is then reset to 120 seconds and the process repeated. Thus, during a 90 min. test session, the rats can earn a maximum of 45 pellets. The behavioral chamber is also equipped with a water bottle that is weighed before and
15 after the session to determine the amount of water consumed.

Administer test compounds on Tuesdays and Fridays. Determine control day performances on Thursdays. Administer compounds either orally at 60 min. before the beginning of a test session, or subcutaneously at 20 min. before the beginning of a test
20 session. Compare the rates of lever pressing and water consumption for each animal's performance during sessions after test compound treatment with that animal's performance during control sessions, expressed as a percent of the control rate. Average the individual percent of control rates for each dose and calculate the standard error of the mean.

25 Clinically effective OCD treatment standard compounds (e.g. chlomipramine, fluoxetine) suppress schedule-induced polydipsia without producing notable changes in motor patterns, food intake, or behavior the following day. The *in vivo* efficacy of 5HT_{2C} compounds at the 5HT_{2C} receptor is confirmed by the prevention of effects of the 5HT_{2C} agonists on excessive drinking by co-administration of the 5HT_{2C} receptor antagonist, 6-
30 chloro-5-methyl-N- {2-[(2-methylpyridin-3-yl-oxy)pyridin-5-yl]aminocarbonyl}-2,3-dihydroindole.

Representative compounds of the present invention are assayed in the schedule-induced polydipsia assay essentially as described above and are surprisingly found to suppress schedule-induced polydipsia without producing notable changes in motor patterns, food intake, or behavior the following day. The behavior suppression is blocked
5 by co-administration of the 5-HT_{2C} antagonist.

In contrast to the compounds of the present invention, the psychomotor stimulant d-amphetamine decreases excessive drinking only at behaviorally stimulating doses and these effects are not prevented by the 5HT_{2C} receptor antagonist.

10

While it is possible to administer compounds employed in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of Formula I or a pharmaceutically acceptable salt thereof.
15 These compositions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. The compounds employed in the methods of this invention are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art. *See, e.g.* REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed.
20 1980).

In making the compositions employed in the present invention the active ingredient is usually mixed with at least one excipient, diluted by at least one excipient, or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or
25 other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound,
30 soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is
5 normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium
10 silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as
15 to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of
20 the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

25 The compounds are generally effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the
30 relevant circumstances, including the condition to be treated, the chosen route of

administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range
5 may be more than adequate, while in other cases still larger doses may be employed.

Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the
10 compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

15


Under some circumstances, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery
20 system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Patent 5,011,472, issued April 30, 1991, which is herein incorporated by reference.

Indirect techniques, which are generally preferred, usually involve formulating
25 the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced
30 by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

The type of formulation employed for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compound employed, the type of pharmacokinetic profile desired from the route of administration, and the state of the patient.

WE CLAIM:

1. A compound of Formula I:



5

where:

R^1 is hydrogen, fluoro, or (C_1-C_3) alkyl;

R^2 , R^3 , and R^4 are each independently hydrogen, methyl, or ethyl;

R^5 is hydrogen, fluoro, methyl, or ethyl;

10 R^6 is $-C\equiv C-R^{10}$, $-O-R^{12}$, $-S-R^{14}$, or $-NR^{24}R^{25}$;

R^7 is hydrogen, halo, cyano, (C_1-C_6) alkyl optionally substituted with 1 to 6 fluoro substituents, (C_2-C_6) alkenyl optionally substituted with 1 to 6 fluoro substituents, (C_3-C_7) cycloalkyl, (C_1-C_6) alkoxy optionally substituted with 1 to 6 fluoro substituents, (C_1-C_6) alkylthio optionally substituted with 1 to 6 fluoro substituents,

15 $Ph^1-(C_0-C_3)$ alkyl, $Ph^1-(C_0-C_3)$ alkyl-O-, or $Ph^1-(C_0-C_3)$ alkyl-S-;

R^8 is hydrogen, halo, cyano, or $-SCF_3$;

R^9 is hydrogen, halo, cyano, $-CF_3$, $-SCF_3$, or (C_1-C_3) alkoxy optionally substituted with 1 to 6 fluoro substituents;

20 R^{10} is $-CF_3$, ethyl substituted with 1 to 5 fluoro substituents, (C_3-C_6) alkyl optionally substituted with 1 to 6 fluoro substituents, (C_3-C_7) cycloalkyl (C_0-C_3) alkyl, $Ar^1-(C_0-C_3)$ alkyl, or $Ph^1-(C_0-C_3)$ alkyl;

25 R^{12} is $Ph^2-(C_1-C_3)$ alkyl, $Ar^2-(C_1-C_3)$ alkyl, (C_1-C_6) alkyl-S- (C_2-C_6) alkyl, (C_3-C_7) cycloalkyl-S- (C_2-C_6) alkyl, phenyl-S- (C_2-C_6) alkyl, Ph^2 -S- (C_2-C_6) alkyl, phenylcarbonyl- (C_1-C_3) alkyl, Ph^2 -C(O)- (C_1-C_3) alkyl, (C_1-C_6) alkoxycarbonyl- (C_3-C_6) alkyl, (C_3-C_7) cycloalkyl-OC(O)- (C_3-C_6) alkyl, phenyloxycarbonyl- (C_3-C_6) alkyl, Ph^2 -OC(O)- (C_3-C_6) alkyl, Ar^2 -OC(O)- (C_3-C_6) alkyl, (C_3-C_7) cycloalkyl-NH-C(O)- (C_2-C_4) alkyl-, Ph^1 -NH-C(O)- (C_2-C_4) alkyl-, Ar^2 -NH-C(O)- (C_2-C_4) alkyl-, or R^{13} -C(O)NH- (C_2-C_4) alkyl;

R¹³ is (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹, Ar², or (C₁-C₃)alkoxy optionally substituted with 1 to 6 fluoro substituents, Ph¹-NH- or N-linked Het¹;

R¹⁴ is Ar² which is not N-linked to the sulfur atom, Ph², R¹⁵-L-, tetrahydrofuranyl, tetrahydropyranyl, or phenyl-methyl substituted on the methyl moiety with a
5 substituent selected from the group consisting of (C₁-C₃)-*n*-alkyl substituted with hydroxy, (C₁-C₃)alkyl-O-(C₁-C₂)-*n*-alkyl, (C₁-C₃)alkyl-C(O)-(C₀-C₂)-*n*-alkyl, and (C₁-C₃)alkyl-O-C(O)-(C₀-C₂)-*n*-alkyl,

wherein Ph² and Ar² when Ar² is pyridyl, may also, optionally be substituted with phenyl-CH=CH- or phenyl-C≡C-,

10 said phenyl-CH=CH- or phenyl-C≡C- being optionally further substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro
15 substituents, and

wherein when Ar² is pyridyl, the pyridyl may alternatively, optionally be substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents, and

20 wherein the tetrahydrofuranyl and tetrahydropyranyl may optionally be substituted with an oxo substituent, or with one or two groups independently selected from methyl and -CF₃;

R¹⁵ is -OR¹⁶, cyano, -SCF₃, Ph², Ar², quinoliny, isoquinoliny, cinnoliny, quinazoliny, phthalimido, -NR¹⁷R¹⁸, -C(O)R²², or a saturated heterocycle selected from the group
25 consisting of pyrrolidiny, piperidiny, morpholiny, and thiomorpholiny, tetrahydrofuranyl, and tetrahydropyranyl,

wherein Ph² and Ar² when Ar² is pyridyl, may also optionally be substituted with phenyl-CH=CH- or phenyl-C≡C-,

30 said phenyl-CH=CH- and phenyl-C≡C- being optionally further substituted on the phenyl moiety with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro

substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and

wherein Ar² may alternatively, optionally be substituted with a substituent selected from the group consisting of (C₃-C₇)cycloalkyl-(C₀-C₃)alkyl, Het¹-(C₀-C₃)alkyl, pyridyl-(C₀-C₃)alkyl, and phenyl-(C₀-C₃)alkyl, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,

said pyridyl-(C₀-C₃)alkyl and phenyl-(C₀-C₃)alkyl optionally being further substituted with 1-3 substituents independently selected from halo, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -SCF₃, and

wherein when Ar² is pyridyl, the pyridyl may alternatively, optionally be substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents, and

wherein the pyrrolidinyl, piperidinyl, morpholinyl, and thiomorpholinyl is substituted with oxo- on a carbon atom adjacent to the ring nitrogen atom, or is N-substituted with a substituent selected from the group consisting of

(C₁-C₆)alkylcarbonyl, (C₁-C₆)alkylsulfonyl,
 (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-,
 (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)₂-, Ph¹-(C₀-C₃)alkyl-C(O)-, and
 Ph¹-(C₀-C₃)alkyl-S(O)₂-, and

may optionally be further substituted with 1 or 2 methyl or -CF₃ substituents, and when oxo-substituted, may optionally be further N-substituted with a substituent selected from the group consisting of

(C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, and Ph¹-(C₀-C₃)alkyl, and

wherein tetrahydrofuranyl and tetrahydropyranyl may optionally be substituted with an oxo substituent, and/or with one or two groups independently selected from methyl and -CF₃;

L is branched or unbranched (C₁-C₆)alkylene, except when R¹⁵ is -NR¹⁷R¹⁸ or Ar²-N-linked to L, in which case L is branched or unbranched (C₂-C₆)alkylene, and when L is methylene or ethylene, L may optionally be substituted with gem-ethano,

and when R^{15} is Ph^2 , Ar^2 , or a saturated heterocycle, L may alternatively, optionally be substituted with a substituent selected from the group consisting of hydroxy, cyano, $-SCF_3$, (C_1-C_6) alkoxy optionally further substituted with 1 to 6 fluoro substituents, (C_1-C_6) alkoxycarbonyl optionally further substituted with 1 to 6 fluoro substituents, (C_1-C_6) alkylcarbonyloxy optionally further substituted with 1 to 6 fluoro substituents, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-O-, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-O-C(O)-, and (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-C(O)-O-;

R^{16} is hydrogen, (C_1-C_6) alkyl optionally substituted with 1 to 6 fluoro substituents, (C_1-C_6) alkylcarbonyl, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-C(O)-, Ph^1 - (C_0-C_3) alkyl, Ph^1 - (C_0-C_3) alkyl-C(O)-, Ar^2 - (C_0-C_3) alkyl, or Ar^2 - (C_0-C_3) alkyl-C(O)-,

R^{17} is (C_1-C_4) alkyl optionally substituted with 1 to 6 fluoro substituents, *t*-butylsulfonyl, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-C(O)-, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl-sulfonyl, Ph^1 - (C_0-C_3) alkyl, Ph^1 - (C_0-C_3) alkyl-C(O)-, Ph^1 - (C_0-C_3) alkylsulfonyl, Ar^2 - (C_0-C_3) alkyl, Ar^2 - (C_0-C_3) alkyl-C(O)-, Ar^2 - (C_0-C_3) alkylsulfonyl, $R^{19}OC(O)-$, or $R^{20}R^{21}NC(O)-$;

R^{18} is hydrogen or (C_1-C_4) alkyl optionally substituted with 1 to 6 fluoro substituents, or R^{17} and R^{18} , taken together with the nitrogen atom to which they are attached form Het^1 where Het^1 is substituted with oxo- on a carbon atom adjacent to the ring nitrogen atom, or

R^{17} and R^{18} , taken together with the nitrogen atom to which they are attached, form an aromatic heterocycle selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, and 1,2,4-triazolyl,

said aromatic heterocycle optionally being substituted with 1 to 2 halo substituents, or substituted with 1 to 2 (C_1-C_4) alkyl substituents optionally further substituted with 1 to 3 fluoro substituents, or mono-substituted with fluoro, nitro, cyano, $-SCF_3$, or (C_1-C_4) alkoxy optionally further substituted with 1 to 3 fluoro substituents, and optionally further substituted with a (C_1-C_4) alkyl substituent optionally further substituted with 1 to 3 fluoro substituents;

R^{19} is (C_1-C_6) alkyl optionally substituted with 1 to 6 fluoro substituents, (C_3-C_7) cycloalkyl- (C_0-C_3) alkyl, Ar^2 - (C_0-C_3) alkyl, or Ph^1 - (C_0-C_3) alkyl,

R^{20} is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl, or Ph¹-(C₀-C₃)alkyl,

R^{21} is hydrogen or (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or

R^{20} and R^{21} , taken together with the nitrogen atom to which they are attached, form Het¹;

R^{22} is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, R^{23} -O-, Ph¹-(C₀-C₃)alkyl, Ar²-(C₀-C₃)alkyl, or $R^{32}R^{33}N$;

R^{23} is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl, or Ar²-(C₀-C₃)alkyl;

R^{24} is (C₁-C₆)alkoxy(C₂-C₅)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₁-C₆)alkylthio(C₂-C₅)alkyl optionally substituted with 1 to 6 fluoro substituents,

(C₃-C₇)cycloalkyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl,

(C₃-C₇)cycloalkyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl, phenyl(C₁-C₃) *n*-alkyl,

Ph²-(C₁-C₃)-*n*-alkyl, Ar²(C₀-C₃) *n*-alkyl, phenyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl,

phenyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl, Ph¹-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl,

Ph¹-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl,

pyridyl-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl,

pyridyl-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl, or Ar³(C₁-C₂)alkyl,

where Ar³ is a bi-cyclic moiety selected from a group consisting of indanyl, indolyl,

dihydrobenzofuranyl, benzofuranyl, benzothiophenyl, benzoxazolyl,

benzothiazolyl, benzo[1,3]dioxolyl, naphthyl, dihydrobenzopyranyl, quinoliny,

and isoquinoliny,

said Ar³ optionally being substituted with phenyl(C₀-C₁)alkyl optionally

further substituted with 1 to 6 fluoro substituents, or substituted with

(C₃-C₇)cycloalkyl(C₀-C₃)alkyl, or substituted with 1-3 substituents

independently selected from the group consisting of halo, oxo, methyl, and

-CF₃,

said phenyl(C₁-C₃) *n*-alkyl, Ph²-(C₁-C₃) *n*-alkyl, or Ar²(C₀-C₃) *n*-alkyl

optionally being substituted on the *n*-alkyl moiety when present with

(C₁-C₃)alkyl, dimethyl, or gem-ethano,

said Ar²(C₀-C₃) *n*-alkyl being alternatively optionally substituted with a

substituent selected from the group consisting of (C₃-C₇)cycloalkyl-

(C₀-C₃)alkyl, Het¹-(C₀-C₃)alkyl, pyridyl-(C₀-C₃)alkyl, and phenyl-(C₀-C₃)alkyl, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,

said pyridyl-(C₀-C₃)alkyl and phenyl-(C₀-C₃)alkyl optionally being further substituted with 1-3 substituents independently selected from halo, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -SCF₃, and said Ph²-(C₁-C₃) *n*-alkyl and Ar²-(C₀-C₃) *n*-alkyl where Ar² is pyridyl, also optionally being substituted on the phenyl or Ar² moiety, respectively, with phenyl-CH=CH- or phenyl-C≡C-,

said phenyl-CH=CH- or phenyl-C≡C- being optionally further substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and

said Ar²-(C₀-C₃) *n*-alkyl where Ar² is pyridyl, alternatively, optionally being substituted with R²⁸R²⁹N-C(O)-, and optionally further substituted with one methyl, -CF₃, cyano, or -SCF₃ substituent, or with 1 to 2 halo substituents,

said phenyl(C₀-C₁)alkyl-O-(C₁-C₅)alkyl, or phenyl(C₀-C₁)alkyl-S-(C₁-C₅)alkyl optionally being substituted on the phenyl moiety with (C₁-C₂)-S(O)₂-, or with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, -SCF₃, (C₁-C₆)alkyl optionally further substituted with 1 to 6 fluoro substituents, and (C₁-C₆)alkoxy optionally further substituted with 1 to 6 fluoro substituents, and

said pyridyl-(C₀-C₁)alkyl-C(O)NH-(C₂-C₄)alkyl and pyridyl-(C₀-C₁)alkyl-NH-C(O)NH-(C₂-C₄)alkyl optionally being substituted on the pyridyl moiety with methyl, -CF₃, or 1 to 3 halo substituents;

R²⁵ is hydrogen, (C₁-C₃)alkyl optionally substituted with 1 to 6 fluoro substituents, or allyl;

R²⁶ is hydrogen, (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or (C₃-C₇)cycloalkyl(C₀-C₃)alkyl;

R²⁷ is hydrogen or (C₁-C₄)alkyl optionally substituted with 1 to 6 fluoro substituents, or R²⁶ and R²⁷, taken together with the nitrogen atom to which they are attached, form Het¹;

R²⁸ is (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, tetrahydropyran-3-yl(C₀-C₃)alkyl, tetrahydropyran-4-yl(C₀-C₃)alkyl, tetrahydrofuranyl(C₀-C₃)alkyl, Ph¹-(C₀-C₂) *n*-alkyl, or Ar²-(C₀-C₂) *n*-alkyl,

said Ph¹-(C₀-C₂) *n*-alkyl and Ar²-(C₀-C₂) *n*-alkyl optionally being substituted on the alkyl moiety when present with (C₁-C₃)alkyl, dimethyl, or gem-ethano;

R²⁹ is hydrogen or (C₁-C₃)alkyl;

R³⁰ is hydrogen, (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, (C₃-C₇)cycloalkyl(C₀-C₃)alkyl, Ph¹-(C₀-C₃)alkyl, or Ar²(C₀-C₃)alkyl,

R³¹ is hydrogen or (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, or R³⁰ and R³¹, taken together with the nitrogen atom to which they are attached, form Het¹,

said Het¹ also optionally being substituted with phenyl optionally further substituted with 1 to 3 halo substituents;

R³² and R³³ are each independently hydrogen or (C₁-C₆)alkyl optionally substituted with 1 to 6 fluoro substituents, or R³² and R³³, taken together with the nitrogen atom to which they are attached, form Het¹;

Ar¹ is an aromatic heterocycle substituent selected from the group consisting of furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, and pyridyl, any of which may optionally be substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C₁-C₃)alkyl, (C₁-C₃)alkoxy, -CF₃, -O-CF₃, nitro, cyano, and trifluoromethylthio;

Ar² is an aromatic heterocycle substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyridazinyl, and benzimidazolyl, any of which may optionally be substituted with 1 to 3 substituents

independently selected from the group consisting of halo, cyano, $-\text{SCF}_3$, $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally further substituted with 1 to 6 fluoro substituents, and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally further substituted with 1 to 6 fluoro substituents, and wherein pyridyl and pyridazinyl may also optionally be substituted with $(\text{C}_1\text{-C}_6)\text{alkylamino}$ optionally further substituted with 1 to 6 fluoro substituents, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}(\text{C}_0\text{-C}_3)\text{alkyl}$, or $(\text{C}_3\text{-C}_7)\text{cycloalkyl}(\text{C}_0\text{-C}_3)\text{alkyl-amino}$;

Het¹ is a saturated, nitrogen-containing heterocycle substituent selected from the group consisting of azetidiny, pyrrolidiny, piperidiny, homopiperidiny, morpholiny, and thiomorpholiny, any of which may optionally be substituted with $(\text{C}_1\text{-C}_6)\text{alkyl}$ or with 2 methyl substituents;

Ph¹ is phenyl optionally substituted with 1 to 5 independently selected halo substituents, or with 1 to 3 substituents independently selected from the group consisting of halo, cyano, $-\text{SCF}_3$, $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally further substituted with 1 to 6 fluoro substituents, and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally further substituted with 1 to 6 fluoro substituents;

Ph² is phenyl substituted with:

- a) 1 to 5 independently selected halo substituents; or
- b) 1 to 3 substituents independently selected from the group consisting of halo, cyano, $-\text{SCF}_3$, nitro, hydroxy, $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally further substituted with 1 to 6 fluoro substituents, and $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally further substituted with 1 to 6 fluoro substituents; or
- c) 0, 1, or 2 substituents independently selected from the group consisting of halo, cyano, $-\text{SCF}_3$, methyl, $-\text{CF}_3$, methoxy, $-\text{OCF}_3$, nitro, and hydroxy, together with one substituent selected from the group consisting of
 - i) $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally further substituted with 1 to 6 fluoro substituents or mono-substituted with hydroxy, $(\text{C}_1\text{-C}_3)\text{alkoxy}$, or $(\text{C}_1\text{-C}_2)\text{-S(O)}_2\text{-}$,
 - ii) $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally further substituted with 1 to 6 fluoro substituents,
 - iii) $(\text{C}_1\text{-C}_6)\text{alkyl-C(O)-(C}_0\text{-C}_3)\text{alkyl}$ optionally further substituted with 1 to 6 fluoro substituents,
 - iv) carboxy,
 - v) $(\text{C}_1\text{-C}_6)\text{alkoxycarbonyl}$ optionally further substituted with 1 to 6 fluoro substituents,

- vi) (C₁-C₆)alkyl-C(O)-(C₀-C₃)-O- optionally further substituted with 1 to 6 fluoro substituents,
- vii) (C₁-C₆)alkylthio optionally further substituted with 1 to 6 fluoro substituents,
- 5 viii) (C₁-C₆)alkylsulfinyl optionally further substituted with 1 to 6 fluoro substituents,
- ix) (C₁-C₆)alkylsulfonyl optionally further substituted with 1 to 6 fluoro substituents,
- x) (C₁-C₆)alkylsulfonyl-(C₀-C₁)alkyl-O- optionally further substituted with 1
10 to 6 fluoro substituents,
- xi) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl,
- xii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-O-,
- xiii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-C(O)-,
- xiv) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-O-C(O)-,
- 15 xv) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S-,
- xvi) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)-,
- xvii) (C₃-C₇)cycloalkyl(C₀-C₃)alkyl-S(O)₂-,
- xviii) Ph¹-(C₀-C₃)alkyl,
- xix) Ph¹-(C₀-C₃)alkyl-O-,
- 20 xx) Ph¹-(C₀-C₃)alkyl-C(O)-,
- xxi) Ph¹-(C₀-C₃)alkyl-O-C(O)-,
- xxii) Ph¹-(C₀-C₃)alkyl-C(O)-(C₀-C₃)alkyl-O-,
- xxiii) Ph¹-(C₀-C₃)alkylthio,
- xxiv) Ph¹-(C₀-C₃)alkylsulfinyl,
- 25 xxv) Ph¹-(C₀-C₃)alkylsulfonyl,
- xxvi) Ar²(C₀-C₃)alkyl
- xxvii) Ar²(C₀-C₃)alkyl-O-
- xxviii) Ar²-(C₀-C₃)alkyl-S-,
- xxix) Ar²(C₀-C₃)alkyl-C(O)-,
- 30 xxx) Ar²(C₀-C₃)alkyl-C(S)-,
- xxxi) Ar²-(C₀-C₃)alkylsulfinyl,
- xxxii) Ar²-(C₀-C₃)alkylsulfonyl,

xxxiii) Het¹(C₀-C₃)alkyl-C(O)- optionally substituted on the Het¹ moiety with Ph¹,

xxxiv) Het¹(C₀-C₃)alkyl-C(S)- optionally substituted on the Het¹ moiety with Ph¹,

5 xxxv) N-linked Het¹-C(O)-(C₀-C₃)alkyl-O-,

xxxvi) R²⁶R²⁷N-,

xxxvii) R²⁸R²⁹N-(C₁-C₃)alkoxy,

xxxviii) R²⁸R²⁹N-C(O)-,

xxxix) R²⁸R²⁹N-C(S)-,

10 xl) R³⁰R³¹N-S(O)₂-,

xli) HON=C(CH₃)-; and

xlii) HON=C(Ph¹)-;

or a pharmaceutically acceptable salt thereof, subject to the following provisos:

- 15 a) no more than two of R¹, R², R³, R⁴, and R⁵ may be other than hydrogen;
b) when R² is methyl, then R¹, R³, R⁴, and R⁵ are each hydrogen;
c) when R³ is methyl, then R² and R⁴ are each hydrogen;
d) when R³ is methyl, R⁷ and R⁸ are each -OH, and R¹, R², R⁴, R⁵, and R⁹ are each hydrogen, then R⁶ is other than cyclohexylthio, furanylthio, or phenylthio; and
20 e) When R¹² is Ar²-(C₁-C₃)alkyl, then R⁷ is other than hydrogen or R⁹ is other than chloro.

25 2. A pharmaceutical composition comprising a compound of Claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

3. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1.

30

4. The method of Claim 3, where the mammal is human.

5. A method for the treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1.

5 6. The method of Claim 5, where the mammal is human.

7. A method for the treatment of depression in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1.

10

8. The method of Claim 7, where the mammal is human.

9. A method for the treatment of anxiety in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound according to Claim 1.

15

10. The method of Claim 9, where the mammal is human.

11. A compound according to Claim 1 for use as a pharmaceutical.

20

12. A compound according to Claim 1 for use in selectively activating 5-HT_{2C} receptors in a mammal.

13. A compound according to Claim 1 for use in the treatment of a 5-HT_{2C} mediated disorder, where the disorder is obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, or hypogonadism.

25

14. A compound according to Claim 1 for use in the treatment of a 5-HT_{2C} mediated disorder, where the disorder is obesity, obsessive/compulsive disorder, anxiety, or depression.

30

15. A compound according to Claim 1 for use in the treatment of obesity in mammals.

5 16. A compound according Claim 1 for use in the treatment of obsessive/compulsive disorder in mammals.

17. A compound according to Claim 1 for use in the treatment of depression in mammals.

10 18. A compound according to Claim 1 for use in the treatment of anxiety in mammals.

15 19. A compound according to any one of Claims 12-18, where the mammal is a human.

20 20. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of a 5-HT_{2C} mediated disorder, where the disorder is obesity, hyperphagia, obsessive/compulsive disorder, depression, anxiety, substance abuse, sleep disorder, hot flashes, and/or hypogonadism.

21. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of a 5-HT_{2C} mediated disorder, where the disorder is obesity, obsessive/compulsive disorders, anxiety, or depression.

25 22. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of obesity in mammals.

23. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of obsessive/compulsive disorder in mammals.

30 24. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of depression in mammals.

25. The use of a compound according to Claim 1 in the manufacture of a medicament for the treatment of anxiety in mammals.

5 26. The use according to any one of Claims 20-25, where the mammal is a human.

 27. A pharmaceutical composition adapted for the treatment of obesity comprising a compound according to Claim 1 in combination with one or more
10 pharmaceutically acceptable excipients, carriers, or diluents therefore.


 28. A pharmaceutical composition adapted for the treatment of obsessive/compulsive disorders comprising a compound according to Claim 1 in combination with one or more pharmaceutically acceptable excipients, carriers, or
15 diluents therefore.

 29. A pharmaceutical composition adapted for the treatment of depression comprising a compound according to Claim 1 in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents therefore.

20 30. A pharmaceutical composition adapted for the treatment of anxiety comprising a compound according to Claim 1 in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents therefore.

ABSTRACT

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT_{2C} receptor agonists for the treatment of 5-HT_{2C} associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:



where:

10 R⁶ is -C≡C-R¹⁰, -O-R¹², -S-R¹⁴, or -NR²⁴R²⁵;
and other substituents are as defined in the specification.